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Abstract 
The work presented in this thesis describes the use of highly magnetic iron oxide silica 
nanoparticles conjugated to herceptin for the targeted detection of human epidermal 
growth factor receptor 2 (HER2) positive breast cancer using magnetic resonance imaging 
(MRI). The main finding of this study was that iron oxide nanoparticles coated in silica 
can be used to detect HER2 positive breast cancers in vivo using MRI.  The iron oxide 
silica nanoparticles produced presented with highly magnetic properties and were able to 
produce MRI contrast. The iron oxide silica nanoparticles were also found to be non-toxic, 
biocompatible, stable and were easily conjugated to a biomarker, herceptin. The results 
from the in vitro and in vivo assessment of these iron oxide silica herceptin nanoparticles, 
demonstrated that significant MRI contrast was visualised relative to HER2 expression 
levels in three human breast cancer cell lines and HER2 positive breast tumours.  
 
A promising use of nanoparticles is in medical imaging where iron oxide nanoparticles are 
increasingly being utilised in MRI as contrast agents for targeted imaging. Iron oxide 
particles have previously been used as contrast agents for imaging the liver, spleen and 
gastrointestinal lumen in MRI. With advancements in nanoparticle technology, iron oxide 
nanoparticles that are less than 100 nm in diameter have been able to be synthesised which 
are capable of imaging specific diseases targeted with a biomarker. This advancement is a 
crucial development for medical imaging as it allows targeted imaging to be possible with 
MRI which, unlike nuclear imaging methods, currently does not have the required 
sensitivity. The improvement in nanoparticle synthesis processes have also enabled the 
production of iron oxide nanoparticles with higher magnetic properties, less toxicity, 
improved stability and solubility and surface layer suitable for the attachment of a variety 
of molecular markers. These properties are important characteristics for iron oxide 
nanoparticles as they influence their ability to produce contrast at the targeted site.  
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An application of iron oxide nanoparticles for targeted imaging in MRI is in breast cancers 
that overexpress HER2 receptors which are associated with poor prognosis. A treatment 
option for HER2 positive tumours is Herceptin® (herceptin) therapy, which is known to 
cause down regulation of HER2 expression eventually causing cell death and a reduction 
in the size of the tumour.  Although the well reported response rates to herceptin therapy 
regimes are high, it is documented that patients acquire resistance to herceptin based 
therapy regimes after several months. The primary mechanism of herceptin resistance is 
unknown and there are varieties of pathways that have been proposed. Although there are 
research efforts to understand the myriad of molecular mechanisms related to herceptin 
resistance, it is also equally important to identify the patients who may be resistant to 
herceptin based therapy  
 
A tool that can be used to image HER2 positive breast tumours and potentially identify 
these patients is in MRI using iron oxide nanoparticles conjugated to herceptin. Previous 
studies demonstrate that HER2 positive breast tumours can be targeted using iron oxide 
nanoparticles in MRI. Unfortunately, these studies do not address all of the characteristics 
described above that are required to achieve targeted imaging in MRI. Due to this, iron 
oxide nanoparticles for targeted imaging in MRI have been limited in their translational 
capability to the clinic.  
 
Therefore, the aim of this study was to synthesise iron oxide nanoparticles addressing all 
of the characteristics required for targeting HER2 positive tumours in vitro and in vivo. To 
confirm that iron oxide silica herceptin nanoparticles possessed the basic characteristics 
needed for targeted imaging, a series of characterisation techniques were conducted. It was 
clearly shown that the synthesised iron oxide silica nanoparticles had the major 
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characteristics needed to be used as targeted contrast and were superior to commercially 
available iron oxide nanoparticles and previously reported iron oxide nanoparticles. 
Furthermore, the conjugation between iron oxide silica and herceptin was shown to be 
stable after exposure to a range of conditions, mimicking different physiological 
conditions.  
 
In vitro studies examined cellular uptake and contrast enhancement capability of the iron 
oxide silica herceptin nanoparticles. The studies confirmed the uptake into HER2 
expressing human breast cancer cells possibly mediated by the herceptin, which was 
consistent with receptor expression and results from previous studies. The in vivo 
investigation demonstrated uptake of the iron oxide silica herceptin nanoparticles at the 
tumour site, producing signal enhancements larger than previously reported. 
Histopathological analysis indicated that there was no toxicity to the liver, lungs, heart and 
kidneys. Overall, the findings of this study demonstrated that the iron oxide silica 
herceptin nanoparticles targeted HER2 positive tumours with nanoparticles that are highly 
magnetic, biocompatible, small in size and size distribution and stable. The results suggest 
that the iron oxide silica herceptin nanoparticles have all of the basic characteristics 
required for potential translation into the clinical setting. 
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Chapter 1 Introduction 
1.1 Nanotechnology and nanoparticles 
 
The idea of nanotechnology was introduced in 1959 when Richard Feynman, a physicist 
from the Californian Institute of Technology, gave the revolutionary speech, “There’s 
plenty of room at the bottom” (Feynman, 1960). Feynman described the idea of building 
miniature factories with nanoscale machines developed by atoms and molecules that could 
be precisely manipulated. He suggested that the laws of physics should make possible the 
creation of objects at a very small scale to carry out tasks with an enormous range of 
technical applications. He explained that there was not just room at the bottom but plenty 
of room at the bottom to achieve anything miniature. In his revolutionary speech he gave 
examples of miniature creations such as building miniature computers with wires with a 
maximum diameter of 100 atoms to store as much information as possible. In addition, he 
explained that encyclopaedias could eventually be written on the head of a pin because, 
there was plenty of room. He envisioned and questioned: if biological systems had 
microscopic cells that move around with multiple functions and store information in DNA 
in such a small scale, then why couldn’t tiny objects that have the potential to track 
biological functions be possible? This vision has developed into what is termed 
nanotechnology and is defined as the engineering of functional systems at the molecular 
scale.  
  
Nanotechnology operates at the first level of organisation of atoms and molecules, where 
the properties and functions are defined, in all systems. Nanotechnology has a wide variety 
of applications and is not limited to areas such as electronics, space, food, cosmetics and 
medicine (Sozer & Kokini, 2009). One of the most important and widely researched areas 
of nanotechnology is the development and use of nanoscale materials such as 
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such as nanoparticles.  
 
According to the most widely accepted definition, nanoparticles are defined as particles in 
the nanoscale that have at least one dimension less than 100 nm. Over the past decade, 
scientists and engineers have been mastering the intricacies of nanoparticles including 
their development, properties and characteristics, opening up vast areas of nanoparticle 
research some of which are highlighted in Table 1.1. 
 
Applications of Nanoparticles   
Area Uses References 
Cosmetics 
 
Sunscreens 
Make-up 
Preservatives 
 
(Katz Linda, 2007; Kokura 
et al., 2010; Mu & Feng, 
2003; Mu & Sprando, 2010; 
Souto & Müller, 2008) 
Computing science 
 
Computers 
Equipment design 
(Matsui, 2005; Reiss & 
Hutten, 2005; West & 
Halas, 2003) 
Medicine 
 
Drug-delivery 
Hyperthermia 
Pharmaceuticals 
Vaccines 
 
(Medina, Santos-Martinez, 
Radomski, Corrigan, & 
Radomski, 2007; Sanvicens 
& Marco, 2008; Shahiwala, 
Vyas, & Amiji, 2007; 
Thiesen & Jordan, 2008) 
Food Packaging 
Formulation 
strategies 
Dry milling 
 
(Degant & Schwechten, 
2001; Sanguansri & 
Augustin, 2006; 
Tharanathan, 2003) 
Table 1. 1 Applications of nanoparticles 
There are many applications of nanoparticles that have evolved over the last decade. This 
table highlights the different areas where nanoparticles are used, which include but are not 
limited to industries such as cosmetics, computers, medicine and food.  
 
In computing science, nanoparticles have been utilised in developing mini transistors 
leading to the production of smaller and more powerful computers and laptops (Matsui, 
2005). In the food sector, nanoparticles have improved techniques such as dry milling, 
where it is now possible to obtain very small particle sizes which are useful in extracting 
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fine wheat flour (Degant & Schwechten, 2001). Nanoparticles have also been utilised in 
the development of biodegradable packaging materials for food items. Traditionally, most 
food packaging materials are made from non-degradable materials, which increase 
environmental pollution as well as increasing the use of fossil fuels (Sozer & Kokini, 
2009; Tharanathan, 2003). The production of alternative packaging materials has been 
made possible by nanoparticles, which have improved their biodegradability (Sorrentino, 
Gorrasi, & Vittoria, 2007; Suyatma, Copinet, Tighzert, & Coma, 2004; Tharanathan, 
2003). In cosmetics, an area where nanoparticles play a crucial role is in preventing 
sunburn. In sunscreens, the properties of titanium dioxide nanoparticles reflect harmful 
sunrays giving maximum ultraviolet A (UVA) and ultraviolet B (UVB) protection (Mu & 
Sprando, 2010). Another field that has seen significant development by utilising 
nanoparticles is medicine. In the last decade, research into nanoparticles has made it 
possible to adjust functional, physical and chemical properties so that they can be tailored 
and applied to almost any biomedical application.  
1.1.1 Nanoparticles in medicine 
 
Over the past decade a great variety of nanoparticles have been synthesised for medical 
applications. These include but are not limited to substances such as silver, gold, iron, 
fluorescent particles, polymers and lipids, which have been widely exploited as 
nanoparticles for a vast range of biomedical applications (De, Ghosh, & Rotello, 2008). 
For example, silver nanoparticles have attracted interest due to their potent antibacterial, 
antimicrobial activity and anti-inflammatory properties (JoseRuben, et al., 2005; 
Nadworny, Wang, Tredget, & Burrell, 2008; Sibbald, et al., 2007). The unique properties 
of silver nanoparticles make them useful in areas such as wound healing (Chaloupka, 
Malam, & Seifalian, 2010), where silver nanoparticle dressings are used to treat minor 
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cuts and grazes, burns and ulcers (Chen, Han, Lin, Tang, & Su, 2006;  Huang, et al., 2007; 
Sibbald, et al., 2007). 
 
Nanoparticles are one billionth of a metre in size, which is smaller than micro sized cells 
and some cellular components. The small size of nanoparticles makes them useful as 
carriers for the delivery of drugs and vaccines to targeted sites (Singh & Lillard, 2009). 
Nanoparticles that are used to deliver drugs vary in their properties depending on their 
method of synthesis and the release characteristics needed for optimal delivery. In some 
cases, hollow nanoparticles, acting as vesicular systems, can be loaded with a drug and 
released in vivo at a targeted site. Polymeric nanoparticles made from poly (D, L-lactic 
acid) (PLA), poly (D,L-lactic-co-glycolic acid) (PLGA) and poly (ethylene glycol) (PEG) 
have been extensively researched for the loading and delivery of drugs because of their 
biodegradability in vivo (Hans & Lowman, 2002; Kumari, Yadav, & Yadav, 2010). PLGA 
nanoparticles are among the most successful biodegradable nanoparticle drug delivery 
systems and currently have FDA approval for human use. PLGA nanoparticles have been 
successfully used to deliver various anti-cancer drugs such as the chemotherapeutic agents 
cisplatin, paclitaxel and 9-nitrocamptotecin to tumour sites, reducing overall systemic 
toxicity (Avgoustakis. et al., 2002; Dadashzadeh, Derakhshandeh, & Shirazi, 2008; 
Derakhshandeh, Erfan, & Dadashzadeh, 2007; Fonseca, Simoes, & Gaspar, 2002; 
Gryparis, Hatziapostolou, Papadimitriou, & Avgoustakis, 2007; Mu & Feng, 2003). Apart 
from chemotherapy drugs, PLGA nanoparticles have also been used to load antipsychotic 
drugs, insulin, hormones, proteins, restenosis drugs and anti-inflammatories, for delivery 
to targeted sites (Hans & Lowman, 2002; Kumari, et al., 2010). 
Apart from wound healing and drug delivery, nanoparticles in medicine are also utilised in 
the development and delivery of vaccines, particularly for treating and preventing cancer. 
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In some vaccines, nanoparticles are used as carriers to deliver the active components to 
stimulate an immune response such as non-specific immune activation or tumour-specific 
immune activation (Sheng & Huang, 2011). These immune responses work together with 
the vaccine by multiple mechanisms to identify and eliminate any cancerous cells that may 
be present or have the potential to invade the immune system. The components of vaccines 
can vary from tumour-specific antigens to DNA and proteins/peptides, and their carriers 
must be appropriate to ensure delivery. Nanoparticles have been shown to be excellent 
carriers, particularly because of easy synthesis and the ability to produce many different 
sizes (Kreuter, 1996; Sheng & Huang, 2011). Larger sized nanoparticles up to 1 μm in 
diameter are ideal for the induction of systemic immunity due to effective internalisation 
by macrophages and dendritic cells. However, smaller nanoparticles, <100 nm in 
diameter, have been shown to provide better immunogenicity compared to larger particles. 
For example, studies by Reddy et al. 2006 and 2007 demonstrated better circulation 
through the lymphatics by smaller nanoparticles (Reddy, Rehor, Schmoekel, Hubbell, & 
Swartz, 2006; Reddy et al., 2007). For vaccine development, nanoparticles that are 
biodegradable polymers, such as PLGA, have shown promising results in the delivery of 
antigens as vaccines (Eldridge, Staas, Meulbroek, Tice, & Gilley, 1991; Singh, et al., 
1997). Similarly, liposomal nanoparticles have shown advantages in attaching to the outer 
surface or encapsulating and delivering DNA and protein vaccines in vitro and in vivo 
(Sheng & Huang, 2011).  
 
Over the last decade, the use of nanoparticles in medicine has also been incorporated in 
medical imaging. In medical imaging, nanoparticles, together with imaging technologies, 
promise to deliver more specific and sensitive detection of diseases for diagnostic and 
therapeutic purposes (Bulte & Modo, 2007). Moreover, as imaging modalities continue to 
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advance, there is also the need to develop and improve tracers or contrast agents that are 
needed for improved resolution and sensitivity. Advances in the development of 
nanoparticles in the field of medicine have produced nanoparticles with improved 
properties and characteristics, which in turn have provided medical imaging with new 
platforms of contrast agents and tracers to complement currently available imaging 
technologies and new imaging technologies (Bulte & Modo, 2007). Nanoparticles can be 
synthesised to display unique chemical properties that can dramatically amplify signal 
changes, making the nanoparticles visible on images, or they can be given physical 
properties that allow selective uptake in vitro and in vivo (Bulte & Modo, 2007; Rudin & 
Weissleder, 2003). As nanoparticles can be utilised to serve many different imaging 
modalities, a great variety of nanoparticles are under investigation for development and 
application in medical imaging, as discussed in greater detail in this chapter. 
1.1.2 Summary of main themes 
 
Nanoparticles are used in a wide variety of applications such as food, cosmetics and 
medicine, providing insight into some of these applications. The use of nanoparticles in 
medicine is emerging, particularly in medical imaging. Over the last decade the use of 
nanoparticles in medical imaging, together with developments in imaging technology, 
began to deliver more specific and sensitive detection of diseases for diagnostic and 
therapeutic purposes. Together with the improvements in medical imaging modalities and 
the discovery of a range of novel nanoparticles, a new platform of contrast agents and 
tracers to complement imaging technologies became possible. 
 
1.2 Imaging technologies 
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1.2.1 Introduction 
 
As discussed in the previous section, nanoparticles can be utilised to serve many different 
purposes including different imaging modalities. Nanoparticles can be synthesised to 
possess unique characteristics that can amplify signals and generate contrast for better 
visualisation. These can be magnetic properties or optical properties that further enhance 
the imaging modality’s signals to provide contrast for better visualisation of anatomy and 
pathology. Moreover, the small size (<100 nm) of nanoparticles allows for improved 
cellular uptake, via passive or active pathways, into various sub-cellular compartments, 
depending on their composition and whether they are conjugated to biomarkers. These 
properties of nanoparticles, along with improved synthesising methods, have opened the 
possibility for specific targeting of molecular and cellular processes using nanoparticles in 
medical imaging. 
 
For targeted imaging to be possible, two prerequisites must be met: firstly, the imaging 
device must have high sensitivity and resolution to be able to image molecular 
interactions, and secondly, there must be target-specific molecular probes. The use of 
nanoparticles in most cases provides the target-specific probes for imaging modalities and 
can help some imaging detectors achieve higher sensitivities. The next section describes 
how nanoparticles are utilised for different imaging modalities, followed by a discussion 
of the ability of nanoparticles to help achieve targeted imaging. 
1.2.2 Imaging technologies and nanoparticles 
 
 
Nanoparticles can be synthesised to possess unique characteristics that can amplify signals 
and generate contrast for better visualisation (Bulte & Modo, 2007; Rudin & Weissleder, 
2003). Magnetic resonance imaging (MRI) uses magnetism to produce images, and the use 
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of magnetic nanoparticles or magnetic compounds can serve to amplify the MRI signal to 
produce contrast for improved visualisation. Magnetic substances used to synthesise 
nanoparticles have either superparamagnetic or paramagnetic properties (Huber, 2005). 
These magnetic properties cause alterations in the MRI signal either by decreasing the 
magnetic resonance signal intensity, producing a dark contrast (superparamagnetic), or by 
increasing the magnetic resonance signal intensity, producing bright contrast 
(paramagnetic) (Huber, 2005). Among the most widely used paramagnetic substances are 
gadolinium compounds, which have been used in MRI to produce contrast in applications 
such as diagnosing pathologies, pre- and post-operation, infection, infarction and 
inflammation (Westbrook, Roth, & Talbot, 2005). several gadolinium products, such as 
Magnevist®, Optimark™, Prohance® and MultiHance®, are commercially available 
(Aime & Caravan, 2009). Although gadolinium agents are frequently used and provide 
signal enhancement, there have been concerns over their safety. Issues such as the possible 
dissociation of gadolinium from its chelating agents in vivo have been suggested, and 
deaths due to nephrogenic systemic fibrosis have been reported in patients (Ergun, et al., 
2006; Erley, et al., 2004; Grobner, 2006; Perazella, 2009; Sam, et al., 2003). As a result, a 
research focus into gadolinium agents is on improving their in vivo stability using 
nanoparticles, and research has also considered the use of compounds other than 
gadolinium for achieving contrast (Perazella, 2009).  
 
Among the superparamagnetic agents, iron-based particles have been the most widely 
used and researched (Gupta & Gupta, 2005). Like gadolinium compounds, there are also 
commercially available iron-based particles, such as Revosist®, Feridex®, Gastromark® 
and Abdoscan® (Lodhia, Mandarano, Ferris, Eu, & Cowell, 2010). These commercial 
iron-based nanoparticles are most useful in imaging the liver, spleen and gastrointestinal 
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lumen. In the pre-clinical setting, iron-based nanoparticles are under development for 
other MRI applications including the lymphatic system, breast, the musculoskeletal system 
and various cancers.  
 
Nanoparticles in medical imaging can also be synthesised with electrical and chemical 
properties that allow them to be visible by modalities such as optical imaging. In optical 
imaging, nanoparticles are utilised in the form of quantum dots, which are made from 
semiconductor materials such as cadmium selenide or zinc selenide. Quantum dots have 
unique optical and electronic properties, such as the emission of photons under excitation 
that are visible to the human eye; moreover, the wavelengths of photon emissions are 
related to the size of the quantum dot, allowing their emission to be tuned to any 
wavelength (Alivisatos, 1996; Qu & Peng, 2002). Quantum dots can also be easily tuned 
beyond visible light to the infra-red or into ultra-violet light (Alivisatos, 1996). The easy 
synthesis of quantum dots of various sizes allows linking of multiple agents such as 
proteins, peptides, and antibodies, and even conjugation of therapeutic agents such as anti-
cancer drugs (Wang, Gao, & Su, 2010). Quantum dots can be easily attached to other 
nanoparticle materials such as magnetic nanoparticles used in MRI or radioisotopes used 
in nuclear medicine, allowing for dual optical MRI imaging or dual optical nuclear 
medicine imaging (Bulte & Modo, 2007). 
 
Another primary aspect of nanoparticles and their application in medical imaging is the 
ability to mediate cellular uptake. The small size (<100 nm) of nanoparticles allows 
cellular uptake, via passive or active pathways, into various sub-cellular compartments 
depending on their composition and conjugated materials. This feature of nanoparticles 
allows imaging modalities such as MRI and optical imaging to utilise their respective 
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nanoparticles (magnetic nanoparticles and quantum dots) to image molecular and cellular 
processes. For example, iron-based nanoparticles can be synthesised to be <100 nm in 
size, highly magnetic in order to amplify the MRI signal and to be conjugated to 
biomarkers. The small size of the iron nanoparticles mediates cellular uptake depending on 
the properties of the biomarker, and the magnetic properties of the iron will allow 
visualisation on the MRI image of the targeted site. Similarly, optical imaging probes can 
also use the same technique to allow imaging of molecular and cellular processes, utilising 
different sized quantum dots to view various wavelengths of different colours. 
 
The ability to image molecular and cellular processes is not a new technology established 
by the development of nanoparticles for medical imaging. In fact, it has been available for 
decades and used by modalities such as nuclear medicine even before the term 
‘nanoparticles’ was defined. As early as the 1970s, nanoparticles such as sulphur colloids 
were labelled to 99mtechnetium (99mTc) for imaging lymph nodes in lymphoscintigraphy 
(Ashburn, Braunwald, Simon, Peterson, & Gault, 1971; Fee, et al., 1978). Magnetic 
nanoparticles were also reported to have the ability to enhance MRI signals in the late 
1970s (Ohgushi, Nagayama, & Wada, 1978), but their use as contrast agents was not 
explored until the mid-1980s (Mendonca Dias & Lauterbur, 1986; Renshaw, Owen, 
McLaughlin, Frey, & Leigh, 1986). During this time, iodinated contrast agents were also 
used for computed tomography (CT) (Havron, Seltzer, Davis, & Shulkin, 1981). Despite 
early discoveries of what are now termed nanoparticles, the last decade has seen 
significant advancement in nanoparticle technology, particularly in relation to synthesis 
methods and conjugation methods available for the attachment of biomarkers. These 
advances have allowed successful utilisation of nanoparticles for imaging molecular and 
cellular processes, particularly for modalities such as MRI and optical imaging 
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(Weissleder, 1999). The use of nanoparticles has helped change the focus of medical 
imaging from anatomical imaging and low-resolution nuclear medicine functional imaging 
to more sophisticated targeted and functional imaging with improved sensitivity and 
specificity (Bulte & Modo, 2007; Weissleder, 1999).  
  
The next section details the concept of targeted imaging in medical technologies and 
describes how nanoparticles have helped play a role in achieving targeted imaging. 
1.2.3 Targeted imaging  
 
As early as 1999, Weissleder reported that medical imaging was expanding its focus from 
anatomical and structural imaging towards targeted molecular and cellular imaging. 
Weissleder believed that significant advances had been made in genomic research, with 
further understanding of the molecular mechanisms of disease processes; thereby, 
discovery of many disease biomarkers was conceivable (Herz, Thomsen, & Yarbrough, 
1997; Pardee, 1997; Weissleder, 1999). In parallel, medical imaging had undergone 
remarkable advances in improving resolution and sensitivity in some modalities (Rudin & 
Weissleder, 2003). With both areas experiencing significant advances, Weissleder 
highlighted that researchers had been able to apply the new discoveries in both fields to 
successfully image new disease markers in the pre-clinical setting (Weissleder, 1999).  
 
Traditionally, in vivo imaging modalities such as MRI, CT and ultrasound (US) have been 
termed anatomical imaging techniques and have relied on imaging gross anatomy, 
physical (absorption, scatting, proton density, relaxation) changes and physiologic (blood 
flow) properties as the main source of contrast for the detection and characterisation of 
diseases (Weissleder, 1999). Nuclear medicine and optical imaging have been termed 
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functional imaging methods and have traditionally relied on low resolution detectors to 
characterise diseases that have been detected by MRI, CT and US. The discovery of new 
biomarkers and molecular mechanisms has made it possible to consider imaging specific 
molecules and molecular processes, utilising new biomarkers, as stated earlier in the 
chapter. For molecular imaging to be possible, it is important to meet two prerequisites: 
first, the detectors must have high sensitivity and resolution to be able to image molecular 
interactions, and second, there must be target-specific molecular probes (Bulte & Modo, 
2007; Rudin & Weissleder, 2003; Weissleder, 1999).  
 
Nuclear medicine, single photon emission computerised tomography (SPECT) and 
positron emission tomography (PET) and optical imaging enable molecular imaging. 
These modalities have high sensitivity compared to modalities such as MRI and CT 
(Rudin & Weissleder, 2003), and it would therefore be useful if molecular imaging could 
be conducted with these modalities only. However, the inherent poor spatial resolution of 
nuclear imaging techniques limits the ability of these modalities to be used routinely in 
targeted imaging (Rudin & Weissleder, 2003). An advance in medical imaging has been 
the introduction of dual imaging modalities by fusing SPECT and or PET with CT or MRI 
to overcome this problem (Beyer, Townsend, Brun, et al., 2000). The introduction of 
PET/CT has markedly improved the effectiveness of imaging with PET, as CT is known 
to have high resolution for identifying anatomical detail (Beyer, et al., 2000). The more 
recent development of PET/MRI also creates a complementary imaging modality, with 
high resolution and high sensitivity, which could be clinically available in coming years. 
This is desirable because MRI does not use ionising radiation and is known to have higher 
resolution and better differentiation of soft tissues compared to CT (Jacobs, & Cherry, 
2001). Another limitation in nuclear medicine and PET is the exposure to ionising 
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radiation, not just of patients but also of sensitive molecular probes, as well as the issue of 
radionuclide decay, which places limitations on the length of time biological processes can 
be imaged. In targeted molecular imaging, longer scanning times may be necessary to 
ensure delivery of the molecular probe to the target. Although nuclear medicine and PET 
have some limitations, the availability of dual modality imaging, combined with the 
discovery of new biomarkers, should in the near future be able to minimise or eliminate 
some of these limitations. The development of nanoparticles has shown promise for 
addressing these issues, providing the possibility of molecular and cellular imaging (Bulte 
& Modo, 2007; Weissleder, 1999).  
 
The next section considers the application of nanoparticles as targeted imaging agents for 
molecular and cellular imaging in modalities such as optical imaging, CT, nuclear 
medicine and PET and MRI. 
1.2.4 Targeted imaging using nanoparticles 
1.2.4.1 Optical imaging 
As discussed previously, optical imaging inherently provides information about molecular 
and cellular processes. In optical imaging, the use of traditional organic fluorophores such 
as free emissive molecules like indocyanine green (ICG) or conjugates of single 
fluorescent dyes to biological targets such as antibodies, proteins, peptides, small 
molecules, nucleic acids, is limited in targeted imaging (Wang, et al., 2010). This is 
primarily due to the small number of biological targets, short circulation half-lives, low 
photo-bleaching thresholds and lack of strong near-infrared (NIR) absorption and emission 
(Ghoroghchian, Therien, & Hammer, 2009; Murray, Kagan, & Bawendi, 2000; Wang, et 
al., 2010). For optical imaging, organic fluorophores are also inherently limited in their 
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ability to generate fluorescent signals at deep tissue depths greater than 1-2cm 
(Ghoroghchian, et al., 2009; Wang, et al., 2010). Semiconductor nanoparticles that are 
quantum dots classify as an important class of inorganic fluorophores, possessing 
characteristics vastly superior to those of organic fluorophores, making them suitable for 
targeted imaging (Wang, et al., 2010).  
 
Quantum dots are nanocrystals made from crystalline clusters of a few hundred to a few 
thousand atoms and are usually composed of atoms from groups II-IV, III-V or IV-VI of 
the periodic table of elements (Alivisatos, 1996; Henglein, 1989). The fluorescence of 
quantum dots is intrinsic, bright, and prolonged, surpassing the resolution and sensitivity 
capability of organic fluorophores and fluorescent proteins. Their small size endows high 
surface-to-volume ratios, making many of their chemical and physical properties 
dominated by the surface. One extraordinary property is that the size of the quantum dot 
depends on the fluorescent emission and wavelength. This enables continuous tuning of 
fluorescent emission from the NIR to the near-ultraviolet region through the visible light 
region by changing the size of the quantum dot (Dabbousi, et al., 1997; Murray, et al., 
2000). In targeted imaging, this property provides significant advantages over other 
nanoparticle imaging systems, as the ‘size effect’ of quantum dots provides the ability to 
utilise a range of quantum dot nanoparticles for simultaneous detection of multiple 
biomarkers. The large surface area of quantum dots allows not only the conjugation of 
almost any biomarker but also the conjugation of multiple diagnostic (such as MRI 
magnetic nanoparticles or radioisotopes) or therapeutic agents (Biju, Itoh, & Ishikawa, 
2010; Bulte & Modo, 2007; Medintz, Uyeda, Goldman, & Mattoussi, 2005; Wang, et al., 
2010). This affords the opportunity for a range of research in targeted imaging and allows 
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the development of multi-functional nanoparticles for multi-modality imaging and 
integrated imaging and therapy.  
 
Despite the immense potential of quantum dots in targeted imaging, one of the drawbacks 
of the semiconductor nanocrystal is its potential toxicity. Most quantum dots are made 
from semiconductor materials such as cadmium, selenide and tellurium, all of which are 
toxic in their elemental state (Bertin & Averbeck, 2006; Taylor, 1996). As a result of 
potential toxicity, there are currently no clinically available NIR-emissive agents for 
optical imaging with ideal properties for human use (Ghoroghchian, et al., 2009). 
Nevertheless, optical imaging probes are available in the preclinical setting, using 
preclinical optical imaging scanners, and have advanced our understanding of molecular 
and cellular processes (Ghoroghchian, et al., 2009). To address safety concerns, research 
efforts have been reported focusing on producing quantum dots with less toxic materials 
such as zinc selenide, zinc sulphide, indium arsenide and indium phosphide, without 
compromising conjugation or optical properties (Xie, Chen, Chen, & Peng, 2008). 
Research efforts have also been directed towards using appropriate ligands, surface shell 
coatings and quantification of dosages for toxic materials like cadmium, selenide and 
tellurium, to reduce or even eliminate toxicity (Xie, et al., 2008).  
 
Quantum dot nanoparticles have applications as fluorescent labels for a range of 
bioanalytical purposes such as detection of DNA, proteins, molecules and cellular 
labelling, but their most widely used application is in fluorescent imaging. For example, 
quantum dots have been utilised for targeted imaging using fluorescent imaging 
techniques for cellular tracking in vitro (Jaiswal, Mattoussi, Mauro, & Simon, 2003; Wu, 
et al., 2003), identifying cancerous cells (Ko, et al., 2009; Orndorff & Rosenthal, 2009; 
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Yezhelyev, et al., 2007), locating infection (Li, et al., 2009), and nicotinic receptors 
(Orndorff, Warnement, Mason, Blakely, & Rosenthal, 2008). The use of quantum dots for 
in vivo targeted imaging is related to four main aspects: biodistribution imaging, vascular 
imaging, cell tracking and tumour imaging (Smith, Duan, Mohs, & Nie, 2009; Wang, et 
al., 2010). For most in vivo applications of targeted imaging, nanoparticles are 
administered intravenously, and many studies have therefore focused on investigating the 
interaction of a variety of quantum dots with blood, biodistribution and excretion by the 
body (Ballou, Lagerholm, Ernst, Bruchez, & Waggoner, 2003; Duconge, et al., 2008; 
Fischer, Liu, Pang, & Chan, 2006; Liu, et al., 2007; Sandros, Behrendt, Maysinger, & 
Tabrizian, 2007). Studies have also investigated the use of quantum dots for imaging the 
lymphatic (Kim, et al., 2004) and blood circulatory systems (Khullar, Frangioni, Grinstaff, 
& Colson, 2009; Larson, et al., 2003; Smith, Duan, Mohs, & Nie, 2009). Quantum dots are 
advantageous for tumour-targeted imaging because of their excellent fluorescent 
properties and their small size. Akerman and colleagues (2002) initiated the application of 
quantum dots in tumour imaging in vivo (Akerman, Chan, Laakkonen, Bhatia, & 
Ruoslahti, 2002). In that study, quantum dots were coated with peptides and injected 
intravenously into tumour-bearing mice. The vasculature of the tumour sections was 
imaged with fluorescence microscopy, showing that the quantum dots localised 
specifically within the tumour vasculature. Other studies have subsequently shown uptake 
and localisation of conjugated-quantum dots in various tumours expressing particular 
biomarkers (Gao, Cui, Levenson, Chung, & Nie, 2004; Papagiannaros, et al., 2010; Yang, 
et al., 2009; Yong, Roy, Law, & Hu, 2010; Yu, et al., 2007; Zheng, Chen, DeLouise, & 
Lou, 2010).  
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Targeted imaging with quantum dots holds great promise for translation into the clinical 
setting, but further research is needed to address the toxicity component of quantum dots 
and to ensure that optimal fluorescence can be detected within in vivo systems.  
1.2.4.2 Computed tomography (CT) 
CT has primarily been regarded as a structural imaging modality because it can identify 
anatomical patterns and provide basic information regarding the size, location and spread 
of certain diseases based on endogenous contrast (Bulte & Modo, 2007). CT also uses 
non-specific, externally administered contrast agents to enhance structures between 
anatomical compartments. Most of the contrast agents for CT are iodine based, being very 
effective in attenuating and absorbing x-rays. The conjugation of iodine-based contrast 
agents to antibodies is limited due to the lack of surface functional groups available for 
stable conjugation (Bulte & Modo, 2007; Tilcock, 1999). This also results in short 
imaging times due to rapid clearance by the kidneys, and further suggests that targeted 
imaging is limited (Bulte & Modo, 2007; Tilcock, 1999). 
 
Liposomal nanoparticles in medical imaging were introduced in the 1990s, and for CT 
contrast agents, new methods of liposomal production were discovered that could entrap 
iodine (Bulte & Modo, 2007). These particles were termed immunoliposomes. This 
technique introduced major advantages, as the liposomal coating allowed longer blood 
circulating times so that the contrast agents could be useful as blood pool agents, and 
permitted the attachment of antibodies to the surface, suggesting that targeted imaging for 
CT could be possible (Allen, 1994; Leander, Höglund, Kloster, & Børseth, 1998; Tilcock, 
1999). At the preclinical level, some studies have used immunoliposomes as CT contrast 
media to image cells of interest (Torchilin, 2005). One example is the work of Johnston, 
Lee, and Hawthorne (2003), who studied tissue-specific enhancement in CT using a small 
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(approximately 100 nm) unmodified iohexol carrying CT immunoliposomes. They 
examined the targeting ability of the immunoliposomes to three different targeting 
antibodies (anti-FasL, anti-CD5, anti-FcR) to cell surface proteins. The results 
demonstrated CT contrast enhancement only in the targeted areas delivered by the 
conjugated liposomes.  
 
Gold nanoparticles have also been used for targeted imaging in CT. Gold as a metal 
induces stronger x-ray attenuation than iodine and contains unique physical, chemical and 
biological properties which make it a better candidate for generating CT contrast (Kim, 
Park, Lee, Jeong, & Jon, 2007). Moreover, gold nanoparticles have flexibility in activation 
of available functional groups for conjugating biomarkers and have demonstrated 
biocompatibility in vivo (Connor, Mwamuka, Gole, Murphy, & Wyatt, 2005; Hauck, 
Ghazani, & Chan, 2008). Various studies have shown biomarkers conjugated to the 
surface of gold nanoparticles and demonstrated targeted imaging (Eck, Nicholson, 
Zentgraf, Semmler, & Bartling, 2010;  Ji, 2010; Popovtzer et al., 2008; Wang, et al., 
2011). Popovtzer et al. (2008) used gold nanorods conjugated to the UM-A9 antibody 
which is specific for squamous cell carcinoma (SCC) of the head and neck. After 
incubation of conjugated gold nanorods with SCC positive cells, distinguishable x-ray 
attenuation could be seen on the targeted SCC cancer cells in the head and neck regions. 
Similarly, Eck et al. (2010) conjugated anti-CD34 antibodies to gold nanoparticles to 
visualise CT contrast in lymph nodes in live mice. They successfully demonstrated in vivo 
contrast enhancement of the peripheral lymph nodes. Like the use of quantum dots for 
optical imaging, the use of CT contrast agents such as gold in molecular imaging is still at 
the preclinical level, with the potential for clinical applications. 
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1.2.4.3 Nuclear medicine (PET and SPECT) 
The use of nanoparticles in nuclear medicine imaging techniques was utilised as early as 
the 1970s, when sulphur colloids were tagged to 99mTc for lymph node imaging in cancer 
staging (Fee, et al., 1978). Nuclear medicine imaging techniques such as planar 
scintigraphy, SPECT and PET use the tracer technique to provide information on function 
and the physiology of diseases, with very high sensitivity. The use of nanoparticles 
enhanced nuclear medicine imaging techniques by allowing easy attachment of 
biomarkers to radionuclides for specific imaging of certain diseases. One example is the 
study by Hu et al. (2007), who compared the use of targeted perfluorocarbon (PFC) 
nanoparticles loaded with 10 111Indium (111In) atoms to one targeted atom of 111In. In this 
study, integrin αvβ3-targeted 111In-labeled PFC nanoparticles were reported for the 
detection of tumour angiogenesis in New Zealand white rabbits implanted with Vx-2 
tumours. Hu and colleagues found that targeted nanoparticles bearing approximately 10 
111In atoms per particle had better tumour-to-muscle ratio than those with approximately 
one 111In atom per particle. These results suggested that the use of the PFC nanoparticles 
allowed better tumour-to-muscle ratios due to the greater loading of radionuclides 
compared to conventional loading of only one radionuclide bound to a biomarker.  
 
Similarly, liposomal nanoparticles have been developed to load or surface label 
radionuclides for applications in areas such as tumour targeting, lymph node tracking, 
location of infection and inflammation (Bulte & Modo, 2007). Liposomal nanoparticles 
have great advantages over other nanoparticles as they are completely biocompatible, they 
can entrap any drug or diagnostic agent either inside or on their surface, are biologically 
stable, and can be used to deliver drugs into cells. In targeting tumours, current 
formulations of liposomal nanoparticles have lipid derivatives of the hydrophilic polymer 
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PEG. PEG prolongs the peripheral blood circulating times of nanoparticles in vivo, 
allowing localisation at tumour sites (Gabizon, Price, Huberty, Bresalier, & 
Papahadjopoulos, 1990; Goins, Klipper, Rudolph, & Phillips, 1994; Huang, et al., 1992). 
PEG-liposomal nanoparticles have successfully been labelled with radionuclides such as 
67Gallium (67Ga), 111In and 99mTc (Belhaj-Tayeb et al., 2003; Goins, et al., 1994; Goins & 
Phillips, 2003; Zheng & Tan, 2004). Furthermore, numerous detection studies at the 
preclinical level have reported accumulation of PEG-liposomes labelled with 111In for 
targeting lung cancer (Harrington, et al., 2001), head and neck cancers (Harrington, et al., 
2001) and metastatic brain cancer (Koukourakis, et al., 2000).  
 
The use of nanoparticles in nuclear medicine facilitates the development of dual imaging 
contrast agents for dual imaging modalities like PET/CT, PET/MRI and nuclear medicine 
SPECT or PET/optical imaging. For targeted imaging, the use of dual modalities is 
valuable as two imaging methods can provide a range of diagnostic information (Jennings 
& Long, 2009). For example, it is difficult to accurately quantify a fluorescence signal in 
living subjects with fluorescence imaging alone, particularly in deep tissues. MRI has high 
resolution and good soft-tissue contrast but very low sensitivity, whereas radionuclide-
based imaging techniques are very sensitive but have relatively poor spatial resolution 
(Massoud & Gambhir, 2003). A combination of multiple molecular imaging modalities 
can offer synergistic advantages over one modality alone (Jennings & Long, 2009). Liang 
et al. (2010) used streptavidin nanoparticles linked to biotinylated anti-HER2 herceptin 
antibody as a marker of breast cancer, using 111In and a fluorophore for targeted imaging 
by dual optical and SPECT imaging. The results showed high accumulation of the anti-
Her-indium-fluorophore-streptavidin nanoparticles at the tumour site in nude mice bearing 
SUM190+ breast tumours in both the optical and SPECT imaging modalities. Similarly, 
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U87MG human glioblastoma cells and mice bearing U87MG tumours were targeted using 
an integrin αvβ3-conjugated quantum dot probe conjugated to 64Copper (64Cu) to permit 
both optical and PET imaging (Cai, Chen, Li, Gambhir, & Chen, 2007). The results 
confirmed the localisation of the probe within the vasculature of the tumour, which was 
indicated by the overlay of the quantum dot signals. Moreover, quantitative probe uptake 
analysis was possible by the PET probe component.  
 
PET and MRI agents have been conjugated to produce images that have the high 
resolution of MRI and the high sensitivity of PET. One example of these bifunctional 
nanoparticle probes was demonstrated in a study conducted by Lee et al. (2008). The 
purpose of the study was to conjugate RGD peptides to iron oxide nanoparticles and 64Cu 
to image tumour integrin vβ3 expression. The results indicated that both PET and MRI 
scanners could detect the conjugated-nanoparticle-probes, which could allow earlier 
detection of tumours with both a higher degree of accuracy and further insight into the 
molecular mechanisms.  
 
Nanoparticles have been used in nuclear medicine imaging techniques for many years. The 
results from preclinical studies show promise in their applications, particularly for tumour-
targeted applications, but there are fundamental issues related to radiation dose, toxicity, 
availability and reproducibility that have limited translation to the clinical setting (Hahn, 
Singh, Sharma, Brown, & Moudgil, 2011; Jennings & Long, 2009). Nanoparticle 
technology advances have provided dual imaging probes, which are particularly useful 
with dual modality imaging. There has been increased research for almost a decade now 
into the development of dual imaging scanners, but progress in this area has been greatly 
hampered by technical problems and cost issues (Jennings & Long, 2009). However, the 
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recent availability of dual imaging scanners affords the possibility of imaging and 
validation of dual imaging probes. 
1.2.4.4 Magnetic resonance imaging (MRI) 
MRI has significantly benefited from the application of nanoparticles, particularly metal-
based nanoparticles. The properties of metal-based nanoparticles have provided a platform 
for the development and application of nano-targeting agents that be used in a variety of 
MRI applications. Magnetic nanoparticles that have been developed can permit contrast-
enhanced MRI, targeted imaging and dual imaging and therapy (Bulte & Kraitchman, 
2004; Mulder, Strijkers, vanTilborg, Griffioen, & Nicolay, 2006). The advantage of MRI 
compared to other imaging modalities lies in its inherent high spatial resolution which 
makes it easier to visualise molecular and cellular targets. Other advantages include the 
use of non-ionising radiation and the ability to conduct longitudinal imaging. As with 
other imaging techniques, the use of nanoparticles in MRI was developed to achieve high 
tissue contrast and to improve imaging sensitivity. Some of the commonly used 
nanoparticles for targeted MRI are based on metal nanoparticles such as iron oxides and 
gadolinium, and newer agents are based on chemical exchange saturation transfer (CEST) 
and paramagnetic chemical exchange saturation transfer (PARACEST) imaging 
techniques (Hahn, et al., 2011).  
 
Larger iron oxide particles, the first generation of nanoparticles, have been used in MRI 
for almost 40 years (Berry & Curtis, 2003; Gilchrist, et al., 1957). Some of these first 
generation nanoparticles like iron-based particles have been commercialised for non-
targeted imaging to provide contrast enhancement in the liver and spleen and the 
gastrointestinal lumen (Bonnemain, 1998; Reimer & Balzer, 2003). Over the last decade 
there have been major advances in the field of nanotechnology, such as the synthesis of 
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smaller sized nanoparticles not only with iron oxide but with other organic and inorganic 
compounds (Huber, 2005). As a result, there has been a shift towards the synthesis and 
application of smaller (<100 nm) nanoparticles in MRI. Initial applications of smaller 
nanoparticles in MRI utilised iron oxides and it was reported that a decrease in size 
prolonged the blood half-life of the iron oxide nanoparticles (Weissleder, et al., 1990). 
This discovery brought the realisation that targeted imaging could be possible with MRI, 
as longer blood circulating times could allow for localisation in targeted structures 
(Weissleder, et al., 1990). It was also recognised that smaller iron oxide nanoparticles 
demonstrated increased uptake by macrophages in lymph nodes, suggesting that non-
specific targeting of the lymph nodes was occurring due to a change in the physical 
properties of the nanoparticles (Harisinghani, et al., 2003; Sigal, et al., 2002). These 
results fuelled further research into the use of small iron oxide nanoparticles in lymph 
node tracking without the need for specific conjugated biomarkers (Harisinghani, et al., 
2003; Sigal, et al., 2002; Weissleder, et al., 1990). 
 
Nanoparticles with incorporated gadolinium have also been developed for MRI. 
These nanoparticles are based on chelated-gadolinium agents that are currently used in 
routine clinical practice as extracellular, blood-pool or hepatobiliary agents to achieve 
tissue contrast (Burtea, Laurent, Elst, & Muller, 2008). Chelated-gadolinium agents have 
been widely used due their favourable magnetic properties that provide a ‘bright’ or 
positive contrast, which is easily distinguished on the MRI image. Although gadolinium-
based contrast agents for MRI are chelated to ligands and may not display toxicity caused 
by the heavy metal, there are still concerns over its use, as possible in vivo decomplexation 
and transmetallation by endogenous ions can occur (Ersoy & Rybicki, 2007). Besides the 
potential toxicity, gadolinium-based contrast agents cannot be used for targeted imaging 
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because they have rapid clearance times. Gadolinium contrast agents have reported 
peripheral blood clearance times of approximately 15-90 minutes, which for targeted 
imaging may not give sufficient localisation and contrast enhancement at the preferred site 
(Na, Song, & Hyeon, 2009). Gadolinium as a metal has therefore been incorporated into a 
variety of nanoparticles for targeted imaging. Carbon nanotubes, mesoporous silica, 
polymers and perfluorocarbon nanoparticles all have the ability to load large amounts of 
gadolinium within the nanoparticles, giving the possibility of targeted imaging with high 
levels of MRI contrast (Hahn, et al., 2011; Shao, et al., 2010; Taylor, et al., 2008).  
 
Another recent development of nanoparticles in MRI is as contrast agents for CEST 
imaging techniques. CEST agents can image metabolites in biological tissues as well as 
anatomy. Upon application of a suitable RF pulse, CEST agents reduce the intensity of the 
bulk water signal by saturation transfer through their chemical exchange sites (Terreno, 
Castelli, Viale, & Aime, 2010; Viswanathan, Kovacs, Green, Ratnakar, & Sherry, 2010). 
CEST contrast can originate endogenously from sugars, amino acids, nucleosides and 
other diamagnetic molecules (DIACEST), thereby making it possible to image molecular 
changes (Terreno, et al., 2010; Viswanathan, et al., 2010). CEST contrast depends on the 
frequency difference (Δω) between the protons associated with the contrast agent and 
water (Terreno, et al., 2010). As there is only a small frequency difference (<5 ppm) 
between exchangeable protons of the contrast agent and water (Na, et al., 2009), it is 
difficult to visualise contrast on the MRI image. One approach to achieve more contrast 
would be to use stronger magnetic fields to increase Δω. Unfortunately, high field 
magnetic imaging is currently suitable for preclinical studies only, making it difficult to 
employ CEST contrast agents in clinical settings. Consequently there has been research 
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into the generation of more efficient contrast agents, such as PARACEST (Na, et al., 
2009).  
 
Paramagnetic complexes like PARACEST agents are lanthanide-based and therefore 
have larger Δω than CEST molecules (Na, et al., 2009; Terreno, et al., 2010). Like 
gadolinium, PARACEST agents can be easily loaded within various nanoparticles such as 
liposomes (Aime, Castelli, & Terreno, 2005), perfluorocarbon and europium ions, which 
can produce large chemical shifts and allow for targeted imaging (Na, et al., 2009). The 
use of CEST and PARACEST imaging techniques seems to be promising, particularly in 
the area of targeted imaging. However, before CEST and PARACEST imaging techniques 
can be developed in the preclinical setting and translated to the clinical setting a series of 
technical challenges need to be overcome. These challenges include the development of 
new imaging sequences that permit CEST imaging (Terreno, et al., 2010) and more 
sensitive and specific CEST imaging agents. 
 
New generation iron oxide nanoparticles that are less than 100nm in diameter have 
been the most widely researched in the preclinical setting, particularly for targeted 
imaging. This is primarily due to their proven biocompatibility (Schwertmann & Cornell, 
1991), magnetic properties such as superparamagnetism (Huber, 2005), variety of 
synthesis processes (Laurent, et al., 2008), versatility in their potential application to 
targeted imaging, and ability to provide negative contrast. Iron oxide nanoparticles have 
been used in MRI for applications such as non-specific contrast, some targeted imaging in 
oncology, drug delivery for dual imaging and therapy, and in the facilitation of inducing 
hyperthermia for ablation of tumours (Gupta & Gupta, 2005; Hahn, et al., 2011; Huber, 
2005; Shubayev, Pisanic, & Jin, 2009).  
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As mentioned earlier in this section, iron oxide nanoparticles have been used as non-
specific contrast agents since the early 1970s (Bonnemain, 1998; Reimer & Balzer, 2003). 
The development of smaller iron oxide nanoparticles and their applications suggested long 
blood circulating times, indicating that targeted imaging could be possible (Weissleder, et 
al., 1990). Along with the initial reports of smaller iron oxide nanoparticles, it was also 
noted that there was increased uptake by macrophages in the lymph nodes, fuelling further 
research and eventually clinical trials of the use of iron oxide nanoparticles for lymph 
node imaging (Harisinghani, et al., 2003; Sigal, et al., 2002). Further research into smaller 
iron oxide nanoparticles demonstrated targeting imaging for a range of pathologies such as 
central nervous system (CNS) diseases where nanoparticles offered a variety of 
transportation mechanisms to deliver CNS-based drugs as well utilisation for MRI 
(Tysiak, et al., 2009; Ulbrich, Hekmatara, Herbert, & Kreuter, 2009; Veiseh, et al., 2009; 
Zhang & Pardridge, 2001).  
 
In targeted tumour imaging there have been reports of iron oxide nanoparticles 
coated in dextran and conjugated to an anti-human E-selectin antibody (Kang, Josephson, 
Petrovsky, Weissleder, & Bogdanov, 2001; Reynolds, et al., 2006). Kang et al. (2001) 
demonstrated that E-selectin positive cells, which are found in vascular rich areas such as 
inflamed tissue and tumours, could be targeted. Another antigen that has been targeted for 
tumour imaging using iron oxide nanoparticles in MRI is underglycosylated mucin-1 
antigen (uMUC-1) (Moore, Medarova, Potthast, & Dai, 2004). uMUC-1 is one of the early 
hallmarks of tumourigenesis and is over-expressed and underglycosylated on almost all 
human epithelial cell adenocarcinomas, non-epithelial cancer cell lines, as well as 
haematological malignancies such as multiple myeloma and some B-cell non-Hodgkin’s 
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lymphomas (Avichezer, Taylor-Papadimitriou, & Arnon, 1998; Burdick, Harris, Reid, 
Iwamura, & Hollingsworth, 1997; Dyomin, et al., 2000; Nacht, et al., 1999; Oosterkamp, 
Scheiner, Stefanova, Lloyd, & Finstad, 1997; Treon, et al., 1999). The ability to target 
uMUC-1 expression could potentially aid in screening prospective patients for early 
cancer detection and in monitoring the efficacy of drug therapy. Other carcinomas targeted 
by iron oxide nanoparticles have included but are not limited to human epidermal growth 
factor receptor 2 (HER2) positive markers for colon (Toma, et al., 2005) and breast 
cancers (Chen, et al., 2009), hepsin for prostate cancer (Kelly, et al., 2008), bombesin 
peptide conjugate for pancreatic cancer (Montet, Weissleder, & Josephson, 2006) and 
183B2 monoclonal antibody for ovarian cancer (Quan, et al., 2010). 
 
Another application for MRI iron oxide nanoparticles is in stem cell tracking. Stem 
cells have been utilised in many clinical trials around the world for the potential treatment 
of blood disorders, tissue regeneration, stroke and myocardial infarction (Fermand, et al., 
1998; Wollert, et al., 2004). Generally, stem cells are tracked using invasive 
immunohistochemical analysis methods from tissues in small animals (Villa, et al., 2010). 
For pre-clinical and clinical trials, however, it is necessary for non-invasive techniques to 
evaluate the therapeutic effect and grafting location to rule out any serious side effects. 
Due to the inherent high resolution and superb soft tissue differentiation of MRI, tracking 
the fate of stem cells is potentially feasible without the use of ionising radiation and toxic 
materials (Villa, et al., 2010). Together with the proven biocompatibility of iron oxide 
nanoparticles, the use of MRI and iron oxide nanoparticles could provide a likely platform 
for labelling stem cells and then tracking their fate in vivo. Some applications have been in 
tracking iron oxide labelled human umbilical mesenchymal stromal cell-derived Schwann 
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cells (HUMSC-SC) in the brain and spinal cord (Xu, et al., 2010) and mesenchymal stem 
cells (MSCs) for tracking hepatocyte liver transplantation (Shi, et al., 2010). 
 
1.2.5 Summary of preceding themes 
 
So far this thesis has presented the theme that nanoparticles are used in medical 
imaging modalities due to their physical properties which give them the potential to assist 
in the diagnosis and treatment of disease.  
 
One property of nanoparticles examined is the capacity for signal amplification and 
image contrast in various imaging modalities. Nanoparticles can be synthesised to contain 
electrical and chemical properties that allow them to be visible by modalities such as 
optical imaging. In optical imaging, nanoparticles are used in the form of quantum dots 
that have unique optical and electronic properties, allowing their emissions to be tuned to 
any wavelength. Similarly in MRI, signals are produced using magnetism, and the use of 
magnetic nanoparticles amplifies the MRI signal, producing image contrast. 
 
Another property of nanoparticles discussed is the possibility of synthesising 
various sizes. For targeted imaging, sizes less than 100 nm in diameter are of particular 
interest for cellular targeting. Sizes less than 100 nm allow cellular uptake, via passive or 
active pathways, into various subcellular compartments depending on their composition 
and conjugated materials.  
 
Finally, the use of nanoparticles in targeted molecular and cellular imaging was 
discussed. With the small size of nanoparticles and their various electrical, chemical and 
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magnetic properties, cellular targeting or targeted imaging by imaging modalities such as 
MRI, CT, optical imaging and nuclear medicine was reviewed. 
 
Comparison of the uses of nanoparticles for targeted imaging within the different 
imaging modalities suggests that MRI offers the greatest potential. This is because 
quantum dots in optical imaging, liposomal or gold nanoparticles in CT are still at the pre-
clinical level. Nanoparticles in nuclear medicine have contributed to more sophisticated 
and new probes, which however currently lack appropriate spatial resolution capabilities. 
In MRI, nanoparticles, particularly iron oxide based nanoparticles, have demonstrated 
potential in targeted imaging, particularly for applications in stem cell tracking and tumour 
targeting. 
 
Consequently, the next theme in this thesis relates to the evidence regarding the 
use of iron oxide nanoparticles in MRI and their optimal characteristics needed to produce 
contrast and to allow targeted imaging, and their in vivo biodistribution. 
 
1.3 Iron oxide nanoparticles and magnetic resonance imaging 
 
1.3.1 Introduction 
 
To ensure that contrast is produced and that targeted imaging can occur with the use of 
iron oxide nanoparticles, it is essential that the nanoparticles display a range of 
characteristics (Gupta & Gupta, 2005). The next section examines the required 
characteristics of iron oxide nanoparticles to generate contrast and be utilised for targeted 
molecular and cellular imaging. It also discusses the principles of MRI and iron oxide 
nanoparticle contrast agents.  
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1.3.2 Generating contrast in MRI  
 
1.3.2.1 Basic Principles of MRI 
The principles of MRI signals rely on the spinning motion of hydrogen nuclei present in 
biological tissues (Weishaupt, Köchli, & Marincek, 2003). Hydrogen nuclei are used in 
MRI due to their abundance in the body and because the solitary proton of the hydrogen 
nucleus gives it a relatively large magnetic moment. This means that the positively 
charged proton spins around the hydrogen (Figure 1.1) and therefore the hydrogen nucleus 
has a small magnetic field around it with a north and south pole of equal strength, 
represented by a magnetic moment (Weishaupt, et al., 2003; Westbrook, et al., 2005). In 
the absence of a magnetic field, the magnetic moments of the hydrogen nuclei are 
randomly orientated (Figure 1.2 a). When they are in an external magnetic field, some of 
the magnetic moments of the hydrogen nuclei align parallel with the magnetic field (in the 
same direction) and some align anti-parallel (in the opposite direction) (Figure 1.2 b) 
(Weishaupt, et al., 2003; Westbrook, et al., 2005). This orientation of the magnetic 
moments of the hydrogen nuclei is governed by the quantum theory described by Max 
Planck in the 1900s, and is related to low and high energy nuclei (Westbrook, et al., 2005). 
The factors that affect the alignment, parallel or anti-parallel, of hydrogen nuclei are 
related to the strength of the external magnetic field and the thermal energy level of the 
nuclei (Brown & Richard Semelka, 2005; Westbrook, et al., 2005). Due to the lack of 
control over thermal energy nuclei in clinical applications, this is not discussed further in 
this thesis.  
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Hashemi, Bradley and Lisanti (2004) 
 
Figure 1. 1 A spinning charged particle hydrogen nucleus generating a magnetic field  
The positively charged proton around the hydrogen spins, generating a small magnetic 
field. This figure is extracted from Hashemi et al. (2004).  
 
 
 
 
 
 
 
 
 
Figure 1. 2 Alignment of hydrogen nuclei in the absence and presence of a magnetic field  
This figure illustrates (a) the random orientation of hydrogen nuclei in the absence of a 
magnetic field, and (b) the alignment of hydrogen nuclei in the presence of an external 
magnetic field. This figure is extracted from Westbrook et al. (2005). 
 
The net magnetic moments of the hydrogen nuclei are relatively low, and a 
radiofrequency (RF) pulse applied at the Larmor frequency produces a net magnetisation 
which can be imaged on MRI (Weishaupt, et al., 2003). The external magnetic field causes 
the magnetic moment of the hydrogen nuclei to spin around the magnetic field at a speed 
(a) (b) 
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of the precessional frequency which is determined by the Larmor equation (Brown & 
Richard Semelka, 2005; Weishaupt, et al., 2003). When RF pulses are applied to the nuclei 
at the Larmor frequency, these nuclei gain energy by absorbing the energy from the pulses 
(Brown & Richard Semelka, 2005; Weishaupt, et al., 2003). This action is termed 
resonance, and is a phenomenon that occurs when an object is exposed to an oscillating 
perturbation that has a frequency close to its own natural frequency, which causes the 
nucleus to gain energy from the external source (Weishaupt, et al., 2003; Westbrook, et 
al., 2005). The resonance that occurs is excitation and the magnetic resonance signal is 
produced when the RF signal is turned off. When this happens the hydrogen nuclei lose 
the energy given to them by relaxation and they try to realign with the external magnetic 
field. During relaxation the hydrogen nuclei give up absorbed RF energy, and concurrently 
the magnetic moments lose their coherency due to de-phasing. This gives rise to T1 
recovery, which is caused by the nuclei giving up their energy to the surrounding 
environment or lattice, and is termed spin lattice relaxation (Westbrook, et al., 2005). The 
rate of recovery of the nuclei is exponential and is called the T2 relaxation time. T2 decay 
occurs when nuclei exchange energy with neighbouring nuclei, and is termed spin-spin 
relaxation or T2 relaxation (Westbrook, et al., 2005).  
 
The RF pulse is controlled by parameters of the pulse sequences. Factors such as 
repetition time (TR) control the time and relaxation from the application of one RF pulse 
to the next RF pulse for each slice and is measured in milliseconds (ms) (Westbrook, et al., 
2005). The TR determines the amount of T1 relaxation that occurs. The echo time (TE) is 
the time from the application of the RF pulse to the peak of the signal induced. The TE 
determines how much decay of transverse magnetisation occurs, and therefore controls the 
amount of T2 relaxation that occurs, in ms. Overall, the magnitude and timing of the RF 
Chapter 1 - Introduction 
   33
RF pulse along with the external magnetic field strength form part of the MRI signal and 
its generation. 
 
1.3.2.2 Contrast  
The term ‘contrast’ refers to image contrast and is related to the relaxation rates that 
produce different levels of black, white and grey on an MRI image. Contrast is essential in 
separating and differentiating between anatomies as well as identifying pathologies. The 
ability to produce contrast depends on differences in the relaxation rates in various tissues 
in vivo, and external agents are administered to affect the MRI signals such as T1 and T2 
rates (Westbrook, et al., 2005). In various tissues, MRI pulse sequences such as T1 and T2 
weighted imaging can be created which alter the way particular organs are imaged. There 
are also other sequences such as T2 star (T2*) and proton density contrast, which are not 
discussed here. In a T1 weighted image, fat has a high MRI signal and therefore appears 
bright, whereas water has a low signal and appears dark (see Figure 1.3 a). Conversely, on 
a T2 weighted image, water has a high signal and appears bright and fat has a low signal 
and appears dark (see Figure 1.3 b). Therefore, the differences in appearance of organs and 
tissues are due to T1 and T2 weighted sequences that can provide contrast for detecting 
certain pathologies. In tumour imaging, tumours have low water content and therefore a 
T2 weighted image would show an area of high signal, appearing bright, allowing the 
tumour to appear different from normal structures on the MRI image (Westbrook, et al., 
2005). However, some pathologies may be difficult to differentiate and characterise from 
normal structures, therefore external enhancement agents can be used to selectively affect 
either T1 or T2 relaxation times in tissues (Westbrook, et al., 2005).  
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Westbrook et al. 
(2005). 
 
Figure 1. 3 Examples of T1 and T2 weighted images  
This figure illustrates (a) a T1 weighted axial image of the brain, where fat has a high MRI 
signal appearing bright and water has a low signal appearing dark, and (b) a T2 weighted 
image of the brain, where water has a high signal and appears bright and fat has a low 
signal and so appears dark. This figure is extracted from Westbrook et al. (2005). 
 
Some contrast agents shorten T1 relaxation times and appear bright on T1 
weighted images; other contrast agents shorten T2 relaxation times and appear dark on T2 
weighted images. The mechanism of action of contrast agents is primarily related to 
dipole-dipole interactions and magnetic susceptibility (Weishaupt, et al., 2003; Westbrook, 
et al., 2005). Contrast enhancement agents have large magnetic moments and in the 
presence of water protons cause local magnetic field fluctuations (Weishaupt, et al., 2003; 
Westbrook, et al., 2005). In the case of T1 weighted imaging, the molecular movement 
reduces the T1 relaxation time, appearing bright on the MRI image. Magnetic 
susceptibility is a property of matter and is defined as the ability of the external magnetic 
field to affect the nucleus of an atom and magnetise it (Weishaupt, et al., 2003; 
Westbrook, et al., 2005). A substance with high positive magnetic susceptibility can affect 
the T2 decay by shortening the relaxation time, causing a darkening effect on T2 weighted 
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images. Examples of magnetic susceptibility effects include diamagnetism, 
paramagnetism, superparamagnetism and ferromagnetism (Weishaupt, et al., 2003; 
Westbrook, et al., 2005). For this thesis, only paramagnetism and superparamagnetism are 
briefly discussed in the following section. 
 
Paramagnetic substances are known to have positive magnetic susceptibilities and 
are suitable as MRI contrast agents. Gadolinium (Gd) is an ideal element as it has seven 
unpaired electrons and a positive magnetic moment causing any water protons in its 
presence to reduce its T1 and T2 relaxation (Na, et al., 2009). Therefore, on a T1 weighted 
image, water causes increases in the signal intensity, appearing bright. As mentioned 
previously in this chapter, gadolinium in its elemental state is highly toxic and for in vivo 
applications it is usually chelated to compounds that potentially inhibit its toxic effects. 
Although some chelated-gadolinium agents do not show toxicity, there are still concerns 
over its safety, due to reported deaths and nephrogenic systemic fibrosis after its 
administration (Ersoy & Rybicki, 2007). Gadolinium-chelates are currently the most 
commonly used contrast agents in MRI, but due to safety concerns significant efforts are 
being made to produce more stable products (Hahn, et al., 2011; Perazella, 2009). Some of 
these, mentioned earlier in this chapter, include the incorporation of gadolinium into 
nanoparticles and the development of other contrast agents like T2 weighted iron oxide 
nanoparticle contrast agents (Hahn, et al., 2011; Perazella, 2009).  
 
Superparamagnetic agents have large magnetic moments, and in the presence of 
nearby hydrogen atoms shorten their relaxation times or reduce the signal intensity, 
producing a darkening contrast effect on the MRI image (Na, et al., 2009). The most 
commonly used superparamagnetic agent is iron oxide. As mentioned previously, iron 
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oxides are commercially available and are used in imaging the liver, spleen and 
gastrointestinal lumen. Unlike gadolinium, iron is found naturally in the body and the 
breakdown of iron oxide contrast agents follows the biological iron excretion pathway 
(Pouliquen, Le Jeune, Perdrisot, Ermias, & Jallet, 1991). Compared to chelated-
gadolinium contrast agents, iron oxide contrast agents are reported to be less toxic in vivo 
(Weissleder, et al., 1990). Unfortunately, the use of iron oxides has been limited to 
applications such as imaging the liver, spleen and gastrointestinal lumen, due to large 
particle sizes that cause rapid elimination by the reticulo-endothelial system (RES) 
(Chouly, Pouliquen, Lucet, Jeune, & Jallet, 1996). However, due to improvement in 
nanoparticle technology, iron oxide nanoparticles are increasingly overcoming these 
limitations. Iron oxide nanoparticles can be created with even better magnetic properties, 
variable sizing and with appropriate surface coatings to attach molecular markers, opening 
the area of targeted molecular and cellular imaging for MRI (Gupta & Gupta, 2005). As 
mentioned previously, MRI has the highest spatial resolution compared to other imaging 
modalities but lacks sensitivity in differentiation and characterisation of pathologies. The 
use of iron oxide nanoparticles can improve the sensitivity of MRI because the 
nanoparticles can be designed to target specific pathologies such as cancer and can be 
developed to deliver drugs for dual imaging and therapy in MRI (Mulder, Strijkers, 
vanTilborg, et al., 2006; Na, et al., 2009).  
 
There are several types of iron oxide nanoparticles, namely maghemite, γ-Fe2O3, 
magnetite, Fe3O4, and haematite, α-Fe2O3, among which magnetite is very promising as a 
MRI contrast agent because of its highly magnetic properties (Laurent, et al., 2008). When 
magnetite or iron oxide is synthesised in a nano (<100 nm) size, its structure can change, 
affecting its magnetic properties. Due to this effect, it is essential to analyse its magnetic 
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properties after synthesis, in particular the magnetic moment. The magnetic moment is an 
essential magnetic property as it determines the ability of the nanoparticles to produce 
MRI contrast enhancement. Another property that iron oxide nanoparticles need is the 
ability to be utilised in targeted molecular and cellular imaging. 
 
The next section discusses characteristics of iron oxide nanoparticles which ensure 
that they can be utilised for targeted molecular and cellular applications. 
 
1.3.3 Characteristics of iron nanoparticles needed for targeted MRI 
 
As explained in the previous section, for targeted molecular and cellular imaging 
purposes, iron oxide nanoparticles need superparamagnetic and high magnetic properties 
such as a large magnetic moment to ensure that contrast is generated. They also need to 
possess other characteristics to further utilise them in targeted molecular and cellular 
imaging. These properties are low toxicity, high biocompatibility and an appropriate 
surface layer to bind to a range of biological targets (Gupta & Gupta, 2005). 
 
 It is important to ensure that iron oxide nanoparticles possess all these properties 
because each method for producing iron oxide nanoparticles results in different 
characteristics (Jun, Lee, & Cheon, 2007). For targeted molecular and cellular imaging, 
the iron oxide nanoparticles need to be coated with a surface or monolayer, usually of 
organic material, that provides an interface between the core and the surrounding 
environment (Rochelle, Arvizo, De, & Rotello, 2007). This interface serves many 
purposes such as biological stability and the facility for attachment of biomarkers for 
targeting. Iron oxide nanoparticles also need to have a uniform particle size (Laurent, et 
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al., 2008; Lawaczeck, Menzel, & Pietsch, 2004), high colloidal stability (Jun, et al., 2007), 
low toxicity and high biocompatibility (Jun, et al., 2007). 
 
The way iron oxide nanoparticles are synthesised has an influence on all of the 
above properties. For MRI, these properties are important as they determine the overall 
effectiveness of the contrast agent. For example, an essential characteristic of an effective 
MRI contrast agent is a high magnetic moment (Jun, et al., 2007; Laurent, et al., 2008; 
Lawaczeck, et al., 2004). A measure of the magnetic moment is the saturation 
magnetisation value: the higher the saturation magnetisation value, the higher the 
magnetic moment, inducing more contrast (Wang, Hussain, & Krestin, 2001). The 
saturation magnetisation value is expressed in electromagnetic units per gram (emu/g) and 
affects the relaxation rates, T1 and T2 of the surrounding water protons. The influence of 
the large magnetic moment and susceptibility causes a reduction in the T1 and T2 
relaxation rate, so that in a T2 weighted scan there is more contrast. Therefore, the 
relaxation rates are an indirect measure of the ability to generate contrast. 
 
Typically, saturation magnetisation values for iron oxide nanoparticles range from 
30-50 emu/g, and higher values such as 90 emu/g have been observed for bulk material 
(Lu, Salabas, & Schuth, 2007;  Lu, Wang, Ye, Vaidya, & Jeong, 2007). Factors 
contributing to the saturation magnetisation value of iron oxide nanoparticles include the 
size of the particles (with the highest emu/g to volume ratio occurring in the 6-20 nm 
particle size range (Jun, et al., 2005), spacing between the nanoparticles (where coatings 
separate magnetic domains allowing each individual magnetite particle to act 
independently, thereby enhancing the net magnetism per gram) and the crystalline 
structure of the iron oxide (Goya, Berquo, & Fonseca, 2003; Gupta & Gupta, 2005). It is 
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therefore essential to use a method of iron oxide nanoparticle production that generates 
particles with one or more of the above characteristics. 
 
The overall size and size distribution of superparamagnetic iron oxide 
nanoparticles (SPIONS) is an important consideration. For applications in targeted 
molecular and cellular imaging, the size can affect the biodistribution in vivo and the 
localisation to a targeted area. It is well known that particles above 60 nm in diameter are 
eliminated by the RES, so the use of iron oxide nanoparticles greater than 60 nm in 
diameter is limited to liver/spleen imaging (Na, et al., 2009; Weissleder, et al., 1990). 
Similarly, the size distribution can limit the number of particles that arrive at the targeted 
area, increasing non-specific uptake, so all the iron oxide nanoparticles within the sample 
must be of similar size. Other properties such as high colloidal stability and low toxicity 
are important because they increase the chances of translating developmental contrast 
agents into the clinical setting.  
 
There are many production methods for iron oxide nanoparticles, each method 
producing nanoparticles with different properties. The following section briefly discusses 
the basic methods of iron oxide nanoparticle production and their resulting characteristics.  
 
1.3.3 Synthesis methods of iron oxide nanoparticles 
 
Iron oxide nanoparticles are crystalline structures that are governed by the principles of 
crystal formation and growth. A crucial characteristic of iron oxide nanoparticles for 
targeted molecular and cellular MRI is uniform particle size. Uniform particles are usually 
prepared via homogeneous precipitation reactions which involve two processes, nucleation 
Chapter 1 - Introduction 
   40
and growth (Laurent, et al., 2008). Generally, for precipitation to occur there must be a 
saturated solution, in which addition of any excess solute will cause precipitation and start 
the nucleation and growth phases for the formation of nanocrystals (Burda, Chen, 
Narayanan, & El-Sayed, 2005).  
 
1.3.4.1 Nucleation and Particle Growth 
For nucleation to occur, the solution must be supersaturated leading to a short single burst 
of nucleation (Jun, et al., 2007; Wang, et al., 2001). Supersaturation can be achieved by 
dissolving the solute at a high temperature or by adding reactants to produce 
supersaturation (Peng, Wickham, & Alivisatos, 1998). After the short burst of nucleation 
the concentration usually drops, stopping the nucleation process. The nuclei then grow by 
diffusion of solutes from the solution onto the surfaces, until an equilibrium concentration 
is achieved. To achieve monodispersed particles, the two phases of nucleation and growth 
need to be separated (Boistelle & Astier, 1988; Burda, et al., 2005; Laurent, et al., 2008; 
Tartaj, Morales, Veintemillas-Verdaguer, Gonzalez-Carreno, & Serina Carlos, 2006). 
There are many different mechanisms which can explain this process, such as the classical 
theory method of the formation of sulphur colloids, which was proposed by LaMer and 
Dinegar (LaMer & Dinegar, 1950), and Ostwald ripening growth as explained by Den 
Ouden and Thompson (Den Ouden & Thompson, 1991; Ng et al., 1996). Size control is 
ultimately achieved by artificially separating nucleation and growth, which would occur 
before the solution reaches critical supersaturation, or by the end of nucleation.  
 
Several different factors can be adjusted to promote separation of the two 
processes to control for size, to obtain superior results to old synthesis methods. Adjusting 
the factors that control size is known to affect the magnetic, biocompatibility and surface 
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properties of iron oxide nanoparticles, suggesting that alterations in synthesis methods can 
produce iron oxide nanoparticles with different particular characteristics. 
 
1.3.4.2 Methods of superparamagnetic iron oxide nanoparticle synthesis 
Many methods of iron oxide nanoparticle synthesis have evolved for applications to MRI. 
This is a result of controlling the nucleation and particle growth phases to achieve uniform 
size, high magnetic properties and biocompatibility (Laurent, et al., 2008). Some of these 
synthesis methods are hydrolytic methods, chemical precipitation, constrained 
environments, and non-hydrolytic methods such as high temperature reactions. In keeping 
with the scope of this thesis, only these selected methods are discussed here, in relation to 
achieving the major characteristics needed for iron oxide nanoparticles applicable for 
targeted molecular and cellular imaging in MRI.  
 
1.3.4.3 Hydrolytic methods – chemical precipitation 
The precipitation method is the simplest chemical pathway to obtain iron oxide 
nanoparticles. Magnetite (Fe3O4), the most common iron oxide nanoparticle, is prepared 
by co-precipitating a stoichiometric mixture of ferrous (Fe2+) and ferric (Fe3+) salts in an 
aqueous medium. The thermodynamics of the reaction require a ratio of 2:1 for Fe2+/ Fe3+, 
and a pH between 8 and 14 (Laurent, et al., 2008). The overall reaction can be written as: 
 
 Fe2+ + 2Fe3+ + 8OH- = Fe3O4 + 4H2O   (1) 
 
The reaction must be carried out under a nitrogen environment to eliminate 
oxidation of the magnetite (Kim, Zhang, Voit, Rao, & Muhammed, 2001). If the reaction 
is not carried out under a nitrogen environment, the ions can become oxidised before 
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precipitation, leading to the formation of maghemite, Fe2O3 (Kim, Zhang, Voit, Rao, & 
Muhammed, 2001). Maghemite is an oxidised form of magnetite and is known to have 
inferior magnetic properties; thus oxidisation of magnetite can critically affect the physical 
properties of the iron oxide nanoparticles (Corot, Robert, Idée, & Port, 2006). The two 
differ from each other in the spinel structure; one occupies positions in the octahedral and 
tetrahedral sites and the other, maghemite, has cationic vacancies in the octahedral 
position (Laurent, et al., 2008). This crystal structure results in a different saturation 
magnetisation value (or emu/g) of the iron particles: at 300oK, 92 emu/g-1 for magnetite, 
and 78 emu/g-1 for maghemite (Corot, et al., 2006). The use of x-ray diffraction (XRD) 
can help in differentiating between the formation of magnetite and maghemite, but most of 
the time it is difficult to separate magnetite from maghemite given that their diffraction 
spectra are very similar (Lawaczeck, et al., 2004). It has been suggested that iron oxide 
nanoparticle synthesis always results in the presence of both magnetite and maghemite 
(Thünemann, Schütt, Kaufner, Pison, & Möhwald, 2006).  
 
Compared to other hydrolytic methods and non-hydrolytic methods, the 
precipitation method can produce large quantities of iron oxide nanoparticles. This is an 
advantage for MRI applications because large quantities of iron oxide nanoparticles are 
needed for administration into humans. There are, however, limitations in the co-
precipitation method, such as wide particle size distribution and limited ability to control 
the size of the nanoparticles (Gupta & Gupta, 2005). For applications in MRI, particularly 
targeted molecular and cellular imaging, small size of the iron oxide nanoparticles is 
needed to ensure that targeted imaging can occur, and a small size distribution is needed to 
decrease non-specific uptake. To control the size and size distribution in the hydrolytic co-
precipitation method it is essential to adjust factors that determine the precipitation process 
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for nanoparticles (Sjogren, Briley-Saebo, Hanson, & Johansson, 1994). Factors such as 
pH, ionic strength, temperature, nature of salts, Fe3+/Fe2+ ratio, and addition of chelating 
agents have been shown to change the size and size distribution as well as the magnetic, 
biocompatibility and surface properties of iron oxide nanoparticles (Sjogren, et al., 1994). 
 
One of the most popular hydrolytic methods of iron oxide nanoparticle production 
is a co-precipitation reaction by the Massart process. In the Massart process there is co-
precipitation of ferrous and ferric chlorides and hydroxides in an alkaline solution 
(Massart, 1981). To understand factors controlling the size, Massart evaluated parameters 
such as the strength of the base (e.g. ammonia or sodium hydroxide), the pH value, added 
cations and the Fe3+/Fe2+ ratio, noting the effect on the yield of the co-precipitation 
reaction and on particle sizes. Massart concluded that the size of iron oxide nanoparticles 
could be decreased by increasing the pH and/or increasing the Fe3+/Fe2+ ratio. Similarly, 
Jolivet and co-workers conducted a comprehensive study evaluating the effects on size, 
morphology and magnetic characteristics of adjusting the ratio of Fe2+/Fe3+ (Jolivet, 
Belleville, Tronc, & Livage, 1992). Small Fe2+/Fe3+ ratios (<0.3) were shown to form 
goethite, and for ratios below 0.5 but above 0.3 there were two phases, consisting of 
smaller (4 nm) and larger iron oxide nanoparticles. It was concluded that using a ratio of 
0.5 corresponded to magnetite stochiometry and the particles were homogeneous in size 
and composition. Other studies have also shown similar results by adjusting factors such 
as ionic strength, size and size distribution (Babes, Denizot, Tanguy, Jeune, & Jallet, 
1999; Jiang, et al., 2004). 
 
Apart from modulating the parameters of the reaction to achieve monodisperse iron 
oxide nanoparticles, the addition, either in combination or individually of chelating 
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organic anions like citric acid (Bee, Massart, & Neveu, 1995), amino acids and 
dimercaptosuccinic acid (DMSA) (Fauconnier, Pons, Roger, & Bee, 1997) can also 
decrease the particle size by inhibiting the growth of the crystal nuclei. Polymer surface 
complexing agents which form monolayers on the surface of the iron oxide nanoparticles, 
such as dextran (Lee, Kim, Kim, & Kim, 2002), carbodextran and silica (Stöber, Fink, & 
Bohn, 1968), can also be added, instead of varying the reaction parameters. Some polymer 
complexing agents such as dextran, carboxydextran and silica are used in iron oxide 
nanoparticles that are commercially available or are currently in clinical trials. Examples 
are silica-coated magnetite, AMI-121 (Lumirem®- US) dextran-coated magnetite, 
Ferumoxides (Endorem® – Europe, Feridex® in the USA and Japan) and carboxydextran 
coated magnetite, Ferucarbotran (Resovist® – Europe and Japan). It should be noted that 
these polymer complexing agents can be used for any method of iron oxide production and 
do not only contribute in reducing the size and size distribution of the iron oxide 
nanoparticles. These agents also provide water solubility, the facility for attachment of 
various functional probes, and stabilisation of the magnetite core from any oxidation (Jun, 
et al., 2007; Rochelle, et al., 2007). 
 
Magnetic properties such as the saturation magnetisation value of iron oxide 
nanoparticles vary according to the method of synthesis. This difference is primarily 
attributed to changes in the structural order of the iron oxide nanoparticles (Taylor, Barry, 
& Webb, 2001), the creation of anti-phase boundaries (Zhou, Wang, O’Connor, & Tang, 
2001) and the existence of a magnetically dead layer on the surface (Kim, et al., 2001). In 
the case of the co-precipitation method to produce iron oxide nanoparticles, the frequent 
transformation from magnetite to maghemite causes a reduction in the saturation 
magnetisation values (Corot, et al., 2006). This is due to the changes in the crystalline 
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structural orientation when magnetite is oxidised to maghemite (Corot, et al., 2006). The 
co-precipitation method therefore produces iron oxide nanoparticles that are not highly 
crystalline, resulting in iron oxide nanoparticles with lower magnetisation values (Laurent, 
et al., 2008). The size of the iron oxide nanoparticles is also known to affect the 
magnetisation values. That phenomenon was first reported in 1971 by Coey et al. and then 
by Varanda et al. in 2002, where a reduction in the size of iron oxide nanoparticles was 
related to reduction in the magnetic properties. It was reported in these studies that the 
curvature of smaller sized particles was much greater, encouraging disordered crystal 
orientation on the surface, leading to lower magnetisation values. Jun et al. (2005) 
reported on the effect of iron oxide nanoparticle size and the resulting contrast 
enhancement demonstrated by decreasing signal intensity. The iron oxide nanoparticles 
were highly crystalline, monodisperse, and ranged in size from 4nm to 12nm in diameter. 
The general trend suggested that as the nanoparticles increased in size, so did the 
magnetisation values along with the T2-weighted MR signal intensity, showing more 
contrast on T2-weighted images. High magnetisation values are important for achieving 
optimal contrast for any MRI application, and it is therefore crucial for iron oxide 
nanoparticles to have a maximum magnetisation value.  
 
Although the co-precipitation method is the simplest and most efficient chemical 
pathway to obtain magnetic nanoparticles, it has disadvantages such as high particle size 
variation, aggregation and poor crystallinity, resulting in low saturation magnetisation 
values. These disadvantages have led to the development of advanced methods of 
magnetite synthesis that have better size control, crystallinity and higher magnetisation 
values (Gupta & Gupta, 2005).  
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1.3.4.4 Hydrolytic method – reactions in constrained environments 
Synthesis reactions in constrained environments are microemulsions and sol-gel processes, 
which are based on the co-precipitation method but make use of lipid-based structures 
such as amphiphiles (Dresco, Zaitsev, Gambino, & Chu, 1999; Gobe, Kon-No, Kandori, & 
Kitahara, 1983; Lee, Sorensen, Klabunde, & Hadjipanayis, 1992; Lopez-Perez, Lopez-
Quintela, Mira, & Rivas, 1997; Nassar & Husein, 2006; Santra, et al., 2001) and 
dendrimers (Strable, et al., 2001) on the surface of the iron oxide nanoparticles during the 
synthesis process.  
 
Lipid-based structures or colloidal aggregates such as liposomes and micelles are 
composed of lipids and/or other amphiphilic molecules. Amphiphiles (sometimes referred 
to as surfactants) are molecules with both hydrophilic (polar head) and hydrophobic (non-
polar tail) parts that spontaneously assemble into aggregates in an aqueous solution 
(Degiorgio, 1985). The hydrophobic tails can vary in length, affecting the ratio between 
hydrophilic and hydrophobic parts, and the hydrophilic heads can also vary in charge and 
size, affecting the overall curvature of the aggregate. Due to these properties, various 
geometries and sizes of iron oxide nanoparticles can be formed, such as cylindrical, 
spherical and bilayered structures (Degiorgio, 1985; Mulder, Strijkers, ilborg, Griffioen, & 
Nicolay, 2006).  
 
Micelles for MRI imaging usually contain a hydrophobic core, where the iron 
oxide core is stabilised by the surfactant, limiting particle nucleation and growth (Burda, et 
al., 2005). Compared to traditional co-precipitation methods, micelles can control the 
particle size and size distribution, making nanoparticles suitable for targeted MRI. The 
first magnetic nanoparticles formed in micelles were produced by oxidation of Fe2+ salts, 
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where the sizes of the magnetite particles were controlled by varying the temperature and 
the surfactant concentration (Inouye, et al., 1982; Lee et al., 2005). Similar to micelles are 
reverse micelles. In reverse micelles, the hydrophilic head groups are towards the core of 
the micelle and the hydrophobic groups are directed outwards. Compared to micelles, 
reverse micelles can solubilise relatively large amounts of water, suggesting easier size 
control of the iron oxide nanoparticles. Reverse micelles have also been found to produce 
better crystalline particles and large amounts of iron oxide nanoparticles, making them a 
better choice for production of iron oxide nanoparticles (Lee, et al., 2005).  
  
Other lipids such as PEG can also be used for reducing the size of the iron oxide 
nanoparticles and also in stabilising the iron oxide core, preventing further oxidisation 
(Wan, et al., 2007). The main advantages of using PEG stabilised lipids is that the 
resulting iron oxide nanoparticles have a PEG coating that helps to prolong blood 
circulation times; however, the feasibility of clinical use of these iron oxide nanoparticles 
is low, because of disadvantages associated with difficult preparation methods and 
excessive size separation processes (Acar, Garaas, Syud, Bonitatebus, & Kulkarni, 2005). 
 
Bi-layer forming lipids are used to create liposomes; they usually have a polar head 
group and two fatty acid chains. Iron oxide nanoparticles can be placed inside the 
liposomal lumen to create magnetoliposomes (Bulte, DeCuyper, & Nejat, 2003). Besides 
better magnetic properties and controllability of size and size distribution, liposomes have 
other advantages. These are the potential to coat the iron oxide surface with repellent 
molecules (to avoid RES clearance), the availability of groups for the easy attachment of 
specific ligands for targeted molecular and cellular imaging, and the ability to load 
particular drugs on their surface (Laurent, et al., 2008). There are two types of 
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magnetoliposomes. The first consists of water-soluble iron oxide nanoparticles within an 
aqueous lumen and the second contains iron oxide nanoparticles of approximately 15 nm 
covered with a lipid bi-layer (Cuyper & Joniau, 1988). Both types have been used for MRI 
applications such as targeting tumours and bone marrow, and have demonstrated excellent 
size and distribution properties, better magnetism values than traditional co-precipitation 
methods, long blood circulating times, and the ability to attach biomarkers for targeted 
imaging (Fortin-Ripoche, et al., 2006; Sabaté, Barnadas-Rodríguez, Callejas-Fernández, 
Hidalgo-Álvarez, & Estelrich, 2008; Soenen, et al., 2011; Soenen, Velde, Ketkar-Atre, 
Himmelreich, & DeCuyper, 2011).  
 
Dendrimers are a class of transfection agents that contain three components: core, 
branches and end-groups. When dendrimers are attached to iron oxides they are termed 
magnetodendrimers. Generally, during the synthesis process dendrimers are added to the 
solution, resulting in the formation of highly stable and water soluble iron oxide 
nanoparticles coated with dendrimers (Strable, et al., 2001). They have a size of 20-30 nm 
and have been shown to have high T2 relaxivities for generating high contrast in MRI 
(Strable, et al., 2001). Magnetodendrimers are well suited for the imaging of cell 
trafficking and migration using MRI (Bulte, et al., 2003; Bulte, et al., 2001; Lee, et al., 
2004; Walter, et al., 2004). This is due to the charge on the polymer, which promotes a 
high non-specific affinity for cellular membranes, resulting in cellular internalisation 
(Bulte & Kraitchman, 2004). Cells from different origins can be easily labelled to 
magnetodendrimers and then imaged on MRI, by introducing the magnetodendrimers to 
the cell culture for 1-2 days at low concentrations (Bulte, Ben-Hur, et al., 2003). 
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Although magnetoliposomes and magnetodendrimers have shown promising 
results in the reducing the size and size distribution of iron oxide nanoparticles and 
producing good magnetisation values during the synthesis process, their use remains in the 
pre-clinical setting. This is most likely due to the difficult synthesis methods required and 
the inability to make the large batches that could be needed for human administration.  
 
1.3.4.5 Non-hydrothermal methods – high temperature 
Unlike co-precipitation methods and their derivatives, high temperature methods can 
produce monodisperse particles with significant size control, higher crystallinity and 
therefore higher magnetic properties, without the use of any size separation processes or 
adjusting any reaction parameters (Laurent, et al., 2008). In high temperature methods, 
iron complexes are decomposed using very high operating temperatures in the presence of 
surfactants and organic solvents. Because of the very high temperatures and the nature of 
the solvents used in these synthesis methods, there is relatively good control in the 
nucleation and growth phases of the iron oxide nanoparticle synthesis process (Laurent, et 
al., 2008). The resulting iron oxide nanoparticles can therefore be controlled to produce a 
variety of sizes with narrow size distributions and high crystallinity and magnetisation 
values (Sun & Zeng, 2002).  
 
One method using high temperatures to produce iron oxide nanoparticles is based 
on seed-mediated growth. Sun and Zeng. (2002) prepared iron oxide nanoparticles of 
different sizes (3 nm to 20 nm) by controlling the quantity of seeds added to obtain various 
sizes. In this reaction, iron (III) acetylacetonate was decomposed by heating at 265oC in 
phenyl ether, alcohol, oleic acid, and oleylamine, to produce iron oxide nanoparticles with 
an initial diameter of 4 nm. To make particles above 4 nm, a seed-mediated growth was 
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used producing monodisperse particles. All the iron oxide nanoparticles produced were 
reported to have very high magnetisation values compared to any of the reported values of 
iron oxide nanoparticles produced by co-precipitation methods. Similarly Hyeon, Lee, 
Park, Chung, and Na. (2001) formed an iron oleate complex from the decomposition of 
iron pentacarbonyl in the presence of octyl ether and oleic acid at 100oC. They reported 
that the resulting iron oxide nanoparticles could be tailored to any size, depending on the 
molar ratios of iron pentacarbonyl and oleic acid, without size separation processes and 
without compromising on size distribution. Their iron oxide nanoparticles also 
demonstrated very high crystallinity compared to co-precipitation methods and yields of 
up to 80% or more. 
 
In a pioneering report by Park et al. (2004), iron oxide nanoparticles were 
produced using a simple high temperature method. Iron oxide nanoparticles were 
produced in an ultra-large scale synthesis process from non-toxic and environmentally 
friendly compounds. In that study, instead of using compounds such as iron pentacarbonyl 
that are potentially toxic in vivo (Brief, Ajemian, & Confer, 1967), the iron oxide 
nanoparticles were prepared by a metal–oleate complex by reacting environmentally 
friendly compounds, namely metal chlorides and sodium oleate. Iron salts are more suited 
for contrast agent research and applications in MRI because they are less toxic and have 
more potential to be translated clinically (Park, et al., 2004). In the study an iron-oleic 
complex was formed using iron chlorides (FeCl3·6H2O) and sodium oleate, which was 
slowly heated to 320oC in 1-octadecene. The solution was aged at this temperature for 30 
minutes, generating monodisperse iron oxide crystals. Various temperatures and solvents 
were tried, which produced large amounts (up to 40 g) of iron oxide nanoparticles of 
different sizes, high magnetisation values and dispersion. It was suggested that 
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monodisperse particles could be attributed to separation of the growth and nucleation 
phases, which occurred at different temperatures, nucleation at 200-240oC and growth at 
300oC. The authors concluded that their method had several advantages over other iron 
oxide nanoparticles synthesis methods: large amounts of nanoparticles produced, high 
magnetisation values, no need for size sorting, non-toxic particles, environmentally 
friendly compounds, inexpensive products and many sizes of iron oxide nanoparticles.  
 
Of all the synthesis methods of iron oxide nanoparticles, the high temperature 
method by Park et al. (2004) has demonstrated the best features for MRI applications. This 
is due to the ability to easily make large amounts of iron oxide nanoparticles in one 
synthesis process without compromising other properties, the ability to produce different 
sizes of iron oxide nanoparticles, the high crystallinity and magnetisation values for 
producing maximum contrast, and the non-toxic nature of iron oxide nanoparticles.  
 
1.3.5 Surface coatings and functionalisation of iron oxide nanoparticles 
 
Surface coatings were discussed in the section dealing with production of iron oxide 
nanoparticles using the co-precipitation method and its derivatives, because they assist in 
the synthesis of monodisperse particles by preventing nucleation and growth, and 
producing superior magnetic nanoparticles by inhibiting oxidation. These were 
dendrimers, lipids, PEG and micelles. Apart from being used in the synthesis process, 
these and other surface coatings are used on the surface of naked iron oxide nanoparticles 
to provide water solubility, reduced aggregation and the facility for attachment of 
biomarkers (Gupta & Gupta, 2005; Laurent, et al., 2008). Surface coatings thus serve 
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multiple purposes on the surface of iron oxide nanoparticles for MRI applications, 
particularly for targeted molecular and cellular imaging.  
 
In the absence of any surface coating, magnetic iron oxide nanoparticles have 
hydrophobic surfaces, with a large surface area to volume ratio (Hamley, 2003). Due to 
hydrophobic interactions between the particles, large clusters and agglomerates form, 
resulting in increased particle size (Hamley, 2003). These clusters exhibit strong magnetic 
dipole-dipole attractions between them, showing ferromagnetic behaviour, and interfere 
with the magnetic field of the neighbouring particles (Hamley, 2003). This results in the 
formation of attractive forces between the particles, further magnetisation and the loss of 
single magnetic domains, which can affect the magnetic properties (Mendenhall, Geng, & 
Hwang, 1996). The particles are then attracted magnetically, in addition to Van der Waals 
forces. To prevent this from occurring there is a need to add a surface layer (Mendenhall, 
et al., 1996). Surface layers can be dendrimers and lipids and can be added during the 
synthesis process or afterwards. Other surface coatings on naked iron oxide nanoparticles 
are dense substances like carboxylates, inorganic materials like silica, and polymers such 
as dextran. 
 
In targeted molecular and cellular MRI a surface layer is essential, as it allows the 
attachment of biomarkers on iron oxide nanoparticles. This ensures that the iron oxide 
nanoparticles can localise to a specific area. For a stable conjugation between a biomarker 
and the iron oxide nanoparticles, the surface layer must be able to provide a variety of 
available binding sites for attachment. 
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The next section discusses three surface coatings, carboxylates, dextran and silica, 
and their use as surface coatings for targeted MRI. 
 
1.3.5.1 Carboxylates 
Citric acid is an example of a carboxylate as a surface coating for iron oxide nanoparticles. 
The surface of the magnetite nanoparticles can be stabilised in an aqueous dispersion by 
the absorption of citric acid (Sahoo, et al., 2005). This process, as described by Sahoo et 
al. (2005), occurs by the citric acid being coordinated via one or two of the carboxylate 
functionalities, depending on steric necessity and the curvature of the surface. As a result, 
one carboxylic acid group conjugates onto the iron oxide core and another carboxylic 
group faces the solvent, creating a surface charge and allowing the iron oxide 
nanoparticles to be hydrophilic. The presence of the terminal carboxylic group provides an 
avenue for the stable attachment of multiple molecules such as fluorescent dyes, proteins, 
hormone linkers, and antibodies, so that specific targeting can occur. 
 
Molecules such as DMSA can also be used as a surface coating to achieve water 
solubility and allow conjugation of molecular precursors (Huh, et al., 2005). DMSA is 
introduced to the iron oxide nanoparticles in excess after the synthesis, through simple 
mixing (Huh, et al., 2005). The DMSA binds to the magnetite surface through its 
carboxylate bonding, and the intermolecular disulfide cross-linking between surface-
bound DMSA ligands increases the stability (Fauconnier, et al., 1997). The remaining free 
carboxylic acid and thiol groups promote the iron oxide nanoparticles to be hydrophilic 
and these remaining free groups can be used for conjugation of a variety of biomarkers 
(Fauconnier, et al., 1997). 
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1.3.5.2 Dextran 
The use of dextran on the surface of iron oxide nanoparticles is common. Dextran is a 
polysaccharide polymer composed of α-D-glucopyranosyl units, and can vary in length 
(1000 to 2,000,000 Da) and branching. Dextran offers a suitable surface layer on iron 
oxide nanoparticles because of its proven biocompatibility and long blood circulating 
times (Berry, Wells, Charles, & Curtis, 2003). Dextran can coat iron oxide nanoparticles 
by reacting a mixture of ferrous chloride and ferric chloride with the dextran polymers, 
under alkaline conditions (Molday & Mackenzie, 1982). It has been reported that reducing 
the size of dextran has an effect on the size and stability of the dextran-coated iron oxide 
nanoparticles (Kim, Zhang, Voit, Rao, &Muhammed, 2001; Lawaczeck, et al., 2004; Paul, 
Frigo, Groman, & Groman, 2004; Thomas & Hütten, 1997). It has also been reported that 
larger molecular weight dextran has significant effects on particle size, coating stability 
and magnetic properties; on the other hand, iron oxide nanoparticles coated with a lower 
molecular weight dextran have been reported to be more stable (Pardoe, Chua-anusorn, St. 
Pierre, & Dobson, 2001; Paul, et al., 2004). Dextran attaches onto the surface of the iron 
oxide nanoparticles via polar interactions, chelation and hydrogen bonding, and its 
hydroxyl groups on the surface allow for further surface modification to attach biomarkers 
(Laurent, et al., 2008). Dextran is used as a surface coating for some iron oxide 
nanoparticles that are preclinically and clinically available, namely Feridex® and 
Resovist®.  
 
1.3.5.3 Silica 
Another surface coating for iron oxide nanoparticles is silica (Sun, et al., 2005). Silica is 
an inert molecule that coats the surface of the iron oxide nanoparticles, serves to prevent 
aggregation of the nanoparticles in solution, and provides stability (Sun, et al., 2004). This 
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is achieved by two processes: (1) sheltering of the magnetic dipole interaction by the silica 
shell and (2) charging the magnetic nanoparticles, as silica is negatively charged (Stober, 
et al., 1968). The silica surface therefore offers high stability for iron oxide nanoparticles 
in suspensions at high volume fractions, changes in pH or electrolyte concentration 
(Mulvaney, Liz-Marzan, Giersig, & Ung, 2000). The advantage of silica on the surface of 
the iron oxide nanoparticles is associated with the availability of silanol groups that easily 
react with alcohols and silane coupling agents to covalently attach to various biomarkers, 
making desorption difficult (Ulman, 1996). Like dextran, silica also has proven 
biocompatibility, and there are commercially available silica coated iron oxide 
nanoparticles, namely Gastromark® (Hahn, et al., 1990; Trewyn, Nieweg, Zhao, & Lin, 
2008; van Schooneveld, et al., 2008).  
 
There are two widely used methods to produce silica-coated iron oxide 
nanoparticles, the Stober process and the microemulsion process (Thorek, Chen, 
Czupryna, & Tsourkas, 2006). The Stober process, comprises the hydrolysis and 
condensation of a sol-gel precursor such as tetraethyl orthosilicate (TEOS) (Stöber, et al., 
1968). Although this method has produced very large silica shells, there have been several 
modifications that have resulted in excellent size control of the silica shell, allowing sizes 
between 2 nm and 100 nm without the use of surfactants (Fang, 2008; Lu, Yin, Mayers, & 
Xia, 2002). The limited or non-use of surfactants means that there is no need to separate 
the produced iron oxide silica nanoparticles from the solution, and simple centrifugation 
can remove particles from solution (Lu, et al., 2002).  
 
The second most common method of generating iron oxide-coated silica 
nanoparticles is via the microemulsion process, where micelles or inverse micelles are 
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used to confine and control the silica coating. Although this method produces smaller 
sized particles, a disadvantage is the considerable effort are required to separate the iron 
oxide coated silica nanoparticles from the numerous surfactants associated with the 
microemulsion system (Philipse, van Bruggen, & Pathmamanoharan, 1994; Tartaj & 
Serna, 2002, 2003). 
 
The use of silica as a coating on iron oxide nanoparticles for molecular and cellular 
MRI has not been investigated. There have been many applications of iron oxide silica 
nanoparticles in other areas of medicine, such as controlled drug release and gene and 
protein delivery (Chowdhury & Akaike, 2005; Lu, Liong, Zink, & Tamanoi, 2007; 
Trewyn, Giri, Slowing, & Lin, 2007). The advantages of silica as a surface coating on iron 
oxide nanoparticles make it a promising material for applications in targeted MRI. 
 
1.3.6 Biodistribution of iron oxide nanoparticles 
 
 
The biodistribution of iron oxide nanoparticles for MRI applications is an important 
consideration, particularly for molecular and cellular targeted imaging. The distribution of 
the iron oxide nanoparticles determines whether localisation can occur at the targeted site. 
Intravenously administered iron oxide nanoparticles are recognised as ‘foreign bodies’ and 
are taken up primarily by the RES cells or macrophages (Bradfield, 1984). Since the liver 
has 90% of the total phagocytic capacity of the mononuclear phagocytic system (MPS), 
the iron oxide nanoparticles distribute mainly to this organ, followed by the spleen, lymph 
nodes and bone marrow (Bradfield, 1984). The removal of the iron oxide nanoparticles 
from the bloodstream and distribution into various organs depends primarily on the size of 
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the iron oxide nanoparticles, followed by the charge and surface nature (Chouly, et al., 
1996).  
 
Earlier studies of large iron oxide nanoparticles showed a trend that larger iron 
oxide nanoparticles have a shorter blood plasma life (Pouliquen, et al., 1991; Weissleder, 
et al., 1989). For larger iron oxide nanoparticles, approximately >60 nm in diameter, 80-
90% of the injected dose can be taken up by the RES within 30 minutes of intravenous 
administration and localised within the liver, showing a maximum uptake by 2 hours 
(Pouliquen, et al., 1991; Weissleder, et al., 1989). Other organs such as the kidneys, lungs 
and brain show minimal or non-detectable amounts of iron oxide nanoparticles 
(Weissleder, et al., 1989). Iron oxide nanoparticles that are less than 60 nm in diameter 
have shown significant changes in biodistribution, such as longer peripheral blood 
circulating times, in the presence of surface coatings (Chouly, et al., 1996; Weissleder, et 
al., 1990). In this case, it has been reported that the initial liver and spleen uptake is low 
and the particles remain in the bloodstream for several hours, suggesting that the iron 
oxide nanoparticles can be available for localisation at a targeted area (Islam & Wolf, 
2009; Moore, Marecos, Bogdanov, & Weissleder, 2000; Weissleder, et al., 1990). After 
this time, iron levels increase in organs such as the liver, spleen, lungs, kidneys and heart 
(Jain, Reddy, Morales, Leslie-Pelecky, & Labhasetwar, 2008;  Weissleder, et al., 1990). 
For the excretion and breakdown of the iron oxide nanoparticles, a half-life of 
approximately 3 days in the liver and 4 days in the spleen has been reported (Pouliquen, et 
al., 1991; Weissleder, et al., 1990). The iron oxide nanoparticles are known to be stored in 
lysosomes where they are ultimately degraded, and enter the haemoglobin of the 
erythrocytes and enter the normal body iron metabolism cycle (Pouliquen, et al., 1991; 
Weissleder, et al., 1990).  
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1.3.7 Summary of main themes 
 
The themes discussed in this section of the thesis related to principles of MRI and 
the characteristics of nanoparticles required to achieve targeted imaging, 
 
The first section, on the principles of MRI, introduced the basics of MRI signal 
generation and the role of contrast agents. In summary, this section presented the 
fundamentals of MRI signals that rely on the spinning motion of hydrogen nuclei present 
in biological tissues because of its relatively large magnetic moment. In the absence of a 
magnetic field the magnetic moments of the hydrogen nuclei are randomly oriented, but 
when the hydrogen nuclei are placed in an external magnetic field their magnetic moments 
align with the magnetic field. The net magnetic moments of the hydrogen nuclei are 
relatively low and a RF pulse applied at the Larmor frequency produces a net 
magnetisation that is termed resonance and causes the hydrogen nuclei to gain energy. 
When the RF signal is turned off the hydrogen nuclei lose the energy given to them by 
relaxation, giving rise to T1 and T2 relaxation that can be imaged on MRI. The ability of 
the MRI image to produce contrast depends on differences in the relaxation rates in 
various tissues, and external agents can be administered to affect the MRI signals such as 
T1 and T2 relaxation. In a T1 weighted image, fat has a high MRI signal and appears 
bright whereas water has a low signal and appears dark. Conversely, on a T2 weighted 
image, water has a high signal and appears bright and fat has a small signal so it appears 
dark.  
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The section reviewed contrast agents and their properties such as large magnetic 
moments that in the presence of water protons cause local magnetic field fluctuations. The 
types of contrast agents examined were those that affect T1 and T2 signals. Paramagnetic 
contrast agents such as gadolinium shorten T1 relaxation times and appear bright on T1 
weighted images. On the other hand, superparamagnetic contrast agents such as iron oxide 
nanoparticles shorten T2 relaxation times, appearing dark on T2 weighted images. 
Furthermore, gadolinium in its elemental state is highly toxic. It is chelated and although 
some chelated-gadolinium agents do not show toxicity there are still concerns over its 
safety due to reported deaths and nephrogenic systemic fibrosis. Due to these concerns 
research has been directed at examining other agents that can be used as contrast agents. 
Studies using traditional iron oxide contrast agents for MRI contrast have had limited 
success. However, recent developments in nanoparticle technology have resulted in iron 
oxide nanoparticles overcoming these limitations.  
 
Accordingly, the application of iron oxides has the potential to complement the 
high resolution of MRI and improve its sensitivity. This is because these biocompatible 
iron oxide nanoparticles have the ability to target specific pathologies such as cancer 
and/or to deliver drugs for dual imaging and therapy in MRI. Of the range of iron oxide 
compounds discussed, magnetite appeared to show most promise because of its high 
magnetic properties. 
.  
Another theme was the range of characteristics necessary for iron oxide 
nanoparticles to provide targeted MRI contrast. These characteristics include 
superparamagnetism or high magnetic moment, uniform size distribution, small sizes less 
than 60 nm, stability and a facility for the attachment of biomarkers. 
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The section also reviewed the various methods of iron oxide nanoparticle synthesis 
and their resulting influences on the characteristics. In summary, hydrolytic methods such 
as co-precipitation and reactions in constrained environments were shown to produce iron 
oxide nanoparticles with lower magnetisation values, higher size distributions and less 
control over particle size. Although some hydrolytic methods have been developed to 
control these parameters, the excessive size separation processes limit their clinical use. 
Non-hydrolytic methods such as high temperature methods are superior in producing large 
quantities of iron oxide nanoparticles with monodispersity and higher magnetisation 
values without the need of size separation processes. 
 
The last theme in the production of iron oxide nanoparticles was a comparison of 
surface coatings such as lipids, carboxylates, dextran and silica. The use of surface 
coatings on iron oxide nanoparticles is essential as they permit water solubility, prevent 
aggregation and allow the attachment of biomarkers. The latter is crucial for iron oxide 
nanoparticles to be utilised for targeted molecular and cellular MRI. Surface coatings can 
be conjugated on the surface of iron oxide nanoparticles either during the synthesis 
process or immediately after. The comparison of the different surface coatings suggested 
dextran was the most common due to its biocompatibility. However, a surface coating 
with immense potential for targeted MRI is silica. 
 
1.4 Breast Cancer 
 
1.4.1 Introduction 
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Breast cancer is classified according to multiple parameters including histopathological 
type, grade and stage, and the expression of proteins and genes, all of which help 
determine the diagnosis, prognosis and treatment options for patients (Ellis, et al., 2003). 
The receptor status is critical for breast cancer diagnosis, prognosis and treatment as it 
determines the ability to tailor therapy regimes such as chemotherapy, immunotherapy and 
adjuvant therapy (van’t Veer, et al., 2002). The epidermal growth factor receptor (EGFR) 
family of tyrosine kinase receptors has been widely studied because of its role in many 
cancers (Schlessinger, 2000; Yarden & Sliwkowski, 2001). The EGFR family of receptors 
includes four distinct types, namely human epidermal growth factor 1 (EGFR/HER1), 
HER2, HER3 and HER4, and is expressed in many human cancers (Yarden & 
Sliwkowski, 2001). In breast cancer, HER2 has been widely studied due to its presence 
being associated with aggressive behaviour of the tumour and poor prognosis (Slamon et 
al., 1987). Fortunately, overexpression of HER2 on breast tumours has opened up the 
ability to target tumour-specific immune therapies, such as Herceptin® (herceptin), which 
is used in adjuvant and neoadjuvant therapies (Carter, et al., 1992). Despite promising 
results for herceptin, there has been reported resistance to herceptin-based therapies and 
there is a need to identify such patients (Slamon, et al., 2001; Vogel, et al., 2002). The use 
of imaging technologies, particularly targeted imaging with MRI, can play an important 
role in selecting patients who have stopped responding to these therapies. This next 
section discusses the different types of breast cancers with a focus on HER2 positive 
breast cancers, herceptin treatments, and the potential role of iron oxide nanoparticles in 
MRI in identifying and monitoring these patients. 
 
1.4.2 Types of breast cancer 
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Breast cancer is classified according to a number of different schemes such as 
histopathological type, grade and stage, and the expression of proteins and genes, to help 
determine the diagnosis, prognosis and treatment options (Ellis, et al., 2003). The grade of 
the cancer refers to the degree of differentiation of the tumour, and reflects its 
aggressiveness (Elston & Ellis, 2002). The grading system compares normal breast tissue 
to breast cancer cells and classifies the tumour cells according to poor, intermediate and 
low differentiation (Elston & Ellis, 2002). The Bloom-Richardson grade is the most 
commonly used scoring system used by the World Health Organization (WHO), but other 
schemes such as the Nottingham Score have also been used (Elston & Ellis, 2002). The 
histopathological type of breast tumour refers to the growth pattern and to morphological 
and cytological patterns identified in tumour biopsies (Ellis et al., 1992). There is a wide 
range of classifications, from benign to malignant breast cancers, available from the WHO 
classification of tumours of breast cancers, the most common being invasive ductal 
carcinoma, ductal carcinoma in situ and invasive lobular carcinoma (Ellis, et al., 2003). 
The histopathological types of breast cancers can be further divided into classifications 
according molecular subtypes and the expression of proteins and genes such as oestrogen 
receptor (ER) positive, ER negative and HER2 receptor positive (Perou, et al., 2000). The 
subtype and receptor status are critical for breast cancer diagnosis, prognosis and treatment 
as they determines the ability to tailor therapy regimes such as chemotherapy, 
immunotherapy and adjuvant therapy (van de Vijver, et al., 2002; van’t Veer, et al., 2002). 
The expression of receptors is generally associated with poor prognosis, shorter time to 
progression and low survival rates (Natrajan, Lambros, & Rodriguez-Pinilla, 2009; 
Natrajan, Weigelt, & Mackay, 2010). Recent studies have classified breast tumours into 
ER positive tumours and ER negative categories, where ER positive tumours have low 
grade and high grade categories (Lopez-Garcia, Geyer, Lacroix-Triki, Marchio, & Reis-
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Filho, 2010; van’t Veer, et al., 2002). ER negative tumours have distinct molecular 
features and include HER2 positive, basal-like, luminal B, claudin-low and molecular 
apocrine tumours (Lopez-Garcia, et al., 2010). It has been suggested that ER negative 
tumours, which include HER2 positive tumours, fall into the category of more aggressive 
tumours due to distinct patterns of genetic aberrations caused by the presence of respective 
molecular entities (Natrajan, et al., 2009; Natrajan, et al., 2010).  
 
1.4.3 HER2 positive breast cancer and herceptin 
 
 
HER2 positive tumours are of interest because they are one of the most aggressive forms 
of breast cancer, associated with poor prognosis, lower survival rates and a faster time to 
disease progression (Slamon, et al., 1987; Slamon, Godolphin, & Jones, 1989). HER2 is 
part of the tyrosine kinase family and is a growth factor receptor gene (Coussens, Yang-
Feng, & Liao, 1985) that is amplified in approximately 25-30% of breast cancers (Slamon, 
et al., 1987). Furthermore, in vitro studies have shown that HER2 amplification is present 
in almost 92% of breast cancers (Pauletti, Godolphin, Press, & Slamon, 1996). The 
function of the HER2 receptor is to mediate growth, differentiation and survival of cells, 
and its expression produces very aggressive tumours (Slamon, et al., 1987). Studies have 
shown that HER2 positive breast cancers are associated with poor prognosis compared to 
HER2 negative breast cancers (Slamon, et al., 1987). Moreover, it has been reported that 
HER2 positive breast cancers are also associated with frequent relapses and reduced 
overall survival (Slamon, et al., 1987;  Slamon, Godolphin, & Jones, 1989). The 
identification of the HER receptor on breast cancers presents the opportunity for tumour-
specific therapies and has had significant implications in the diagnosis, management and 
outcomes of patients with HER2 positive breast cancers. 
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In 1998, the United States Federal Drug Administration (FDA) approved the use of 
a humanised monoclonal antibody, trastuzumab or herceptin, for the treatment of HER2 
positive breast cancers. Trastuzumab or herceptin is a humanised monoclonal antibody 
that targets the extracellular domain of the protein encoded by HER2 (Carter, et al., 1992). 
Herceptin was initially developed from a mouse monoclonal antibody which reacts with 
HER2, and was later humanised (Carter, et al., 1992). The HER2 receptor is not a tumour-
specific antigen because HER2 is expressed by many cells (Schlessinger, 2000). However, 
when HER2 receptors are expressed 10–100 times above normal levels, it becomes a 
target for herceptin therapy (Schlessinger, 2000). This attribute of HER2 receptors is 
useful when the purpose is to target only cancer cells, and this discrimination may 
contribute to the success of herceptin in breast cancer treatment. For patients to qualify for 
herceptin treatment they must show high levels of HER2 receptor expression as 
determined by immunohistochemistry (IHC) (Hudis, 2007). At the molecular level, the 
primary effect of herceptin is to induce regression of tumours that are positive for HER2. 
Although the mechanism of action is not fully understood, a variety of mechanisms have 
been proposed (Hudziak, et al., 1989; Shepard, et al., 1991). Herceptin on its own 
selectively binds to HER2 receptors due to antibody-antigen-specific binding, as 
illustrated in Figure 1.4. This is followed by internalisation of the herceptin via receptor-
mediated endocytosis. It has been suggested that upon internalisation various intra-cellular 
and extra-cellular events occur, such as cell cycle arrest which is induced due to down-
regulation of HER2, eventually leading to a reduction in cell proliferation, suppression of 
angiogenesis, antibody-dependant cell-mediated toxicity and finally cell death (Baselga, 
Albanell, & Molina, 2001; Izumi, Xu, & Tomaso, 2002; Roberto, Menard, & Fagnoni, 
2004). Further studies have reported that herceptin also causes increased cellular 
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sensitivity, and therefore when used in combination with chemotherapy therapy can 
produce synergistic effects (Konecny, Pegram, & Beryt, 1999; Pegram, et al., 1999; 
Pietras, et al., 1994). 
 
 
Figure 1. 4 The proposed mechanism of action of herceptin 
A variety of mechanisms have been proposed for the action of herceptin. Herceptin on its 
own selectively binds to HER2 receptors present on the surface of breast cancer cells, due 
to antibody-antigen-specific binding. When herceptin is internalised, cell cycle arrest is 
induced due to down-regulation of HER2 eventually leading to a reduction in cell 
proliferation, suppression of angiogenesis, antibody-dependant cell-mediated toxicity, and 
finally cell death. This figure is reproduced from Burstein et al. (2005). 
 
Initial clinical trials of herceptin in patients with HER2 positive metastatic breast 
cancer, who had relapsed after chemotherapy, demonstrated that herceptin was active and 
well tolerated (Baselga, et al., 1996; Cobleigh, et al., 1999). Phase 2 clinical trials also 
investigated the effects of herceptin when used in combination with chemotherapy drugs, 
such as cisplatin (Pegram, et al., 1998). This multi-centre trial reported objective clinical 
Action of herceptin 
Burstein et al., (2005)  
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response rates higher than previously reported for cisplatin or herceptin alone, confirming 
the success of herceptin in pre-clinical studies when used in combination with 
chemotherapy agents. The use of herceptin was then trialled in Phase 3 clinical trials, as a 
first-line treatment in combination with chemotherapy agent, paclitaxel, in patients with 
metastatic breast cancer (Slamon, et al., 2001). The aim of this trial by was to investigate 
the time to disease progression and the incidence of adverse effects in patients receiving 
chemotherapy alone or in combination with herceptin. The most troubling adverse effect 
of herceptin reported in this trial was associated cardiac dysfunction, which had not been 
reported in previous studies. Patients in this trial who received concurrent treatment with 
herceptin, anthracycline and cyclophosphamide significantly increased the risk of cardiac 
dysfunction. Nonetheless, outweighing the poor prognosis of HER2 positive breast 
tumours with cardiac toxicity, the results showed both increased survival times and 
increased time to disease progression in patients who received concurrent treatment with 
herceptin and first-line chemotherapy (Slamon, et al., 2001) .  
 
Since the results of this Phase 3 clinical trial, multiple trials have been conducted 
to evaluate herceptin with various chemotherapy regimes and different modes of 
administration and durations (Joensuu, et al., 2009; Perez, et al., 2007; Slamon, et al., 
2009; Spielmann, et al., 2009). Herceptin has also been trialled in the neoadjuvant setting, 
where multiple Phase 2 and 3 trials have been conducted in early and advanced stages, 
which have shown complete responses in some cases and better overall response rates 
compared to adjuvant settings (Buzdar, et al., 2005; Buzdar, et al., 2007; Gianni, et al., 
2010). 
 
Chapter 1 - Introduction 
   67
Despite the positive results of herceptin therapy, primary and secondary resistance 
to herceptin in both early and advanced disease has been shown (Goel, et al., 2010; Nahta 
& Esteva, 2006; Slamon, et al., 2001; Vogel, et al., 2002). Clinical evidence from Phase 2 
trials have shown response rates to herceptin alone ranging from 11% to 26%, suggesting 
that the majority of patients with HER2 expressing tumours demonstrate intrinsic 
resistance to herceptin alone (Baselga, et al., 1996; Cobleigh, et al., 1999; Vogel, et al., 
2002). Furthermore, although adjuvant therapy results in higher response rates, it has been 
reported that the duration of response to herceptin therapy either alone or in combination 
with chemotherapy was 5-9 months (Seidman, et al., 2001; Slamon, et al., 2001). The 
mechanism of acquired resistance is not fully understood and a number of mechanisms 
have been proposed (Nahta & Esteva, 2006). Price-Schiavi et al. (2002) and Nagy et al. 
(2005) proposed a mechanism involving disruption of the binding of herceptin to the 
target receptor protein. According to these studies, the disruption could be caused by a 
membrane associated glycoprotein mucin-4 (MUC-4) via multiple processes (Nagy, et al., 
2005; Price-Schiavi, et al., 2002). Furthermore, the function of MUC4 has been suggested 
to contribute to cancer progression because of its ability to inhibit immune recognition of 
cancer cells, promote tumour progression and metastasis, suppress apoptosis and activate 
HER2 (Carraway, et al., 2001). Another proposed mechanism of herceptin resistance is the 
signalling of other HER receptors that could contribute to the growth of HER2 positive 
tumours during herceptin treatment (Diermeier, et al., 2005). Herceptin causes the down-
signalling of HER2 by binding to HER2 receptors, but the function of herceptin does not 
reduce the action of other receptors that are part of the human epidermal growth factor 
receptor family, affecting the sensitivity of HER2 receptors to herceptin (Wick, Bürger, 
Funk, & Müller, 1995). Other proposed mechanisms of herceptin resistance include the 
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activation of pathways such as insulin-like-growth-factor-1 (Lu, Zi, & Pollak, 2004; Lu, 
Zi, Zhao, Mascarenhas, & Pollak, 2001).  
 
There is no doubt that elucidating the molecular mechanisms by which tumours 
escape herceptin-directed cytotoxicity is critical to improving the prognosis of patients 
with HER2 positive breast cancers. Combining herceptin with other novel biologic agents 
and therapeutic strategies for targeting HER2 receptors may increase the magnitude and 
duration of the clinical response (Nahta & Esteva, 2006). Many new agents are currently 
being tested, such as vaccines and novel HER-targeting agents, in combination with 
herceptin to target the epidermal growth factor receptor family in HER2 positive tumours 
(Nahta & Esteva, 2006). Equally important is the identification of those patients who 
could stop responding to herceptin and/or herceptin-therapy regimes. Accordingly there is 
a clinical need to select the best therapies for clinical indications, based on predictors of 
response, to identify cost-effective therapies for patients needing treatment. 
 
One aspect which is currently increasingly explored in the evaluation of patients 
receiving herceptin-based therapy is the use of nanoparticles in medical imaging. 
Nanoparticles such as iron oxides can be easily conjugated to herceptin and then imaged 
by imaging technologies such as MRI. This targeted imaging could potentially assist in the 
selection of patients who have stopped responding to herceptin-based treatment. The 
advantages of MRI over other imaging modalities lies primarily in its superior resolution, 
non-ionising radiation and longitudinal imaging capability (Kuhl, 2007). Results from 
preclinical studies have shown that iron oxide nanoparticles conjugated to herceptin can be 
used to image HER2 positive breast tumours (Chen, et al., 2009; Hilger, et al., 2007). 
Imaging the progress of herceptin treatment using iron oxide nanoparticles in MRI has the 
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potential to provide critical information about the efficacy of herceptin concurrently with 
treatment. Eventually, this technology could be used to develop a diagnostic and 
therapeutic evaluation tool for patients receiving herceptin-based treatment. 
 
1.4.4 Herceptin conjugated iron oxide nanoparticles in MRI 
 
  
The use of iron oxide nanoparticles for targeted imaging in MRI is currently at the 
preclinical stage. This is due to the inability of currently available iron oxide nanoparticles 
to be utilised in targeted imaging because of their large size and rapid clearance from the 
body. Furthermore, most iron oxide nanoparticles currently used in the preclinical setting 
cannot be used for routine clinical use because of several limitations such as the need for 
large dosages, the low magnetisation values, small scale synthesis capabilities and large 
particle size distribution (Budde & Frank, 2009; Corot, et al., 2006; Long & Bulte, 2009). 
A number of studies using iron oxide nanoparticles conjugated to herceptin have achieved 
successful targeting of HER2 positive breast tumours in vitro and in vivo, but each of these 
studies has particular limitations such as low magnetisation values, reduced contrast 
enhancement and small-scale production capabilities (Chen, et al., 2009). For example, a 
study by Hilger et al. (2007) showed less than 20% MRI signal enhancement at the breast 
tumour site using a minimum dosage of 20 mg/kg of iron oxide nanoparticles. Similarly, 
Chen et al. (2009) demonstrated low magnetic properties for their iron oxide nanoparticles 
conjugated to herceptin. In both these studies, higher contrast enhancement could have 
been observed if iron oxide nanoparticles with high magnetisation properties had been 
used. Interestingly, Huh et al. (2005) reported high magnetisation values and successful 
targeting of HER2 breast positive tumours in vitro and in vivo. However, the method used 
to produce their iron oxide nanoparticles conjugated to herceptin produced only small 
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amounts of iron oxide nanoparticles in one synthesis process and required several size 
separation processes.  
 
The principle of using iron oxide nanoparticles for targeted imaging of HER2 
positive breast tumours has been observed in previous studies (Chen, et al., 2009; Hilger, 
et al., 2007; Huh et al., 2005). However, these studies have not demonstrated that their 
iron oxide nanoparticles had all the desired characteristics such as high magnetic 
properties, high contrast enhancement, biocompatibility and a large-scale synthesis 
method. As discussed in the previous sections, these factors can greatly influence the 
translation of iron oxide nanoparticles to the clinical setting. Translation to a clinical 
application requires the synthesis of iron oxide nanoparticles that have the necessary 
characteristics for targeted molecular and cellular imaging such as high magnetisation 
values, low toxicity, biocompatibility, small size and low size distribution. Also desirable 
are an easy synthesis process and the ability to produce large amounts of iron oxide 
nanoparticles.  
 
To this end, the iron oxide nanoparticles produced in this study will be synthesised 
and tested for use in targeted imaging, as they will need to possess all the characteristics 
discussed above and be successfully conjugated to a tumour seeking agent such as 
herceptin.  
   
1.4.5 Summary of main themes 
 
  
This section of thesis introduced the different types of breast cancer that are categorised 
according to various schemes such as histopathological type, grade, stage, and the 
expression of proteins and genes, which determine diagnosis, prognosis and treatment 
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options. The classification according to expression of proteins and genes of breast tumours 
is important because it helps identify the prognostic and treatment options for the patient. 
One of the themes presented in this section related to HER2 positive breast cancers, which 
are characterised by an over-expression of HER2 receptors. Patients who present with 
HER2 positive breast tumours have a poor prognosis and decreased overall survival 
compared to patients with HER2 negative breast tumours. It has been proposed that 
identification of HER2 receptors on breast cancers will allow the use of more targeted 
tumour specific therapies using herceptin in suitable patients. Herceptin-based therapies 
have significant implications in the diagnosis, management and outcomes for patients with 
HER2 positive breast cancers. In this section, the assessment of herceptin therapy 
highlighted that patients eventually acquire resistance to herceptin, which could be due to 
multiple factors. As a result, many new agents are currently being tested including 
vaccines, novel HER2 receptor targeting agents and agents that target the epidermal 
growth factor receptor family in combination with herceptin. Concurrently, it is also 
proposed that before other treatment options become available and even after new 
treatment options are available it will be equally important to identify patients who could 
stop responding to HER2 based therapies. Overall, there is a clinical need to select the best 
therapies for particular clinical indications based on predictors of response. Equally 
important is the identification of cost effective therapies for patients needing treatment of 
HER2 positive tumours.  
 
An area of promise is the use nanotechnology in MRI for patients receiving 
herceptin-based therapies. Iron oxide nanoparticles conjugated to herceptin could be used 
to select herceptin resistance and improve treatment outcomes in patients using MRI. It 
was emphasised that the ability to image the progress of herceptin treatment using iron 
Chapter 1 - Introduction 
   72
oxide nanoparticles in MRI could provide critical information about the efficacy of 
herceptin concurrently with treatment. The principle of targeting HER2 positive tumours 
using MRI was shown to be well documented, but the inability to translate to the clinical 
setting lies in poor magnetisation properties, small signal enhancement, large size 
distribution and difficult synthesis processes. The aim therefore for future studies is to 
synthesise iron oxide nanoparticles that have the all the characteristics required for 
targeted molecular and cellular imaging, such as high magnetisation values, low toxicity, 
biocompatibility, small size and size distribution, and an easy synthesis process for 
producing large amounts of iron oxide nanoparticles. To demonstrate that the iron oxide 
nanoparticles produced in this study can be used for targeted imaging with all the 
characteristics discussed above, they will need to be conjugated to a tumour targeting 
agent such as herceptin in order to investigate the possibility for translation to clinical 
applications.  
 
1.5 Main aims of the thesis  
The main aims of this thesis are: 
1. To create a targeted contrast agent for MRI, 
2. To synthesise iron oxide silica nanoparticles addressing the five major 
characteristics of contrast agents for MRI, 
3. To create a targeted iron oxide silica nanoparticle via conjugation to herceptin, 
4. To evaluate the ability of the iron oxide silica herceptin nanoparticles to target 
HER2 positive breast cancer cells and demonstrate contrast enhancement in vitro, 
and 
5. To evaluate the ability of the iron oxide silica herceptin nanoparticles to target 
HER2 positive tumours and demonstrate contrast enhancement in vivo. 
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Chapter 2 Materials and Methods 
2.1  General chemicals and reagents 
Table 2.1 General chemicals and reagents 
Reagent Supplier 
1-octadecene Sigma-Aldrich (St Louis, MO, USA) 
Ammonia Sigma-Aldrich (St Louis, MO, USA) 
Carbon coated copper grids ProSciTech (Thuringowa, QLD, Australia) 
Cystamine Sigma-Aldrich (St Louis, MO, USA) 
Cystine Sigma-Aldrich (St Louis, MO, USA) 
Ethanol Sigma-Aldrich (St Louis, MO, USA) 
Formalin  Amber Scientific (Midvale, WV, Australia)
Hexane Sigma-Aldrich (St Louis, MO, USA) 
Iron chloride Sigma-Aldrich (St Louis, MO, USA) 
Matrigel BD Biosciences (Bedford, MA, USA) 
Oleic acid  Sigma-Aldrich (St Louis, MO, USA) 
Sephadex G-25M column Pharmacia (Rydalmere, NSW, Australia) 
Sodium oleate Sigma-Aldrich (St Louis, MO, USA) 
Tetraethyl orthosilicate (TEOS) Sigma-Aldrich (St Louis, MO, USA) 
 
2.2  Kits 
Table 2.2 Kits 
Reagent Supplier 
CellTiter 96 Aqueous One Solution Cell 
Proliferation kit 
Promega (Madison, WI, USA) 
FITC conjugation kit Sigma-Aldrich (St Louis, MO, 
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USA) 
Micro BCA protein assay kit Invitrogen (Carlsbad, CA, 
USA) 
 
2.3  Antibodies and conjugates  
Table 2.3 Antibodies and conjugates 
Reagent Supplier 
FITC Sigma-Aldrich (St Louis, MO, 
USA) 
FITC-anti-human IgG Pharmingen (BD Biosciences, 
Bedford, MA, USA) 
Herceptin* Roche Diagnostics (Castle Hill, 
NSW, Australia) 
Hoechst nucleus stain Molecular Probes (Invitrogen, 
Carlsbad, CA, USA) 
Novacastra antibody ** Novacastra (Leica Microsystems, 
GmbH, Germany) 
anti-Her2neu antibody Novacastra (Leica Microsystems, 
GmbH, Germany) 
Secondary antibody Dako Dual Envision  
anti-mouse and anti-rabbit HRP 
Dako (Glostrup, Germany) 
*Herceptin was kindly provided by Mr Peter Eu from the Peter MacCallum Cancer 
Centre. 
** Novacastra antibody was kindly provided by Dr Janine Danks from RMIT 
University 
 
2.4 Tissue culture reagents, drugs and equipment 
Table 2.4 Tissue culture reagents, drugs and equipment 
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Reagent Supplier 
24-well plates and 96-well plates Greiner Bio-one (Frickenhausen, 
Germany) 
Cell culture flasks Greiner Bio-one (Frickenhausen, 
Germany) 
Eppendorf Tubes Greiner Bio-one (Frickenhausen, 
Germany) 
Fetal bovine serum 10% Bovogen Biologicals (Victoria, 
Australia) 
Glass chamber slide 6-well Nunc Lab-Tek II (Roskilde, 
Denmark) 
Haemocytometer Hirschmann EM Techcolor 
(Heilbronn, Germany) 
L-glutamine 1mM Greiner Bio-one (Frickenhausen, 
Germany) 
RPMI 1640 medium Greiner Bio-one (Frickenhausen, 
Germany) 
Streptomycin/penicillin 1% Greiner Bio-one (Frickenhausen, 
Germany) 
Trypan blue Sigma-Aldrich (St Louis, MO, USA) 
Trypsin-EDTA solution (0.25% trypsin, 1 
mM EDTA) 
Invitrogen (Carlsbad, CA, USA) 
 
2.5  Cell lines 
Table 2.5 Cell lines 
Reagent Supplier 
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SKBR3 American Type Culture Association (ATCC) (Manassas, VA, USA)
BT474 American Type Culture Association (ATCC) (Manassas, VA, USA)
MCF7* American Type Culture Association (ATCC) (Manassas, VA, USA)
* MCF7 cells were kindly provided by Professor Geoffrey Pietersz from the 
Burnet Institute 
 
2.6 Animals  
Female BALB/c nude mice 4-6 weeks of age were sourced from the Animal 
Resource Centre (ARC; Canning Vale, WA, Australia). BALB/c nude mice were 
used for studying the uptake and contrast enhancement of the iron oxide silica 
herceptin nanoparticles after intravenous injection for MRI in HER2 positive 
tumours. SKBR3 tumours were grown by subcutaneously injected 3x106 SKBR3 
cells in BALB/c nude mice. All animal experiments were performed as approved 
by RMIT Animal Ethics Committee (AEC approval number 0906). 
 
2.7 Common buffers and solutions 
Table 2.6 Common buffers and solutions 
Reagent Composition 
0.01M citrate buffer 0.01M, pH 6 
FACS Fix buffer 1% paraformaldehyde
2% glucose 
0.02% azide 
96.98% PBS 
PBS pH 7.4 
 
2.8 Equipment 
Eppendorf Mini Spin Plus Centrifuge (Eppendorf, Hamburg, Germany) 
Beckman Coulter Allegra X-22 Centrifuge (Becman Coulter, CA USA) 
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Unisonics Sonicator Model FXP08M (Unisonics, NSW, Australia) 
Harvard Apparatus PHD 22/2000 Syringe Pump (Harvard Apparatus, MA, USA) 
IKA RW 16 basic overhead stirrer (IKA Works Asia, Petaling Jaya, Malaysia) 
JEOL 1010 electron microscope (Jeol Korea, Korea) 
Bruker D8 ADVANCE X-ray diffractometer (MBraun, NH,USA) 
SQUID Quantum Design MPMS-XL5 (CA, USA) 
Atomic absorption spectrometer (AAS) Varian AA280FS Fast Sequential (CA, 
USA) 
3.0 Telsa Siemens Trio Magnetom Whole Body Clinical MRI Scanner (Siemens, 
Medical Solutions, PA, USA) 
Q- Sense E4 QCM-D (ATA Scientific, NSW, Australia) 
Becton Dickinson FACSCalibur Flow Cytometer (BD Biosciences, Bedford, MA, 
USA) 
UV/Visible Spectrophotometer Cintra 5 (Victoria, Australia) 
Zeiss Confocal microscopy 
 
2.9 Synthesis of iron oxide nanoparticles 
The iron oxide nanoparticles were synthesised jointly by Jos Campbell and me at the 
School of Applied Sciences. The iron oxide nanoparticles were synthesised using a two-
step process modified from Park et al. (2004). An iron oleate complex was first formed by 
dissolving 5.4 g of iron chloride and 18.25 g of sodium oleate in a solution comprised of 
40 mL ethanol, 30 mL distilled water and 70 mL hexane. Once homogenised, the solution 
was refluxed at 70°C for 4 hours, followed by separation of the upper organic layer using 
a separatory funnel, washing and evaporating off hexane, thereby leaving a waxy iron 
oleate complex. The iron oxide nanocrystals were formed by dissolving 9.0 g of the iron 
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oleate complex in 1.425 g of oleic acid and 63.3 mL of 1-octadecene, followed by reflux 
under nitrogen until it reached 320°C, at which point the temperature was held for 30 
minutes and the solution was then allowed to cool to room temperature. 250 mL of ethanol 
was added to the solution and the magnetite particles were separated via centrifugation, 
followed by three wash cycles with ethanol. At least 40 g magnetic nanoparticles per 
reaction could be achieved under these laboratory conditions. 
 
2.10 Synthesis of iron oxide silica nanoparticles  
Silica-coated iron oxide nanoparticles were prepared using a method modified from Fang 
et al. (2008). 1 mg of iron oxide nanoparticles from the previous step were sonicated in a 
solution consisting of 15 mL ethanol and 2 mL deionised water. 1 mL of ammonia (25% 
solution) was added to the above solution while it was immersed in a sonicator 
programmed to switch on for 1 in every 10 min. As well, an overhead stirrer was used to 
mix the solution while 4 mL of 1:60 (tetraethyl orthosilicate:ethanol, TEOS) was added at 
the rate of 0.4 mL per hour using a syringe pump, and the solution was stirred at room 
temperature for 12 hours. The silica coated iron oxide nanoparticles were then centrifuged 
and washed three times with ethanol and redispersed in milli-Q water. 
 
2.11 Synthesis of iron oxide silica herceptin nanoparticles 
Iron oxide silica nanoparticles from the previous method were resuspended in milli-Q 
water and then conjugated to herceptin using a cystamine linker. 2 mg of iron oxide silica 
nanoparticles and 0.04 mg of cystamine were incubated for 2 hours at room temperature 
and then washed several times in milli-Q water using a centrifuge. 6 mg of herceptin (1:3 
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ratio, with herceptin in excess) was added and incubated at room temperature for another 2 
hours and then washed several times in milli-Q water by centrifugation.  
2.12 Characterisation of iron oxide silica nanoparticles 
2.12.1 TEM 
Transmission electron microscopy (TEM) analysis was performed jointly by Jos Campbell 
and me using a JEOL 1010 electron microscope (Jeol Korea, Korea) operating at an 
accelerating voltage of 100 KeV. The resulting iron oxide silica herceptin nanoparticles 
were drop cast on strong carbon-coated copper grids and allowed to dry for one hour prior 
to scanning. The micrographs were enlarged at magnification of 400,000. The size of 
nanoparticles were assessed manually using the scale bar and generating an average 
particle size after each synthesis process (n = 20) 
 
2.12.2 XRD 
XRD spectra were collected at room temperature on a Bruker D8 ADVANCE X-ray 
diffractometer, fitted with a graphite-monochromated copper tube source and a 
scintillation counter detector (MBraun, USA). The samples were drop cast onto glass 
sample holders to form a thick layer before undergoing XRD analysis. The samples were 
then placed inside the XRD and irradiated with copper per Kα radiation (wavelength 
1.5406 Ã). The diffraction patterns were measured with 0.020 step size, 2.0 seconds 
time/step at 40 kV and 35 mA. The peak areas were determined from computer integration 
of the diffraction patterns. 
 
2.12.3 SQUID 
The synthesised iron oxide nanoparticles (50 g) were dried overnight to form a fine 
powder. The particles were then posted the Indian Technology Institute in Kanpur, Uttar 
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Pradesh, India. The particles were prepared and analysed using a superconducting 
quantum interference device (SQUID) by Dr Ashish Garg. Specifically, the magnetisation 
measurements were obtained at ambient temperatures and nonstoichiometric magnetite 
samples were measured as control. 
 
2.12.4 T2 Relaxation 
The iron oxide silica nanoparticles 10 μg, 50 μg and 100 μg, were suspended in milli-Q 
water, in a volume of 1 ml, in triplicates. A 3.0 Tesla Siemens Trio MRI scanner with a 
12-channel head coil was used to scan the samples (Siemens, USA). T2 relaxation times 
were determined by using a single echo sequence (SE) with a constant repetition time 
(TR) of 2000 ms and multiple echo times (TE) ranging from 0.99 to 100 ms. The signal 
was plotted as a function of TE and fitted to the established mono-exponential expression. 
The T2 values were determined by plotting the relaxation time (i.e. reciprocal of the 
relaxation rates) at a TE of 10.86 ms, as a function of molar iron concentration in 
respective samples (determined by AAS), and extracting the T2 value from the slope by 
linear regression. The mean was calculated from triplicate measurements and the error was 
calculated as the standard error of the mean. 
 
2.12.5 Micro BCA protein assay and QCM 
The amount of herceptin on the surface of the iron oxide-silica nanoparticles was 
quantified using a BCA protein assay kit following the manufacturer’s instructions 
(Invitrogen, USA). Triplicate measurements were taken where samples were prepared in 
96-well plates and read using a plate reader at absorbance 562 nm. 
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The quartz crystal microbalance (QCM) flow was controlled by an ISMATEC pump IPC 
(high precision multichannel dispenser). The QCM was run using gold coated quartz 
microbalance chips that were new before use. The chips were washed as per 
manufacturer’s instructions and during the experimental process iron oxide silica 
nanoparticles, herceptin, cystine and cystamine were suspended in PBS solution at pH 7. 
Triplicate experiments were carried out in duplicates, using identical cells running in 
parallel on the same instrument. Each component was added in sequence and allowed to 
bind to the surface of the chip for 30 minutes before washing with PBS. First cystine was 
added, followed by cystamine, iron silica nanoparticles and then herceptin. The data was 
analysed visually by the amount of frequency drop generated by the addition of each 
component. The measurements were recorded for each run and then an average was 
calculated.  
 
2.12.6 Stability of iron oxide silica herceptin nanoparticles 
The stability of the iron oxide silica herceptin nanoparticles was assessed by conjugating a 
fluorescein isothiocyanate (FITC) molecule to the herceptin antibody on the iron oxide 
silica nanoparticles in triplicates. The FITC conjugation was performed using a FITC 
conjugation kit according to the manufacturer’s protocol for a small-scale conjugation 
procedure. The iron oxide silica herceptin-FITC nanoparticles were exposed to pH buffers 
(5, 7.14, 10) and human serum concentrations (25%, 50%, 100%) over a 24 hour time 
course (1 h, 3 h, 5 h, 8 h and 24 h). The degradation of the particles was assessed by loss 
of protein in the supernatant indicated by an increase in fluorescence in the supernatant 
based on a standard concentration series of herceptin-FITC molecules. The iron oxide 
silica nanoparticles were added to various pH and human serum conditions at a 
concentration of 2.067 mg and incubated at 370ºC for the time points listed above. The 
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nanoparticles were then centrifuged and the supernatant was transferred to 96-well plates 
and read using a micro plate reader. The amount of herceptin-FITC in the supernatant was 
calculated and compared to a standard curve of a known amount of herceptin. The results 
were analysed according to the amount of herceptin retained on the iron oxide silica 
nanoparticle sample. The mean value was calculated from triplicate samples and the error 
was calculated as standard error of the mean. 
 
2.13 In vitro studies 
 
2.13.1 Preparation of the fluorescently labelled iron oxide silica herceptin nanoparticles 
To conduct flow cytometry cell uptake studies, fluorescently labelled iron oxide silica 
herceptin nanoparticles were made. The herceptin was conjugated to FITC using a FITC 
conjugation kit following the small-scale conjugation procedure according to the 
manufacturer’s recommended protocol. 6 mg of herceptin was first purified using a 
sephadex G-25M column and then FITC was added three-times in excess and incubated 
for 2 hours at room temperature. Un-bound FITC was removed using a sephadex-G25M 
column following the manufacturer’s protocol of the FITC-conjugation kit. Excess 
herceptin was then removed by washing several times via centrifugation. The amount of 
herceptin on FITC was calculated by absorption readings from a UV/visible 
spectrophotometer for FITC-IgG conjugates according to the following equations: 
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(1) Molar F/P     =   2.77 X A495 
                      A280 – (0.35 X A495) 
 
      (2) Protein concentration IgG (mg/ml)  =   A280 – (0.35 X A495) 
    1.4 
  
The FITC-herceptin complex was then added to the iron-silica via the cystamine linker 
and after 2 hours incubation at room temperature was washed several times with milli-Q 
water. 
 
2.13.2 Human breast cancer cell lines 
Three breast cancer cell lines (SKBR3, BT474 and MCF7) were routinely cultured at 37˚C 
in a humidified atmosphere with 5% CO2 using RPMI 1640 medium supplemented with 
10% fetal bovine serum (FBS), 1% streptomycin/penicillin and 1mM L-glutamine. For 
subculturing, the breast cancer cells were detached by washing with PBS and incubating 
with trypsin-EDTA solution (0.25% trypsin, 1 mM EDTA) for 5 min at 37˚C, followed by 
washing and incubation with supplemented RPMI 1640 medium.  
 
2.13.3 Quantification of HER2 surface expression  
Quantification of HER2 expression on SKBR3, BT474 and MCF7 cells was assessed by 
flow cytometry. Cells were cultured using the previously described method, seeded onto 
24-well plates and grown to 90% confluency. Cells were detached using trypsin and media 
was removed by centrifugation. Cells were quantitated by trypan blue stain and then 
resuspended in PBS. 10mg of herceptin was added to the cells for 30 minutes at 4ºC 
followed by two PBS washes and then incubated with anti-human IgG-FITC for 30 
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minutes at 4ºC. The removal of the primary antibody from these treatments was used as a 
measurement of non-specific binding of the secondary antibody. The cells were washed 
and then analysed by flow cytometry (FACSCanto, BD Biosciences; RMIT Flow 
Cytometry Facility) where a population of 10,000 live cells was collected and the mean 
fluorescence intensity was analysed. The stimulation index of mean fluorescence intensity 
was calculated by dividing the mean fluorescence intensity value of the treated cells by the 
mean fluorescence intensity value of the controls. The stimulation index of staining above 
the control was calculated for triplicate studies and then plotted as the stimulation index 
mean ± standard deviation.  
 
2.13.4 Dose response of iron oxide silica herceptin nanoparticles in vitro  
SKBR3, BT474 and MCF7 cells were cultured until 90% confluency, detached with 
trypsin-EDTA solution for 4 min at 37ºC. The cells were centrifuged to remove media 
with serum and live cells were counted using trypan blue staining. The cells were then 
seeded on 24-well plates and resuspended in 1 ml of serum-free media. 10 µg, 50 µg and 
100 µg of iron oxide silica herceptin nanoparticles were added to each cell line and 
incubated for 24 hours at 37ºC in a humidified atmosphere with 5% CO2. Cells were 
detached as described above, washed by centrifugation as described above, and 
resuspended in PBS and analysed by flow cytometry as previously described. 10,000 
viable cells were analysed on the basis of forward versus side scatter and the stimulation 
index of the mean fluorescence intensity was calculated as previously described. An 
average of the mean fluorescence intensity was calculated for the triplicate data. The 
stimulation index of staining above the control was calculated as described above and then 
plotted as the stimulation index mean ± standard deviation.  
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2.13.5 Time course of iron oxide silica herceptin nanoparticles uptake in vitro 
For the time course study, the same procedure was conducted as with the dose response 
study, in triplicates. The iron oxide-silica herceptin nanoparticles (50 µg) conjugated to 
FITC were incubated at various time points (0.5, 1, 3, 5 and 24 hours) at 37ºC in a 
humidified atmosphere with 5% CO2. Cellular uptake was assessed by flow cytometry and 
analysis as previously described. 
 
2.13.6 Uptake of iron oxide silica herceptin nanoparticles by confocal microscopy 
In vitro visualisation of iron oxide silica herceptin nanoparticles was assessed by confocal 
microscopy. SKBR3 cells were cultured until 60% confluency, detached, centrifuged and 
then seeded onto a 6-well slide glass chamber. The cells were treated with 50 mg of iron 
oxide silica herceptin-FITC nanoparticles for 4 hours at 37ºC in a humidified atmosphere 
with 5% CO2 for 30 minutes before imaging, a Hoechst nuclear stain was added and cells 
were washed several times with PBS before imaging by confocal microscopy. The uptake 
of the particles were assessed visually by identifying FITC and the nucleus stain. 
 
2.13.7 In vitro toxicity of iron oxide silica herceptin nanoparticles 
The viability of SKBR3 cancer cells exposed to iron oxide silica herceptin nanoparticles in 
the absence of a cell growth medium was determined by a CellTiter 96 AQueous One 
Solution Cell Proliferation Assay kit containing the tetrazolium compound 3-(4,5-
dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium 
(MTS) according to the manufacturer’s recommended protocol (Promega, USA). SKBR3 
cells were cultured until 90% confluency, detached using tryspin/EDTA, and viable cells 
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were counted using trypan blue, all as described above. The cells were seeded into 96-well 
plates in triplicates and resuspended in serum-free media and incubated with 1, 3, 5, 10, 
30, 50, 100 µg/ml of iron oxide silica herceptin nanoparticles for 24 and 48 hours at 37ºC 
in a humidified atmosphere with 5% CO2. MTS colour change was monitored using a 
plate reader at 490 nm, and cell viability data was plotted by considering the viability of 
untreated cells as 100%. The mean was calculated from triplicate samples and error was 
calculated as the standard error of the mean. Statistical analysis was performed by one-
way ANOVA and Dunnett’s test. Toxicity was considered significant for p < 0.05. 
2.14 In vivo animal studies  
 
2.14.1 HER2 positive tumours 
HER2 tumours were grown in the right flank of BALB/c nude mice by subcutaneous 
injection. 2.5-3 x106 SKBR3 breast cancer cells were suspended in an equal volume of 
Matrigel (BD Biosciences, USA) and made up with PBS to a total volume of 200 μL. A 
pilot study monitoring tumour growth was conducted prior to iron oxide silica herceptin 
nanoparticle injection to monitor and confirm the growth pattern of SKBR3 tumours in 
BALB/c nude mice (n= 3) over a 2 week period. The mean was calculated from the 
triplicate tumour measurements. The error bars were calculated by standard deviation of 
the mean.  
 
2.14.2 HER2 receptor expression of SBKR3 tumours grown in vivo 
SBKR3 tumours were confirmed for their HER2 expression by dissecting SKBR3 grown 
tumours in BALB/c nude mice by immunohistochemical analysis. Dissected tumours were 
fixed in 10% neural buffered formalin for 24 hours, processed and embedded in paraffin 
wax and cut onto microscopic slides at 4 μM thickness. Immunohistochemical staining of 
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HER2 was performed according to standard protocols with antigen retrieval performed 
using heat and citrate buffer at pH 6. Sections were stained with an anti-HER2 antibody 
(Novacastra, Germany), followed by a pre-diluted dual link anti- mouse/anti-rabbit 
polymer conjugated to horseradish peroxidase (HRP) which was used as secondary 
antibody (DAKO, Glostrup, Germany), and the chromagen 3, 3’-diaminobenzidine (DAB) 
was used to visualise the localisation of probed antigens through HRP catalysed reaction. 
Images of stains were taken using DMD108 micro-imager (Leica microsystems, 
Germany).  
2.14.3 Toxicity analysis of iron oxide silica herceptin nanoparticles 
To evaluate the toxic effect of iron oxide silica herceptin nanoparticles in vivo, acute 
toxicity by histopathological analysis was performed. Three experimental groups of 
BALB/c nude mice (n=3) were established. The first group was injected intravenously 
with iron oxide silica herceptin nanoparticles at 20 mg/kg in a maximum volume of 200 
µl, a second group injected intravenously with iron oxide silica nanoparticles at 20 mg/kg 
and a third group injected intravenously with PBS. Any change in behaviour, health and 
weight was closely monitored and recorded daily for 7 days post-injection. After 7 days, 
the mice were anaesthetised with ketamine (80 mg/kg body weight) and xylazine (5 mg/kg 
body weight). Blood was collected from each mouse by cardiac puncture and samples 
were sent to Animal Pathology Laboratory PTY LTD for full biochemistry, liver function 
and kidney function analysis. Mice were sacrificed and liver, lungs, kidneys and heart 
were dissected and embedded in OCT medium and snap frozen in liquid nitrogen for 
cryosectioning. Frozen samples were cut, stained and analysed by the Australian 
Phenomics Network (APN) at the University of Melbourne. Cryosections were cut at 5 
mm thickness and stained for hematoxylin and eosin (H&E). The tissues were analysed 
and a report prepared by a veterinary pathologist.  
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2.15 MRI studies 
 
2.15.1 Phantom contrast enhancement 
The phantoms for MRI were prepared with iron oxide silica nanoparticles 10 µg, 50 µg, 
100 µg were suspended in 1 ml of milli-Q water and a control was prepared containing 
milli-Q water without any nanoparticles. The MRI of the phantoms were performed in 
triplicates on a 3.0 Tesla Siemens MRI scanner (Siemens, USA) using a 12-channel head 
coil and the following parameters: T2-weighted imaging, gradient echo sequence, multiple 
TE ranging from 0.99-100 ms, TR= 2000 ms, matrix 128x128, slice thickness of 3 mm. 
Data analysis was performed manually by placing regions of interest (ROIs) around each 
sample concentration on the MRI image. The signal enhancement of each of the phantom 
concentrations was calculated relative to the control using the formula: ∆R2/R2control 
*100. The mean was calculated from triplicate measurements and the error was calculated 
as the standard deviation of the mean. 
 
2.15.2 In vitro contrast enhancement 
Iron oxide nanoparticles were prepared and conjugated to herceptin via the previously 
discussed protocols. SKBR3, BT474 and MCF7 cells were cultured, detached with 
trypsin-EDTA as previously described, washed and seeded onto 6-well plates and 
incubated with supplemented RPMI 1641 medium without serum as previously described. 
The experiment was conducted in triplicates. Cells were treated with 50 μg of iron oxide 
silica herceptin nanoparticles and incubated for 5 hours at 37ºC. Before imaging on MRI 
the cells were washed three times with PBS and resuspended in 1 ml of milli-Q water. A 
T2-weighted gradient echo sequence was used with the same parameters as in the phantom 
studies. Signal enhancement of each of the cell lines was calculated relative to the control, 
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using ∆R2/R2control *100. The mean was calculated using triplicate measurements and 
the error was calculated as the standard deviation of the mean. 
 
2.15.3 In vivo contrast enhancement 
Nude mice bearing subcutaneously grown SKBR3 xenografts were studied by MRI when 
tumours reached a diameter of approximately 8 mm in diameter. The first group of mice 
(n=5) were injected intravenously with iron oxide silica herceptin nanoparticles (400 µg in 
200 µl), the second group of mice (n=5) were injected intravenously with iron oxide silica 
nanoparticles (400 µg) and the third group of mice (n=5) were injected with PBS. Before 
MRI scanning mice were anaesthetised with ketamine (80 mg/kg body weight) and 
xylazine (5 mg/kg body weight). The MRI scan was performed at 4 hrs and 24 hours post-
injection of contrast agents or saline using a 3.0 Tesla magnetic resonance scanner and a 
head coil (Siemens, USA). All animals were measured using a T2-weighted sequence with 
the following parameters: TE 76 ms, TR 2000 ms, FOV 100x100 mm, slice thickness 1.7 
mm. Data analysis was performed manually by placing ROIs around the tumour and tissue 
areas on the images and signal enhancement of the tumours was calculated relative to the 
control using the formula: ∆R2/R2control *100. The mean was calculated using the data 
from each group of five mice. The error bars represent standard deviation of the mean.
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Chapter 3 Synthesis of Iron Oxide Nanoparticles and their Conjugation 
to Herceptin 
3.1 Introduction 
There is an increasing demand to develop iron oxide nanoparticles as targeted contrast 
agents for use in MRI. For targeted imaging, iron oxide nanoparticles are precisly 
conjugated to molecular or cellular biomarkers which act as vehicles driving the 
nanoparticles to a targeted area, allowing precise detection of particular pathologies. 
Newly developed iron oxide nanoparticles allow the attachment of tumour-associated 
markers. One example is the attachment of the anti-carcinoembryonic antigen (CEA) 
monoclonal antibody rch 24 (Hu, et al., 2006). The CEA rch 24 antibody is specifically 
expressed by human colon carcinoma cells, allowing direct in vitro and in vivo imaging of 
the cancer cells using MRI (Hu, et al., 2006). The benefit of using MRI for targeted 
imaging over other imaging modalities such as nuclear medicine and PET arises because 
of its superb spatial resolution (Mitchell & Cohen, 2003). The iron oxide nanoparticles are 
utilised in MRI to provide contrast enhancement between anatomical structures, improving 
the specificity of MRI. This enhanced specificity, combined with the inherent high spatial 
resolution of MRI, together provide a powerful tool for targeted imaging.  
 
For iron oxide nanoparticles to be utilised as targeted imaging contrast agents, a number of 
characteristics to facilitate optimal targeted imaging need to be considered (Gupta & 
Gupta, 2005; Jun, Lee, & Cheon, 2007). These characteristics include high magnetic 
properties, biocompatibility and low toxicity, ease of conjugation to biomarkers, and size 
and size distribution of the nanoparticles. Currently commercially available iron oxide 
nanoparticles are not suitable for targeted imaging because they do not possess all the 
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characteristics required for optimal targeted imaging. The most important characteristic of 
iron oxide nanoparticles for targeted imaging in MRI is their magnetic property, as it 
determines their ability to be used as a contrast agent (Gupta & Gupta, 2005). High 
magnetic properties such as large mass magnetisation values and T2 relaxation values are 
required so that the maximum possible contrast can be visualised in MRI both in vitro and 
in vivo (Gupta & Gupta, 2005; Lee, et al., 2007). Commercially available contrast agents 
such as Resovist® are primarily made via the common co-precipitation method (see 
Chapter 1 Section 1.3.3.1) which produces large amounts of nanoparticles at the expense 
of low mass magnetisation values and lower T2 relaxation values. 
 
Another important characteristic for iron oxide nanoparticles for targeted imaging is the 
size of the contrast agent. This factor is important as the hydrodynamic diameter of the 
nanoparticle can affect its biodistribution in vivo (Berry & Curtis, 2003). The 
biodistribution and excretion pathway of iron oxide nanoparticles was discussed in detail 
in Chapter 1 Section 1.3.5. Iron oxide nanoparticles are eventually taken up by the RES 
where they are cleared by the liver and spleen. In general, particles larger than 60 nm are 
taken up by the RES upon intravenous injection (within 1 hour) and accumulate in the 
liver and spleen (Qiao, Yang, & Gao, 2009). Particles smaller than 60 nm, do not 
accumulate in the RES as quickly, and their presence for longer periods within the 
circulation allows particles to localise at a targeted area more effectively. For targeted 
imaging of iron oxide nanoparticles, therefore, one of the main requirements is a size 
smaller than 60 nm to ensure uptake at the targeted area before clearance by the RES. 
Commercially available Feridex® and Resovist® are iron oxide nanoparticles with size 
ranges of 80-180 nm and 60 nm respectively, and are used only for imaging of the liver 
and spleen (Josephson, 2006; Qiao, et al., 2009). Because the size of Feridex® is greater 
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than 60 nm these iron oxide nanoparticles would be unsuitable for targeted imaging; 
moreover, Feridex® has a large range of particle size distribution. Other iron oxide 
nanoparticles such as GastroMARK™ and Abdoscan® are specifically designed for 
imaging the gastrointestinal lumen (Josephson, 2006; Qiao, et al., 2009), but their size is 
no less than 300 nm and the only administration route is oral. These properties also make 
both GatstroMARK™ and Abdoscan® unsuitable for targeted imaging.  
 
Another important factor is the size distribution of iron oxide nanoparticles, as different 
sizes of iron oxide nanoparticles will distribute differently in vivo. For targeted imaging it 
would be optimal to ensure that most of the administered iron oxide nanoparticles localise 
first at the targeted area, with minimal non-specific uptake. In a sample with large particle 
size distribution, there would be non-specific uptake of larger nanoparticles and reduction 
in the amount of iron oxide nanoparticles available to reach the targeted area. 
Commercially available Feridex® has a size distribution of 80-180 nm, making it 
unsuitable for targeted imaging (Advanced-Magnetics, 2007). Thus currently approved 
iron oxide nanoparticles are not suitable for use in targeted imaging, because they do not 
possess the most important characteristics required for targeted contrast agents, namely 
magnetic properties, size and particle size homogeneity. Therefore, study is needed of the 
development of iron oxide nanoparticles that address these characteristics (Jun, et al., 
2007; Qiao, et al., 2009). This study addresses all of the characteristics required to achieve 
targeted imaging using iron oxide nanoparticles in MRI. 
 
As discussed in Chapter 1 (Section 1.3.3.1), there are many methods of iron oxide 
nanoparticle synthesis, each having a significant affect on the overall characteristics of the 
iron oxide nanoparticles produced. The chemical methods of iron oxide nanoparticle 
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production that have been explored so far include hydrothermal and non-hydrothermal 
methods. It has been highlighted in this thesis that the non-hydrothermal method produces 
iron oxide nanoparticles which are more suitable for use as MRI contrast agents because 
they have higher magnetic properties and better control over individual size and size 
distribution of the nanoparticles (Gupta & Gupta, 2005). The thermal decomposition 
method developed by Park et al. (2004) is the only reported method to produce iron oxide 
nanoparticles that were biocompatible, non-toxic, easily reproduced in large batches, and 
display a good particle size distribution. Park et al. (2004) utilised iron oleate as a 
precursor and then thermally decomposed the nanoparticles at temperatures up to 3200C, 
and were able to produce large-scale amounts (>10 g) of nanoparticles compared to other 
non-hydrothermal production methods. The authors suggested that the high temperatures 
were an effective tool for achieving iron oxide nanoparticles of different sizes, and the key 
to monodispersity was in separating nucleation and growth processes. This thermal 
decomposition method has significant advantages over hydrothermal methods as the 
particles produced have smaller size distributions (<5%), better control over 
hydrodynamic diameter, higher crystallinity and therefore highly magnetic particles. The 
method also has an advantage over other non-hydrothermal methods as the process is 
relatively easy to reproduce and bulk masses of iron oxide nanoparticles can be created in 
one synthesis process (up to 10 g). 
 
Despite these advantages of the thermal decomposition method, one of the disadvantages 
is the inability to produce water soluble particles. Different approaches have been 
developed for achieving increased water solubility, including modifying the surface of the 
iron oxide particles by ligands such as DMSA (Huh, et al., 2005) and polymers such as 
PEG and dextran (Berry, et al., 2003; Kim, et al., 2001;  Paul, Frigo, Groman & Groman, 
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2004). Attachment to the surface layer is advantageous because a selection of biomarkers 
can be attached depending on the purpose of the study. Having stated this, it is important 
to note that in any iron oxide nanoparticle production there is an inherent need for surface 
coating in the iron oxide nanoparticle synthesis process. Not only do these surface 
coatings serve to increase water solubility, but the hydrothermal methods also utilise 
surface coatings for the attachment of various biomarkers onto the surface. Another reason 
for the use of a surface coating is to reduce aggregation of the particles in vivo due to 
protein adsorption and to bypass the RES, increasing blood circulating time (Berry & 
Curtis, 2003; Gupta & Gupta, 2005; Laurent, et al., 2008). Overall, the thermal 
decomposition method is suggested to be a superior method of producing iron oxide 
nanoparticles, and the need for a surface layer only helps to improve its suitability for use 
as a targeted iron oxide contrast agent. 
 
One of the most widely used surface coatings for iron oxide nanoparticles is dextran 
because of its proven inert nature and biocompatibility (Bonnemain, 1998; Jung & Jacobs, 
1995; Qiao, et al., 2009). Dextran is used with approved contrast agents such as Feridex® 
and Resovist® (Bonnemain, 1998; Jung & Jacobs, 1995; Qiao, et al., 2009). Other surface 
coatings have also been investigated, including carbohydrates and small molecules such as 
DMSA (Fauconnier, Pons, Roger, & Bee, 1997) and citric acid (Bee, Massart, & Neveu, 
1995) and results appear promising, although they remain in a prelinical setting. Silica is 
another promising surface coating because there are approved silica coated iron oxide 
nanoparticles which are used as oral contrast agents imaging for the gastrointestinal lumen 
(GastroMARK™ and Abdoscan®) (Bonnemain, 1998; Hahn, et al., 1990; William, 
Christophoros, Gladys, Eugene, & Pablo, 1996). The approved contrast agents, 
GastroMARK™ and Abdoscan®, are large iron oxide particles, approximately 300 nm in 
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diameter and are adminstered orally (Advanced-Magnetics, 2007); for other applications 
the size would need to be reduced. The use of silica coated iron oxide nanoparticles in 
targeted imaging has not been widely investigated because there has been difficulty in 
controlling the size of the silica shell on the surface of the iron oxide nanoparticle.  
 
In the last few years interest in silica coatings has increased, and many studies have shown 
the ability to control the size of the silica shell, thereby increasing the potential for silica 
coated iron oxide nanoparticles to be used in targeted imaging (Deng, Wang, Hu, Yang, & 
Fu, 2005; Fang, et al., 2008; Im, Herricks, Lee, & Xia, 2005; Liu, Xing, Guan, Shan, & 
Liu, 2004; Morel, et al., 2008). Several modifications have resulted in excellent size 
control of the silica shell, allowing sizes between 2 nm and 100 nm (Fang, 2008; Lu, et al., 
2002). It has been shown that silica is an inert material and as a surface coating can 
prevent aggregation of iron oxide nanoparticles in liquids, thereby improving stability 
(Deng, et al., 2005; Laurent, et al., 2008). Another advantage of silica is that it can bind to 
a range of biomarkers due to its terminal available silanol groups (Ulman, 1996). These 
advantages increase interest in designing and synthesising magnetic iron oxide carriers 
that can be used to deliver specific ligands to target organs. 
 
An important and widely investigated biomarker is HER2, which is overexpressed in 
many cancers. In breast cancer, HER2 receptors are associated with increased disease 
recurrence and poor prognosis in patients (Slamon, et al., 1987, 1989). Approximately 20-
25% of breast cancers overexpress HER2 (Slamon, et al., 1987), and for this reason the 
HER2 receptor has been used as a target for immunotherapy agents such as herceptin. 
Herceptin works by binding to the HER2 receptor on the surface of the tumour cell, 
causing downregulation of HER2 production, eventually causing cell death and reduction 
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in the size of the tumour (Nahta & Esteva, 2006). Herceptin has also been shown to 
increase the sensitivity of the tumour cells to chemotherapeutic agents (Pegram, et al., 
2004), therefore its use in conjunction with a variety of chemotherapy agents has 
synergistic effects, improving overall survival rates and time to disease progression 
(Slamon, et al., 2001). Despite the positive effects of herceptin on HER2 expressing breast 
cancers, herceptin-based therapies eventually acquire resistance (Esteva, et al., 2002; 
Nahta & Esteva, 2006; Slamon, et al., 2001; Vogel, et al., 2002). The mechanisms of 
acquired resistance and low response rates are not fully understood but a range of 
possibilities has been suggested (as discussed in Chapter 1). Since it is difficult to predict 
which patients will respond and stop responding to herceptin therapy regimes, an area of 
increasing research is using imaging technologies such as MRI to predict treatment 
responses. The ability to image the progress of herceptin treatment using iron oxide 
nanoparticles as contrast agents in MRI might be useful in providing critical information 
about the efficacy of herceptin concurrently with other treatment.  
 
Many studies have not used clinically available iron oxide nanoparticles but have prepared 
newly synthesised iron oxide nanoparticles to successfully target HER2 receptors 
(Artemov, Mori, Okollie, & Bhujwalla, 2003;  Chen, et al., 2009; Hilger, et al., 2007; Huh, 
et al., 2005). There have been limitations, however, in the newly developed iron oxide 
nanoparticles in the translation from pre-clinical to clinical settings. This is primarily 
because those nanoparticles have the same deficiencies as commercially available iron 
oxide nanoparticles; that is, they do not address important characteristics such as high 
magnetism, size and size distribution. Hilger et al. (2007) produced iron oxide 
nanoparticles coated with dextran via a hydrothermal method, conjugated to herceptin. 
The iron oxide dextran-herceptin nanoparticles localised within HER2 positive breast 
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cancer cells and tumours, but there was poor signal enhancement (<20%). The low signal 
enhancement could be related to the hydrothermal method of iron oxide nanoparticle 
production, which is known to produce low magnetic properties (Laurent, et al., 2008). 
Similarly, other studies using dextran coated cross-linked iron oxide nanoparticles (Chen, 
et al., 2009) and iron oxide microbeads (Artemov, et al., 2003) targeting HER2 receptors 
have reported problems of low magnetisation values. A study was conducted using iron 
oxide nanoparticles produced via the thermal decomposition method to produce highly 
magnetic iron oxide nanoparticles (Huh, et al., 2005). These particles were then 
conjugated to herceptin via DMSA and tested in vitro and in vivo, showing that the 
thermal decomposition method provided highly magnetic particles for targeted MRI. 
Despite the advantanges of this method, one of its disadvantages is the low numbers of 
particles produced per synthesis. Currently, the only published method that is reported to 
produce large amounts of iron oxide nanoparticles and not compromise the magnetic 
properties is that of Park et al. (2004). Park and co-authors pioneered the novel high 
temperature method which is based on the thermal decomposition of an iron oleate 
complex and is known to produce an ultra-large-scale amount of iron oxide nanoparticles 
(up to 40g per synthesis). Interestingly, the iron oxide nanoparticles produced by this 
novel production method have not been investigated for targeted MRI. Also, studies 
targeting HER2 receptors have used dextran or DMSA as their surface coatings; no 
reported studies have used silica. As a result of this preliminary work, this chapter aims to 
investigate whether highly magnetic iron oxide nanoparticles produced via the large scale 
thermal decomposition method could be utilised as a targeted contrast agent for MRI. 
 
The specific aims of this study were to: 
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1. Synthesise iron oxide nanoparticles via the non-hydrothermal decomposition 
method and modify the surface with a conformal silica shell, 
2. Confirm that the iron oxide silica nanoparticles possess the major characteristics 
(size, size distribution, high magnetism, biocompatibility, bonds available for 
conjugation to biomarkers) for use as targeted contrast agents for MRI, and 
3. Conjugate the surface of the silica coated particles to herceptin for eventual 
targeting of HER2 receptors on breast cancer cells. 
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3.2 Results  
3.2.1 Transmission electron microscopy (TEM) 
To demonstrate the size of the magnetite nanoparticles, TEM and high resolution TEM 
were conducted. Figure 3.1 A shows that the iron oxide nanoparticles with no silica 
coating had an approximate diameter of 25 ± 2nm. The morphology of the core particle 
appeared to be spherical in nature. The many particles imaged in the solution appeared to 
be of the same size, indicating that the iron oxide silica nanoparticles were monodisperse. 
Figure 3.1 B shows the iron oxide nanoparticles coated in silica having a total diameter of 
35 ± 3 nm. The sample distribution shows one iron oxide covered in a silica shell, again 
having a spherical morphology. 
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Figure 3. 1 TEM and HR-TEM of the synthesised iron oxide silica nanoparticles  
Images (A) and (B) of iron oxide nanoparticles coated in silica demonstrating their size 
and distribution are shown. The insets show the respective high resolution TEM images. 
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3.2.2 X-ray diffraction (XRD) 
The iron oxide nanoparticles coated in silica were analysed for their chemical composition 
to confirm the formation of iron oxide via XRD. The observed spectra from the iron oxide 
nanoparticles is shown in Figure 3.2. This diffraction pattern is characteristic of spinel 
phases for iron oxide, magnetite Fe3O4. The pattern in Figure 3.2 marked Mag was 
matched to the known standard diffraction spectra pattern (JCPDS file No 75-0449) that 
typically arises from iron oxide, magnetite. The major peaks indexed in the known 
diffraction spectra were the same as the diffraction spectra seen from the iron oxide 
nanoparticles on their own (Figure 3.2 marked Mag). This confirmed the possibility that 
iron oxide nanoparticles were formed using the synthesis process in the form of magnetite, 
Fe3O4 or maghemite, Fe2O3. Although it is difficult to rule out the presence of maghemite, 
the diffraction did not indicate the presence of a large 221, 203 and 116 peak, suggesting 
that maghemite was not present in these samples. After the iron oxide nanoparticles were 
coated in silica, the diffraction spectra appeared similar (Figure 3.2 marked SiO2@Mag) to 
the diffraction spectra for iron oxide (Figure 3.2 marked Mag) with the addition of distinct 
peak (marked *). This additional peak at about 30.5˚ 2θ could be assigned to a mixed iron-
silica phase). The overall diffraction spectra suggests that the presence of the silica has not 
diminished the iron oxide in any way and that most of the peaks from the magnetite 
nanoparticles are still visible, with multiple low angle peaks which correspond to the silica 
surface coating.  
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Figure 3. 2 XRD of synthesised iron oxide silica nanoparticles  
XRD patterns obtained from the iron oxide nanoparticles and iron oxide 
nanoparticles coated in silica are shown. The XRD peaks with corresponding to 
Bragg’s reflections (numbers in parentheses) of iron oxide are shown. The peak 
marked with * could indicate a mixed iron-silica phase. 
 
Chapter 3 – Nanoparticle synthesis and conjugation to herceptin 
   103
3.2.3 Superconducting quantum interference device (SQUID) 
The saturation magnetisation is the magnetic moment per unit mass. The saturation 
magnetisation value shows the overall magnetisation of the nanoparticles with respect to 
the weight of iron (emu/g). The saturation magnetisation value for the silica coated iron 
oxide nanoparticles was calculated using SQUID. A maximum value of 74.4 emu g-1 was 
obtained (Figure 3.3). The curve from the SQUID data shows a lack of hysteresis and 
remanence at ambient temperatures and suggests that the silica coated iron oxide 
nanoparticles were characteristic of superparamagnetic materials with magnetic domains 
(Figure 3.3).  
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Figure 3. 3 SQUID measurements of synthesised iron oxide silica nanoparticles  
This figure shows the saturation magnetisation value of the iron oxide silica nanoparticles 
measured on SQUID in emu/g calculated at ambient temperature. 
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3.2.4 T2 relaxation 
To assess the capability of the silica coated iron oxide nanoparticles to act as a T2 contrast 
agent in MRI, phantom studies were conducted in triplicates of 5 μg, 10 μg, 50 μg, 100 μg 
of iron oxide silica nanoparticles to determine the T2 relaxation. Figure 3.4 shows the 
relaxation rate of the iron oxide silica nanoparticles on a 3 Tesla Clinical MRI scanner at a 
TE of 10.86 ms, plotted as a function of iron concentration. It can be deduced from Figure 
3.4 that the T2 relaxation was 263.23 mM.s. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 3 – Nanoparticle synthesis and conjugation to herceptin 
   106
0.0 0.5 1.0 1.5 2.0
0
100
200
300
400
 
 Fe@SiO2 in phantoms - experimental
 Exponential fit
T2
 (m
M
.s
)
Fe concentration (mM)  
Figure 3. 4 T2 relaxation of synthesised iron oxide silica nanoparticles  
The T2 relaxation values calculated in a 3T Clinical MRI scanner are shown. T2 values 
are shown from various concentrations of iron oxide silica nanoparticles within aqueous 
phantom solutions and calculated as a function of iron concentration and relaxation rates, 
extracting the slope by regression. Error bars represent standard error of the mean from 
triplicate measurements. 
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3.2.5 MRI contrast enhancement 
The magnetic performance of the iron oxide silica nanoparticles was known from the 
SQUID measurements as 74.4 emu/g and the T2 relaxation measurements as 263.23 
mM.s. These measurements provided valuable information about how the iron oxide silica 
nanoparticles would perform as contrast agents. To measure the contrast capability of the 
iron oxide silica nanoparticles and put into context the SQUID and T2 relaxation 
measurements, phantom studies of aqueous iron oxide silica nanoparticles were conducted 
to evaluate the degree of negative contrast. This was measured by the signal change or T2 
shortening of iron oxide silica nanoparticles (10 µg, 50 µg and 100 µg) suspended in 
phantoms. From Figure 3.5 it is visually evident from the respective MRI phantom images 
that as the concentration increases from 0 µg to 100 µg, the image progressively appears 
hypointense. This is confirmed by the signal enhancement data relative to the control 
phantom as demonstrated by drop in T2 signal intensity with increasing iron 
concentration. The signal change relative to the control (0 μg) confirms the negative 
contrast, where at 100 µg of iron oxide silica concentration a signal enhancement of 
approximately 90% is evident in comparison to 70% signal intensity at a concentration of 
10 µg. The large MRI signal enhancement is expected from the iron oxide silica 
nanoparticles because of their relatively high T2 values and saturation magnetisation 
values. 
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Figure 3. 5 MRI phantom and T2 signal change of synthesised iron oxide silica 
nanoparticles  
The changes in relative T2 MRI signal to the control of iron oxide silica nanoparticle 
suspended in phantoms are shown. Signal changes are shown respective to the 
corresponding T2 MRI images. 
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3.2.6 Conjugation of iron oxide silica nanoparticles to herceptin 
Figure 3.6A illustrates the iron oxide silica nanoparticles conjugated to herceptin via a 
cystamine linker. The surface of the silica shell contains OH-, which attaches to the 
cystamine due to its available NH2+ group. The herceptin antibody, which has a negative 
charge, is then adsorbed onto the silica shell via the other available NH2+ group, attaching 
at the fragment crystallisable (Fc) region of the herceptin antibody. To confirm the 
adsorption and characterise the binding of herceptin onto the iron oxide silica 
nanoparticles, quartz crystal microbalance (QCM) experiments were performed to obtain 
real-time kinetic information. 
 
The iron oxide silica nanoparticles were deposited onto the crystal where the mass change 
was monitored using QCM. Figure 3.6B. i shows an immediate decrease in frequency 
(≈28 Hz) when the iron oxide silica nanoparticles were added, with no decrease in 
frequency after washing. Figure 3.6B. ii shows an immediate decrease in frequency (≈10 
Hz) when the cystamine was added to the iron oxide silica nanoparticles. This indicates 
rapid binding of the cystamine to the surface of the silica shell, of which a large proportion 
remained after washing. Similarly, when the herceptin antibody was deposited on the iron 
oxide silica nanoparticles with cystamine, a sharp decrease in its frequency (≈30Hz) was 
observed, indicating binding of the antibody to the iron oxide silica nanoparticles via the 
cystamine linker (Figure 3.6B. iii). In both cases conjugation of the respective molecules 
to the surface of the iron oxide silica nanoparticles was confirmed by increases in mass on 
the QCM which remained after successive washing steps.  
 
The amount of protein on the particle surface was quantified using the BCA protein assay. 
This colorimetric assay determines the amount of protein on the particle surface, based on 
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a standard concentration series of the protein. Approximately, 0.66 μg of herceptin was 
calculated to be present on 1 μg of iron oxide nanoparticles of 35 nm in diameter. 
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Figure 3. 6 Formation of iron oxide silica herceptin nanoparticles via a cystamine linker  
(A) Shows a schematic illustration (not to scale) of the formation of iron oxide silica 
herceptin nanoparticles using a cystamine linker. (B) QCM data showing a characteristic 
representation of the physical adsorption of cystamine and herceptin to the surface of iron 
oxide coated silica nanoparticles. (i) iron oxide silica deposition onto the crystal, (ii) 
adsorption of the cystamine on the surface and (iii) adsorption of the herceptin onto the 
iron oxide silica via cystamine. 
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3.2.7 Stability of iron oxide silica herceptin nanoparticles 
The stability of the iron oxide silica herceptin nanoparticles was assessed (n=3) by 
conjugating a FITC molecule to the herceptin antibody and exposing iron oxide silica 
herceptin-FITC nanoparticles to pH of 5, 7.4, 10 (3.7A) and human serum (3.7B) at 
various concentrations (25%, 50%, 100%) over a 24-hour period at 37O C. The 
degradation of the particles was calculated by an increase in fluorescence in the 
supernatant based on a standard concentration series of the herceptin-FITC molecules. 
Figure 3.7A shows the amount of protein retained across pH ranges of 5, 7.4, and 10, and 
Figure 3.7B shows the amount of protein retained after exposure to human serum at 
concentrations of 25%, 50%, and 100%. Figure 3.7A and 3.7B both show that less than 
5% of herceptin-FITC could be detected within the supernatant at the different pH and 
human serum concentrations.  
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Figure 3. 7 Stability analysis of iron oxide silica herceptin nanoparticles over a 24 hour 
period in various pH and human serum concentrations  
The stability of the iron oxide silica herceptin nanoparticles-FITC was assessed after 
incubation over a 24 hour period in various conditions and analysing unbound FITC in the 
supernatant based on a standard concentration series of the herceptin-FITC molecules. (A) 
Shows the percent of protein retained after exposure to pH of 5, 7.4 and 10. (B) Shows the 
percent of protein retained after exposure to human serum concentrations of 25%, 50% 
and 100% at 37o C. Error bars represent standard error of the mean calculated from 
triplicate measurements 
 
 
(A) 
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3.2.8 Iron oxide silica-herceptin nanoparticle cytotoxicity 
Previous studies indicate that iron oxide nanoparticles are mildly toxic at high 
concentrations. To explore the biocompatibility profile of the iron oxide silica-herceptin 
nanoparticles, MTS-based in vitro cytotoxicity experiments were performed on SKBR3 
breast cancer cells in vitro (n=3). Figure 3.8 shows the results of MTS-based cytotoxicity 
testing performed on SKBR3 cells after 24 and 48 hour incubation with iron oxide silica-
herceptin nanoparticles. It is evident that the iron oxide silica-herceptin nanoparticles at 24 
hours did not significantly affect SKBR3 cell viability up to 50 µg/ml (P>0.05) of iron 
oxide silica herceptin nanoparticles, where a cell viability of 75% can be measured. 
However, as the concentration of iron oxide silica nanoparticles increased to 100µg/ml 
(P<0.001) a significant toxic effect can be seen when the viability of the SKBR3 decreases 
to 65%. After 48 hours incubation of the iron oxide silica-herceptin nanoparticles, the 
viability of SKBR3 cells is significantly affected where, a concentration of 50 µg/ml 
(p<0.01) of iron oxide silica herceptin nanoparticles to reduces the viability to 60%. 
Similarly, at a concentration of 100 µg/ml (p<0.001) of iron oxide silica herceptin 
nanoparticles a significant toxic effect can be seen, where a viability of only 50% was 
calculated. 
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Figure 3. 8 MTS cell viability of iron oxide silica-herceptin nanoparticles  
Viability of human breast cancer cells SKBR3 after incubation with iron oxide silica-
herceptin nanoparticles assessed at 24 and 48 hours (shown as % viability) by MTS assay. 
Error bars represent standard error of the mean from triplicate measurements. *= p<0.05, 
**= p<0.01, ***= p<0.001 one-way ANOVA and Dunnett’s.  
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3.3 Discussion  
 
The prerequisite to enable iron oxide nanoparticles to be used as molecular and cellular 
targeted contrast agents is the fabrication of materials with the following properties: high 
magnetism, a size less than 60 nm, small size distribution and biocompatibility. These 
characteristics are all important as they can influence the MRI signals and cellular uptake 
of the contrast agent (Gupta & Gupta, 2005; Laurent, et al., 2008). Hydrothermal methods 
produce particles with low crystallinity, low magnetisation values and limited control over 
size and size distribution, and therefore the non-hydrothermal high temperature method 
outlined by Park et al. (2004) was used in this study to synthesise iron oxide nanoparticles.  
 
For this method, the iron oxide nanoparticles were synthesised by thermally decomposing 
an iron oleate complex using a high boiling solvent i.e. sodium oleate and metal chlorides. 
The iron oxide nanoparticles produced appeared to be spherical, monodisperse, and 
contained a core size of approximately 25 ± 2 nm in diameter as shown in TEM data 
(Figure 3.1A). The iron oxide nanoparticles at this point were coated with oleic acid and 
therefore were insoluble in water. To make them water soluble and biocompatible and to 
provide an attachment for biomarkers, the iron oxide nanoparticles were coated in silica. 
As a coating for iron oxide nanoparticles, silica has previously been demonstrated to 
provide biocompatibility and particle stability as well as a facile surface for further bio-
functionalisation in different nanomaterials (Mulvaney, Liz-Marzan, Giersigc, & Ung, 
2000; Sun, et al., 2005). The silica coating of the iron oxide nanoparticles formed around 
the core iron oxide shell and the iron oxide silica nanoparticle with a total diameter 
approximately 35 ± 3 nm silica (Figure 3.1B and inset). The small size of the nanoparticles 
was important, as nanoparticles larger than 60 nm can be taken up by the RES, making it 
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impossible for the them to localise at the targeted site. The iron oxide nanoparticles that 
were synthesised in this study were less than 60 nm in size, making them suitable to be 
utilised for targeted imaging in MRI. 
 
The silica shell on the surface of the iron oxide nanoparticles was formed by magnetite 
particles acting as nucleation sites during the hydrolysis of TEOS via the alkaline solution 
produced by the addition of ammonia within the ethanol and water solvent. From the TEM 
image in Figure 3.1B, the silica shell appeared to be thin compared to other studies where 
diameters of up to 100 nm were produced (Fang, 2008; Lu, et al., 2002). The advantage of 
this method was that it allowed control of the shell thickness by virtue of the continuous 
addition of silica to the solution by simply changing the hydrolysis duration. The addition 
of a coating material can sometimes affect the shape of iron oxide core particles, but in 
this process the iron oxide nanoparticles retained their original morphology and were 
individually coated with a silica shell. Only a small number of the nanoparticles in the 
sample were found to contain two or three iron oxide nanoparticles within a silica coating. 
This issue is inherent in a typical chemical synthesis route of coating nanoparticles with a 
surface layer and is not always acknowledged in the literature. However, it can be 
controlled easily by limiting the concentration of iron oxide nanoparticle seeds during the 
coating process.  
 
Observations were made throughout the study that the iron oxide nanoparticles remained 
stable without producing any aggregates either in solution (phosphate buffered saline, 
PBS) or as a powder for up to 6 months. TEM images in Figure 3.1 show that the 
morphology of the iron oxide nanoparticles after 6 months was similar to that immediately 
after synthesis. This data supports the literature which suggests that a silica coating over 
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iron oxide nanoparticles can significantly improve long-term stability, in particular 
reducing aggregation of the nanoparticles (Mulvaney, et al., 2000; Sun, et al., 2005). 
Long-term particle stability is a crucial factor for iron oxide nanoparticles, particularly for 
use in the clinical setting. Another notable factor in the synthesis method was the ability to 
produce more than 10g of iron oxide nanoparticles within one synthesis, as earlier reported 
Park et al. (2004). The ability to produce ultra-large scale batches of iron oxide 
nanoparticles is of particular advantage, especially in translating iron oxides to the clinical 
setting where an average patient could require up to 20 mg/kg of iron oxides. Most 
synthesis methods cannot produce significant amounts of monodisperse particles without 
tedious size separation processes which compromise the shape and magnetism of the 
nanoparticles (Gupta & Gupta, 2005).  
 
The XRD patterns (Figure 3.2) of the iron oxide nanoparticles indicated that the core 
particles were characteristic of spinel phases of iron oxides. The pattern could also be 
indexed based on the standard diffraction pattern typically arising from magnetite with the 
major peaks indexed (JCPDS file No 75-0449). Six crystal planes took on reflection, 220, 
311, 400, 422, 511 and 440 (Figure 3.2). It is well known that in all preparations of iron 
oxide nanoparticles, maghemite, a lower form of iron oxide, is commonly present among 
magnetite, the preferred form of iron oxide (Jung & Jacobs, 1995). Both forms of iron 
oxide have comparable line positions and intensities on XRD and it can therefore be 
difficult to preclude the presence of maghemite unless the minor differences between the 
XRD patterns of maghemite and magnetite are closely investigated. In the iron oxide 
nanoparticles produced in this study, a minor detail such as the prominence of the 211 iron 
oxide magnetite peak in the XRD pattern (Figure 3.2) could be indicative that a separate 
cubic maghemite is not present. In further support of this statement, maghemite is known 
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to have two reflections at 23.9 (203) and 26.1 (116) (Jung & Jacobs, 1995). In the XRD 
pattern of the iron oxide nanoparticles produced these weak maghemite lines did not 
appear, thus suggesting that maghemite may not be present. However, an expanded 
diffraction pattern would be needed to confirm this. After the iron oxide nanoparticles 
were coated in silica, the diffraction pattern peaks arising from the iron oxide 
nanoparticles could still be detected, confirming that the addition of the silica layer did not 
affect the iron oxide core. An interesting observation in the XRD pattern after the addition 
of silica is the presence of an additional peak at ca. 29.5˚ 2θ. This additional peak could be 
assigned to a mixed iron oxide-silica phase (111 silica phase) possibly formed at the 
interface of silica and magnetite during core-shell synthesis of the iron oxide silica 
nanoparticles. There is no reported literature on this additional peak and therefore the 
origin of this mixed iron oxide-silica phase is not clear at this stage. Subsequent 
investigation to analyse the additional peak within this study was not conducted, as it was 
beyond the scope of this project. Subsequent analysis of this peak is warranted to assess its 
significance. 
 
With respect to the magnetisation properties of the iron oxide silica nanoparticles, the 
specific magnetisation and the T2 values determine how the iron oxide silica nanoparticles 
would perform as contrast agents. In Figure 3.3, the SQUID data shows a lack of 
hysteresis and remanence and suggests that the silica coated iron oxide nanoparticles are 
characteristic of superparamagnetic material with magnetic domains. The 
superparamagnetic performance of these particles is similar to that in other studies that 
have reported superparamagnetic properties of iron oxide nanoparticles (Jung & Jacobs, 
1995; Zhang et al., 2009). From the SQUID data (Figure 3.3), the magnetite silica 
nanoparticles have a saturation magnetisation value of 74.4 emu g-1. Compared to the 
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value in currently available iron oxide nanoparticles such as commercial Resovist®, this 
value is slightly higher than Resovist’s® reported mass magnetisation value of 72.9 emu 
g-1. Other studies that have prepared iron oxide nanoparticles via thermal decomposition, 
using DMSA as a surface coating, have reported saturation magnetisation values of up to 
80 emu/g (Huh, et al., 2005). The higher saturation magnetisation value of the iron oxide 
silica nanoparticles compared to Resovist® could be attributed to the method of 
production, in that the non-hydrolytic thermal decomposition method is known to produce 
particles with higher crystallinity and small size distributions, therefore superior magnetic 
properties (Laurent, et al., 2008). The reason for the reported higher saturation 
magnetisation value of the DMSA coated iron oxide nanoparticles (Huh, et al., 2005) 
compared to the iron oxide nanoparticles prepared in this study via the thermal 
decomposition method is at this stage unknown. It was expected that because both 
methods involve thermal decomposition the values would be similar; differences could be 
related to the surface coating, variations in the method of production, and the use of 
different surfactants. 
 
It is essential, especially in translational research, for contrast agents to possess high 
magnetism, especially high saturation magnetisation values or a high magnetic moment. 
This is because the contrast enhancement effects are directly related to the saturation 
magnetisation values (Jang, et al., 2009; Sun, et al., 2005). The transverse relaxation, T2 
or spin-spin relaxation of the protons is roughly proportional to the square of the saturation 
magnetisation value; therefore higher saturation magnetisation values will cause faster T2 
relaxation and generate a reduction in the signal intensity (Jang, et al., 2009). A high MRI 
contrast is also significant for clinical purposes, as the probe dosage levels can be reduced 
when using highly magnetic nanoparticles.  
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The T2 relaxivity value of the iron oxide silica nanoparticles was reported to be 263.23 
mMs (Figure 3.4). A high T2 relaxation was expected due to the high saturation 
magnetisation values seen in Figure 3.3. In MRI, the relaxation rate is a measure of the 
efficiency of the contrast agent to enhance the proton relaxation and increase image 
contrast. Therefore, a high T2 relaxation would cause surrounding water protons to relax 
more quickly, generating maximum possible contrast. When compared to other iron oxide 
nanoparticles, the T2 relaxation of the iron oxide silica nanoparticles synthesised in this 
study was shown to be higher. The commercially available Resovist® nanoparticles have 
reported T2 values of 151.0 mM.s, and other iron oxide studies have reported values of 
200 mM.s even with a saturation magnetisation value of 80 emu/g (Chen, et al., 2009). In 
that case, the low T2 value could be associated with many factors, one being the influence 
of surface coatings possibly causing mild aggregation of the nanoparticles in solution, in 
vitro and/or in vivo. For the iron oxide silica nanoparticles produced in this thesis, it is 
known that silica is an inert material and as a surface coating can prevent aggregation of 
the iron oxide nanoparticles in liquids, allowing them to act as single magnetic domains 
(Gupta & Gupta, 2005; Laurent, et al., 2008). Another suggested reason for the low T2 
values seen in previous studies could also be that the hydrothermal method of iron oxide 
production, as previously discussed, produced particles with less strong magnetic 
properties. No T2 values have been reported by other studies that have prepared iron oxide 
nanoparticles via the thermal decomposition method, but Jun et al. (2007) and Huh et al. 
(2005) have provided the saturation magnetisation values discussed above. The higher T2 
values of the iron oxide silica nanoparticles reported in this study can provide a significant 
advantage over commercial MRI contrast agents and over synthesised iron oxide 
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nanoparticles in previous studies, facilitating faster relaxation of surrounding water 
protons, along with an expected significant enhancement in MRI image contrast. 
 
A large MRI signal enhancement is expected from the iron oxide silica nanoparticles, 
because of the relatively high T2 values and saturation magnetisation values. To measure 
the performance of the iron oxide silica nanoparticles in generating contrast, phantom 
studies were conducted to evaluate the degree of signal intensity change or negative 
contrast relative to the control. This was conducted by measuring the T2 shortening at 10, 
50 and 100 µg of iron oxide silica nanoparticles. From Figure 3.5 it was evident that as the 
amount of iron oxide silica nanoparticles increased from 0 µg to100 µg, the MR signal 
change relative to the control progressively appeared hypointense. The signal change 
confirmed the negative contrast, where at 100 µg of iron oxide silica concentration a 
signal enhancement of approximately 90% was shown compared to 70% signal intensity at 
a concentration of 10 µg. As there are no previous studies that show signal enhancement 
data for phantom studies, it is difficult to compare the performance of our iron oxide silica 
nanoparticles to other iron oxide nanoparticles. However, previous researchers have 
reported that their iron oxide nanoparticles provided increased negative contrast as 
indicated by a drop in the T2 value (Hilger, et al., 2007). Indirectly, the drop in the T2 
value is related to a darkening effect or contrast enhancement on MRI. So, although the 
signal enhancement values were not calculated, the relative T2 value drop can be used as 
an indication to compare performance. The pattern of signal intensity changes seen with 
the increase in concentration of the iron oxide silica nanoparticles in this study is similar to 
the pattern of T2 signal reduction in previous studies (Hilger, et al., 2007). 
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Since the iron oxide silica nanoparticles possessed high magnetic properties, good contrast 
capability, small size distribution, water-solubility and biocompatibility, the claim as to 
their suitability for targeted contrast imaging was valid and was therefore examined. This 
was achieved by conjugation of the iron oxide silica nanoparticles to herceptin, which 
binds specifically to HER2 receptors. HER2 receptors are found on many cells, but they 
are overexpressed in HER2 positive breast tumours. The schematic illustration in Figure 
3.6A demonstrates the formation of iron oxide silica nanoparticles conjugated to herceptin. 
The hydroxyl groups present on the surface of the silica confer a net negative charge on 
the overall nanoparticle, thereby allowing one of the positive amine groups on the 
cystamine linker to electrostatically bind. The remaining free amine group of the 
cystamine linker was used to adsorb the herceptin antibody, as confirmed by QCM (Figure 
3.6A). From the rapid decrease in frequency in Figure 3.6A it could be deduced that the 
iron oxide silica nanoparticles were conjugated to the cystamine linker even after several 
washing cycles (Figure 3.6B i). Subsequently, Figure 3.6B ii also showed an immediate 
decrease in frequency upon deposition of cystamine on the iron oxide silica nanoparticles, 
and a decrease in frequency upon deposition of herceptin, which indicates binding of the 
antibody to the silica shell via cystamine. The binding of herceptin to the silica shell is 
most likely due to electrostatic forces between positive charges on the remaining amine 
group of the cystamine and the negatively charged Fc terminal of herceptin. In the 
literature it is suggested that the electrostatic binding can also occur at the isoelectric point 
of the antibody, as the pH of the incubation medium (pH 7.4) is close to the isoelectric 
point of the herceptin, which is known to favour adsorption onto the surface of the 
nanoparticles (Tsai, Mehta, & DeLuca, 1996). The results from this study are similar to 
other studies that have shown irreversible binding of nanoparticles to antibodies via 
physical adsorption, quantified by QCM (Cortez, et al., 2006).  
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It is known that optimal bioconjugation should involve the covalent attachment of the 
antibody only through the Fc region, leaving Fab sites available for receptor recognition 
(Arruebo, Valladares, & González-Fernández, 2009). The advantage in using covalent 
linkages compared to adsorption lies in avoiding possible competitive displacement of the 
adsorbed antibodies by blood components (Arruebo, et al., 2009; Kocbek, Obermajer, 
Cegnar, Kos, & Kristl, 2007). Several studies have investigated whether displacement of 
the antibodies does occur, and have looked at the feasibility of antibodies being absorbed 
onto nanoparticles, with differing results (Cortez, et al., 2006; Illum, Jones, Baldwin, & 
Davis, 1984; Illum, Jones, Kreuter, Baldwin, & Davis, 1983; Kocbek, et al., 2007; 
Tengvall, Lundström, & Liedberg, 1998). Further investigations need to be carried out to 
confirm whether the adsorption of antibodies onto the surface of nanoparticles is 
competitively displaced by blood components in vitro and in vivo. Despite this, some 
researchers favour the adsorption of antibodies onto the surfaces of nanoparticles over 
covalent linkages. They indicate that covalent binding occurs randomly at multiple sites 
and can possibly impair the Fab binding sites (Cortez, et al., 2006; Kocbek, et al., 2007; 
Nobs, Buchegger, Gurny, & Allémann, 2004). Thus when biomarkers covalently attached 
to nanoparticles are utilised for targeting, small amounts of the nanoparticle complex 
could arrive at the targeted site. Kocbek et al. (2007) reported that covalent binding using 
EDC directly onto antibodies adversely affected the recognition properties of antibodies 
for the target antigen compared to adsorption, occurring at the Fc region. This could be 
due to proteins having numerous functional groups, as several side reactions could take 
place in the presence of EDC. They concluded that adsorption of antibodies was preferable 
to covalent bonding. Similarly, Cortez et al. (2006) reported successful in vitro targeting 
of human colorectal cancer cells using PAH/PSS nanoparticles electrostatically bound to 
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huA33 antibodies. Their study demonstrated the irreversible binding of huA33 antibodies 
on PAH/PSS nanoparticles using QCM, and they concluded that their conjugated 
nanoparticles could be used as effective drug delivery molecules.  
 
For in vitro and in vivo studies, stability of the iron oxide silica herceptin nanoparticles is a 
priority that needs to be addressed particularly for adsorbed complexes. To address 
stability concerns, the iron oxide silica herceptin nanoparticles were incubated over a 48 
hour period at various pH and human serum values (Figure 3.7). From the stability data it 
was demonstrated that the particles remained bound to the herceptin antibody over a 48-
hour period in various pH strengths together with different concentrations of human 
serum. Stability testing (Figure 3.7) along with the QCM data (Figure 3.6) indicated that 
the iron oxide silica herceptin nanoparticles were bound through electrostatic interaction. 
The stability results for the iron oxide silica nanoparticles conjugated to herceptin were 
similar to those of other studies that have reported stable adsorbed nanoparticles 
conjugated in various pH levels, indicating that competitive displacement in vivo was 
unlikely but could not be ruled out (Cortez, et al., 2006).  
 
Apart from magnetic properties and size considerations, iron oxide silica herceptin 
nanoparticles need to be biocompatible to be used at the preclinical and clinical level. The 
biocompatibility of iron oxide and silica has already been proven and considerable 
evidence exists showing that iron oxide nanoparticles are non-toxic at lower 
concentrations and can be mildly toxic at higher concentrations (Gupta & Gupta, 2005; 
Laurent, et al., 2008). To explore the biocompatibility profile of the iron oxide silica 
herceptin nanoparticles, cytotoxicity assays were performed on SKBR3 cancer cells in 
vitro (Figure 3.8). Results showed that the iron oxide silica herceptin nanoparticles did not 
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affect SKBR3 cell viability up to 50 µg of iron, where more than 75% cell viability was 
demonstrated. However, further increases in iron oxide silica herceptin nanoparticles 
equivalent to 100 µg resulted in a cell viability loss of 35%. The loss in cell viability could 
be an indication of the action of herceptin inhibiting the growth of SKBR3 cells that are 
overexpressing HER2 receptors. Other studies that have assessed iron oxide nanoparticles 
conjugated to herceptin have reported similar results, with higher concentrations that were 
potentially toxic to the cells being consistent with the function of herceptin (Chen, et al., 
2009).  
 
3.4 Conclusion 
The aim of this chapter was to produce iron oxide nanoparticles coated in silica via the 
thermal decomposition method and to investigate their characteristics to warrant their use 
as a targeted contrast agent for MRI. Investigations confirmed that the iron oxide silica 
nanoparticles had the major characteristics necessary for use as a targeted contrast. These 
characteristics were high magnetic properties, small size and size distribution, 
biocompatibility, and the ability to be conjugated to a biomarker. The study also compared 
literature on commercial iron oxide nanoparticles and synthesis methods and the findings 
suggested that the iron oxide silica nanoparticles prepared via this method had superior 
properties and therefore were potentially more suitable for targeted contrast applications. 
In conclusion, these results support the use of iron oxide silica herceptin nanoparticles for 
targeted MRI. 
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Chapter 4 Assessment of the Iron Oxide Silica Herceptin Nanoparticles 
in vitro 
4.1 Introduction 
 
The experimental results in Chapter 3 suggested that the iron oxide nanoparticles produced 
exhibited the major characteristics for use as targeted contrast agents for MRI.. These 
characteristics are size, size distribution, high magnetism, biocompatibility, bonds 
available for conjugation to biomarkers, and stability. These nanoparticles were coated in 
a silica layer to improve water solubility, particle stability and also to present a facility for 
attachment of biomarkers. Futhermore, the iron oxide silica nanoparticles were conjugated 
to a biomarker called herceptin, which is specific for targeting HER2 receptors, present in 
human breast cancer. The findings of Chapter 3 suggested that the synthesised iron oxide 
silica herceptin nanoparticles had the potential to be utilised as targeted imaging agents for 
MRI. These results from the assessment of the physical characteristics warranted further 
investigation in a biological system. The aim of this chapter was to investigate the ability 
of iron oxide silica herceptin nanoparticles to target HER2 expressing human breast cancer 
cell lines in vitro.  
 
Approximately 20-30% of breast cancers overexpress HER2, which is associated with 
increased disease recurrence and poor prognosis (Slamon, et al., 1987). Herceptin is a 
well-known humanised monoclonal antibody directed at the epidermal growth factor 
receptor HER2, which is found in HER2 positive breast cancers (Slamon, et al., 1987). 
Herceptin is one of the few targeted immunotherapies currently used in breast cancer 
patients in adjuvant and neoadjuvant settings. The mechanism of action of herceptin is 
thought to be mediated by antibody-antigen specific binding to the HER2 receptors 
followed by internalisation via receptor mediated endocytosis (Baselga, et al., 2001). It has 
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also been reported that herceptin induces cell cycle arrest due to downregulation of HER2 
leading to decreased cell proliferation, inhibition of angiogenesis, increased cytotoxicity 
and eventual cell death (Carter, et al., 1992; Hudziak, et al., 1989; Shepard, et al., 1991). 
The action of herceptin has been reported to cause increased cellular sensitivity, and when 
used in combination with chemotherapy therapy it can produce synergistic effects 
(Konecny, et al., 1999). Clinical trial data has shown positive responses to herceptin in 
HER2 positive breast cancer patients in combination with various chemotherapy drugs in 
early and late stages (Pegram, et al., 1999; Slamon, et al., 2001; Vogel, et al., 2002). 
However, evidence from phase 2 clinical trials has also shown response rates to herceptin 
alone ranging from 11% to 26%, suggesting that the majority of patients with HER2 
expressing tumours demonstrate intrinsic resistance to herceptin alone (Baselga, et al., 
1996; Cobleigh, et al., 1999; Vogel, et al., 2002). Furthermore, while adjuvant and 
neoadjuvant therapy result in higher response rates, it has been reported that the duration 
of response to herceptin therapy either alone or in combination with chemotherapy ranges 
from 5 to 9 months (Seidman, et al., 2001; Slamon, et al., 2001). The mechanism of 
acquired resistance is not fully understood and there are several mechanisms that could 
contribute to this process (Nahta & Esteva, 2006). While many new agents are being 
developed and tested, identification of patients who could stop or have stopped responding 
to herceptin and/or herceptin-regimes is important (Nahta & Esteva, 2006). The use of 
MRI and iron oxide silica nanoparticles conjugated to herceptin could potentially help 
identify these patients. 
 
From the QCM data in Chapter 3, it can be assumed that the herceptin antibody is attached 
to the surface of the iron oxide silica nanoparticles. As herceptin is specific for HER2 
receptors, it is possible that the iron oxide silica herceptin nanoparticles can target HER2 
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positive receptors in the same way that herceptin individually interacts with the receptor. 
Previous studies conducted with iron oxide nanoparticles but with different surface layers 
conjugated to herceptin have indicated that the nanoparticles were able to target the HER2 
receptors in vitro and in vivo (Artemov, et al., 2003; Chen, et al., 2009; Hilger, et al., 
2007; Huh, et al., 2005). These previous studies observed the uptake of the nanoparticles 
conjugated to herceptin within different cell lines of varying levels of HER2 expression 
and suggest that the nanoparticles were taken up relative to the HER2 expression levels 
(Artemov, et al., 2003; Chen, et al., 2009; Huh, et al., 2005). Targeting cells with different 
levels of HER2 expression provides a good indication of the sensitivity of the 
nanoparticle-herceptin detection system as well as of whether the nanoparticles are taken 
up specifically at HER2 receptor sites. A range of other studies that have not used iron 
oxide nanoparticles but have used other nanoparticles such as manganese doped (Lee, et 
al., 2007), human serum albumin (HSA) (Steinhauser, Spänkuch, Strebhardt, & Langer, 
2006), poly(lactic-co-glycolic acid) (PLGA) (Sun & Feng, 2009) and fluorescent probes 
labelled to herceptin (Liang, et al., 2010) have demonstrated uptake at HER2 receptor 
sites. Based on these studies, the uptake of herceptin conjugated nanoparticles by HER2 
expressing cells is well known. To confirm whether the nanoparticles synthesised in the 
previous chapter performed similarly, the current study investigated uptake of the iron 
oxide silica herceptin nanoparticles in HER2 expressing cells. This chapter also aimed to 
measure the uptake of the iron oxide silica herceptin nanoparticles in cells with varying 
levels of HER2 expression.  
 
Once the nanoparticles were localised within the cells it was not necessary to characterise 
the mechanism of their uptake, which was detailed earlier within this chapter. It was 
important, however, to determine the impact of dosage and time on the uptake of the 
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nanoparticles within the various cell lines. Investigations of the effect of different dosages 
and time points of herceptin-nanoparticles were designed to identify whether the uptake 
was related to dose, time and/or HER2 expression levels of the cells. It was anticipated 
that this would provide evidence that the conjugation of the nanoparticles to herceptin 
could specifically target HER2 positive cells. This was particularly important for the 
potential translation of the nanoparticles conjugated to herceptin to the clinical setting. 
Few previous dose and time course studies have involved iron oxide nanoparticles 
conjugated to herceptin for MRI. Wartlick et al. (2004) utilised HSA nanoparticles 
conjugated to herceptin to demonstrate that the binding was related to HER2 expression 
levels as well as dosage. Several time course studies have shown that 30 minutes after 
incubation of conjugated nanoparticles, specific uptake was seen, between 30 minutes and 
5 hours (Steinhauser, et al., 2006; Wartlick et al., 2004). These uptake studies have also 
suggested that non-specific uptake could be occurring after 24 hours (Steinhauser, et al., 
2006; Wartlick, et al., 2004). To ensure maximum uptake of the iron oxide silica herceptin 
nanoparticles within HER2 positive breast cancer cells, this study sought to investigate 
dose response and time course phenomena. 
 
Assessment of the nanoparticles in vitro plays an important role in estimating contrast 
enhancement biologically. In phantom studies the iron oxide nanoparticles might 
demonstrate good T2 relaxivity and produce contrast enhancement, but in vitro and in vivo 
these particles can have reduced contrast enhancement and lower T2 values. The 
mechanism of this phenomenon is unknown. Some theories suggest the confinement of 
nanoparticles within the endosome of the target cells as the reason (Billotey, et al., 2003). 
After subcellular compartmentalisation of the nanoparticles there can be a build-up of 
magnetic field inhomogeneities (Billotey, et al., 2003; Kato et al., 1999). This was found 
Chapter 4 – in vitro assessment of herceptin-nanoparticles 
   131
to be absent in phantoms where the nanoparticles were uniformly distributed (Billotey, et 
al., 2003; Kato, et al., 1999). In particular, the geometrical arrangement of the 
nanoparticles as a result of clustering within the cells is expected to make an important 
contribution to this effect. Despite the different sizes of nanoparticles and cell systems 
used, several groups have shown that the relaxivities of native iron oxide nanoparticles in 
phantoms were higher than those after accumulation in cells (Billotey, et al., 2003; Hilger, 
et al., 2007; Simon, et al., 2006). The iron oxide silica nanoparticle phantoms in Chapter 3 
were found to produce significant contrast enhancement. To ensure that high levels of 
contrast were still evident in an in vitro system, contrast enhancement within cells needed 
to be investigated to demonstrate whether this had any clinical utility. 
 
To assess the in vitro performance of the synthesised nanoparticles, a comprehensive cell 
uptake study was designed and conducted on HER2 positive breast cancer cells. The aim 
of this study was to viewing the uptake of the herceptin-nanoparticles, including 
identifying the effect of dosage and time. Furthermore, the contrast enhancement effect of 
the iron oxide silica herceptin nanoparticles after localisation within HER2 positive cells 
needed to be addressed, due to previous reported problems related to reducing contrast. As 
a result, the study aimed to view the uptake of the synthesised iron oxide silica herceptin 
nanoparticles in various breast cancer cells lines of different HER2 expression.  
 
The specific aims of this chapter were to: 
1. Confirm and compare the uptake of iron oxide silica herceptin nanoparticles 
by breast cancer cells lines (SKBR3, BT474 and MCF7) in vitro;  
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2. Quantify the uptake of iron oxide silica herceptin nanoparticles by dose and 
time coursestudies using three breast cancer cell lines (SKBR3, BT474 and 
MCF7)  in vitro; and  
3. Observe the ability of the synthesised nanoparticles to generate MRI contrast 
enhancement from within breast cancer cell lines expressing different levels 
of HER2 (SKBR3, BT474, MCF7). 
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4.2 Results 
4.2.1 HER2 expression levels in different breast cancer cells 
 
Before the dose- and time-dependent uptake of iron oxide silica herceptin nanoparticles 
was assessed in human breast cancer cells lines, it was important to assess the expression 
levels of HER2 on each cell line, as long-term culturing can affect surface receptor 
expression. Three human breast cancer cell lines, SKBR3, BT474 and MCF7, were used. 
Among these it has been documented that SKBR3 has the highest level of HER2 
expression, followed by BT474 and MCF7 (Chen, Yeung, & Wang, 2000). 
Characterisation of HER2 expression via flow cytometry surface expression staining 
showed that the SKBR3 cell line had the highest level of HER2 expression, with a 
simulation index of staining above 7. The BT474 cell line had a stimulation index of 
staining above 4 and the MCF7 cell line had the lowest stimulation index of staining, of 2 
(Figure 4.1).  
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Figure 4. 1 Stimulation index of HER2  
Flow cytometry results represent the HER2 surface expression levels via a stimulation 
index. The results show the surface expression of the three breast cancer cell lines, 
SKBR3, BT474, and MCF7. Stimulation index was calculated by mean fluorescence 
intensity of HER2 expression/mean fluorescence intensity isotype control. Error bars 
represent standard error of the mean calculated from triplicate measurements 
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4.2.2  Dose-dependent uptake of iron oxide silica herceptin nanoparticles by human 
breast cancer cells in vitro  
 
Herceptin-mediated cellular binding and uptake of the iron oxide silica herceptin 
nanoparticles were investigated by flow cytometry using 5, 10, 50 and 100 μg of 
nanoparticles after a 24 hour incubation time. SKBR3, BT474 and MCF7 cells were used 
to test the binding and uptake efficacy of the iron oxide silica herceptin nanoparticles 
relative to HER2 expression levels. The binding of iron oxide silica herceptin 
nanoparticles appeared to be related to the HER2 cell expression levels (Figure 4.2). 
SKBR3 cells had the highest iron oxide silica herceptin nanoparticle uptake, the 
stimulation index indicating that uptake was approximately 150 at 5 μg and increased to 
200 at 100 μg (Figure 4.2). As indicated by the stimulation index the uptake of the BT474 
and MCF7 cell lines was 15 and 10 respectively, much less than that of the SKBR3 cell 
line (Figure 4.2). This result correlated with the surface expression data in Figure 4.1 that 
showed the HER2 surface expression levels by a stimulation index of staining. In Figure 
4.1, the SKBR3 cell presented with a level 1.5 times higher than the BT474 cells and 
approximately 3 times higher than the MCF7 cells. This suggested that uptake levels 
should be higher for SKBR3 cells than for BT474 and MCF7 cells. Comparing the BT474 
and MCF7 cell lines, the uptake appeared to increase gradually as the amount of 
nanoparticles increased from 5 to 100 μg. Uptake in BT474 cells appeared to be higher, 
with a stimulation index of 10 at 10 μg and 25 at 100 μg, compared to 5 at 10 μg and 18 at 
100 μg for the MCF7 cells. Figure 4.1 also showed maximal uptake of iron silica oxide 
herceptin nanoparticles at 5 μg, and there was no further increase in uptake as the 
concentration increased. This representation could possibly indicate that the iron oxide 
silica herceptin nanoparticles were attached to most of the cells at 5 μg, although 
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saturation might not have been reached as there was a continued increase in uptake as the 
concentration increased.  
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Figure 4. 2 Dose-dependent uptake of iron oxide silica herceptin nanoparticles by human 
breast cancer cell lines  
The amount of uptake of iron oxide silica herceptin nanoparticles calculated as stimulation 
index of staining above the control for herceptin + αhuman FITC. The graph shows the 
dose-dependent uptake after an incubation time of 24 hours of the iron oxide silica 
herceptin nanoparticles in each of the cell lines, SKBR3, BT474 and MCF7 Error bars 
represent standard error of the mean calculated from triplicate measurements 
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4.2.3 Time-dependent uptake of iron oxide silica herceptin nanoparticles by 
human breast cancer cells in vitro 
 
To assess the uptake kinetics of the iron oxide silica herceptin nanoparticles by HER2 
positive breast cancer cells, time-dependant uptake was investigated using flow cytometry. 
50 μg of iron oxide silica herceptin nanoparticles was incubated for various time points. 
Figure 4.3 showed that the binding of the iron oxide silica herceptin nanoparticles to the 
breast cancer cell lines was related to the HER2 cell expression levels. The SKBR3 cells 
took up more of the iron oxide silica herceptin nanoparticles than either the BT474 or 
MCF7. This was in accordance with the surface expression data presented in Figure 4.1 
and also the dose response data in Figure 4.2. The SKBR3 stimulation index of staining 
was 80 at 0.5 hours and increased to 100 at 24 hours (Figure 4.3). The uptake of BT474 
cells was higher than that of MCF7 cells, where at 0.5 hours uptake was similar but at 3 
hours and 24 hours, the stimulation index of staining was 15 and 10 at 3 hours and 25 and 
15 at 24 hours, respectively. Uptake of iron oxide silica herceptin nanoparticles by all the 
breast cancer cells was evident as early as 30 minutes and continued to increase up to 5 
hours (Figure 4.3). Uptake was monitored to 24 hours, and the kinetics of uptake increased 
significantly between 5 and 24 hours, consistent with non-specific passive uptake of the 
nanoparticles as suggested by other time course studies (Steinhauser, et al., 2006). 
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Figure 4. 3 Time-dependent uptake of iron oxide silica herceptin nanoparticles by breast 
cancer cells  
The amount of uptake of iron oxide silica herceptin nanoparticles calculated stimulation 
index of staining above the control for herceptin + αhuman FITC. The graph shows time-
dependant uptake of the iron oxide silica-herceptin nanoparticles incubated at a 
concentration of 50 μg for each of the cell lines, SKBR3, BT474 and MCF7. Error bars 
represent standard error of the mean calculated from triplicate measurements 
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4.2.4  Cellular uptake via confocal microscopy 
 
For iron oxide silica herceptin nanoparticles to be imaged on MRI, the imaging agent must 
not only bind to the HER2 receptors present on the cell membrane but must also gain entry 
into cells via active endocytosis so that it is internalised. Cellular internalisation of the iron 
oxide silica herceptin nanoparticles was investigated using SKBR3 cells using FITC-
herceptin conjugated iron oxide silica nanoparticles at a concentration of 50 μg for 3 
hours. SKBR3 cells were imaged using confocal microscopy to visualise green 
fluorescence to indicate cellular internalisation. A Hoechst nuclear stain was also added to 
the cells to indicate the presence of live cells. Uptake of iron oxide silica herceptin 
nanoparticles was observed within the cells as shown in Figure 4.4. In all cells imaged, a 
bright green rim was seen around the SBKR3 cells, demonstrating binding to the cell 
surface. These appeared as spots or clusters on or just beneath the surface membrane 
(Figure 4.4B), indicating the binding of the FITC-herceptin iron oxide silica nanoparticles 
to HER2 receptors. The green fluorescence was further seen throughout the cell membrane 
for more of the cells shown in Figure 4.4B. It is well known that HER2 receptors are on 
the surface of SKBR3 cells as well as extending through the cell membrane (Cho, et al., 
2003). The FITC-herceptin iron oxide silica nanoparticles appeared to be confined to the 
cytoplasm and did not localise in the nucleus, as seen in Figure 4.4A and B. Furthermore, 
the presence of the FITC-herceptin iron oxide silica nanoparticles could be located in the 
phase-contrast images (Figure 4.4C), supporting the theory that the iron oxide silica 
nanoparticles were taken up by the cells and did not just remain on the surface of the cells. 
The data generated here supports the dose and time course uptake studies suggesting that 
HER2 expressing breast cancer cell lines were able to take up and internalise the iron 
oxide silica herceptin nanoparticles which were specific to the HER2 surface expression 
levels.  
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Figure 4. 4 Cellular internalisation of the FITC conjugated iron oxide silica herceptin nanoparticles by SKBR3 cells  
Cellular internalisation of the herceptin-FITC iron oxide silica nanoparticles at a concentration of 50μg for a period of 3 hours in SKBR3 cells 
is illustrated by confocal microscopy. (A) Hoechst (nuclear) staining of the SKBR3 cells; (B) FITC-herceptin conjugated iron oxide silica 
nanoparticle uptake in SKBR3 cells; and (C) phase contrast images of iron oxide silica herceptin nanoparticles.  
A B C A 
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4.2.5  MRI contrast enhancement by human breast cancer cells 
 
The uptake of iron oxide silica herceptin nanoparticles by human breast cancer cells was 
confirmed in in vitro studies as shown in Figures 4.2, 4.3 and 4.4. For these nanoparticles 
to be used as MRI contrast agents, the particles must be able to demonstrate signal 
enhancement related to the uptake of the nanoparticles. Since SKBR3, BT474 and MCF7 
have different levels of HER2 surface expression, it was anticipated that the iron oxide 
silica herceptin nanoparticles would be taken up relative to these expression levels and on 
MRI display respective contrast enhancement. SKBR3, BT474 and MCF7 cells were 
incubated with 50 μg of iron oxide silica herceptin nanoparticles for a period of 3 hours 
and controls consisting of the respective breast cancer cell line were incubated with water. 
MRI images were acquired in live cells after washing each cell line several times with 
water. MRI images of the three cell lines are shown in Figure 4.5. Figure 4.5A is the 
control image for each cell line and Figure 4.5B is the cell line incubated with the 
nanoparticles. When the control images for each cell line (4.5A) are compared with the 
images of the cell incubated with nanoparticles (4.5B), contrast enhancement can be seen 
relative to their respective control. Comparing each of the cell lines to their controls, the 
MRI image appears hypointense. Comparing the three cell lines in Figure 4.5B, the 
SKBR3 cell line appears to be more hypointense than the BT474 and MCF7 cell lines. To 
confirm this, a signal enhancement relative to control graph was generated using the T2 
signals from the control and nanoparticle treated cells to indicate the drop in the T2 
weighted signal intensity (amount of darkening) for the three cell lines (Figure 4.5C). It 
can be observed from the signal enhancement graph that the SKBR3 cell lines had the 
lowest signal intensity (50%) compared to the BT474 (65%) and MCF7 (85%) cell lines. 
This suggests that the SKBR3 cell line had greater signal enhancement than the BT474 
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and MCF7 cell lines. The signal enhancement graph confirms Figures 4.5A and 4.5B, 
where visually a more hypointense image is seen for the SKBR3 cell line than for the 
BT474 and MCF7 cell lines. The results from Figure 4.5 also confirm the uptake of the 
iron oxide silica herceptin nanoparticles and also confirm the results seen in Figures 4.2, 
4.3 and 4.4. 
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B) MRI Contrast 
 
 
 
 
 
 
        SKBR3       MCF-7         BT474  
0
10
20
30
40
50
60
CONTROL MCF7 BT474 SKBR3
Si
gn
al
 E
nh
an
ce
m
en
t R
el
at
iv
e 
to
 C
on
tr
ol
 (%
)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   C)  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. 5 MRI images and signal enhancements showing contrast generated from 
SKBR3, BT474 and MCF7 cell lines  
MRI signal enhancement of SKBR3, BT474 and MCF-7 cell lines after 3 hours incubation 
with iron oxide silica herceptin nanoparticles at a concentration of 50 μg. (A) MRI 
contrast image of SKBR3, BT474 and MCF7 cells with no nanoparticles, (B) MRI 
contrast image of SKBR3, BT474 and MCF7 cells with iron oxide silica herceptin 
nanoparticles, and (C) percentage (%) of signal enhancement of SKBR3, BT474 and 
A) Control  
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MCF7 cells relative to their control MRI T2 signal values. The error bars represent 
standard error of the mean calculated from triplicate measurements. 
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4.3 Discussion 
 
Iron oxide silica nanoparticles synthesised via a high temperature method and 
demonstrating crystalline structure, monodispersity, biocompatibility, high T2 relaxation 
and phantom contrast enhancement were used in an in vitro system to test their ability to 
be used in targeted imaging for MRI. The humanised monoclonal antibody herceptin is a 
well characterised biomarker against HER2 receptors. HER2 is overexpressed in 20-30% 
of breast cancers, and is known to have poor prognosis and limited responses to treatment 
(Nahta & Esteva, 2006; Slamon, et al., 1987). Therefore, the attachment of herceptin on 
the surface of iron oxide silica nanoparticles potentially provides the ability to target 
HER2 receptors, which could provide valuable information about the efficacy of herceptin 
and concurrent treatments. In targeted imaging, it is essential that the nanoparticles which 
are tagged to a biomarker can localise at the area of interest, particularly if the 
nanoparticles are designed to provide visual contrast. In this study, to ensure that the 
herceptin drove the iron oxide silica nanoparticles to HER2 positive tumours, in vitro 
studies were performed to demonstrate the uptake of the iron oxide silica nanoparticles via 
herceptin by HER2 expressing cells.  
 
The in vitro targeting ability of the synthesised iron oxide silica herceptin nanoparticles 
was investigated using flow cytometry, where a dose response and time course response 
uptake study was conducted to test the ability of the nanoparticles to bind specifically to 
HER2 receptors. Initially, a surface stain experiment was conducted to quantify the level 
of HER2 expression of SKBR3, BT474 and MCF7 breast cancer cell lines. Flow 
cytometry results demonstrated that SKBR3 cells had the highest level of HER2 
expression followed by BT474 and then MCF7 cell lines (Figure 4.1). The results of this 
study are consistent with the literature, which indicates that of the three breast cancer cell 
Chapter 4 – in vitro assessment of herceptin-nanoparticles 
   147
lines, SKBR3 has the highest HER2 expression levels (Chen, et al., 2000; Steinhauser, et 
al., 2006). Although the expression levels of these cell lines are well known and widely 
reported, it was important to validate the cells used in this study, as factors such as passage 
number, freezing, thawing and cell culture techniques can affect surface receptor 
expression levels. 
 
As herceptin is attached to the surface of the iron oxide silica nanoparticles, it is known 
from other studies using nanoparticle-herceptin systems, that the delivery is due to the 
herceptin acting as the vehicle to drive the nanoparticles to HER2 expressing cells 
(Artemov, et al., 2003; Chen, et al., 2009; Hilger, et al., 2007; Huh, et al., 2005). To 
confirm that the uptake of the iron oxide silica herceptin nanoparticles was mediated via 
the herceptin, a dose response and time course study was conducted to ascertain the 
kinetics of uptake using the three breast cancer cell lines, SKBR3, BT474 and MCF7. The 
dose response study showed that as the amount of herceptin-FITC iron oxide silica 
nanoparticles increased, uptake of iron oxide silica herceptin nanoparticles also increased 
(Figure 4.2). Furthermore, the level of herceptin-FITC iron oxide silica nanoparticles 
uptake seen in this study correlated with expression levels of HER2, suggesting that 
uptake of the nanoparticles was likely to be mediated by presence of herceptin 
(Steinhauser, et al., 2006; Wartlick, et al., 2004).  
 
As well as dose, the time required for uptake of nanoparticles is another important 
consideration when assessing uptake kinetics. A study quantifying the uptake of HSA 
nanoparticles conjugated to herceptin in SBKR3, BT474 and MCF7 cells over a period of 
24 hours suggested that time-dependant uptake of the nanoparticles occurred related to 
HER2 expression levels over a 5-hour period, and after this time point uptake could be 
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related to non-specific mechanisms (Steinhauser, et al., 2006; Wartlick, et al., 2004). In 
this study, Figure 4.3 demonstrated that the nanoparticle uptake increased over a 5-hour 
time period and that the amount of uptake correlated with HER2 expression levels. 
Furthermore, a large increase in uptake kinetics of the iron oxide silica herceptin 
nanoparticles occurred between 5 and 24 hours. Although no measurements were taken 
during 5 and 24 hours, the large increase in uptake kinetics could be indicative of a passive 
non-specific uptake mechanism, similar to the study using HSA nanoparticles conjugated 
to herceptin (Steinhauser, et al., 2006). 
 
It is interesting to note that most of the uptake studies that used nanoparticles conjugated 
to herceptin have not shown dose response curves, instead reporting only the differences 
in uptake using MRI. For example, Chen et al. (2009) investigated the use of herceptin 
conjugated dextran-coated iron oxide nanoparticles in four human breast cancer cells lines 
in vitro. They demonstrated uptake of the nanoparticles relative to HER2 expression as 
indicated by the different signal enhancements seen in MRI. Similarly, other studies (Lee, 
et al., 2007; Huh, et al., 2005; Artemov, et al., 2003) used cell lines with different levels of 
HER2 expression (characterised by western blot analysis and/or flow cytometry) and 
showed specific binding of the herceptin-nanoparticle conjugates using MRI signal 
enhancement change. This method is essential in understanding the MRI contrast 
enhancement behaviour between phantoms and in vitro systems, but it is not useful in 
understanding the behaviour of the herceptin-nanoparticles in in vitro systems. The 
disadvantage in not accurately characterising uptake of the nanoparticles is in targeting 
efficiency. For targeted imaging in MRI, it is important to ensure that the uptake of the 
nanoparticles seen is related to the targeting mechanisms of the biomarker and not just 
non-specific uptake of the nanoparticles. 
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To achieve targeted imaging with the iron oxide silica herceptin nanoparticles, the 
nanoparticles must bind to HER2 receptors on the membrane of cells and mediate cellular 
internalisation. This cellular internalisation was viewed by confocal microscopy after 
incubating the iron oxide silica herceptin-FITC nanoparticles with SKBR3 cells. 
Intracellular fluorescence was observed within the cell membrane and cytoplasm with 50 
μg of iron oxide silica herceptin nanoparticles over a 3-hour time period (Figure 4.4). The 
results seen were similar to those of previous studies investigating the uptake of herceptin 
conjugated nanoparticles by SKBR3 cells (Chen, et al., 2009; Huh, et al., 2005). It is well 
known that herceptin binds to HER2 receptors that are located on the surface of the cell 
membrane and extend throughout the whole membrane (Cho, et al., 2003). Herceptin is 
known to be internalised within HER2 positive cells via receptor mediated endocytosis 
and signals a variety of pathways to exhibit its effect, resulting in the herceptin 
accumulating within the cytoplasm. 
 
For iron oxide silica herceptin nanoparticles to be utilised in targeted imaging, a maximum 
amount of nanoparticles must arrive at the targeted area so that the highest contrast can be 
visualised on the MRI image. In studies that do not report data on dose response and time 
course response studies of the herceptin conjugated nanoparticles it is impossible to 
accurately determine the concentration of nanoparticles required to produce contrast prior 
to imaging.  
 
For targeted imaging, the ability to view contrast in vitro at a similar level to phantom 
studies is necessary for research that is intended to be translated from a preclinical to 
clinical settings. It is well known that phantom studies can represent better contrast 
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enhancement of the nanoparticles than in vitro cell studies, where the nanoparticles can 
present lower signal enhancement. This phenomenon is not related to the amount of 
nanoparticles within cells but is related to theories of nanoparticles being confined within 
the endosome of target cells creating a build-up of magnetic field inhomogeneities, which 
are absent in phantoms where the nanoparticles are uniformly distributed (Billotey, et al., 
2003; Kato, et al., 1999). In particular, the geometrical arrangement of the nanoparticles as 
a result of clustering within the cells is expected to be an important mechanism 
contributing to the effect of lower signal intensities in vitro.  
 
Studies have used different mechanisms to overcome this phenomenon, such as the 
determination of T2 values in phantoms and within cells to confirm that the signal 
reduction in vitro is not significant (Hilger, et al., 2007). Other studies have not included 
phantoms but simply showed in vitro cell phantoms and calculated signal enhancements 
relative to a control (Chen, et al., 2009; Hilger, et al., 2007; Huh, et al., 2005; Lee, et al., 
2007). In the current study, phantom experiments were conducted which showed signal 
enhancements of up to 80% for an iron oxide silica concentration of 50 μg (Chapter 3 
Figure 3.5). In this chapter, in vitro localisation of the iron oxide silica herceptin 
nanoparticles at a concentration of 50 μg for 3 hours demonstrated a maximum signal 
enhancement of 50% relative to the control (Figure 4.5). The results suggest that although 
there was a reduction in the contrast enhancement from phantoms, the level of signal 
enhancement seen in vitro was still sufficient for in vitro and in vivo targeting MRI 
studies. The results from this study are comparable to studies that have used high 
performance nanoparticles such as metal-doped iron oxides which were superior to iron 
oxides alone, showing signal enhancements greater than 50% in vitro (Lee, et al., 2007). 
Although metal-doped iron oxides are ideal as contrast enhancements due to their high 
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magnetic capabilities, translation to the clinical settings could be difficult due to the 
biological toxicity of metals such as manganese. Nevertheless, the results from this study 
showed contrast enhancement at the same level as reported for metal-doped iron oxides.  
 
Maintaining the ability to provide contrast in phantoms and then in in vitro assays using 
MRI is fundamental in developing targeted imaging conjugates. Another important aspect 
is the ability for conjugated nanoparticles to demonstrate selective binding to target cells. 
In this case, the iron oxide silica nanoparticles conjugated to herceptin demonstrated 
selective binding, as indicated by the dose and time course studies (Figures 4.2 and 4.3) 
and also by the MRI contrast enhancement studies (Figure 4.5). The data indicated that the 
SKBR3 cells, which had the highest level of HER2 expression (Figure 4.1), demonstrated 
the highest level uptake (Figures 4.2 and 4.3) and highest level of contrast (Figure 4.5) 
compared to BT474 and MCF7 cells. A similar trend of selective binding of iron oxide 
nanoparticles conjugated to herceptin has also been reported in other studies (Chen, et al., 
2009; Huh, et al., 2005). 
 
4.4 Conclusion 
  
This chapter sought to confirm whether synthesised iron oxide silica nanoparticles 
conjugated to herceptin could potentially be used for targeted imaging in vitro. The iron 
oxide silica herceptin nanoparticles were tested for their targeting ability using three breast 
cancer cell lines with different levels of HER2 expression in a dose and time course 
response uptake study. The breast cancer cell lines were then scanned on MRI to see 
whether MRI contrast could also be detected. These investigations confirmed that the iron 
oxide silica herceptin nanoparticles were able to target breast cancer cells based on HER2 
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expression, and uptake was both dose- and time-dependent. The data also suggested that 
the iron oxide silica herceptin nanoparticles localised within the cells, and demonstrated 
MRI contrast enhancement in vitro relative to controls. The level of contrast or signal 
enhancement was related to the HER2 expression levels, indicating specific uptake of the 
iron oxide silica herceptin nanoparticles by breast cancer cell lines. The results showed a 
potential use for the iron oxide silica herceptin nanoparticles in an in vitro biological 
system, warranting the use of iron oxide silica herceptin in an in vivo system.  
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Chapter 5 Assessment of the Iron Oxide Silica Herceptin Nanoparticles 
in vivo 
 
5.1 Introduction 
 
The previous chapter analysed the in vitro performance of the synthesised iron oxide silica 
herceptin nanoparticles and concluded, based on dose and time evidence, that breast 
cancer cells of various HER2 expression levels could be targeted. The investigation also 
demonstrated that the iron oxide silica herceptin nanoparticles localised within breast 
cancer cells and produced significant MRI contrast. This data suggested successful 
targeted imaging in vitro and that the synthesised iron oxide silica herceptin nanoparticles 
might be utilised for in vivo imaging. This chapter therefore investigated the in vivo 
performance of the synthesised iron oxide silica herceptin nanoparticles.  
 
As discussed in previous chapters of this thesis, herceptin is currently a targeted therapy 
against HER2 proteins, which are overexpressed in 20-30% of breast cancers (Slamon, et 
al., 1987). The association of HER2 positive expression in these breast cancers is linked 
with increased disease recurrence and poor prognosis (Slamon, et al., 1987). At the 
molecular level, herceptin induces regression of HER2 expressing tumours (Carter, et al., 
1992; Hudziak, et al., 1989; Shepard, et al., 1991). Although the mechanism of this action 
of herceptin has not yet been fully elucidated, several mechanisms have been reported 
(Nahta & Esteva, 2006). Herceptin selectively binds to HER2 receptors, followed by 
internalisation via receptor-mediated endocytosis (Nahta & Esteva, 2006). It has been 
suggested that herceptin induces cell cycle arrest due to down regulation of HER2, 
eventually leading to reduced cell proliferation, suppression of angiogenesis, antibody-
dependent cell-mediated toxicity, and finally cell death (Nahta & Esteva, 2006). Herceptin 
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was initially tested as a first-line therapy for its safety and efficacy in Phase II clinical 
trials for metastatic breast cancer (Vogel, et al., 2002). While it was found that the therapy 
was well tolerated and active in these patients, the overall response rate for herceptin on its 
own was less than 25% (Vogel, et al., 2002). 
 
One of the early findings relating to herceptin therapy concerned the synergistic effects 
that occurred when it was used in combination with a variety of chemotherapy agents 
(Pietras, Pegram, Finn, Maneval, & Slamon, 1998; Pegram, et al., 1999; Pegram, et al., 
2004; Slamon, et al., 2001). As a result, the effects of herceptin in combination with 
chemotherapy agents were investigated further. The findings from a landmark randomised 
phase III clinical trial indicated that herceptin significantly enhanced the activity of first-
line chemotherapy (Slamon, et al., 2001). The outcome of this trial triggered various 
investigations using several chemotherapy agents in combination with herceptin for 
further evaluation of adjuvant therapy in clinical trials (Slamon, et al., 2001). It was shown 
that adding various combinations of chemotherapy agents including single (Gasparini, et 
al., 2007; Marty, et al., 2005; Slamon, et al., 2001), double or triple combinations 
(Pegram, et al., 2007; Robert, et al., 2006)could improve median survival rates, reduce 
disease progression and yield higher response rates. The use of herceptin was also 
investigated in patients with disease progression after treatment and in locally advanced 
breast cancer, where results showed improved response rates, overall survival and time to 
disease progression in these patients (Bontenbal, et al., 2008; O'Shaughnessy et al., 2008; 
von Minckwitz, et al., 2009). 
 
Despite the anti-tumour effects of herceptin on HER2 positive breast cancers, there were 
reports of primary and secondary resistance to herceptin-based therapies (Goel, et al., 
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2010; Slamon, et al., 2001; Vogel, et al., 2002). The mechanisms of acquired resistance 
and low response rates are not fully understood. The range of possible contributing factors 
includes the quantification and levels of HER2 expression, altered receptor-antibody 
interaction, increased cell signalling, and over-expression of the insulin-like growth factor-
I receptor, which were discussed in detail in Chapter 1 Section 1.4.3 of this thesis. There is 
no doubt that elucidating the molecular mechanisms by which tumours escape herceptin-
based cytotoxicity is critical to improving the prognosis of breast cancer patients whose 
tumours overexpress HER2. Equally important is identification of those patients who 
could stop responding to herceptin-based therapy regimes. A large body of evidence 
suggests that herceptin resistance is acquired (Slamon, et al., 2001; Vogel, et al., 2002) 
and because various mechanisms are possible it is difficult to predict which outcome a 
patient will exhibit. Therefore a clinical need exists to select the best therapies for clinical 
indications based on predictors of response which will identify effective therapies for 
patients needing treatment (Goel, et al., 2010). 
 
A critical area of development involving apotential predictor of therapy is the use of iron 
oxide nanoparticles in MRI. Compared to other imaging methods MRI is the preferred 
complementary imaging tool for targeted imaging. This is because MRI offers superb 
resolution without the use of ionising radiation that can potentially be harmful to 
biomarkers used for targeting (Long & Bulte, 2009). The ability to image the progress of 
herceptin treatment using iron oxide nanoparticles with MRI presents the possibility of 
providing critical information about the efficacy of herceptin concurrently with treatment.  
 
At the present time, all iron oxide nanoparticles for targeted imaging using MRI in 
oncology are at the preclinical stage where there is research and development into 
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applications such as in cell tracking (Budde & Frank, 2009; Long & Bulte, 2009). The 
slow development of iron oxide nanoparticles for targeted imaging using MRI is largely 
attributable to the lack of studies that translate to the clinical setting. This is due to many 
areas of difficulty, such as quantifying dosages to ensure maximum contrast, particles with 
low magnetisation values, manufacturing large amounts of nanoparticles without 
compromising quality, and the ability to target nanoparticles to the area of interest in vivo 
(Corot, et al., 2006; Gupta & Gupta, 2005; Laurent, et al., 2008; Peng et al., 2008).  
 
The iron oxide nanoparticles that have been developed for targeting HER2 positive breast 
cancers also present some of these issues. For example, Chen et al. (2009) successfully 
targeted HER2 positive tumours using dextran coated iron oxide nanoparticles, but their 
particles had low magnetisation values. Similarly, Hilger et al. (2007) also used dextran 
coated iron oxide nanoparticles with low magnetic properties and reported signal 
enhancement of the targeted area to be less than 20% in an in vivo model of breast cancer. 
On the other hand Huh et al. (2005) successfully targeted HER2 positive tumours using 
highly magnetic cross-linked iron oxide nanoparticles conjugated to herceptin. Although 
their study showed signal enhancement at the targeted area to be higher than other studies, 
the process to reproduce cross-linked iron oxide nanoparticles would require a number of 
complicated steps. Nevertheless, all these studies provide valuable insight into the use of 
iron oxide nanoparticles for targeting HER2 positive breast cancers and areas of possible 
improvement. 
 
The iron oxide silica herceptin nanoparticles that were investigated in Chapters 3 and 4 of 
this thesis have been shown to overcome some of these limitations. For example, they can 
be produced in large quantities, they have high magnetisation values, and they produce 
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significant MRI contrast in phantoms and in vitro. The aim, therefore, of experiments in 
this chapter was to utilise them for in vivo imaging of HER2 positive breast cancers. 
 
Iron oxide nanoparticles are well known to be phagocytosed by the RES cells of the 
spleen, lymph nodes, bone marrow, and liver when administered intravenously 
(Pouliquen, et al., 1991; Weissleder, et al., 1989). They are stored in lysosomes where the 
iron oxide nanoparticles are ultimately degraded and enter the biological iron metabolism 
cycle (Pouliquen, et al., 1991; Weissleder, et al., 1989). For larger iron oxide 
nanoparticles, above approximately 60 nm in diameter, 80-90% of the injected dose can be 
taken up by the RES within 30 minutes of intravenous administration and then eliminated 
(Pouliquen, et al., 1991; Weissleder, et al., 1989). This means that if the iron oxide 
nanoparticles need to be targeted to an area of interest there would not be enough of them 
available for localisation. Thus large iron oxide nanoparticles are unsuitable for targeted 
imaging. It is well known that reducing the size of iron oxide nanoparticles and adding a 
surface coating increases their half-life in the systemic blood pool circulation in 
vivo(Gupta & Gupta, 2005; Laurent, et al., 2008; Weissleder, et al., 1990). Studies using 
smaller iron oxide nanoparticles with a surface coating have shown that the initial liver 
and spleen uptake is low and that the particles remain in the bloodstream for several hours, 
suggesting that they can be available for localisation at a targeted area (Chouly, et al., 
1996; Islam & Wolf, 2009; Moore, et al., 2000; Weissleder, et al., 1990). After this period, 
iron levels have been shown to increase in organs such as the liver, spleen, lungs, kidneys 
and heart (Jain, et al., 2008; Weissleder, et al., 1990). This is followed by the breakdown 
and elimination of iron from the system, which is reported to take up to 3 weeks, 
following the normal biodistribution and elimination patterns of biological iron (Islam & 
Wolf, 2009; Jain, et al., 2008; Weissleder, et al., 1989). 
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The biodistribution of iron oxide nanoparticles coated in silica has not been widely 
investigated, primarily due to the recent emergence of the use of silica in the nanoscale as 
nanoparticles or coatings on nanoparticles. As stated in Chapter 3, silica is known to 
possess extraordinary properties such as easy synthesis, low cost, high hydrophilicity and 
facile surface modification, with the result that silica is increasingly used for biomedical 
applications (Rieter, et al., 2007). The biodistribution of the commercially available large 
iron oxide silica nanoparticles such as GastroMARK® and Abdoscan® is well known. 
Both these contrast agents are administered orally, the iron oxide nanoparticles coated in 
silica are minimally absorbed through the bowel, and within several hours the compound 
is excreted primarily through the bowel (Advanced-Magnetics, 2007). There are a few 
reports of the biodistribution in vivo of smaller iron oxide nanoparticles coated with silica. 
Kim et al. (2006) studied 50 nm iron oxide nanoparticles coated with silica and conjugated 
to a fluorescent marker. The biodistribution was noted in organs such as the liver, spleen, 
heart, lungs, kidneys, brain, testes and uterus. The maximum uptake, which occurred in the 
liver and spleen, was negligible immediately after injection but increased over a 4-week 
period, where minimum uptake was seen in the lungs (Kim, et al., 2006). The 
biodistribution of lipid-coated silica nanoparticles conjugated to gadolinium metal has 
showed long circulating blood times (approximately 164 mins) (van Schooneveld, et al., 
2008). These nanoparticles remained in the circulation for up to 4 hours and then 
increasingly accumulated within the liver and spleen, where they were cleared from the 
blood (van Schooneveld, et al., 2008). Another investigation of the biodistribution of silica 
nanoparticles approximately 45 nm in diameter showed similar distribution patterns, 
where the silica nanoparticles remained in the blood circulation for 3 hours, after which 
they increased in uptake in the liver and were then excreted via the urinary system (He, et 
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al., 2008). All these studies suggest that silica on the surface of the iron oxide 
nanoparticles can be beneficial for targeted imaging, based on the reported biodistribution 
patterns and size parameters. 
 
The uptake of nanoparticles into tumours has been described as related to the high 
vasculature nature of the tumours. Studies have shown that nanoparticles are taken up in 
the peripheries of tumours and then heterogeneously accumulate throughout the tumour 
site (Huh, et al., 2005; Moore, et al., 2000). This heterogeneous uptake corresponds to the 
presence of blood vessels in the tumour periphery and is related to natural tumour 
vasculature (Moore, et al., 2000). With the attachment of an antibody such as herceptin to 
the surface of the iron oxide nanoparticle, the internalisation of the nanoparticles in breast 
tumours would occur by the antibody-antigen recognition action at the surface of the 
tumours. Studies using iron oxide nanoparticles for targeting HER2 positive breast cancers 
in vivo have not shown the mechanism of uptake of the nanoparticles to the tumour site. 
Specific imaging of a target site, such as a solid HER2 overexpressing breast tumour, 
requires several steps: long circulation of the conjugated nanoparticles to ensure 
availability, permeation of the conjugated nanoparticles into tissues, recognition of the 
conjugated nanoparticles at the antigen-antibody receptor site, and receptor-mediated 
endocytosis of the conjugated nanoparticles into the tumour site. On the evidence from 
previous studies, iron oxide nanoparticles and iron oxide silica nanoparticles with a 
smaller size can remain in the circulation for a minimum of 3 hours (Chen, et al., 2009; 
He, et al., 2008; Kim, et al., 2006). It can then be assumed that iron oxide silica herceptin 
nanoparticles can localise at the tumour site, most likely due to the receptor mediated 
action of the herceptin, as in the in vitro studies detailed in Chapter 4. Other studies have 
shown that uptake at the tumour site after intravenous injection occurs as early as 3 hours 
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and up to 24 hours (Chen, et al., 2009; Hilger, et al., 2007; Huh, et al., 2005), when the 
uptake begins to clear. 
 
Apart from localisation of the iron oxide silica herceptin nanoparticles, no toxicity is one 
of the fundamental requirements for the use of iron oxide silica herceptin nanoparticles in 
vivo and is one of the key factors in the determination of clinical use. The in vitro toxicity 
of the iron oxide silica herceptin nanoparticles was assessed in Chapter 4, and toxic effects 
were consistent with the literature and the action of herceptin was consistent with previous 
studies. The earliest reports of iron oxide nanoparticles demonstrated no acute or sub-acute 
toxic effects in vivo, as the excretion of iron oxide nanoparticles followed the natural 
channels of iron metabolism (Weissleder, et al., 1989). Although the toxic effects of iron 
oxide nanoparticles coated in silica have not been widely investigated, silica on its own 
has demonstrated toxic effects that caused DNA cleavage (Chen & von Mikecz, 2005) 
especially when used in large concentrations (Chang, Chang, Hwang, & Kong, 2007; Jin, 
Kannan, Wu, & Zhao, 2007). Most of the earlier studies assessing silica have shown toxic 
effects caused by silica in the lungs (Lin, Huang, Zhou, & Ma, 2006), primarily due to the 
inhalation of large amounts of silica (Castranova & Vallyathan, 2000). However, in vivo 
toxicity studies assessing nanoparticles with silica have shown almost little to no 
localisation of the silica-based nanoparticles within the lungs (Kim, et al., 2006). The 
studies utilising silica nanoparticles have reported no biological toxicity, suggesting that 
silica is safe to use in minimal amounts (Gregersen, Lopez, & York, 2003; He, et al., 
2008; Kim, et al., 2006). On the basis of earlier studies it was expected that the iron oxide 
silica nanoparticles would have minimal or negligible toxic effects in vivo.  
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The previous chapters showed that iron oxide silica herceptin nanoparticles could be 
produced on a large scale, had significant magnetic properties, were biocompatible and 
stable. Furthermore, Chapter 4 found that these nanoparticles could be applied as contrast 
agents to target HER2 receptors in vitro and that they provided significant MRI contrast 
enhancement. Based on the investigations of these two experimental chapters, the 
experiments in this chapter aimed to investigate the in vivo potential of the synthesised 
iron oxide silica herceptin nanoparticles. 
 
On the basis of these previous studies, the aims of this chapter were to: 
1. Grow HER2-expressing SKBR3 xenograft tumours in BALB/c nude mice; 
2. Image SKBR3 xenografts in BALB/c nude mice at 4 hours and 24 hours post-
injection with iron oxide silica herceptin nanoparticles and observe signal 
enhancement relative to the control; and 
3. Investigate acute toxicity of the iron oxide silica herceptin nanoparticles post-
injection in BALB/c nude mice in vivo. 
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5.2 Results 
 
 
5.2.1 Growth of HER2 positive tumours in BALB/c nude mice 
 
The growth of SKBR3 tumour cells in BALB/c nude mice was confirmed after conducting 
a xenograft tumour growth curve analysis study. The results indicated that SKBR3 cells 
formed tumours as early as 4 days post-injection in the right flank of BALB/c nude mice. 
By day 5, the SKBR3 tumours had reached approximately 3.5mm2 and by day 12 had 
reached approximately 8mm2 (Figure 5.1).  
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Figure 5. 1 Tumour growth curves of SKBR3 xenograft tumours in BALB/c nude mice  
3x106 SKBR3 cells were injected subcutaneously into the right flank of BALB/c nude 
mice (n=3) and tumour growth was monitored daily; measurements (length x width) were 
recorded as tumour size (mm). Error bars were calculated by standard deviation of the 
mean. 
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5.2.2 HER2 expression in SKBR3 xenograft tumours 
 
Immunohistochemical analysis of SKBR3 xenograft tumours was performed using 
immunohistochemistry to confirm expression of HER2 receptors. Following the growth of 
xenograft SKBR3 tumours in BALB/c nude mice, to a maximum size of 8 mm2 over a 12-
day period, the mice were killed and tumours were dissected and processed for 
histological analysis. Figure 5.2 shows the staining pattern of HER2 in SKBR3 xenograft 
tumours grown in BALB/c nude mice. The inset shows clear membranous (M) and 
cytoplasmic (C) staining within the tumours cells. This pattern of staining was consistently 
seen with all the SKBR3 xenograft tumours. 
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Figure 5. 2 Immunohistochemical analysis of HER2 expression in SKBR3 xenograft 
tumours using HRP 
Dissected SKBR3 tumours were processed for histological analysis. The samples were 
stained with an anti-HER2 antibody and the inset shows membranous (M) and 
cytoplasmic (C) staining of the SKBR3 tumour clusters grown in BALB/c nude mice at 
the time of animal sacrifice (magnification x20).  
C
M
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5.2.3 Intratumoral MRI contrast enhancement of SKBR3 xenografts  
 
To assess optimal MRI contrast enhancement within SKBR3 xenograft tumours, 50 μg of 
iron oxide silica herceptin nanoparticles was injected intratumorally and then assessed for 
contrast enhancement. After injection at the tumour site, significant enhancement could be 
seen visually as indicated by the hypointense signal (Figure 5.3). Figure 5.3A (i) shows 
the sagittal slice of a SKBR3 xenograft tumour that was injected with saline (control 
group), demonstrating no contrast as indicated by the white arrow. Figure 5.3A (ii) 
indicates contrast enhancement demonstrated by a large hypointense signal after 
intratumoral injection of 50 μg of iron oxide silica herceptin nanoparticles (as indicated by 
the white arrow). The calculated signal enhancement relative to the control mouse was 
presented and a maximum signal enhancement of 80% was calculated (Figure 5.3B). 
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Figure 5. 3 MRI Signal enhancement of SKBR3 tumours after intratumoral injection of 
iron oxide silica herceptin nanoparticles  
(A) (i) MRI image of a control mouse injected intratumorally with saline and (ii) MRI 
image of mouse injected intratumorally with 50 μg of iron oxide silica herceptin 
nanoparticles. (B) Signal enhancement of the mouse injected with saline and 50 μg of iron 
oxide silica herceptin nanoparticles. Error bars represent standard deviation of the mean 
calculated from triplicate measurements. 
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5.2.4 In vivo toxicity of iron oxide silica herceptin nanoparticles 
 
The in vivo acute toxicity of the iron oxide silica herceptin nanoparticles was assessed in 
three groups of BALB/c nude mice (n=3) each with a separate experimental condition. 
The first group of mice received an intravenous injection of saline. The second group of 
mice received an intravenous injection of iron oxide silica nanoparticles at a maximum 
dose of 20 mg/kg. The third group of mice received an intravenous injection of iron oxide 
silica herceptin nanoparticles at a maximum dose of 20 mg/kg. The mice were monitored 
over a 7-day period after which organs including liver, lungs, heart and kidneys were 
collected for histopathological analysis to assess acute toxicity. The results indicate that 
injection of iron oxide silica herceptin nanoparticles had no effect on mortality, morbidity, 
body weight or food consumption in the BALB/c nude mice.Laboratory values of blood 
biochemistry, liver and kidney function were all within normal limits (data not shown). 
Histologic studies of liver, lungs, kidneys and heart demonstrated no necrosis, no loss of 
nuclei, no inflammation or any other pathological processes. The conjugated nanoparticles 
were not identifiable, possibly due to insufficient resolution.  
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Figure 5. 4 Histological analysis of in vivo toxicity in BALB/c nude mice after 
intravenous injection of iron oxide silica herceptin nanoparticles  
(I) Group 1 shows histological analysis showing liver, kidney, lung and heart of control 
mice injected with saline. (II) Group 2 shows histological analysis showing liver, kidney, 
lung and heart of mice injected with iron oxide silica nanoparticles (20 mg/kg). (III) Group 
3 shows histological analysis showing liver, lung and heart of mice injected with iron 
oxide silica herceptin nanoparticles (20 mg/kg). Magnification at 10X. 
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5.2.5 MRI targeting and contrast enhancement of SKBR3 xenograft 
breast tumours in vivo 
 
To evaluate the targeting ability and MRI contrast enhancement of iron oxide silica 
herceptin nanoparticles in vivo, SKBR3 xenograft breast tumours were grown in BALB/c 
nude mice (n=5) and injected intravenously with iron nanoparticles at a dose of 400 µg. To 
demonstrate targeted imaging by contrast enhancement, iron oxide silica herceptin 
nanoparticles were intravenously injected and imaged at 4 hours and 24 hours post-
injection. To complement the control mice, iron oxide silica nanoparticles with no 
herceptin were also injected and imaged at 4 and 24 hours post-injection. Figure 5.5 shows 
the T2 weighted images of a tumour-bearing mouse with (A) no contrast agent, (B) 4 
hours post-injection with iron oxide silica nanoparticles, (C) 24 hours post-injection with 
iron oxide silica nanoparticles, (D) 4 hours post-injection with iron oxide silica herceptin 
nanoparticles and (E) 24 hours post-injection with iron oxide silica herceptin 
nanoparticles. The data suggests that mice with SKBR3 tumours injected with iron oxide 
silica herceptin nanoparticles (Figure 5.5D-E) had the most significant contrast 
enhancement, as indicated by a hypointense signal compared to the control mice who 
received iron oxide silica nanoparticles without herceptin (Figure 5.5B-C) and saline with 
no contrast agent (Figure 5.5A). The appearance of the hypointense signal in mice who 
received iron oxide silica herceptin nanoparticles would be seen only if the iron oxide 
silica herceptin nanoparticles were present. To confirm this, signal enhancement analysis 
calculation was conducted by placing a region of interest over the entire tumour. These 
calculations suggest that the average enhancement was approximately 50% for iron oxide 
silica herceptin nanoparticles at 4 hours and less than 8% for iron oxide silica 
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nanoparticles and controls at 4 and 24 hours (Figure 5.5F). This suggests that the mice 
who received iron oxide silica herceptin nanoparticles demonstrated signal enhancement at 
the tumour site relative to the controls. Comparison of the iron oxide silica herceptin 
nanoparticles contrast at 4 and 24 hours indicated that uptake at both these time points was 
similar, suggesting that localisation of the iron oxide silica herceptin nanoparticles 
remained within the tumour at 24 hours post-injection. 
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Figure 5. 5 T2 weighted images and signal enhancement of SKBR3 tumours  
SKBR3 tumours were grown in BALB/c nude mice and the uptake of iron oxide silica and 
iron oxide silica herceptin nanoparticles (400μg) after intravenous injection was observed 
(n = 5). T2 weighted images show (A) control (saline), (B) iron oxide silica nanoparticles 
with no herceptin at 4 hours, (C) iron oxide silica with no herceptin at 24 hours, (D) iron 
oxide silica herceptin nanoparticles at 4 hours and (E) iron oxide silica herceptin 
nanoparticles at 24 hours. The calculated % MRI signal enhancement analysis relative to 
the control for each conjugate is shown in (F). Error bars represent standard deviation of 
the mean 
(F) 
 (E) 
(A) (B)
(C) (D)
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5.3 Discussion 
 
One of the promising areas of targeted imaging is the use of iron oxide nanoparticles in 
detecting HER2 positive receptors in breast tumours. Previous studies have used iron 
oxides for in vitro and in vivo targeting of HER2 positive breast cancers, but nanoparticles 
have presented critical problems which have limited their development to the clinical 
setting (Chen, et al., 2009; Hilger, et al., 2007; Huh, et al., 2005). Issues such as low 
magnetisation values, low signal enhancement and high amounts of iron required are 
important as they impair the basic fundamental properties for successful in vivo targeted 
imaging. In the current study, iron oxide silica herceptin nanoparticles with high 
magnetisation values and that had shown high contrast enhancement in vitro were tested in 
an in vivo setting. The results indicated that significant contrast enhancement could be 
visualised at the tumour site in breast tumour bearing BALB/c nude mice, with 
approximately 50% contrast enhancement relative to the control.  
 
Before the iron oxide silica herceptin nanoparticles were analysed for their targeting 
ability, the growth of the HER2 positive tumours was first monitored in BALB/c nude 
mice. The tumour growth study indicated that SKBR3 tumours could be grown 
successfully in BALB/c nude mice using Matrigel™ over a 12-day period where an 
average maximum diameter of 8 mm2 was noted (Figure 5.2.1). That initial step in 
assessing the growth of tumours using SKBR3 cells was important as variations in cell 
culture passages and the origin of the nude mice could affect growth patterns of xenograft 
tumours. Analysis of HER2 receptors on the SKBR3 xenograft tumours grown in BALB/c 
mice was shown by immunohistochemistry where the tumours retained their HER2 
receptor expression, a finding that was similar to previous studies which have retained 
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HER2 expression in SKBR3 tumour xenografts (Chen, et al., 2009; Hilger, et al., 
2007).This result therefore warranted the use of the SKBR3 cells in developing HER2 
positive tumours in nude mice as the animal tumour model for this study. 
 
It is well known that for any nanoparticle design for applications in MRI, iron oxide 
nanoparticles with the highest T2 relaxation or contrast enhancement in phantoms need to 
be considered, followed by assessment of their efficiency in in vitro and in vivo studies. 
Thus the iron oxide silica herceptin nanoparticles were initially assessed for their 
intratumoral contrast before investigating contrast in vivo. From the phantom studies, a 
dosage above 50 μg of iron oxide silica nanoparticles was sufficient to generate 80% of 
signal enhancement (Chapter 3, Figure 3.5) and for in vitro studies a dosage of 50 μg of 
iron oxide silica herceptin was sufficient to generate 55% signal enhancement (Chapter 4, 
Figure 4.5). Furthermore, a dosage of 50 μg demonstrated lower cytotoxic effects than the 
higher dosage of 100 μg (Chapter 3, Figure 3.8). On the basis of these studies, a dosage of 
50 μg of iron oxide silica herceptin nanoparticles was injected intratumorally into BALB/c 
nude mice bearing HER2 positive tumours to investigate the amount of MRI signal 
enhancement at the tumour site. The results indicated an MRI signal enhancement of 
approximately 80%, similar to the phantom studies, suggesting that there was no loss of 
contrast enhancement due to body mass or tumour tissue. This suggests that the iron oxide 
silica herceptin nanoparticles were highly magnetic and that body fat present within the 
mice had minimal or no effect of reducing the signal enhancement. There are no previous 
studies with which to compare these results, and it can not be ruled out that body mass 
and/or tumour tissue contributed to the effect of lower signal enhancement. Overall, the 
results suggest that the contrast seen after intratumoral injection of nanoparticles was 
similar to that in the phantom studies. The fact that the maximum contrast was seen after 
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intratumoral injection could suggest that the nanoparticles were not compartmentalised 
sub-cellularly and the nanoparticles were uniformly distributed, as in the phantom studies. 
This was discussed in detail in Chapter 3, where one of the factors contributing to the 
phenomenon of reduced contrast in vitro was the build-up of magnetic field 
inhomogeneities after the nanoparticles were in subcellular compartments of the cells. 
 
Acute toxicity of the iron oxide silica herceptin nanoparticles was investigated and was not 
evident at a dose of 20 mg/kg body weight. The median lethal dose (LD50) of iron is 
known to be 30 mg/kg (Weissleder, et al, 1989) a dosage of iron oxide silica herceptin 
nanoparticles (20mg/kg) is well below this number. It is known that cirrhosis and 
hepatocellular carcinoma can develop if iron levels in the liver exceed 4000 μg/g wet 
weight (normal, 200 μg/g wet weight) (Bassett, Halliday, & Powell, 1986; Weir, Gibson, 
& Peters, 1984). Furthermore, the amount of iron used in this study was very small 
compared to normal liver iron stores. If these iron oxide nanoparticles were used in 
humans, an average 70 kg adult would receive a dosage of 1400 mg. It has been reported 
that a dose of up to 80 mg of iron is known to increase liver iron from 200 to 212 μg/g wet 
tissue, suggesting that the dosage used in this study was well below the limits reported to 
induce any hepatotoxic changes (Weissleder, et al, 1989). The assessment of the hepatic 
parenchyma and hepatocytes showed no toxicity as there were no histopathological 
changes detected including inflammation, necrosis or loss of cellular nuclei. Iron oxide 
nanoparticles have previously demonstrated localisation in other organs such as kidneys 
and lungs (Weissleder, et al, 1989). Histopathological analysis demonstrated that there 
were no toxic effects in the kidneys and lungs of mice that received iron oxide silica 
herceptin nanoparticles compared to control groups. Therefore, there was no evidence of 
acute toxicity caused by the iron oxide silica herceptin nanoparticles used here. These 
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results are consistent with other studies that have investigated the acute toxicity of iron 
oxide nanoparticles in mice (Weissleder, et al., 1989). The administration of herceptin is 
also known to cause toxic effects on the myocardium (Chien, 2006; Slamon, et al., 2001), 
and therefore histopathological assessment of the heart tissue of the mice was undertaken. 
As with the other organs, there was no evidence of acute toxicity. The cause of 
cardiotoxicity induced by administration of herceptin is uncertain, and it has been reported 
that in approximately 10% of patients who receive herceptin treatment there is a decrease 
in cardiac function (Chien, 2006). The possible reason for the lack of toxic effects in this 
study could be the low amount of our labelled iron oxide silica herceptin nanoparticles 
used.  
 
In vivo imaging showed that after intravenous administration of the iron oxide silica 
herceptin nanoparticles a maximum signal enhancement of approximately 50% at 4 hours 
and at 24 hours was calculated. The results suggested that the iron oxide silica herceptin 
nanoparticles successfully localised and bound to the HER2 positive tumour,producing 
significant MRI contrast enhancement at the tumour site. Compared to previous studies, 
the iron oxide silica herceptin nanoparticles used in this study for in vivo targeting appear 
to have achieved better performance in generating contrast enhancement at the targeted 
area. A study that used iron oxide nanoparticles coated with dextran demonstrated 
maximum in vivo contrast enhancement of up to 20% (Hilger, et al., 2007). The most 
likely explanation for the difference in contrast enhancement could be that the iron oxide 
nanoparticles used in that study had limited magnetic properties and therefore produced 
lower amounts of MRI contrast enhancement. As discussed in Chapter 3, the iron oxide 
nanoparticles used by Hilger et al. (2007) were produced via a co-precipitation method, 
which is known to produce large amounts of particles at the expense of lower 
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magnetisation values. Furthermore, a study that produced iron oxide nanoparticles via a 
thermal decomposition method, similar to method used in this study, coated their particles 
in DMSA and observed a maximum drop in T2 intensity of only 20% (Huh, et al., 2005). 
Although the authors did not calculate the signal enhancement value, a small drop in the 
T2 intensity suggests a possible low signal enhancement. The difference in the results 
could be due to a range of factors such as T2 values, which were not stated, size of the 
nanoparticles, and the influence of the surface coating. A study by Chen et al. (2009) used 
a novel iron oxide dextran herceptin nanoparticle in a cross-linked pattern and 
demonstrated a 45% enhancement at the tumour site. This large value demonstrates the 
effect of the well-known high magnetisation value capability of cross-linked iron oxide 
nanoparticles (Högemann, Josephson, Weissleder, & Basilion, 2000). The disadvantage in 
the usage of cross-linked iron oxide nanoparticles is the low production yield and limited 
surface coatings that can be used. The iron oxide silica herceptin nanoparticles in this 
study were not cross-linked but still provided greater than 50% signal enhancement after 
intravenous injection, higher than the cross-linked iron oxide nanoparticles previously 
reported. The results from this study can also be compared to dual doped metals used in 
MRI targeting studies (Lee, et al., 2007). Dual doped metal nanoparticles have been 
developed to produce more MRI contrast than iron oxide nanoparticles on their own (Lee, 
et al., 2007). The theory behind dual doped metal particles is that a high magnetic moment 
performance metal such as manganese (Mg) II ions can be impregnated within iron oxides 
to enhance the contrast (Lee, et al., 2007). The enhancement seen in SKBR3 tumours by 
iron oxide doped with Mg (II) conjugated to herceptin was under 40% at 8 hours post-
intravenous injection, which is significantly lower than the contrast seen in this study.  
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The signal enhancements of the SKBR3 tumours at 4 and 24 hours post-injection with iron 
oxide silica herceptin nanoparticles were similar, with enhancements of 50% and 52%, 
respectively. Firstly, the uptake of the iron oxide silica herceptin nanoparticles was seen as 
early as 4 hours, suggesting that the nanoparticles could be visualised within the tumour as 
early as 4 hours. Secondly, the calculated signal enhancement at 4 and 24 hour time points 
showed similar values of 50% and 52%, respectively. This data suggests that the iron 
oxide silica herceptin nanoparticles could remain within the tumour for up to 24 hours 
post-intravenous injection, potentially allowing longitudinal studies. The overall uptake 
pattern of the nanoparticles was consistent with other studies that have used iron oxide 
nanoparticles with different surface coatings such as DMSA and dextran (Chen, et al., 
2009). For example, in their time-dependant study, Huh et al. (2005) observed contrast 
enhancement as early as 1 hour as well as 4 and 12 hours post-intravenous injection, 
where the uptake at 12 hours was similar or unchanged to that at 4 hours. Similarly, Chen 
et al. (2009) reported MRI contrast enhancement as early as 3 hours post-injection.  
 
If the signal enhancement data is compared between the iron oxide silica herceptin time 
points (Figure 5.2.5D and 5.2.5E) and iron oxide silica time points (Figure 5.2.5B and 
5.2.5C), it can be observed that there was little to no signal enhancement by the iron oxide 
silica nanoparticles at 4 and 24 hours within the SKBR3 tumours. The aim of 
intravenously injecting iron oxide silica nanoparticles was to demonstrate any non-specific 
tumour uptake caused by the iron oxide silica nanoparticles. From the results shown, it can 
be deduced that the iron oxide silica nanoparticles did localise within the SBKR3 tumours 
and did not induce any non-specific tumour uptake. This suggests that only the 
nanoparticles conjugated to herceptin localised within the SKBR3 tumours and produced 
contrast. Therefore, it is suggested that the iron oxide silica herceptin nanoparticles 
Chapter 5 – in vivo assessment of herceptin-nanoparticles 
   179
localised within the tumour due to the action of the herceptin conjugated on the surface of 
the iron oxide silica nanoparticles. As far as we know, no other reported studies have 
compared conjugated and non-conjugated nanoparticles in producing MRI contrast.  
 
Another observation of interest is the similar uptake pattern of the nanoparticles in this 
study and in other studies. The uptake of the nanoparticles within the tumour occurred 
towards the bottom region (Figure 5.2.5E and 5.2.5F) and then gradually built up to the 
central and upper regions of the tumour (Huh, et al., 2005; Moore, et al., 2000). It is 
presumed that this time-dependant MRI signal change and nanoparticle uptake could be 
related to the heterogeneous pattern of the intratumoral vasculature, where the iron oxide 
nanoparticles were easily permeable in the highly vasculature region of the tumour and 
afterward gradually reached the less vascular region as time progressed (Huh, et al., 2005; 
Moore, et al., 2000; Weidner, Semple, Welch, & Folkman, 1991). The unbound 
nanoparticles recirculate continuously in the blood and if they are not taken up by the RES 
to be eliminated, continue to target the HER2 expressing tumour cells. Liver uptake of the 
iron oxide silica nanoparticles is inevitable as this is the primary excretion pathway, 
particularly after intravenous injection. However, as the in vivo results from this study 
show, it appears that the amount of iron oxide silica herceptin nanoparticles reaching the 
tumour washigh. Future investigators should consider conducting a longitudinal study 
evaluating the clearance of the iron oxide silica herceptin nanoparticles from the tumour, 
to investigate whether longitudinal scanning could be considered for these nanoparticles in 
tumour tracking or turnover kinetics. Such investigation is particularly useful, especially in 
tracking the progression of tumours, identifying sentinel nodes, and also in monitoring 
responses to treatment such as herceptin. Other future areas of investigation should include 
a biodistribution study and using these iron oxide silica nanoparticles to image tumours of 
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tumours of different sizes, which would provide valuable information in relation to further 
optimising targeted HER2 imaging with iron oxides. 
 
5.4 Conclusion 
 
The aim of this chapter was to confirm whether the iron oxide silica herceptin 
nanoparticles could be utilised for in vivo tracking of HER2 positive breast cancers. 
SKBR3 tumour cells were used to produce subcutaneous xenografts in BALB/c nude mice 
to a maximum diameter of 8mm2, and the histopathological staining analysis confirmed 
the expression of HER2 positive tumours. MRI studies showed that after intravenous 
injection of the iron oxide silica herceptin nanoparticles significant targeted uptake was 
present in the SKBR3 tumours, as indicated by the contrast enhancement in comparison to 
the control injected with saline and the control injected with iron oxide silica nanoparticles 
only. The results further showed that the tumour site continued to produce contrast 
enhancement even 24 hours post-intravenous injection of the iron oxide silica herceptin 
nanoparticles. The in vivo investigations therefore confirmed that the iron oxide silica 
herceptin nanoparticles could target HER2 positive breast tumours in vivo and could 
potentially be used with MRI in the clinical setting.  
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Chapter 6 Conclusions and Future Directions 
 
6.1 Summary 
 
The work presented in this thesis describes the use of highly magnetic iron oxide silica 
nanoparticles conjugated to herceptin for the targeted detection of HER2 positive breast 
cancer using MRI. The main finding of this study was that iron oxide nanoparticles coated 
in silica could be used to detect HER2 positive breast cancers in vivo using MRI. The iron 
oxide silica nanoparticles produced presented with highly magnetic properties and were 
able to produce MRI contrast. The nanoparticles were also found to be non-toxic, 
biocompatible and easily conjugated to a biomarker, herceptin. The conjugation of 
herceptin to the iron oxide silica nanoparticles was shown to be stable in various 
conditions. Furthermore, the results from the in vitro assessment of these nanoparticles 
demonstrated that significant MRI contrast was visualised relative to HER2 expression 
levels in three human breast cancer cell lines. Other findings of this study arose from the 
in vivo assessment of the iron oxide silica herceptin nanoparticles, whichshowed 
successful localisation to the HER2 positive tumour site, demonstrated by contrast 
enhancement seen at various time points after injection on the MRI images. 
 
6.2 Overview 
 
It is well known that HER2 positive breast cancers are associated with poor prognosis, 
increased disease progression and low responses to herceptin therapy even when treated 
with adjuvant and neoadjuvant therapies. The use of iron oxide nanoparticles in MRI is an 
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area of interest, which can potentially be used to help identify patients who have stopped 
responding to herceptin-based therapies.  
 
6.2.1 Synthesis of iron oxide silica herceptin nanoparticles 
 
The principles in manufacturing and utilising iron oxide nanoparticles for targeted imaging 
of HER2 positive tumours in breast cancer were described in Chapter 1. For the synthesis 
of iron oxide nanoparticles, many previous studies had not addressed essential 
characteristics such as high magnetic properties, high contrast enhancement, 
biocompatibility and a simple large-scale synthesis method for iron-based nanoparticles. 
These properties are important as they form the basic requirements and key features to 
ensure that successful targeted imaging with MRI can occur and can be translated to the 
clinical setting.  
 
Therefore, the first aim of this study, therefore, was to synthesise iron oxide nanoparticles 
conjugated to herceptin that had the necessary characteristics for targeted imaging, 
including high magnetisation values, low toxicity, biocompatibility, small size and size 
distribution, and a simple large-scale production method.  
  
Previous studies related to the synthesis of iron oxide nanoparticles were based on either 
hydrolytic or non-hydrolytic methods. It was identified that hydrolytic methods produced 
lower performing iron oxide nanoparticles, had poor control over size and size 
distribution, and lower magnetic properties. Non-hydrolytic methods, particularly the 
ultra-large-scale synthesis process described by Park et al. (2004), demonstrated superior 
iron oxide nanoparticles, with better control over size, smaller size distributions, higher 
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magnetic properties and an easier production process with larger quantities of 
nanoparticles. The authors describing this method also indicated that iron oxide 
nanoparticles with these properties had not been previously reported for use in MRI.  
 
To ensure targeted imaging in MRI, another essential component of these nanoparticles 
that was discussed was the surface layer properties. Surface layers are necessary on iron 
oxide nanoparticles for a variety of reasons: they stabilise the iron oxide core to prevent 
further oxidation, allow the iron oxide nanoparticles to be soluble in water, prevent 
aggregation of the iron oxide nanoparticles, and provide a surface for the attachment of 
biomarkers. One of the most widely documented surface coatings on nanoparticles 
discussed was dextran, primarily due to its high biocompatibility. However, another 
surface coating that has also shown biocompatibility and suitability for use in MRI is 
silica. Silica as a surface layer had not previously been investigated for targeted MRI, 
although silica had shown promising results for targeted drug delivery.  
 
The conjugation of the iron oxide silica nanoparticles to a biomarker is mandatory for 
targeted imaging. In this study the iron oxide silica nanoparticles were conjugated to 
herceptin. The conjugation of herceptin to the iron oxide silica nanoparticles was shown to 
be stable in various conditions. To develop iron oxide silica nanoparticles conjugated to 
herceptin with the major characteristics needed for targeted MRI, iron oxide nanoparticles 
were developed using the non-hydrolytic synthesis method of Park et al. (2004), and 
coated with silica. The results of this assessment were presented in Chapter 3.  
 
6.2.2 In vitro assessment of the iron oxide silica herceptin nanoparticles 
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Previous studies had demonstrated that iron oxide nanoparticles conjugated to herceptin 
were non-toxic, were able to target HER2 positive receptors in breast cancer, and 
demonstrated MRI contrast enhancement relative to HER2 expression levels of breast 
cancer cells. In vitro uptake studies had also shown localisation of the nanoparticles to the 
tumour site over time.To our knowledge, however, there have been no reported studies for 
the uptake of various dosages of herceptin-conjugated nanoparticles within HER2 positive 
cells. To investigate the toxicity and uptake of the iron oxide silica herceptin nanoparticles 
synthesised in this study, a thorough cell uptake study was conducted to investigate the 
effect of dose and time on HER2 positive breast cancer cells. MRI signal enhancement of 
the breast cancer cell lines was also quantified. The results of these studies were presented 
in Chapter 4. 
 
6.2.3 In vivo assessment of the iron oxide silica herceptin nanoparticles 
 
The biocompatibility of iron oxide nanoparticles has been described in earlier reports and 
the principle of targeted imaging using iron oxide nanoparticles has also been reported by 
other studies targeting HER2 tumours. To prove that the iron oxide silica herceptin 
nanoparticles synthesised in this study were biocompatible, highly magnetic and capable 
of producing MRI contrast enhancement in vivo, an in vivo investigation was conducted in 
BALB/c nude mice bearing HER2 positive xenograft tumours. The results from this study 
were presented in Chapter 5. 
 
6.3 Key findings of this study 
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The aim of this study was to synthesise highly magnetic iron oxide nanoparticles for 
targeted MRI of HER2 positive tumours to be tested in vitro and in vivo in animal models. 
To confirm that the synthesised nanoparticles possessed the basic characteristics needed 
for targeted imaging, a series of characterisation techniques were conducted. It was clearly 
shown that the synthesised iron oxide silica nanoparticles had the major characteristics 
required for use as a targeted contrast for MRI and were superior to commercially 
available iron oxide nanoparticles and previously reported iron oxide nanoparticles. These 
characteristics included high magnetic properties (74.4 emu/g), high T2 relaxation (T2 
263.23 mMs.) small size and size distribution (<35 ± 3 nm), low toxicity, and easy 
conjugation to herceptin. Furthermore, the conjugation between iron oxide silica and 
herceptin was shown to be stable after exposure to a range of conditions, mimicking 
different physiological conditions. 
 
In vitro studies examined cellular uptake and contrast enhancement capability of the iron 
oxide silica herceptin nanoparticles. The studiesconfirmed the uptake into HER2 
expressing human breast cancer cells possibly mediated by the herceptin, which was 
consistent with previous studies. The uptake of the iron oxide silica herceptin 
nanoparticles was shown to be relative to the HER2 expression levels of the breast cancer 
cells as well as to dose and incubation times. The MRI signal enhancement produced by 
the iron oxide silica herceptin nanoparticles in human breast cancer cell lines was also 
analysed, and it was demonstrated that there was higher contrast enhancement than 
reported in previous studies. It was concluded that the iron oxide silica herceptin 
nanoparticles could detect HER2 positive cells under in vitro conditions and could 
produce significant amounts of MRI contrast.  
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This study also investigated the in vivo targeting capability of the iron oxide silica 
herceptin nanoparticles. SKBR3 breast cancer cells were injected subcutaneously into 
BALB/c nude mice, allowed to grow, and histopathological staining confirmed the 
presence of HER2 positive cells, consistent with previous studies. The MRI study 
demonstrated uptake of the iron oxide silica herceptin nanoparticles at the tumour site, 
producing signal enhancements greater than previously reported. The tumour uptake 
pattern was consistent with other studies, indicating localisation of herceptinnanoparticles 
at the tumour site 4-24 hours post-injection. To address the biological safety of the iron 
oxide silica herceptin nanoparticles, an in vivo toxicity analysis was also conducted. The 
results showed no toxicity to the liver, lungs, heart and kidneys, as indicated by 
histopathological analysis. In vivo studies confirmed that the iron oxide silica herceptin 
nanoparticles were safe and produced high amounts of MRI contrast at the tumour site as 
early as 4 hours and up to 24 hours post-injection.  
 
Overall, the findings of this study demonstrated that the iron oxide silica herceptin 
nanoparticles targeted HER2 positive tumours with nanoparticles that were highly 
magnetic, biocompatible, small in size and size distribution, and stable. Furthermore, the 
results suggested that the nanoparticles had all the basic characteristics required for 
translation into the clinical setting. 
 
6.4 Future directions 
 
This study has presented preliminary data on the use of iron oxide silica herceptin 
nanoparticles for targeted imaging with MRI. The iron oxide silica nanoparticles 
synthesised demonstrated all the characteristics necessary for translation of MRI contrast 
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agents into the clinical setting. The next step for thesenanoparticles is to further address 
the safety component. The results from this study showed that no acute toxicity was 
caused by the iron oxide silica herceptin nanoparticles,but for translation into clinical trials 
a full toxicity analysis investigating chronic toxicity needs to be undertaken. 
 
The next stage of further investigations should be related to the sensitivity of the iron 
oxide silica herceptin nanoparticles in relation to detecting HER2 positive breast tumours. 
Studies are neededthat image HER2 positive tumours of different sizes, to demonstrate the 
ability of the iron oxide silica herceptin nanoparticles to target and localise within tumours 
of different levels of HER2 expression. In vitro cell uptake studies from this study have 
shown that thesenanoparticles can detect varying levels of HER2 expression, and these 
findings provide a good basis for investigation in in vivo settings.  
 
These nanoparticles have all the basic requirements for targeted imaging,are superior to 
nanoparticles used in previously reported studies, and have the potential to be translated 
clinically. However, for the iron oxide silica herceptin nanoparticles to be used in patients 
who are being treated with herceptin-based therapies, further studies need to focus on the 
ability of thesenanoparticles to detect and provide diagnostic and prognostic information 
regarding response to therapy. Another avenue for further investigation is the ability of 
these iron oxide silica nanoparticles to be conjugated to other biomarkers and to be used in 
MRI for targeted imaging. The results from this thesis show that targeted imaging is 
possible.Yet its progress in medical imaging has been greatly hindered by the inability to 
generate iron oxide nanoparticles that meet all the requirements for targeted imaging 
agents. The results from this thesis have demonstrated a superior contender for targeted 
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imaging and, based on these results, these iron oxide silica nanoparticles should be 
investigated for other targeted imaging applications. 
    189
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Abstract Top 
Development of magnetic resonance imaging (MRI) contrast agents that can be readily applied 
for imaging of biological tissues under clinical settings is a challenging task. This is 
predominantly due to the expectation of an ideal MR agent being able to be synthesized in large 
quantities, possessing longer shelf life, reasonable biocompatibility, tolerance against its 
aggregation in biological fluids, and high relaxivity, resulting in better contrast during biological 
imaging. Although a repertoire of reports address various aforementioned issues, the previously 
reported results are far from optimal, which necessitates further efforts in this area. In this 
study, we demonstrate facile large-scale synthesis of sub-100 nm quasi-cubic magnetite and 
magnetite/silica core-shell (Mag@SiO2) nanoparticles and their applicability as a biocompatible 
T2 contrast agent for MRI of biological tissues. Our study suggests that silica-coated magnetite 
nanoparticles reported in this study can potentially act as improved MR contrast agents by 
addressing a number of aforementioned issues, including longer shelf life and stability in 
biological fluids. Additionally, our in vitro and in vivo studies clearly demonstrate the 
importance of silica coating towards improved applicability of T2 contrast agents for cancer 
imaging. 
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INTRODUCTION Top 
Interest in magnetic nanomaterials has persisted over the last few decades primarily due to 
their applications across many fields such as magnetic data recording, sensing, catalysis and 
biomedicine [1]–[5]. Magnetic nanomaterials have attracted particular attention in biomedicine 
due to their great potential in improving the currently available disease diagnostics, prevention, 
and therapeutic approaches [6]. For instance, the potential of magnetic nanoparticles to 
precisely deliver highly biotoxic drugs to specific locations in the body [6], as well as their use 
as highly specialized bio-probes for diagnostic imaging has been demonstrated by attaching 
biomolecular markers to their surface [1], [7]. With these developments, there is an increasing 
demand to develop biocompatible magnetic nanomaterials with ultra-sensitive imaging 
capabilities in order that they can be used for a wide range of in vivo medical imaging 
applications. 
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Magnetic resonance imaging (MRI) is regarded as a powerful imaging tool because of its high 
spatial resolution capability, non-invasive nature and its capability to avoid ionizing radiation in 
contrast to nuclear imaging techniques such as positron emission tomography (PET) [8]–[10]. 
Briefly, MRI operates by taking advantage of the exceptionally small magnetic moment inherent 
on each proton that, under the presence of a large magnetic field, produces an effect 
measurable as a signal on the MR image. The signals produced via T1 relaxation (spin-lattice 
relaxation) or T2 relaxation (spin-spin relaxation) depends on the sequence parameters 
programmed to acquire the MR image. Overall, T1 weighted and T2 weighted imaging provide 
different contrasting effects between fluid and body tissue. For instance T1 weighted images 
show fluid as dark, water-based tissues as grey and fat-based tissues as bright, thereby very 
clearly showing the boundaries between different tissues. Conversely, on T2 weighted images, 
fluid appears bright and water- and fat-based tissues appear grey. The use of contrast agents 
greatly improves the specificity and sensitivity of MRI by shortening either T1 or T2 relaxation 
of the water protons adjacent to them, thus providing more detailed information about 
pathology. Gadolinium-based T1 contrast agents are most commonly used in MRI, however 
growing concerns over the safety of gadolinium-based contrasts have lead to a major shift 
towards iron oxide based T2 contrast agents that are deemed to be relatively biologically safe 
[11]–[13]. 
Although, iron oxide based contrast agents have been clinically approved for MRI, their use has 
been predominantly restricted to liver/spleen imaging (AMI-25 Feridex® - not in use anymore) 
and the gastrointestinal lumen imaging (Lumirem®/Gastromark®). This limitation is primarily 
due to the larger size of the iron oxide particles involved in these agents, which are either 
taken up immediately by the reticuloendothelium system after intravenous administration 
(Feridex®), or are administered orally (Lumirem®/Gastromark®). Therefore, there is a clinical 
urgency to develop commercially viable and biologically safe contrast agents that can be used 
for MR imaging of a wide range of body tissues [14]–[16]. Moreover, there have been 
numerous reports on different synthesis routes to magnetic nanoparticles-based contrast 
agents, including biologically synthesized magnetic nanoparticles [17]–[18], magnetic 
nanoparticles with dendrimer cores [19], superparamagnetic liposomes [20], lipid-based MR 
contrast agents [21], metal-doped magnetic nanoparticles [22]–[25], CoFe2O4@SiO2 particles 
with fluorescent dyes incorporated [26], and magnetic nanoparticles for both imaging and 
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therapeutic applications [27]. Additionally, in the pre-clinical setting, the trend over the last few 
years has been towards the development of small (sub-100 nm) iron oxide nanoparticles [24], 
[28]–[31]. The previous studies suggest that to shift from sub-micron iron oxide particles to 
their nanoparticulate form in the clinical environment, the challenges that need to be overcome 
include their low chemical and biological stability, small shelf life, inherent low-to-high 
cytotoxicity, and low magnetization associated with the iron oxide nanoparticles, which has 
although been addressed by few recent studies to some extent, it still requires additional efforts 
in this area [32]–[34]. This is predominantly because the aforementioned properties of MR 
contrast agents can strongly depend on their synthesis route. 
In this manuscript, we address most of the aforementioned issues by demonstrating the 
development of a T2-weighted, iron oxide-based MRI contrast agent with reasonably low 
cytotoxicity, high relaxivity, and particularly notable high stability that can be stored at room 
temperature for more than 6 months without any visible aggregation. The chemical stability of 
these nanoparticles is achieved by coating them with an inorganic silica (SiO2) layer, leading to 
Mag@SiO2 core-shell nanoparticles. The resulting nanoparticles were analyzed by a 
superconducting quantum interference measurement device (SQUID), high resolution 
transmission electron microscopy (HRTEM), X-ray diffraction (XRD) and a 3 Tesla clinical MRI 
scanner. Our in vitro studies indicate that coating with SiO2 renders these nanoparticles 
biocompatible and they are actively taken up by prostate cancer cells under in vitro conditions. 
Our preliminary in vivo studies with a breast tumor animal model further suggests their 
potential utility as good MRI contrast agents for tumor imaging. 
RESULTS AND DISCUSSION Top 
Figure 1A shows the TEM image of the magnetic (Mag) nanoparticles, which indicates that the 
as-synthesized Mag nanoparticles prepared by our synthesis route were quasi-cubic in 
morphology with good monodispersity and an average size of 40±5 nm. Notably, using our 
approach, large scale synthesis of Mag nanoparticles could be achieved (at least up to 10 g 
particles per batch) without compromising the nanoparticle shape or monodispersity. From the 
higher magnification TEM image, these Mag nanoparticles were found to have spherical edges, 
and it appears as if these nanoparticles consist of several smaller spherical particles that 
assemble together giving rise to quasi-cubic structures (inset Figure 1A). It is important to note 
    223
that under room temperature storage conditions, pristine Mag nanoparticles lose their quasi-
cubic morphology and turn spherical after two weeks of synthesis. The shelf life of commercially 
available MRI contrast agents is in fact one of the major limitations associated with clinical 
applicability of such materials. SiO2 shell coating has been previously demonstrated to provide 
biocompatibility, particle stability as well as a facile surface for further biofunctionalisation in 
different nanomaterials [27]–[29]. Therefore, to provide chemical stability to magnetic 
nanoparticles, a silica shell was grown around quasi-cubic Mag particles (within 3 days of their 
synthesis), thereby producing Mag@SiO2 core-shell nanoparticles (Figure 1B). The controlled 
silica coating of Mag nanoparticles led to formation of Mag@SiO2 core-shell structures with a 
ca. 20±2 nm silica shell around 40±5 nm quasi-cubic Mag nanoparticles (Figure 1B and inset). 
Large area TEM analysis of Mag@SiO2 core-shell structures indicated that most of the Mag 
nanoparticles retained their quasi-cubic morphology after silica coating, and more than ca. 75% 
of particles in the sample were found to be individually coated with a silica shell. However, less 
than ca. 25% of structures consisted of either two or three or no Mag particles within the silica 
shell. Notably, this type of particle distribution is typical of a chemical synthesis route, which is 
not necessarily always explicitly acknowledged in the prevailing literature. Additionally, we 
observed that after coating Mag nanoparticles with silica, the Mag@SiO2 particles remain stable 
in phosphate buffer saline (PBS) solution for at least up to 1 mg/mL concentration, as well as in 
the readily-dispersible powder form for at least up to 6 months. The TEM image shown in Figure 
1B was acquired after 6 months of storage of Mag@SiO2 nanoparticles at room temperature 
and was similar to those imaged immediately after synthesis. This suggests that a silica coating 
over Mag nanoparticles can significantly improve their stability for long-term storage conditions, 
thus retaining their magnetic properties by improving their shelf life. This is one of the crucial 
parameters for developing MRI-based contrast agents for clinical and commercial 
applications. 
 
Figure 1. TEM images of (A) Mag and (B) Mag@SiO2 core-shell nanoparticles. 
Insets show the respective higher resolution TEM images. 
doi:10.1371/journal.pone.0021857.g001  
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Figure 2 shows the XRD patterns of Mag and Mag@SiO2 nanoparticles. The XRD pattern 
obtained from quasi-cubic Mag nanoparticles (curve 1) could be indexed based on standard 
diffraction pattern typically arising from magnetite (Fe3O4) with major peaks indexed (JCPDS 
file No 75–0449). After silica coating, most of the diffraction peaks arising from Mag 
nanoparticles could still be detected. However interestingly, after silica coating, an additional 
peak at ca. 29.3° 2θ was observed that could be assigned to the (220) plane of a FeSi2 phase 
(curve 2) (JSPDS file no. 73-0963). The mixed Fe-Si phase is most likely formed at the 
interface of silica and magnetite during core-shell synthesis of Mag@SiO2 
nanoparticles. 
 
Figure 2. XRD patterns obtained from Mag and Mag@SiO2 nanoparticles. 
XRD peaks with corresponding Bragg reflections of magnetite have been indicated. (*) corresponds to the XRD 
peak arising from a mixed Fe-Si phase. 
doi:10.1371/journal.pone.0021857.g002  
High saturation magnetization of MR contrast agents is an important requirement for the 
magnetic nanoparticles to be used for MRI application. The magnetic hysteresis curve of 
Mag@SiO2 nanoparticles obtained by SQUID measurement is shown in Figure 3, which was 
found to have no coercive fields, thus confirming their superparamagnetic nature. Mag@SiO2 
nanoparticles were found to possess a relatively high mass magnetization value of 74.4 emu/g, 
which is comparable to the previously reported mass magnetisation values of 72.9 emu/g for 
commercially available Resovist iron oxide particles [35]. 
 
Figure 3. Magnetic hysteresis curve of Mag@SiO2 nanoparticles used for MR imaging of tumor cells and 
tissues. 
doi:10.1371/journal.pone.0021857.g003  
The Mag and Mag@SiO2 synthesized in this study were further tested for their ability to be 
internalised by human prostate cancer PC3 cells (Figure 4). When subjected to cell uptake 
studies for 24 h, 50 µg/mL Mag@SiO2 nanoparticles were found to be uptaken by PC3 prostate 
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cancer cells more efficiently than similar a concentration of bare Mag nanoparticles (compare 
Figures 4B and C). When PC3 cancer cells were exposed to Mag nanoparticles, we observed 
that bare Mag nanoparticles without any SiO2 coating tended to form large aggregates (of 
dimensions similar to cell size) in the solution over a 24 h exposure period, which restricted 
their ability to be uptaken by PC3 cells (Figure 4B). As can be inferred from Figure 4B, these 
large clusters of bare Mag nanoparticles predominantly attach to the exterior of the cells, and 
are difficult to be internalized by PC3 prostate cancer cells. Conversely, after SiO2 coating, 
Mag@SiO2 nanoparticles remain well-dispersed in the solution even after 24 h, which facilitates 
their efficient uptake by PC3 cells, as can be seen from a higher density of Mag@SiO2 
nanoparticles inside PC3 prostate cancer cells (Figure 4C). Our group and others have 
previously demonstrated that nanoparticle size and aggregation in biological media can play a 
crucial role in cellular uptake processes, as non-specific uptake of sub-100 nm nanoparticles is 
generally observed via endocytosis mechanism of the cells [36]–[39]. Aggregation of bare 
(pristine) Mag nanoparticles in biological media, and avoidance of their aggregation after silica 
coating clearly suggests the important role of SiO2 coating, and advantage of Mag@SiO2 core-
shell nanoparticles over bare Mag nanoparticles for biological applications. Based on results 
from cell uptake studies, pristine Mag nanoparticles were found to be unsuitable for biological 
applications, and therefore only Mag@SiO2 nanoparticles were chosen for further studies 
regarding their suitability for MRI applications. 
 
Figure 4. Optical microscopy images of PC3 human prostate cancer cells (control) grown 
for 24 h (A) in the absence of nanoparticles, and in the presence of (B) Mag and (C) Mag@SiO2 
nanoparticles followed by three washings with PBS. 
doi:10.1371/journal.pone.0021857.g004  
From the cell uptake studies, it is also evident that Mag@SiO2 nanoparticles do not cause any 
significant change to the morphology of PC3 prostate cancer cells. Previous studies indicate that 
iron oxide nanoparticles are non-toxic at lower concentration, but can be mildly toxic at higher 
concentrations [40]–[41]. Before exploring Mag@SiO2 nanoparticles for MRI application, 
biocompatibility profile of these particles was assessed by performing MTS-based in vitro 
cytotoxicity experiments on PC3 prostate cancer cells, which is one of the measures of 
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biocompatibility (Figure 5). It is evident from Figure 5 that Mag@SiO2 nanoparticles did not 
significantly affect PC3 cell viability for at least up to 50 µg mL-1 Fe concentrations, at which 
more than 85% PC3 cells viability was maintained. However further increase in Mag@SiO2 
nanoparticles concentration equivalent to 100 µg mL−1 Fe resulted in a cell viability loss of ca. 
30%. This suggests that Mag@SiO2 nanoparticles reported in this study may be suitable for 
MRI applications within 50 µg mL−1 Fe concentration range. However, this aspect may require 
further detailed investigation, wherein effect of Mag@SiO2 nanoparticles on cytokine production 
profile of cells will need to be investigated. 
 
Figure 5. Biocompatibility of Mag@SiO2 nanoparticles assessed using MTT assay after their 
exposure to PC3 cancer cells for 24 h with respect to different Fe concentration in 
Mag@SiO2 nanoparticles. 
doi:10.1371/journal.pone.0021857.g005  
Since magnetic nanomaterials can modulate MR signal enhancement effects, the capability of 
Mag@SiO2 nanoparticles as T2 MR contrast agent was further assessed in terms of their 
relaxivity (R2 or relaxation rate, which equals 1/T2 where T2 is spin-spin relaxation time) on a 
3 Tesla clinical MRI scanner at an echo time (TE) of 10.86 ms. Relaxivity is a measure of the 
efficiency of a MR contrast agent to enhance the proton relaxation and increase the efficiency to 
which image contrast is produced during MRI [42]. The relaxivity measurements were 
performed both on nanoparticles as suspension in phantoms as well as after being uptaken by 
PC3 prostate cancer cells. Mag@SiO2 nanoparticles were found to have a high relaxivity value 
of 263.23 l/mmol/s in cell free suspensions, and 230.90 l/mmol/s for Mag@SiO2 nanoparticles 
within the PC3 cells. High relaxivity value (that is, better MR contrast) along with high mass 
magnetisation value for MRI are important considerations when developing T2 contrast agents, 
as the spin-spin relaxation process of protons in water molecules surrounding the nanoparticles 
is facilitated by the large magnitude of magnetic spins in nanoparticles [43]–[44]. Mag@SiO2 
nanoparticles with high mass magnetization and high relaxivity values may therefore result in 
strong T2-weighted MR signal intensity decrease as measured by MRI [45]. This is critical in 
allowing nanomolar activity of contrast agents, which will facilitate in reducing the overall 
contrast agent dose to the patients. 
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The relaxivity data also suggests a reduction in the relaxivity value of Mag@SiO2 nanoparticles 
in PC3 cells after cellular uptake compared with that in suspension. This finding corroborates 
well with previous studies, which showed that the relaxivities of native iron oxide nanoparticles 
were higher compared to those after accumulation in the cells [46]–[47]. The mechanisms 
responsible for this effect have not yet been fully understood, however it can possibly be 
attributed to the confinement of nanoparticles within endosomes of the target cells, which 
might cause a build-up of magnetic field inhomogeneities after sub-cellular 
compartmentalization, which would conversely be absent in uniformly distributed nanoparticles 
in suspensions [48]. Additionally, the different geometrical arrangement of nanoparticles in 
suspensions and in cells, and possibly antiferromagnetic coupling as a result of clustering within 
the sub-cellular compartments may play some role in reducing relaxivity values after cellular 
uptake [28], [48]. Notably, in contrast to relaxivity values of 230–269 l/mmol/s observed for 
Mag@SiO2 nanoparticles in this study, commercial Resovist based nanoparticles have been 
reported with lower values of 151 l/mmol/s [35]. The observed relaxivity value of Mag@SiO2 
nanoparticles prepared in this study is also relatively higher than those reported for undoped 
magnetite particles (218 l/mmol/s) in recent detailed studies [24]. For doped magnetic 
particles, it has been reported that high relaxivities of up to 358 l/mmol/s can be achieved by 
doping magnetite with Mn (MnFe2O4) [24]. However, potential leaching of Mn during 
administration of these MR contrast agents in the body might pose cytotoxicity issues, and to 
the best of authors' knowledge, undoped Mag@SiO2 nanoparticles with such high relaxivity 
values have not hitherto been reported. 
Furthermore, relaxivity studies as a function of different concentrations of Fe in Mag@SiO2 
nanoparticles, both as a nanoparticle suspension in phantoms (Figure 6A), and after 24 h of 
nanoparticle uptake by PC3 prostate cancer cells (Figure 6B) revealed that Mag@SiO2 
nanoparticles act as outstanding T2-weighted contrast agents. This is shown by an image 
darkening effect, demonstrated by drop in R2 (ΔR2/R2control) signal intensity with increasing Fe 
concentrations. For instance, at 100 µg/mL Fe concentration, Mag@SiO2 nanoparticles provide 
a signal enhancement of ~90% in comparison to more than 70% signal enhancement during 
imaging of PC3 prostate cancer cells. This is a significant signal enhancement in comparison to 
most of the previously reported materials, in which generally only 15–20% signal enhancement 
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has been observed [28]. Such strong MR signal enhancement is expected from Mag@SiO2 
nanoparticles because of their relatively high relaxivity and saturation magnetization 
values. 
 
Figure 6. Evaluation of Mag@SiO2 nanoparticles as a T2 MR contrast agent is shown in the form of % 
signal enhancement with increasing concentration of Fe using a 3 Tesla MR scanner. 
Panel A shows the studies performed in phantoms for particles in suspension, while panel B shows the similar 
studies in PC3 human prostate cancer cells after nanoparticles uptake for 24 h. Corresponding T2-weighted MR 
images of different samples, showing the image darkening effect with increasing Fe concentration are also shown 
under each bar. 
doi:10.1371/journal.pone.0021857.g006  
In vivo MRI studies in a breast tumor mouse model also demonstrated T2 signal enhancement 
at the tumor site by Mag@SiO2 nanoparticles (Figure 7). The images following in vivo 
administration of 10 µg dose of Mag@SiO2 nanoparticles demonstrate its ability to produce MR 
enhancement of the tumor site relative to the body. T2-weighted signal enhancement effects by 
the Mag@SiO2 nanoparticles on an MR image are visualised as darkening or contrast between 
areas infiltrated with Mag@SiO2 nanoparticle and those without nanoparticles. Future studies 
on Mag@SiO2 can be tailored for targeted MRI, utilising its superior magnetic characteristics in 
the diagnosis of pathologies. 
 
Figure 7. T2-weighted MR images of nude mice with breast tumor obtained (A) before and 
(B) after injection of MR contrast agent, obtained using a 3 Tesla MR scanner. 
Mouse 2 was injected with Mag@SiO2 nanoparticles as T2 contrast agent, while Mouse 1 was injected with saline 
as a control. Tumor sites in the control (mouse 1) and in the treated mouse (mouse 2) have been labelled as blue 
and red circles respectively. Panels C and D show the higher magnification transverse section images of tumor site 
corresponding to Panels A and B respectively, wherein tumor region injected with MR contrast agent has been 
highlighted using white circles. 
doi:10.1371/journal.pone.0021857.g007  
    229
In summary, important considerations for an efficient MRI contrast agent include smaller 
particle size, their efficient uptake by cells, reduced aggregation in biological fluids, improved 
shelf life, and improved biocompatibility. A control over all these parameters will provide an 
ability to target a range of molecular/cellular imaging applications without causing acute 
toxicity to the normal cells. Particularly for tumor imaging applications, sub-100 nm particles 
can provide significant an advantage, as the cut-off diameter of tumor vessel pores is 400–600 
nm [41]–[43], [49]–[51]. 
In this study, we have demonstrated a facile, large-scale synthesis of quasi-cubic magnetite 
and Mag@SiO2 nanoparticles of sub-100 nm size. The Mag@SiO2 nanoparticles reported here 
have a shelf life of more than 6 months, and they are efficiently uptaken by the cells without 
causing significant aggregation or cellular toxicity. The biological half-life of smaller and silica-
coated iron oxide nanoparticles is expected to be further increased due to their reduced 
interaction with the body fluids. This study therefore clearly underlines the importance of SiO2 
coating towards improving the uptake of Mag@SiO2 nanoparticles by PC3 prostate cancer cells, 
and improving the shelf life of MR contrast agents. The magnetic-silica composite nanoparticles 
act as promising T2 contrast agents offering a potentially viable option as a commercial MR 
contrast agent. This is attributable to their small size, high MR signal enhancement, relative 
biocompatibility, longer shelf life, and highly modifiable silica surface chemistry which will allow 
the adhesion of multiple molecular markers for targeted MRI in the future. These characteristics 
of a T2 contrast agent are highly desirable for magnetic resonance imaging applications at the 
pre-clinical level and for later use clinically. 
MATERIALS AND METHODS Top 
Ethics Statement 
The breast tumor mice model was developed in-house, and all the studies involving animals 
were pre-approved by institutional animal ethics committee. 
Materials 
All chemicals were purchased from Sigma-Aldrich and used as received without further 
modification. The prostate cancer cells (PC3 cell line) were purchased from American Type 
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Culture Collection (ATCC). CellTiter 96 Aqueous One Solution Cell Proliferation Assay (Promega) 
kit was purchased from Promega Corporation. 
Synthesis of iron oxide nanoparticles 
Quasi-cubic iron oxide nanoparticles (referred as ‘Mag’) were synthesized using a two step 
process significantly modified from Park et al, thus leading to controlled large-scale synthesis 
[52]. During synthesis, an iron oleate complex was first formed by dissolving 5.4 g of iron 
chloride and 18.25 g of sodium oleate in a solution comprised of 40 mL ethanol, 30 mL distilled 
water and 70 mL hexane. Once homogenized, the solution was refluxed at 70°C for 4 h, 
followed by separation of the upper organic layer using a separatory funnel, washing and 
evaporating off hexane, thereby leaving a waxy iron oleate complex. The iron oxide 
nanocrystals were formed by dissolving 9.0 g of the iron oleate complex in 1.425 g of oleic acid 
and 63.3 mL of 1-octadecene, followed by reflux under nitrogen until it reached 320°C, at 
which point the temperature was held for 30 min and then allowed to cool to room 
temperature. 250 mL of ethanol was then added to the solution and the magnetite particles 
were separated via centrifugation, followed by three washing cycles with ethanol. Notably, by 
designing this protocol, scale up of at least up to 10 g magnetic nanoparticles per reaction 
could be easily achieved under laboratory conditions. 
Synthesis of silica-coated iron oxide (Mag@SiO2) nanoparticles 
Silica-coated iron oxide nanoparticles (Mag@SiO2) were prepared using a method significantly 
modified from Fang et al and Morel et al [53]–[54], wherein controlled hydrolysis of silica 
precursor in the presence of magnetite nanoparticles was performed. In our approach, pre-
formed magnetic particles were used as nucleating sites for subsequent hydrolysis of silica 
precursor around them. Briefly, 1 mg of iron oxide nanoparticles prepared in the previous step 
were sonicated in a solution consisting 15 mL ethanol and 2 mL deionized water (MilliQ). 1 mL 
of ammonia (25% solution) was added to the above solution while immersed in a sonicator 
programmed to switch on for 1 min in every 10 min. Further, an overhead stirrer was 
additionally used to mix the solution while 4 mL of 1:60 (tetraethyl orthosilicate:ethanol) was 
added at the rate of 0.4 mL/h using a syringe pump, and the solution was allowed to stir at 
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room temperature for 12 h. The silica coated iron oxide nanoparticles were centrifuged, washed 
three times with ethanol and redispersed in MilliQ water. 
Materials characterisation 
The morphology and size of Mag and Mag@SiO2 nanoparticles was characterized using JEOL 
2010 high resolution transmission electron (HRTEM) microscope operated at an accelerating 
voltage of 200 kV. Samples for HRTEM measurements were prepared by drop casting particles 
on to a carbon-coated copper grid, followed by air drying. The crystallography of the 
nanomaterial powders was obtained on a Bruker D8 ADVANCE X-ray diffractometer using Cu Kα 
radiation. For magnetic measurements, a superconducting quantum interface device based 
magnetometer (Quantum Design MPMS-XL5) was used. The iron content of the nanoparticle 
solutions used for in vitro and in vivo studies was ascertained on a Varian AA280FS Fast 
Sequential Atomic Absorption Spectrometer (AAS) after digestion of particles overnight in nitric 
acid. 
In vitro cell studies and cytotoxicity assays 
Human prostate cancer cells (PC3 cell line) were routinely cultured at 37°C in a humidified 
atmosphere with 5% CO2 using RPMI 1640 medium supplemented with 10% fetal bovine 
serum (FBS), 1% penicillin, 1% streptomycin/penicillin and 1 mM L-glutamine. For sub-
culturing, PC3 prostate cancer cells were detached by washing with phosphate buffered saline 
(PBS) and incubating with trypsin-EDTA solution (0.25% trypsin, 1 mM EDTA) for 5 min at 
37°C, followed by washing and incubation with supplemented RPMI 1641 medium. For cell 
uptake, the cells were first seeded in 24-well polystyrene dishes for 24 h, followed by 
incubation with Mag and Mag@SiO2 nanoparticles for 24 h at 37°C in complete cell media, and 
subsequent three times washing of cells with PBS, before imaging under an inverted 
microscope. For cytotoxicity assays, the viability of PC3 prostate cancer cells exposed to 
Mag@SiO2 nanoparticles in the absence of cell growth medium was determined. A CellTiter 96 
AQueous One Solution Cell Proliferation Assay (Promega) kit containing the tetrazolium 
compound 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tet
razolium(MTS), was used to monitor cell viability according to the manufacturer's protocols. 
MTS color change was monitored using a plate reader at 490 nm, and cell viability data was 
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plotted by considering the viability for the untreated cells as 100%. Experiments were 
performed in triplicates, and error bars represent standard experimental errors. 
Magnetic resonance imaging (MRI) studies 
MRI studies were performed for nanoparticle solutions stored in phantoms, in PC3 prostate 
cancer cells after nanoparticle uptake, and in a mouse model with breast cancer. For phantom 
MRI studies, phantoms were prepared in Eppendorf tubes with Mag@SiO2 nanoparticles at 
three different Fe concentrations (0.18 mM, 0.9 mM, 1.79 mM) and a saline solution without 
any nanoparticles was used as a control. For in vitro MRI studies, PC3 cancer cells were 
cultured using the above protocol in 24 well polystyrene plates, and incubated for 24 h with 
Mag and Mag@SiO2 nanoparticles at three different concentrations (0.18 mM, 0.9 mM, 1.79 
mM) and a control with cells but no nanoparticles. MRI measurements for phantoms and PC3 
cells were performed with a clinical 3.0 Tesla Clinical Siemens Trio MRI scanner using a 12-
channel head coil and the following parameters: T2-weighted imaging, gradient echo sequence, 
multiple echo time (TE) ranging from 0.99–100 ms, repetition time (TR) = 2000 ms, matrix 
128×128, slice thickness of 3 mm. Relaxation rates (R2) were determined by using a single 
echo sequence (SE) with a constant TR of 2000 ms and multiple TE ranging from 0.99–100 ms. 
The signal was plotted as a function of echo time and fitted to obtain the R2 values. The R2 
values of the Mag@SiO2 in phantoms and PC3 cells were determined by plotting the relaxivity 
at a TE of 10.86 ms, as a function of molar iron concentration in respective samples, and 
extracting the T2 value from the slope by linear regression of data points obtained at lower Fe 
concentration values. Only lower Fe concentrations were used to determine the T2 values, 
predominantly because with increasing Fe concentrations above a particular threshold, the MR 
signals tend to loose their linearity. For the in vitro MRI measurements in phantoms and PC3 
cells, enhancement of the R2 signal within the PC3 cells was calculated by: ΔR2/R2control*100. 
For in vivo MRI experiments, breast tumor bearing mice were developed in-house, 
anaesthetised with ketamine (80 mg per kg body weight) and xylazine (5 mg per kg body 
weight), and placed within the 12-channel head coil. Images were acquired before and after 
injection of 100 µL of Mag@SiO2 particles suspension of 100 µg/mL concentration in saline 
locally at the tumor site. A T2-weighted spin echo sequence was acquired with TE/TR of 
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60/2000 ms, a slice thickness of 3 mm and a 128x128 matrix. Data analysis was performed 
manually by placing ROIs in tumor and tissue areas on the images. 
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Introduction 
Iron oxide nanoparticles have been widely researched in the pre-clinical setting for 
various applications in magnetic resonance imaging (MRI) such as enhanced image 
contrast in the liver  (Reimer & Balzer, 2003) and gastro-intestinal lumen (MacVicar, 
Jacobsen, Guy, & Husband, 1993; Vlahos et al., 1994), magnetic cell labelling (Bulte, 
2009) and local therapy in the form of hyperthermia in cells(Hadjipanayis et al., 2008).  
Despite years of pre-clinical research, iron oxide nanoparticles have not been successfully 
translated to the clinical setting primarily due to non-optimal properties such as limited 
magnetisation values, low contrast enhancement, difficulties in producing large amounts 
of particles and large intravenous dosages; therefore there is continued interest in their 
development. One of the areas of interest is applications of iron oxide nanoparticles in 
cellular and molecular imaging, where biomarkers are attached to the iron surface which 
drives the particles to an area of interest and as a result, the nanoparticles provide MRI 
contrast enhancement at the targeted area providing valuable diagnostic and therapeutic 
information. The aim therefore has been to produce iron oxide nanoparticles that have 
high magnetisation values, small size, biocompatibility and a particle surface that is easily 
functionalised by various biomarkers(Jun, Lee, & Cheon, 2007; Laurent et al., 2008; 
Lawaczeck, Menzel, & Pietsch, 2004).  
Magnetisation values are important for MRI applications of nanoparticles because 
they influence the ability to provide enhanced contrast on the magnetic resonance image 
(Lu, Wang, Ye, Vaidya, & Jeong, 2007). Values such as the electromagnetic unit per gram 
(emu/g) and the T2 relaxation (spin-spin relaxation) determine the degree of T2 relaxation 
shortening that occurs in the surrounding water protons. Shorter T2 relaxation times 
produce image contrast appearing as dark on a magnetic resonance image relative to 
longer T2 relaxation times that appear brighter. 
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In addition to magnetic characteristics, MRI applications of iron oxide 
nanoparticles also require a small nanoparticle size and size distribution, as larger particles 
limit in-vivo applications. It is well known that particles larger than 50nm in diameter are 
eliminated by the reticulo-endothelial system (RES) therefore these particles are only 
useful for imaging the liver and spleen. An example of this is the commercially available 
Resovist which has a hydrodynamic diameter of 60nm and upon intravenous injection, is 
immediately taken up by the liver therefore allowing imaging of liver lesions.  Non-
commercially, numerous studies have been conducted over the years adjusting factors 
such as pH, ionic strength, temperature, nature of salts, Fe3+/Fe2+ ratio, and addition of 
chelating agents, which improve the size and size distribution of the iron oxide 
nanoparticles produced (Babes, Denizot, Tanguy, Jeune, & Jallet, 1999; Jiang et al., 2004; 
JOLIVET, BELLEVILLE, TRONC, & LIVAGE, 1992; Massart, 1981). Recent studies 
have looked at high temperature methods of iron oxide nanoparticle production to control 
the size and produce particles with exceptional magnetic characteristics (Hyeon, Lee, 
Park, Chung, & Na, 2001; PARK et al., 2004). Other methods that have been investigated 
include the addition of surface coatings such as dextran(Jarrett, Frendo, Vogan, & Louie, 
2007; Moore, Marecos, Bogdanov, & Weissleder, 2000), monolayer ligands (Yee et al., 
1999) and polymers (Harris et al., 2003). These coatings not only help reduce the size of 
the iron oxide nanoparticles but also play a role in achieving biocompatibility and acting 
as a surface for the attachment of various biomarkers. 
Biocompatibility is particularly important for iron oxide nanoparticles used in 
molecular and cellular imaging as water-soluble iron oxide nanoparticles can not 
withstand harsh biological conditions such as changes in pH and inability to escape uptake 
by the RES. The later is a fundamental consideration, because applications in molecular 
and cellular imaging need iron oxide nanoparticles to have long blood circulating times to 
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ensure that they localise to an area of interest. Biocompatibility is therefore ensured by the 
addition of lipids (Y. Lee et al., 2005; Tartaj & Serna, 2002) or polymers on the surface of 
the iron oxides such polyethylene glycol (PEG)(Acar, Garaas, Syud, Bonitatebus, & 
Kulkarni, 2005; Wan et al., 2007). Other ways biocompatibility has been achieved is by 
the addition of chelating agents such as dimercaptosuccinic acid (DMSA) on the surface of 
the iron oxides(Fauconnier, Pons, Roger, & Bee, 1997; Huh et al., 2005b) or transfection 
agents such as dendrimers (I. H. Lee et al., 2004; Walter et al., 2004).  
For molecular and cellular applications of iron oxide nanoparticles need to be 
conjugated to a particular biomarker. Herceptin or trastuzumab is a monoclonal antibody 
that targets the epidermal growth factor receptor HER2, which is overexpressed in 
HER2/neu positive metastatic breast cancers(Valabrega, Montemurro, & Aglietta, 2007). 
It is well known that these breast cancers are expressed in 25-30% of all breast cancers 
and are usually diagnosed at a late stage, this combined with the aggressive nature of the 
cancer generally lead to an overall poor prognosis(Borg et al., 1990; SLAMON et al., 
1987). Trastuzumab was developed to target HER2/neu receptors via an antibody-receptor 
complex and undergoes internalisation via receptor-mediated endocytosis at the HER2/neu 
receptor site. Trastuzumab then causes down regulation of HER2/neu production 
eventually causing cell death(Valabrega, et al., 2007). Unfortunately, despite the positive 
effects Trastuzumab has on HER2/neu positive breast cancers, the overall response rates 
are low. The low response rates are due to many factors, such as the development of 
resistance to Herceptin and the level of HER2/neu protein and gene expression within the 
tumour. The ability to image the progress of trastuzumab treatment can be useful, 
providing critical information about the efficacy of trastuzumab concurrently with 
treatment.  
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A range of studies have already reported in-vitro and in-vivo detection using 
trastuzumab conjugated to a variety of iron oxide based nanoparticles. Studies have looked 
at in-vitro models using a biotinylated antibody conjugated to streptavidin 
microbeads(Dmitri, Noriko, Baasil, & Zaver, 2003) and other studies have looked at 
dextran coated iron oxide nanoparticles with low T2 characteristics(T. Chen et al., 2009). 
More recent studies have looked at highly magnetic DMSA coated(Jun et al., 2005) and 
metal doped(J.-H. Lee et al., 2007) iron oxides made vial a novel high temperature 
method, conjugated to herceptin. Recently, we reported quasi-cubic iron oxide 
nanoparticles coated with a silica shell of 60nm in hydrodynamic diameter having superb 
magnetic characteristics and significant MRI signal enhancement capabilities (add our 
ref). Our previous study showed low cellular toxicity of the silica coated quasi-cubic 
particles to PC3 prostate cancer cells, and in-vitro studies with up to 90% MRI signal 
enhancement. In this report, we now present the successful synthesis of 25nm iron oxide 
silica nanoparticles conjugated to herceptin. In this investigation we present the in vitro 
diagnosis of breast cancer in various cell lines (SKBR-3, BT474 and MCF-7) and the in 
vivo diagnosis of breast cancer within HER2/neu overexpressing tumours.  
 
 
 
 
MATERIALS AND METHODS 
Reagents, chemicals and assay kits 
All chemicals were purchased from Sigma Aldrich Pty LTD and used as received without 
further modification. Cell lines (SKBR3, BT474) were purchased from American Type 
Culture Association (ATCC). CellTiter 96 Aqueous One Solution Cell Proliferation Assay 
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(Promega) kit was purchased from Promega Corporation. BCA protein assay was 
purchased from Invitrogen. Herceptin was a generous gift from the Pharmacy Department 
at The Peter MacCallum Cancer Centre. 
Synthesis of silica coated iron oxide nanoparticles 
The iron oxide nanoparticles were fabricated using a high temperature method previously 
described by Park et al. In brief, an iron oleate complex was refluxed with oleic acid in 1-
octadecene at 320°C. The resulting magnetite nanoparticles were centrifuged from the 
solution and washed. The magnetite was then treated with nitric acid to remove any 
surface contaminants, washed and surface treated with citric acid to aid suspension and 
stabilisation of the particles during the silica addition process. Using a modified method of 
silica coating previously presented by Fang et al. the magnetite particles were coated with 
a thin layer of silica by slow addition of tetraethylorthosilane (TEOS) to a solution of 
ethanol, water ammonia and highly dispersed magnetite nanoparticles over several hours.  
Conjugation of iron oxide nanoparticles to Herceptin 
Iron oxide-silica nanoparticles were resuspended in milli-Q water and then conjugated to 
herceptin using 5mg/ml of cysteamine linker. The iron-silica and herceptin were incubated 
at room temperature for 2 hours and then washed several times in milli-Q-water by 
centrifugation. The amount of herceptin on the surface of the iron oxide-silica 
nanoparticles was quantified via a BCA protein assay kit according to the manufacturer’s 
instructions. 
Assessment of nanoparticle-herceptin stability 
The stability of the iron oxide silica nanoparticles tagged to herceptin was assessed by 
conjugating a FITC molecule to the herceptin antibody using a FITC conjugation kit 
(Sigma, USA) according to the manufacturer’s protocol small scale conjugation 
procedure. The iron oxide silica herceptin-FITC nanoparticles were exposed to a range of 
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pH (5, 7.14, 10) and human serum concentrations (25%, 50%, 100%). The degradation of 
the particles was assessed by loss of protein in the supernatant indicated by an increase in 
fluorescence in the supernatant based on a standard concentration series of the herceptin-
FITC molecules. 
In vitro studies 
Cell culture 
Breast cancer cell lines, SKBR-3, BT474 and MCF-7 cells were routinely cultured at 37˚C 
in a humidified atmosphere with 5% CO2 using RPMI 1640 medium supplemented with 
10% fetal bovine serum (FBS), 1% penicillin, 1% streptomycin/penicillin and 1mM L-
gultamine (manufacturer, country). For sub-culturing, cells were detached by washing 
with phosphate-buffered saline (PBS) and incubating with trypsin-EDTA solution (0.25% 
trypsin, 1 mM EDTA) for 4 mins at 37 ˚C, followed by washing and incubation with 
supplemented RPMI 1641 medium.  
Cell cytotoxicity studies 
To assess cytotoxicity of the iron oxide-silica herceptin nanoparticles on breast cancer 
cells, the viability of SKBR-3 cells incubated with the herceptin labeled particles was 
assessed after 24 and 48 hours in vitro.  SKBR-3 cells were seeded into 24-well plates for 
24 hours, after which medium without serum was added with iron oxide-silica 
nananoparticles at concentrations ranging between 1 μg/ml to 100 μg/ml. A CellTiter 96 
AQueous One Solution Cell Proliferation Assay kit (Promega, USA) containing the 
tetrazolium compound 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-
sulfophenyl)-2H-tetrazolium (MTS) was used to monitor cell viability according to the 
manufacturer’s instructions and the MTS colour change was measured at 490 nm using a 
microplate reader (manufacturer, country) and cell viability was plotted against 100% 
viability for untreated cells. 
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Conjugation of iron-oxide herceptin nanoparticles to FITC  
Herceptin was conjugated to FITC using a FluoroTag FITC conjugation kit (Sigma, USA) 
The herceptin was first purified using a Sephadex G-25M column (Pharmacia, Sweden) 
and then added to the FITC using the small scale conjugation procedure following the 
manufacturer’s protocol. The FITC-Herceptin complex was then added to the iron-silica 
via the cysteamine linker and after 2 hours incubation at room temperature, washed 
several times with milli-Q water. 
Cellular uptake 
Confocal microscopy 
SKBR3, BT474 and MCF-7 were cultured and then seeded onto a 6-well slide glass 
chamber. All cell lines were treated with 50 μg/ml of iron oxide-silica herceptin-FITC 
nanoparticles for 4 hours at 37oC and cellular uptake was assessed by confocal microscopy 
(Zeiss, model, country). Thirty minutes before imaging, a Hoechst nuclear stain was added 
to the cells and then washed several times with PBS to aid in the identification of live cells 
within the culture.  
Flow cytometry 
To quantify the uptake of the iron oxide-silica herceptin nanoparticles by SKBR3, BT474 
and MCF7, dose response and time course studies were performed using flow cytometry. 
Cells were grown to 90% confluence in 24-well plates and for the dose-response study, 10 
μg/ml, 50 μg/ml and 100 μg/ml of iron oxide-silica herceptin nanoparticles were added to 
cells and incubated for 24 hours. For the time-course studies, the iron oxide-silica 
herceptin nanoparticles conjugated to FITC were incubated at varying time points of 30 
min, 1, 3, 5 and 24 hours and at a constant concentration of 50 μg/ml. After incubation for 
both dose-response and time-course studies, the cells were detached from the plates with 
trypsin-EDTA and washed twice in PBS and resuspended in FACS-fix buffer for analysis 
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by flow cytometry and a minimum of 8,000-10,000 viable cells were assayed 
(FACSCanto, BD Biosciences, RMIT Flow Cytometry Facility, Bundoora, Australia).  
Quantification of Her-2 neu expression 
Quantification of HER-2 expression of SKBR-3, BT474 and MCF-7 was assessed by flow 
cytometry. Cells were cultured using the previously mentioned method, seeded onto 24-
well plates and grown to 90% confluency. Herceptin was added to the cells at a 
concentration of 10 μg/ml for 30 min at 4oC followed by two washes and then incubation 
with FITC-anti-human IgG secondary antibody (company, country) for 30 min at 4oC. The 
removal of the primary antibody from these treatments was used as a measurement of non-
specific binding of the secondary antibody. The cells were washed and then analysed by 
flow cytometer as previously described. The mean fluorescence was determined by 
subtracting the mean channel number for the background from the mean channel number 
for the primary antibody treated cells. 
MR imaging 
MR Imaging in vitro 
Iron oxide nanoparticles were prepared and conjugated to herceptin using the described 
protocols. SKBR-3, BT474 and MCF-7 cells were cultured, detached using trypsin-EDTA 
solution, washed and seeded onto 6-well plates and incubated with supplemented RPMI 
1641 medium without serum. Each cell line was treated with 50 μg/ml of iron oxide silica-
herceptin nanoparticles and incubated for 5 hours at 37 ˚C.  Before imaging on MRI, the 
cells were washed 3 times with PBS and then fixed with glutaraldehyde. A T2-weighted 
gradient echo sequence was used with the same parameters as the phantom studies. Signal 
enhacement of each of the cell lines was calculated relative to the control using: 
∆R2/R2control *100. 
Mouse Experiments 
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We obtained ~6 week old female BALB/c nude mice (ARC) in accordance with the 
guidelines and under approval of the Animal Ethics Committee of RMIT University. The 
nude mice were injected subcutaneously with equal volume of SKBR3 cells (2.5 x 106 ) 
and Matrigel (BD, USA) into the right flank. A full tumour growth analysis was conducted 
to ensure growth of the tumours as well as the average time to reach a maximum diameter 
of approximately 1c. 
MR imaging in vivo 
Nude mice (n= 15) bearing SBKR3 tumours were studied by MRI when the subcutaneous 
tumours reached a diameter of approximately 1cm. A solution of iron oxide silica 
herceptin nanoparticles (400ug) was infused via the tail vein of a group of mice and a 
solution of iron oxide silica nanoparticles (400ug) was infused via the tail vein of another 
group of mice. The MRI of ketamine-xyalazine-anesthetised mice was performed at 4 hrs 
and 24 hours on a 3.0 Tesla clinical Siemens Trio MRI scanner using a 12-channel head 
coil and the following parameters: T2-weighted imaging, spin echo sequence, transverse 
orientation, echo time= 76 ms(TE), repetition time (TR)= 2000 ms, matrix 320x320, slice 
thickness= 1.70mm, FoV= ?, number of averages=? 
 
Results and Discussion 
The in vitro and in vivo studies demonstrate that we were able to specifically apply 
iron oxide nanoparticles to molecular/cellular imaging using MRI. Our study shows that 
iron oxide nanoparticles conjugated to Herceptin can target breast cancers that overexpress 
HER2/neu receptors and provide optimal MRI contrast enhancement. 
The iron oxide nanoparticles in this study were synthesised via a high temperature 
method outlined above to maintain high crystalinity and then surface modified with a thin 
silica coating to infer higher biocompatibility and provide a surface compatible for 
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molecular labelling. Before utilising iron oxide nanoparticles as contrast agents for MRI, it 
is important to accurately characterise the particles in terms of size, solubility, 
biocompatibility, targeting ability and image contrast capabilities, because the MRI signal 
can affected by any one of these characteristics.  
 Figure 1 shows the HRTEM image of the iron oxide nanoparticles, where Figure 
1B illustrates the synthesised iron oxide nanoparticles with no coating and suggests that 
they are approximately Xnm in diameter. It is well known that iron oxide nanoparticles in 
their pure chemical form are unstable therefore need to be stabilised by the addition of a 
surface layer.( not sure if you need that sentence) Furthermore, iron oxide nanoparticles 
are insoluble in water restricting their use in a biological system. To stabilise the iron 
oxide core and provide aqueous solubility a silica layer was added to the surface of the 
iron oxide (Figure 1A). The HRTEM images illustrates that they are approximately Xnm 
in diameter. Will have to get new images before we can quote these figures. 
For successful MRI applications in vivo , the iron oxide nanoparticles need to 
retain a size smaller than 50nm in diameter (Jun, et al., 2007). This consideration arises 
because studies have reported that particles larger than this size limit cell targeting 
capability and reduce uptake efficiency. Another problem that occurs due to larger particle 
size is non-specific uptake in the RES as well as biological instability (Jun, et al., 2007). In 
our previous investigation we reported iron oxide silica nanoparticles with a 
hydrodynamic diameter of 60nm, making these particles unsuitable for in vivo targeted 
MRI. Therefore the method of synthesis was modified to reduce the size of the particles 
making them suitable to in vivo use (already have, I don’t know how much materials stuff 
you want to add directly to this paper). 
The iron oxide nanoparticles demonstrated a crystalline structure, monodispersity, 
high T2 relaxation and excellent contrast enhancement and we went further to investigate 
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the ability of our particles to be surface functionalised with the well-known trastuzumab 
and then test its in vitro and in vivo detection and MRI contrast capabilities. 
The iron oxide silica nanoparticles were conjugated to herceptin by modifying the 
surface of the silica layer with a cysteamine linker. The chemistry of the nanoparticles-
cystamine-herceptin indicates the particles are bound electrostatically. The formation of 
the iron oxide silica herceptin nanoparticles was confirmed and quantitated by a 
bicinchoninic acid protein assay kit. Under these experimental conditions the herceptin 
concentration was 0.66 µg of herceptin per 1 µg of iron oxide silica particles. For in vitro 
and in vivo studies, stability is a concern that needs to be addressed particularly for 
adsorbed complexes. To address stability concerns, the iron oxide silica herceptin 
nanoparticles were incubated over a 24 hour period at a range of pH and human serum and 
the iron oxide silica nanoparticles remained bound to the herceptin antibody over a 24-
hour period in various pH strengths and human serum (data not shown). The stability 
results are similar to other studies that have reported stable particles in various pH 
indicating that competitive displacement in vivo is unlikely(Cortez et al., 2006). 
 It is well known that low toxicity is associated with lower iron oxide nanoparticle 
concentrations (Weissleder et al., 1989) and silica shells have also previously 
demonstrated to provide biocompatibility as well as particle stability(Ohmori & Matijevi, 
1993; Ohmori & Matijevic, 1992). It is also well known that herceptin is cytotoxic to 
tumour cells as it undergoes internalisation via receptor-mediated endocytosis at the 
HER2/neu receptor site and then causes down regulation of HER2/neu production 
eventually causing cell death(Valabrega, et al., 2007). To investigate the cytotoxic 
potential of the iron oxide silica herceptin nanoparticles, MTS based assays were 
conducted on SKBR3 cells (Figure 2).  SKBR-3 cells were incubated with iron oxide 
silica herceptin nanoparticles for 24 and 48 hours at varying concentrations ranging from 
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1-100 μg/ml. Figure 2 shows that lower concentrations (1-30 μg/ml) have no significant 
toxicity on SKBR-3 cells however the toxic effect increases between 50-100 μg/ml.  These 
results are consistent with the function of herceptin causing down regulation of HER2/neu 
production and eventual cell death. The degree of toxicity is similar to previous studies 
that have used iron oxide conjugated herceptin to target SKBR3 cells (T. Chen, et al., 
2009).  
In order to achieve targeted imaging, the iron oxide silica-herceptin nanoparticles 
must be able to specifically bind the Her2/neu receptors on the surface of breast cancer 
cells and be taken up by trigger active endocytosis. To show cellular uptake and 
internalisation into SKBR-3 cells, FITC-labeled iron oxide silica-herceptin nanoparticles 
were analysed by confocal microscopy. 50 μg/ml of iron-oxide silica-herceptin 
nanoparticles were added to SKBR-3 cells in vitro for 3 hours at 37oC showed significant 
uptake (Fig. 3A). Uptake was also confirmed by phase contrast whereby the iron oxide 
silica-herceptin nanoparticles can clearly be seen within the cells (Fig. 3B).  The images in 
this study are similar to that of previous studies that have looked at the uptake of herceptin 
conjugated nanoparticles by SKBR-3 cells (T. Chen, et al., 2009; Huh et al., 2005a). It is 
well known that HER2/neu undergoes receptor mediated endocytosis, therefore resulting 
in the herceptin-tagged nanoparticles being accumulated within the cells.  
We then examined the in vitro binding specificity and efficiency by dose response 
and time course of iron oxide silica-herceptin nanoparticles by breast cancer cell lines that 
express different amounts of HER2/neu and analysed by flow cytometry. Initially, 
expression of HER2/neu was assessed in SKBR3, BT474 and MCF-7 cell lines. Analysis 
by flow cytometry showed that SKBR3 showed the highest HER2/neu expression 
followed by BT474 and then MCF-7 (Table 1). The results of this study are consistent 
with the literature which indicates that amongst SKBR3, BT474 and MCF-7, SKBR3 cells 
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have the highest HER2/neu expression (add more appropriate reference) (X. Chen, Yeung, 
& Wang, 2000; Steinhauser, Spänkuch, Strebhardt, & Langer, 2006). Although the 
expression levels of these cell lines are well known and widely reported, it was important 
to confirm expression levels as factors such as passage number, freezing, thawing and cell 
culture techniques can decrease expression levels. 
The mechanism of cellular uptake by the iron oxide silica-herceptin nanoparticles 
should mediated by herceptin. To confirm this a dose response and time course response 
of iron oxide silica-herceptin nanoparticles by SKRBR3, BT474 and MCF7 was 
conducted. For the dose response study, the iron oxide silica-herceptin FITC nanoparticles 
were incubated at different concentrations (5, 10, 50, 100 μg/ml) for 24 hours with the 
SKBR3, BT474 and MCF7 and then by flow cytometry. The results show that level of 
FITC fluorescence increases as the concentration of the iron oxide silica-herceptin 
nanoparticles increases in all cell lines suggesting, that more nanoparticles are being 
uptaken (Fig. 4A). Furthermore, the level of iron oxide silica herceptin FITC nanoparticle 
uptake is consistent with the amount of HER2.neu expression shown in Table 1 for each of 
the cells lines, indicating specific HER2/neu mediated uptake. The results from this study 
are in accordance with cellular uptake studies of human serum albumin nanoparticles 
conjugated to Herceptin which also demonstrate linear uptake of nanoparticles at varying 
concentrations. It is interesting to note that most of the studies that use nanoparticles 
conjugated to Herceptin do not show dose response uptake studies and instead only show 
the differences in uptake via MRI. For example the study by Chen et al (T. Chen, et al., 
2009) investigated the use of Herceptin conjugated dextran-coated iron oxide 
nanoparticles in vitro in 4 human breast cancer cells lines and in vivo. This method is 
essential in understanding the MRI contrast enhancement behaviour between phantoms 
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and in vitro systems however is not useful in understanding the behaviour of the tagged 
nanoparticles in in vitro biological systems.  
In addition to dose response, the time required for uptake of nanoparticles is 
another important consideration. Time-dependent cellular uptake of iron oxide silica-
herceptin nanoparticles used a constant concentration of 50 μg/ml and were incubated with 
SKBR3, BT474 and MCF7 for 30 mins, 1hr, 3hr, 5hr and 24hr. Similarly, the results show 
that as the time increases, nanoparticle uptake also increases and the level of uptake 
appears to be consistent with the surface expression of the cell lines as shown in Table 1 
(Fig. 4B). These findings are concurrent with previous studies suggesting uptake to be 
associated with HER2/neu receptors (Steinhauser, et al., 2006; Wartlick et al., 2004). As 
with the dose response studies, there is limited data available on time course response 
studies of nanoparticles conjugated to herceptin except for one study showing uptake of 
HSA conjugated to Herceptin in SBKR3, BT474 and MCF-7 cells over a 24 hour time 
period (Steinhauser, et al., 2006). The results showed time dependant uptake of the 
nanoparticles and the influence of incubation times greater than 5 hours to be associated 
with non-specific uptake.  
The ability to provide contrast in phantoms and then in vitro using MRI is one 
fundamental aspect in targeted imaging. Another important aspect is the ability for the 
targeted nanoparticles to demonstrate selective binding at the target cells. In this case, the 
iron oxide nanoparticles conjugated to Herceptin show selective binding as indicated by 
the dose and time course response studies (Figures) but also by the MRI contrast 
enhancement study (Figure). This can be visualised in Figure 6A where SKBR3 cells 
appear to be dark relative to BT474 and MCF-7 cell lines which is also confirmed by a 
plot of the drop in T2 values against the cell lines (Figure). The signal enhancement 
relative to the control of SKBR-3, BT474 and MCF-7 cells were calculated to be 52.3%, 
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34.7% and 12.5% respectively, and no enhancement was observed for the control cells. 
These results are consistent with the surface expression data from Table 1 suggesting that 
as the expression level of HER2/neu increases more particles are taken up thus producing 
a drop in T2 signals or higher signal enhancement. 
On the basis of our successful verification of iron oxide silica herceptin 
nanoparticles for in vitro imaging, we further tested their capability for in vivo use. Nude 
mice (n=15) were subcutaneously injected with SKBR3 cell lines which overexpress 
HER2/neu receptors. MR imaging of the mice were performed at 4 hours and 24 hours 
after intravenous tail injection. The study consisted of two control groups (saline and iron 
silica with no herceptin) and one experimental group (iron silica herceptin). The first set of 
control subjects received only saline and the second set received 400ug of iron oxide silica 
nanoparticles. The experimental group received 400ug iron oxide silica herceptin 
nanoparticles. Figure (X) shows the MR images at 4 hours and 24 hours post injection of 
the three groups. The results indicate that by 4 hours post injection uptake of the iron 
oxide silica herceptin nanoparticles can be seen as indicated by the signal enhancement 
relative to the control. To further confirm the specific binding, the signal enhancement was 
also calculated against the second control group which received iron oxide silica 
nanoparticles. The results suggest that the iron oxide silica herceptin nanoparticles have 
specifically targeted the HER2/neu receptor expressing tumours. 
Conclusion 
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Extra 
IHC using immunoperoxidase was done to confirm expression of her2/neu in 
tumours from mice.  Staining patterns show membranous cytoplasmic staining of 
her2/neu indicated by dark blue (cell clusters) and dark brown (her2neu). Fc 
receptors were blocked to inhibit non specific uptake. 
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o Abstract INTRODUCTIONSYNTHESIS OF IRON OXIDE 
NANOPARTICLES REFERENCES 
Contrast agents, such as iron oxide, enhance MR images by altering the relaxation times of 
tissues in which the agent is present. They can also be used to label targeted molecular 
imaging probes. Unfortunately, no molecular imaging probe is currently available on the 
clinical MRI market. A promising platform for MRI contrast agent development is 
nanotechnology, where superparamagnetic iron oxide nanoparticles (SPIONS) are tailored 
for MR contrast enhancement, and/or for molecular imaging. SPIONs can be produced 
using a range of methods and the choice of method will be influenced by the 
characteristics most important for a particular application. In addition, the ability to attach 
molecular markers to SPIONS heralds their application in molecular imaging. 
There are many reviews on SPION synthesis for MRI; however, these tend to be targeted 
to a chemistry audience. The development of MRI contrast agents attracts experienced 
researchers from many fields including some researchers with little knowledge of medical 
imaging or MRI. This situation presents medical radiation practitioners with opportunities 
for involvement, collaboration or leadership in research depending on their level of 
commitment and their ability to learn. Medical radiation practitioners already possess a 
large portion of the understanding, knowledge and skills necessary for involvement in 
MRI development and molecular imaging. Their expertise in imaging technology, patient 
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care and radiation safety provides them with skills that are directly applicable to research 
on the development and application of SPIONs and MRI. 
In this paper we argue that MRI SPIONs, currently limited to major research centres, will 
have widespread clinical use in the future. We believe that knowledge about this growing 
area of research provides an opportunity for medical radiation practitioners to enhance 
their specialised expertise to ensure best practice in a truly multi-disciplinary environment. 
This review outlines how and why SPIONs can be synthesised and examines their 
characteristics and limitations in the context of MR imaging. 
Keywords: Magnetic resonance imaging (MRI), iron oxide, nanoparticles, synthesis 
o Abstract INTRODUCTIONSYNTHESIS OF IRON OXIDE 
NANOPARTICLESREFERENCESINTRODUCTION 
Nanotechnology has evolved into a multidisciplinary field, revolutionising industries such 
as applied physics, mechanical, chemical, electrical and biological engineering, machine 
design, robotics, and medicine [1]. In medical imaging, the development of nanoparticles 
has attracted a phenomenal amount of research, particularly for applications in molecular 
imaging. 
The nano size (<100nm) of these particles enables conjugation with many molecular 
markers, which can interact at molecular and cellular levels, thereby offering an ever 
increasing range of disease targets for molecular imaging. 
Nanoparticles also have the potential to revolutionise conventional imaging techniques [2]. 
Conventional imaging modalities lack the combination of high sensitivity and high spatial 
resolution required for molecular imaging. MRI has high resolution, but lacks sensitivity 
to molecular signals, while high sensitivity nuclear medicine modalities such as single 
photon emission computed tomography (SPECT) and positron emission tomography 
(PET) provide superb sensitivity, at the cost of reduced spatial resolution [2-4]. 
The use of nanoparticles in modalities like MRI can greatly increase sensitivity, presenting 
the potential for high-resolution molecular imaging. MRI has high spatial resolution [2, 5], 
is non-invasive in nature, uses non-ionising radiation, and offers multi-planar tomographic 
capabilities [2]. Nanoparticles can be engineered to have magnetic characteristics that can 
be detected by MRI at low concentrations, and at the same time contain ligands which 
target specific molecules [2]. 
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Iron oxide nanoparticles have been widely researched for MRI, as they are mainly 
superparamagnetic. There are several types of iron oxide nanoparticles, namely 
maghemite, γ-Fe2O3, magnetite, Fe3O4, and haematite, α-Fe2O3, among which magnetite, 
Fe3O4, is very promising, because of its proven biocompatibility [1]. 
For molecular imaging purposes, superparamagnetic iron oxide nanoparticles (SPIONS) 
need to be biocompatible, non-toxic and magnetic. They also need to bind to a range of 
drugs, proteins, enzymes, antibodies, or other molecular targets. 
There have been a number of approaches to the production of SPIONS for use as MRI 
contrast agents, and each method produces particles with different sizes and magnetisation 
parameters. The iron oxide nanoparticles can also be coated with a surface layer, usually 
of organic material, that provides an interface between the core and the surrounding 
environment [6]. This surface layer can be used to direct the particles to a target site. 
In this review, we summarise some of the chemical routes for the synthesis of SPIONS, 
such as classical synthesis, reactions in constrained environments, and high temperature 
reactions. It will also discuss some of the major methods for structural and 
physicochemical characterisation of the SPIONS, such as x-ray powdered diffraction 
(XRD), transmission electron microscopy (TEM), dynamic light scattering (DLS), nuclear 
magnetic resonance spectroscopy (NMR), and atomic absorption spectroscopy (AAS). 
  Abstract 
o INTRODUCTIONSYNTHESIS OF IRON OXIDE 
NANOPARTICLESREFERENCESSYNTHESIS OF IRON OXIDE NANOPARTICLES 
Nanoparticle design 
Nanoparticles, being the smallest building block, can essentially be synthesised to have 
any structure, and can comprise a core and/or monolayer(s). For example, some drug 
delivery applications use multiple polymer layers surrounding an organic core [7], while 
some imaging applications use a basic structure that incorporates an inorganic core 
surrounded by an organic monolayer. The main materials used for the cores include metals 
such as gold (Au), platinum (Pt), silver (Ag), cobalt (Co), semiconductors cadmium 
selenide (CdSe), lead selenide (PbSe), or hybrids CdSe/zinc selenide(ZnS) [8]. 
Materials suitable for composing the organic monolayer can include; silica shells [12, 13], 
lipids [14-17], polymers [18, 19] and amphiphilic ligands [3, 9-11]. This layer can also be 
augmented with non-specific ligands or DNA fragments, antibodies, proteins, and drugs. 
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The choice of core and monolayer material is critical to the design of specialised contrast 
agents as each layer dictates a specific function. The composition of the core material 
dictates the primary physical and chemical properties of the nanoparticle, which in turn 
determine how it can be imaged. Iron particles, for example, are potentially very useful as 
MRI contrast agents because they are magnetic and behave as single magnetic domains 
when exposed to an external magnetic field. On the other hand, CdSe nanoparticles or 
‘quantum dots’ can be used as optical probes for fluorescent imaging. 
The monolayer provides the interface between the core and the surrounding environment 
[6] and can serve two purposes. Firstly, to act as a barrier between the nanoparticle core 
and the environment, to protect and stabilise the core [6]. Some materials used for the core 
such as iron oxides, on their own, are not stable, and are readily oxidised, changing 
valuable properties of the nanoparticle. Secondly, the chemical nature of monolayers 
dictate the reactivity, solubility and interfacial interactions [6], and may also determine the 
biological handling, of the nanoparticle. Most of the inorganic cores are not soluble in 
aqueous environments, and monolayer designs serve to overcome this problem, 
particularly for in-vivo applications. The inorganic core, when used alone, does not have a 
specific target, however if the monolayer is a particular molecular precursor or is 
conjugated to a specific molecule, it can direct the particle to an area of interest. 
Nanoparticle design for MRI 
As well as having a suitable iron core and monolayer, SPIONS, need to possess a range of 
other properties to ensure they are useful as MRI contrast agents. These are: 
• uniform particle size [20, 21]  
• a uniform and high superparamagnetic moment [2, 20, 21]  
• high colloidal stability [2]  
• low toxicity and high biocompatibility [2] 
The way SPIONs are produced has an influence on all of the above properties [2]. For 
MRI, these properties are important as they determine the overall effectiveness of the 
contrast agent. For example, an essential characteristic of an effective MRI contrast agent 
is a high saturation magnetisation value, (expressed in electromagnetic unit/gram, 
[emu/g]). Saturation magnetisation values are a measure of the magnetic moment, so 
higher values produce more magnetic susceptibility, and therefore stronger MRI signals 
[22]. 
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Relaxation rates are a measure of the ability of a contrast agent to enhance the relaxation 
rate of water protons, i.e. increase the efficiency with which image contrast is produced 
[23]. SPIONS with high T2 values have faster relaxation with surrounding water protons, 
and therefore faster relaxation rates (1/T1 and 1/T2). 
Typically, magnetisation values for SPIONS range from 30-50emu/g, while higher values 
such as 90emu/g have been observed for bulk material [24, 25]. Factors contributing to the 
magnetisation value of SPIONS include; the size of the particles (with the highest emu/g 
to volume ratio occurring in the 6-20nm particle size range [26]), spacing between the 
nanoparticles (where coatings such as silica separate the magnetic domains, allowing each 
individual magnetite particle to act independently and thus enhancing the net magnetism 
per gram) and the crystalline structure of the iron oxide. It is therefore essential to use a 
method of SPION production that generates particles with one or more of the above 
characteristics. 
The overall size and size distribution of the SPIONS is an important consideration as it 
can affect the biocompatibility and biodistribution in-vivo. It is well known that particles 
above 50nm in diameter are eliminated by the reticulo-endothelial system (RES) so 
SPIONs greater than 50nm in diameter are limited to liver/spleen imaging. A range of 
synthesis methods have been developed to produce SPIONs with varying sizes and this 
relationship between size and biocompatibility will be discussed in the following section. 
Other properties, such as high colloidal stability and low toxicity, are important, because 
they increase the chances of translating developmental contrast agents into the clinical 
setting. 
The following sections will briefly discuss the basic method of SPION growth, and then 
discuss the different methods of SPION production and their respective properties for 
MRI. 
Nucleation and particle growth 
In making iron oxide nanoparticles for MRI, the particles need to be of uniform size. 
Uniform particles are usually prepared via homogeneous precipitation reactions [2], which 
involve two processes, nucleation and growth. This is because iron oxide nanoparticles are 
crystalline structures that are governed by the principles of crystal formation and growth. 
Generally, for precipitation to occur, there must be a saturated solution, in which addition 
of any excess solute will cause precipitation, and the formation of nanocrystals [8]. 
For nucleation to occur, the solution must be supersaturated [2], leading to a short single 
burst of nucleation [27]. Supersaturation can be achieved by dissolving the solute at a high 
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temperature, or by adding reactants to produce supersaturation [28]. After the short burst 
in nucleation, the concentration drops and nucleation stops. The nuclei then grow, by 
diffusion of solutes from the solution onto the nuclear surfaces, until an equilibrium 
concentration is achieved. 
In order to achieve monodisperse particles, the two phases of nucleation and growth need 
to be separated [8, 20, 27, 29]. There are many different mechanisms which can explain 
this process, however we refer the reader to LaMer and Dinegar [30], who proposed the 
classical theory method of the formation of sulphur colloids, Den Ouden and Thompson 
who explained ‘Ostwald ripening growth’ [31, 32] and other mechanisms proposed by 
Morales et al. [33], and Ocana et al. [34]. 
Size control is ultimately achieved by artificially separating nucleation and growth. This 
would occur before the solution reaches critical supersaturation, or by the end of 
nucleation [20]. A wide variety of factors have been adjusted in many ways to promote 
separation of the two processes to control size, magnetic characteristics, or surface 
properties. Some of the factors have contributed to the development of new synthesis 
methods, and some have just improved classical methods. A few of these factors will be 
discussed below. 
Methods of superparamagnetic iron oxide nanoparticle synthesis 
There are numerous methods of iron oxide nanoparticle synthesis for applications to MRI 
[20], for example; chemical precipitation, constrained environments and high temperature 
reactions. In keeping with the scope of this paper, only these selected methods will be 
discussed. 
Chemical precipitation  
The precipitation method is the simplest chemical pathway to obtain SPIONS [8, 20]. 
The SPIONS, either magnetite (Fe3O4), or maghemite (γFe2O3), are prepared by co-
precipitating a stoichiometric mixture of ferrous and ferric salts in an aqueous medium. 
The thermodynamics of the reaction require a ratio of 2:1 for Fe2+/ Fe3+, and a pH between 
8 and 14. The precipitated magnetite is black in colour. The overall reaction can be written 
as [1, 20]: 
 (1) 
The ions can become oxidised before precipitation, critically affecting the physical and 
chemical properties of the SPIONS. For iron oxide, or magnetite, oxidation usually means 
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the formation of maghemite. The reaction must therefore be carried out under a nitrogen 
environment to eliminate oxidation. 
The transformation from magnetite to maghemite can pose a serious problem for the 
production of contrast agents. The two differ from each other in the spinel structure; one 
occupies positions in the octahedral and tetrahedral sites, and the other, maghemite, has 
cationic vacancies in the octahedral position. This crystal structure results in a different net 
spontaneous magnetisation (or emu/g) of the iron particles : at 300oK, 92 emu/g-1 for 
magnetite, and 78 emu/g-1 for maghemite [35]. 
Most of the time it is difficult to separate magnetite from maghemite [36], given that their 
diffraction spectra are very similar [21]. Some synthesis methods suggest the presence of 
both magnetite and maghemite in the resulting preparations [37]. 
In the co-precipitation process there are two main processes involved. The first is a short 
single burst of nucleation, followed by growth of the nuclei, as discussed in the previous 
section. The precipitation method provides an advantage because large quantities can be 
synthesised; however, problems arise from the wide particle size distribution. 
As mentioned above, size affects the magnetisation values as well as the biodistribution 
in-vivo. Factors that influence the biodistribution of a particle are important, as they also 
determine the possible MRI applications. To control the size, and size distribution, it is 
essential to adjust factors that determine the precipitation process. Numerous studies have 
been conducted adjusting factors such as pH, ionic strength, temperature, nature of salts, 
Fe3+/Fe2+ ratio, and addition of chelating agents, which improve the size and size 
distribution of the SPIONS produced. 
The Massart process describes the co-precipitation of ferrous and ferric chlorides, and 
hydroxides in an alkaline solution [38]. Parameters such as strength of the base (eg 
ammonia or NaOH), the pH value, added cations, and the Fe3+/Fe2+ ratio were evaluated, 
noting the effect on yield of the co-precipitation reaction and particle sizes. It was 
concluded that the size decreases as the pH, and/or Fe3+/Fe2+ ratio, increase, and as ionic 
strength in the medium increases. 
A comprehensive study on the ratio of Fe2+/Fe3+ was conducted by Jolivet et al. In 1992 
[39] and 1994, illustrating the effects on size, morphology and magnetic characteristics. 
Small values of the Fe2+/Fe3+ ratio (<0.3) were known to form goethite. For ratios less than 
0.5, but greater than 0.3, there were two phases, consisting of smaller (4nm) and larger 
nanoparticles. However, a ratio of 0.5 corresponded to magnetite stochiometry, and the 
particles were homogenous in size and composition. 
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In 1999, Babes et al. [40] investigated different properties such as iron concentration, 
temperature and oxygen. It was highlighted that one of the most important parameters was 
the Fe2+/Fe3+ molar ratio. A high ratio produced larger particles, which is consistent with 
the literature [39, 41], suggesting that only ratios between 0.4 and 0.6 produce 
monodisperse particles, suitable for use as contrast agents in MRI [20]. 
It is reported that the higher the pH and the ionic strength, the smaller the particle size and 
size distribution [41, 42]. Vayssières et al. [42] observed that for a higher pH and ionic 
strength, the particles were smaller due to the thermodynamics of the solution. At a lower 
pH and ionic strength, the particles continued to grow during the ageing phase associated 
with Ostwald ripening, thus forming larger particles. 
A recent study on the size of the SPIONS, and its effect on magnetisation and MR signal, 
was conducted by Young-wook Jun et al. [26]. The SPIONS were highly crystalline, 
monodisperse, and stoichiometric for magnetite, and ranged in size from 4nm to 12nm in 
diameter. The general trend suggested that as the nanoparticles increased in size, the T2-
weighted MR signal intensity decreased, the particles therefore appearing hypointense on 
T2-weighted images. 
Apart from modulating the parameters of the reaction to achieve monodisperse particles, 
the addition, either in combination or individually, of chelating organic anions like citric 
acid [43, 44], amino acids, and dimercaptosuccinic acid (DMSA) [45], can also decrease 
the particle size by inhibiting the growth of the crystal nuclei. Polymer surface complexing 
agents, which form monolayers on the surface of the iron oxide, such as dextran [46], 
carbodextran, and silica [47] can also be added, instead of varying the reaction parameters. 
Some polymer complexing agents such as dextran, carbodextran and silica are 
commercially available, and are currently used in iron oxide-based MRI contrast agents. 
Examples are: silica-coated magnetite, AMI-121 (Lumirem®- US) dextran-coated 
magnetite, Ferumoxides (Endorem® – Europe, Feridex® in the USA and Japan) and 
carboxydextran coated magnetite, Ferucarbotran (Resovist® – Europe and Japan). 
It should be noted that these agents can be used for any method of iron oxide production. 
The coatings often serve multiple purposes; they allow for water solubility [2], the 
attachment of various functional probes [2, 48], promote the formation of monodisperse 
particles [20, 45] and stabilise the magnetite core [6]. 
Although the co-precipitation method is the simplest and most efficient chemical pathway 
to obtain magnetic particles, it has disadvantages such as large particle size distribution, 
aggregation and poor crystallinity, resulting in low saturation magnetisation values. These 
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disadvantages have led to the development of advanced methods of magnetite synthesis 
[1]. 
Reactions in constrained environments  
Synthesis reactions in constrained environments have made use of lipid-based structures 
with amphiphiles [12, 49-53] and dendrimers [54]. 
Lipid-based nanoparticles, or colloidal aggregates such as liposomes, micelles or 
microemulsions, are composed of lipids and/or other amphiphilic molecules. Amphiphiles 
(sometimes referred to as surfactants) are molecules with both hydrophilic (polar head) 
and hydrophobic (non-polar tail) parts that spontaneously assemble into aggregates in an 
aqueous solution [55]. Because of these properties, there are various geometries and sizes 
that can be formed due to unfavourable interactions between the hydrophobic tails and 
water [55], such as cylindrical, spherical, and bilayered. 
The hydrophobic tails can vary in length, affecting the ratio between hydrophilic and 
hydrophobic parts, and the hydrophilic heads can also vary in charge and size, affecting 
the overall curvature of the aggregate. Other factors, such as pH, temperature and 
concentration, can also affect the end-product. 
Mulder et al. [14] illustrate the various geometries that can be formed. 
In micelle-forming lipids, the hydrophobic chains are oriented toward the inside of the 
micelle, and the hydrophilic chains outward. Micelles for MR imaging contain a 
hydrophobic core, where the iron oxide core is stabilised by the surfactant, which limits 
particle nucleation and growth [8]. 
The first magnetic nanoparticles formed in micelles were produced by oxidation of Fe2+ 
salts [56]. The size of the magnetite particles were controlled by varying the temperature 
and the surfactant concentration [57]. Micelles give control to the particle size formed, 
however reverse micelles are of importance for applications to MRI. 
In reverse micelles, the hydrophilic head groups are towards the core of the micelle and 
the hydrophobic groups are directed outwards. Reverse micelles can solubilise relatively 
large amounts of water, which can be controlled, to make them suitable for the synthesis 
of nanoparticles. A diverse range of nanoparticles can be obtained by varying the nature 
and amount of surfactant, co-surfactant, and solvent. 
Reverse micelles are essentially formed by aqueous iron salt solutions, encapsulated by a 
surfactant that separates them from the surrounding organic solution. Publications have 
suggested that iron oxide nanoparticles synthesised via the reverse micelle process can be 
used for MRI applications [58]. For example Lee et al. [57], investigated an inexpensive, 
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large-scale, and highly crystalline method of magnetite production. The synthesis was 
carried out at high temperatures whilst varying the relative proportion of iron salts, 
surfactant and solvents. It was suggested that the particle size could be controlled to 
produce monodisperse particles in one sample. 
Poly(ethylene glycol) (PEG) stabilised lipids can also be used for targeting and stabilising 
the iron oxide core [59]. The advantages of using PEG stabilised lipids are long blood 
circulation times, and water solubility, while the disadvantages are associated with 
difficult preparation methods, and excessive size separation processes [60]. 
Bi-layer forming lipids are used to create liposomes; they usually have a polar head group 
and two fatty acid chains. Iron oxides can be placed inside the liposomal lumen to create 
magnetoliposomes [61]. There are two types of magnetoliposomes; the first consists of 
water-soluble iron oxide particles within an aqueous lumen [62]. The second contains iron 
oxide particles of approximately 15nm, covered with a lipid bi-layer [63]. 
The second type, developed by De Cuyper and Joniau [63], has been used in-vivo for MRI 
as a bone marrow contrast agent [15]. The magnetoliposomes are produced by first 
synthesising iron oxides in solution. The particles are then solubilised and stabilised by the 
addition of laurate, which acts as a surfactant. A solution with excess phospholipids is then 
added to the particles and undergoes dialysis for a number of days. The surfactant 
molecules on the iron oxide surface exchange with the phospholipid molecules which, 
over time, cause the formation of a lipid bi-layer on the iron oxides nanoparticles. 
Furthermore, molecules such as PEG can also be added to the lipid bi-layer, increasing the 
half life in blood [64] and therefore increasing the number of applications for MRI 
contrast. 
Dendrimers are a class of transfection agents that contain three components: core, 
branches and end-groups. When dendrimers are coated to iron oxides they are termed 
magnetodendrimers. Carboxylated polyamidoamine dendrimers have been used to coat 
and stabilise the iron oxide nanoparticles [54, 65]. More importantly, magnetodendrimers 
are well suited for the imaging of cell trafficking and migration using MRI [66-68]. This is 
due to the charge on the polymer, which promotes a high non-specific affinity for cellular 
membranes, resulting in cellular internalisation [65, 67]. 
Generally, the oxidation of Fe(II) at an elevated temperature and pH, in the presence of 
dendrimers, results in the formation of highly stable and soluble SPIONS with dendrimers 
[54]. They have an approximate size of 20-30nm, and high T2 relaxivities [54]. Cells from 
different origins: mouse, rat or human, can then be easily labelled to the 
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magnetodendrimers, by introducing the magnetodendrimers to the cell culture for 1-2 days 
at low concentrations [66]. 
High temperature methods  
Monodisperse particles with significant size control, and high crystallinity, can be 
achieved using high temperature methods. In this method, iron complexes are decomposed 
in the presence of surfactants and organic solvents. The high temperatures used in this 
method, and the nature of the solvent, result in the SPIONS having suitable size, and size 
distribution, with high crystallinity [69]. 
There are many studies on the synthesis of SPIONS using the high temperature method, 
for example Sun and Zeng [70] prepared iron oxide nanoparticles of different sizes, 3nm 
to 20nm. In this reaction, iron(III) acetylacetonate was decomposed by heating at 265oC in 
phenyl ether, alcohol, oleic acid, and oleylamine, to produce SPIONS 4nm in diameter. To 
make larger particles, a seed-mediated growth was used, controlling the quantity of seeds 
added to obtain various sizes. 
Similarly, Hyeon et al. [71] formed an iron oleate complex from the decomposition of iron 
pentacarbonyl in the presence of octyl ether and oleic acid at 100oC. After cooling to room 
temperature, (CH3)3NO was added, and then the SPIONS were obtained by heating, 
followed by refluxing. When the molar ratios of iron pentacarbonyl and oleic acid were 
changed from 1:2 to 1:4, the particle size increased from 7nm to 11nm. 
In another study by Park et al. [72], iron salts were used instead of toxic organometallic 
compounds such as iron carbonyl. Iron salts are more suited for contrast agent research 
and applications in MRI because they are less toxic. An iron-oleic complex was formed 
using iron chlorides, (FeCl3·6H2O) and sodium oleate, which was slowly heated to 320oC 
in 1-octadecene. The solution was aged at this temperature for 30 minutes, generating 
monodisperse iron oxide crystals. Various temperatures and solvents were also tried, 
which produced particles of different sizes and dispersity. It was concluded that 
monodisperse particles could be attributed to the separation of growth and nucleation 
phases, which occured at different temperatures; nucleation at 200-240°C, and growth at 
300°C. 
Monolayers for superparamagnetic iron oxide nanoparticles 
On their own, iron oxides are not very stable, and are not soluble in water. Stabilisation of 
SPIONS is essential to prevent against aggregation and oxidisation. Furthermore, for use 
as MRI contrast agents in-vivo, the SPIONS need to be soluble in water and be easily 
conjugated to molecular and cellular markers. 
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As discussed briefly in the previous sections, there are numerous ways for SPIONS to 
achieve water solubility and stability. Some of these methods include coating with 
carboxylates (such as citric acid), inorganic materials such as silica, and polymers such as 
dextran and PEG. These compounds protect the iron core, and also provide an avenue for 
conjugation of molecular precursors, therefore providing a biocompatible functional 
component for the SPIONS. 
Carboxylates  
The surface of the magnetite nanoparticles can be stabilised in an aqueous dispersion by 
the absorption of citric acid [72]. This process, as described in Sahoo et al. [45], occurs by 
the citric acid being coordinated via one or two of the carboxylate functionalities, 
depending on steric necessity, and the curvature of the surface. As a result, at least one 
carboxylic acid group is exposed to the solvent, and this group is responsible for making 
the surface charged and hydrophilic. The presence of the terminal carboxylic group 
provides an avenue to extended bond formation with fluorescent dyes, proteins, hormone 
linkers, and other molecules, so that specific targeting within biological systems can be 
facilitated. 
Molecules such as DMSA can also be used to stabilise the SPIONS, achieve water 
solubility and allow conjugation of molecular precursors [73]. DMSA has successfully 
been used as a monolayer [74], where the DMSA is introduced to the SPIONS, in excess, 
through simple mixing. The DMSA binds to the magnetite surface through its carboxylate 
bonding, and the intermolecular disulfide cross-linking between surface-bound DMSA 
ligands strengthens the stability. The remaining free carboxylic acid and thiol groups make 
the SPIONS hydrophilic, and can be used for further conjugation of target-specific 
antibodies. 
Silica  
Iron oxide nanoparticles can also be coated with silica [74]. Silica is an inert molecule that 
coats the surface of the iron oxide nanoparticle, and, as a result, prevents aggregation of 
the SPIONS, and provides stability [75]. This is achieved by two processes: (1) sheltering 
of the magnetic dipole interaction by the silica shell; and (2) charging the magnetic 
nanoparticles, as silica is negatively charged [47]. These two features are essential, 
particularly for applications in MRI, as aggregation of the magnetite particles can reduce 
or diminish their ability to be superparamagnetic [76]. 
There are two widely used methods to produce silica-coated iron oxide nanoparticles. The 
first method is based on the Stober process [76], which comprises the hydrolysis and 
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condensation of a sol-gel precursor such as tetraethyl orthosilicate (TEOS). There have 
been numerous studies conducted on the formation of iron oxides coated with silica using 
the Stober process [46, 77]. 
The second most common method of generating iron oxide-coated silica nanoparticles is 
via the microemulsion process, where reverse micelles are used to confine and control the 
silica coating. In this method, non-ionic surfactants are used to form inverse 
microemulsions for preparation or suspension of magnetic nanoparticles [78]. The silica is 
formed around the magnetic nanoparticles by hydrolysis and condensation of TEOS [79]. 
Dextran  
Dextran is a polysaccharide polymer that is composed of α-D-glucopyranosyl units and 
can vary in length (1000 to 2,000,000 Da) and branching. Dextran offers a suitable 
monolayer for SPIONS because of its biocompatibility [80]. The formation of iron oxide 
coated by dextran was first documented by Molday and Mackenzie [80]. In this study, 
dextran 40 000 was coated to the iron oxide nanoparticles by reacting a mixture of ferrous 
chloride and ferric chloride with the dextran polymers, under alkaline conditions. 
Other studies have looked at smaller dextran coatings such as dextran 10 000 [21, 81, 82]. 
Reducing the size of dextran has an effect on the formation and stability of the dextran-
coated iron oxide nanoparticles [83, 84]. Paul et al. [85] describe that the smaller dextran 
has significant effects on particle size, coating stability, and magnetic properties. It was 
concluded that SPIONS coated with a reduced dextran were more stable than those coated 
with a larger molecular weight dextran. Higher molecular weight dextran produced larger 
particles, and only the 10,000 Da dextran gave a particle with high magnetic properties. 
Characterisation of superparamagnetic iron oxide nanoparticles 
There is a wide variety of analysis tools to characterise SPIONS. It is important to define 
the exact characteristics of SPIONS, as these characteristics can influence the application 
of SPIONS in MRI. 
For any biological application, a range of tests such as biocompatibility, toxicity and 
efficacy, needs to be considered. However, within the scope of this paper, and for 
preliminary development of SPIONS in MRI, the most general properties that need to be 
analysed are the physical (size, shape, chemical phases) and magnetic (MR properties, 
magnetic saturation values (emu/g)) properties. 
Physical properties  
When analysing the size of the SPIONS, we are in fact measuring a range of dimensions. 
This includes different parts of the nanoparticle: size of the iron oxide core, size of the 
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monolayer e.g. silica or DMSA, size of the iron oxide core and monolayer, e.g. silica or 
DMSA, combined. It also includes the size range of the particles present in the sample. 
The size of the iron oxide core can be determined by transmission electron microscopy 
(TEM) [83-85]. TEM gives the total particle size, core and monolayer, and also provides 
details on the size distribution and the shape of the SPIONS. There are two different types 
of TEM; low resolution and high resolution. With the high resolution TEM, the atomic 
arrangement of the SPIONS can be deduced. It also allows better characterisation, or 
separation, between the core and monolayer. The lattice arrangement and the surface 
atomic arrangement of the crystals can also be studied, by the use of diffraction patterns. 
Generally for TEM, a small portion of the sample is placed on a coated copper grid and 
then imaged. Although it provides precise direct information about size, size distribution 
and shape of the particles, it has several disadvantages such as operator bias, a risk of 
change in particle properties as the sample dries and contrasting of the sample [21]. 
Dynamic light scattering (DLS) is also a useful technique in particle size characterisation, 
and holds some advantages over TEM. DLS can obtain information about the size and size 
distribution in solutions generally at a lower cost and with less time. In DLS, the 
distribution of diffusion coefficients are calculated which are transformed into 
measurements of the hydrodynamic or total diameter of the particles [21, 86]. Like all 
modalities, DLS also has disadvantages such as contamination by dust or small amounts of 
aggregates in the sample; these can create misleading results [21]. 
X-ray powdered diffraction (XRD) can also be used to estimate the size of the particles, 
and the crystalline structure. XRD gives a diffraction pattern of the sample, and this is 
compared to a reference peak or pattern. Line broadening from the XRD pattern is used to 
calculate the crystal sizes [87], using the Scherrer formula, and these results can indeed be 
compared to the TEM results. 
Mossbauer spectroscopy is another method that can be used to approximate the size of the 
SPIONS [87] to complement DLS and TEM results. A resonant absorption of nuclear 
gamma radiation, e.g. of the non-radioactive 57Fe isotopes, gives information on the 
magnetic coupling of the sample, the valence state of the iron ions, and also on the size of 
the core. 
Magnetic properties  
Measurements of the magnetisation as a function of the applied magnetic field allow the 
determination of magnetic properties: magnetic susceptibility, saturation magnetisation, 
and r1 and r2 relaxivities. 
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A vibrating sample magnetometer (VSM) or Superconducting Quantum Interference 
Device (SQUID) magnetometer can be used to analyse the magnetic properties. 
Parameters such as magnetic moment and hysteresis loop measurements can be measured. 
The necessary equipment is scarce, and although these parameters are useful, for the 
requirements of MRI, other analytical tools can be used. 
Nuclear magnetic resonance spectroscopy (NMR) can be used to analyse properties such 
as the T1 and T2 relaxivities. After analysing the iron concentrations (see below), the r1 and 
r2 relaxivities can be calculated by plotting the T1 and T2 over the iron concentration [88]. 
Alternatively, MRI can be used, using the same process for analysis. 
Iron concentration  
The iron concentration of the sample is generally measured using atomic absorption 
spectroscopy (AAS), or inductively coupled plasma mass spectrometry (ICPMS). 
AAS compares light absorbance of the unknown sample with light absorbance from 
known calibrated standards. It is relatively easy to use and well understood; however some 
limitations are that only one sample can be measured at a time and there can be 
interference with some elements. On the other hand, ICPMS is a form of mass 
spectrometry that is highly sensitive and can determine a range of metals and non-metals 
at very low concentrations. 
MRI with SPIONS: current status and future directions 
The previous sections discuss many studies that have researched and developed SPIONS. 
Some research has improved magnetic characteristics, while other studies have developed 
novel methods for reducing the size of the SPIONS, as well as producing monodisperse 
particles. Despite research over many years, SPIONS as MRI contrast agents, particularly 
for molecular imaging, are still not available clinically. The problems in the translation of 
SPION research for MRI to the clinic lie primarily in particle size: larger particles limit 
applications; dosage: large amounts of SPIONS are needed to produce adequate contrast; 
and production: the ability to adapt synthesis methods to industrial levels of production. 
SPIONS that are larger than 50nm are eliminated by the RES, therefore they are mainly 
useful for liver/spleen imaging applications. Smaller SPIONS are also taken up by the 
RES; however, because of their smaller size, their blood circulation time is longer, 
providing greater opportunity for specific localisation. SPIONS produced commercially 
generally have had narrow applications and have been withdrawn from some markets due 
to low demand. An example is SHU-55A, Resovist. Resovist has an iron oxide core of 
4.3nm and is coated with carbodextran to a total diameter of 60nm. Resovist also has 
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excellent T2 relaxivities of 151.0 mmol-1sec -1, and was used only for liver/spleen 
imaging. Products like OMP (Abdoscan) and AMI-121 (Lumirem, Gastromark) have total 
diameters of approximately 300nm and are coated with polystyrene and silica. They are 
administered orally and used for gastro-intestinal contrast. Unfortunately the prices of 
these products are high, and they are only available on the European and US markets. 
Smaller-sized SPIONS such as AMI-227 (Sinerem, Combidex) and SHU-55C (Supravist 
an optimisation of Resovist, SHU-55a) are ultra-small iron oxide particles coated with 
dextran and carboxy-dextran respectively. Both products yielded a total diameter of 
approximately 20nm.They have been proposed for applications in lymph node and bone 
marrow imaging, as well as the imaging of inflammatory processes. These products are 
not yet approved and are still undergoing development and/or clinical trials. Another 
product, NC100150 (Clariscan) for perfusion/MR angiography was discontinued. The iron 
core was 5-7nm, and it was coated with PEG, having a total diameter of 20nm. 
There are other SPION contrast agents that are available at a pre-clinical imaging level. 
Monocrystalline iron oxide particles (MION) are used for angiography, lymphography, 
tumour detection, and infarction. Companies such as BioPhysics Assay Laboratory 
(BioPAL) Inc. provide products such as Molday ION and FerroTrack that can be used for 
molecular and cellular imaging at the pre-clinical level. See Table 1 for a summary of 
SPION contrast agents. 
1Table 1  
Summary of SPION Contrast Agents 
For SPIONS to be used for more than one application, they need to be coated with a 
monolayer that can promote the attachment of molecular and cellular probes. An example 
is a study by Hilger et al. [88], in which iron oxide nanoparticles were coated with 
dextran, and then attached to anti-Her2/neu antibodies via the carboxyl groups on the 
dextran surface, for breast cancer imaging. Most of the SPIONS available or undergoing 
developments (see Table 1) have suitable surface coatings for molecular/cellular imaging; 
however, their clinical and/or proposed uses have been restricted to relatively narrow 
generic roles. 
Another drawback in the translation of contrast agent research to the clinic has been the 
large amount of iron needed to produce adequate contrast. The challenge is to develop 
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highly magnetic particles that can produce the strong signal enhancement, allowing low 
doses of SPION to be administered without compromising the MR signal. 
Other problems are in translating the synthesis of SPIONS, easily made in the lab, to 
industrial processes able to produce large quantities on a consistent basis. 
With the wide range of SPIONS that are currently being developed for single MR 
applications there are possibilities that in the future these SPIONS will be available for use 
as MR contrast agents. As for molecular and cellular imaging with MRI, the current 
research sets a platform for the further development of SPIONS. If SPIONS as MR 
contrast agents for single applications can be utilised, then the next step in SPION 
development would be towards molecular imaging. Although molecular imaging with 
MRI will not likely replace nuclear medicine and PET, it may play a useful 
complementary role. The current decade has seen extensive progress in SPION design, 
utilisation and characteristics, and we expect that the future will see highly magnetic 
SPIONS available for molecular and cellular imaging in MRI. 
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ABSTRACT 
Magnetic resonance imaging (MRI) is a medical imaging tool that can incorporate contrast agents to enhance 
its ability to identify and characterise pathologies. MRI contrast agents can be paramagnetic such as 
gadolinium, or superparamagnetic such as iron oxide. Significant concerns of Nephrogenic Systemic Fibrosis 
(NSF) have arisen involving gadolinium-based contrast media.  
Recent research has focused on iron oxide nanoparticles because their sizes are more comparable to 
biological units. These can give MRI the potential to detect a broader range of pathology, while also track and 
observe biological processes.  
This is the second article of a two-part series and will review iron oxide nanoparticles as a MRI contrast 
agent, and the potential applications of iron oxide nanoparticles to a range of pathologies and processes 
involving MRI. © 2010 Biomedical Imaging and Intervention Journal. All rights reserved. 
Keywords: Iron oxide nanoparticles, MRI 
INTRODUCTION 
Since its clinical introduction, Magnetic Resonance Imaging (MRI) has been viewed as a highly advanced 
imaging modality. In particular, over the past decade, MRI has demonstrated its capability to generate images 
of anatomy and pathology with excellent contrast and spatial resolution. Also noteworthy has been MRI’s 
capability of imaging physiological processes with functional MRI (fMRI), Diffusion Weighted Imaging (DWI) 
and Perfusion Weighted Imaging (PWI). This of course has coincided with improved hardware and software 
developments. Overall, this has resulted in the medical community having a greater understanding and 
awareness of biological processes. Therefore, the clinical role and utility of MRI has evolved and is 
continually expanding. 
Broadly defined, a contrast agent or medium is any substance that can be used together with an imaging 
technique to provide additional and useful information. Contrast media can be either exogenous or 
endogenous. Endogenous material which can be used include water molecules inherent within the blood 
stream when performing Arterial Spin Labelling (ASL) or Tagging (AST). Exogenous substances include the 
already well-known paramagnetic gadolinium-based agents and now emerging from literature, we are noting 
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an increasing experimental usage of superparamagnetic iron oxide nanoparticles. 
This is the second publication in a two-part series reviewing the potential use of iron oxide nanoparticles. 
Specifically, we will discuss the characteristics essential in iron oxide nanoparticles for MR imaging (as a 
contrast agent) as well as their potential clinical applications for a range of pathologies and physiological 
processes. 
CONTRAST MEDIA IN RADIOLOGY AND THE CURRENT INTRAVASCULAR MRI CONTRAST 
MEDIA 
Intravascular contrast agents have been continually used since the early 1900’s across all imaging modalities 
in the field of radiology [1]. Over the past century, there has been a continual evolution of contrast media in 
medical imaging. These changes have been based on safety concerns (adverse reactions by patients), 
improved chemical technology (oil-based, water-soluble, ionic, non-ionic) and designing contrast agents 
dedicated to a particular imaging modality or technique [1, 2]. Additional concerns surrounding their 
implementation and use include the cost of contrast media, the need for certain contrast media preparations 
to be warmed to body temperature (viscosity, minimise adverse reactions) and also the need to have a recent 
reading of a patient's renal function (prior to administration of contrast media). There are also concerns 
surrounding compatibility, whereby a patient having an intravenous contrast media administered for a 
computed tomography (CT) study will be unable to have a nuclear medicine thyroid examination for several 
months; furthermore, this same contrast media is incompatible with metformin-based diabetic medication. 
When MRI first became a clinical reality, it was thought that no contrast media would ever be needed 
because of MRI’s superior contrast and spatial (isotropic voxels) resolution compared with other modalities 
[3]. It was soon realised that a contrast media was needed to improve the specificity of MRI [4]. In 1988 the 
first MRI-specific contrast media preparation was approved by the Food and Drug Administration (FDA) for 
intravascular administration in clinical use [3, 5]. This was needed to define a pattern of contrast 
enhancement so that a characteristic enhancement pattern of a particular disease process could be 
recognised and also to narrow the differential diagnosis. This contrast media preparation contained 
gadolinium as its base. However, there have always been some concerns in relation to this preparation. 
These include its expense (cost per millilitre and patents are strongly held and continually renewed) and its 
degradation with exposure to ambient light. 
The way that such gadolinium-based contrast media is chemically altered and eliminated by the body is not 
entirely understood [6]. For some time now, a condition known as “cross reactivity” has existed. It cannot be 
entirely explained, however, it is thought to result either from the chelated molecules or elements, or the 
chelated structure themselves [7]. 
Within the last several years, a more serious condition has been attributed to gadolinium-based preparations. 
This condition is referred to as nephrogenic systemic fibrosis (NSF) and can lead to eventual death. This 
condition is almost always seen in patients with reduced renal function (less than normal glomeruli filtration 
rate, GFR) and there have been a number of deaths recorded and attributed to NSF. In early 2008, the Royal 
Australian and New Zealand College of Radiologists (RANZCR) has recommended that all clinical centres 
offering gadolinium-based contrast media for MRI scanning examinations to establish a new policy 
concerning intravascular administration and, in particular, with respect to NSF and patients with impaired 
renal function [8]. Due to the above trends, anecdotal reports suggest more caution and less reliance upon 
gadolinium-based contrast media even though no alternative currently exists in Australia. 
The current commercially available contrast media is gadolinium-based and also referred to as para-magnetic 
and only benefits T1-weighted MR imaging. No mainstream commercially available contrast media for T2-
weighted imaging is currently available in Australia. There are benefits attributed to contrast media if it can be 
prepared for T2-weighted MR imaging [6]. Coincidently, an increasing trend is underway towards clinical MRI 
scanners with higher field strengths such as 3 Tesla (6). The main drivers are improved capital and running 
costs and increased signal-to-noise (SNR) ratio. However, at higher field strengths such as 3 Tesla, T1 and 
T2 relaxation times of human tissue are altered compared to 1.5 Tesla. Gadolinium-based contrast media 
“works” by shortening T1 tissue relaxivity values and therefore only T1 optimised sequences can be used (T2 
relaxivity values are not altered significantly for MR imaging practicality).  
It is proposed that contrast media preparations based on nanoparticles can overcome all of the 
abovementioned challenges related to MRI scanning while simultaneously addressing the current medical 
    283
safety concerns [6, 9]. More specifically, iron oxide-based nanoparticles have the following attractive 
attributes:  
• it can offer T2-weighted imaging opportunities  
• it has a well-recognised and understood pathway for breakdown and excretion from the human body 
○        Degradation causes iron to enter plasma, where it is processed by the body 
○        Risk of iron overload is minimal 
○        Average dose of iron in contrast agent is comparable to iron contained in less than 
one unit of blood  
• It provides “negative” enhancement  
Depending on the physio-chemical property of the coating (surrounding the iron oxide nanoparticle), both 
generalised and specific contrast media can be created [9, 10]. The term “specific” means that contrast media 
preparations can be targeted to a particular organ within the body or a particular disease process. If this can 
be achieved, then it follows that not only can diagnostic imaging be successful, but also therapeutic 
drugs/medication can be tagged to the preparation so that it can reach and work on the target tissue.  
At one point, it was estimated that 30% to 40% of MR examinations were performed with intravascular 
contrast media [7]. With the awareness of NSF, no hard data currently exists to determine if the use of 
intravascular contrast media has decreased or remains at the same level.  
The most commonly available intravenous contrast media contains gadolinium. A gadolinium ion has seven 
unpaired electrons in its outer shell [11] and is considered a paramagnetic substance because it has an 
overall positive effect on the local magnetic field [3]. In brief, when placed within a magnetic field, the 
negatively charged gadolinium ion demonstrates characteristics such as a magnetic moment, producing a 
large time-varying magnetic field in its vicinity, allowing rapid exchange of bulk water, altering the relaxation 
rates (both T1 and T2, or longitudinal and horizontal) of adjacent water protons [7, 11, 12]. Gadolinium is 
referred to as a T1 enhancement contrast agent as it affects T1 to a greater extent than it does T2. The act of 
molecular tumbling and local magnetic field alterations occur near the Larmor frequency value. This leads to a 
reduction of the T1 relaxation value of adjacent water protons, which in turn, leads to an increased signal 
strength on T1 weighted images [11]. This is due to an increased rate of longitudinal magnetisation recovery 
[7]. For acceptable biocompatibility, gadolinium is chelated to other molecules. This reduces any acute toxicity 
effects, and also allows the gadolinium-based agent to remain circulating within the body for a relatively 
longer period (than without chelation) [12] with an elimination half life of 1 hour to 2 hours. 
Currently available paramagnetic contrast agents are commonly administered intravenously. Its biodistribution 
is into the blood stream and then into the extra cellular space. It is therefore not taken up by any specific body 
organ, tissue type or pathologic lesion. Hence, gadolinium compounds are also regarded as non-specific 
contrast agents [12]. However, enhancement patterns are known to be characteristic of certain pathology 
groups. For example, a hyperintense circular rim with a hypointense centre may be representative of a cystic 
lesion.  
CURRENT CONCERNS WITH NEPHROGENIC SYSTEMIC FIBROSIS AND GADOLINIUM 
Up until about ten years ago, gadolinium-based contrast agents have been regarded as having a relatively 
excellent safety record [13]. NSF was originally referred to as nephrogenic fibrosing dermopathy by Cowper et 
al. in 2000 [14]. It was described as being scleromyxoedema-like cutaneous disorder and thought to only 
affect the skin or dermis. It was noted in patients undergoing renal dialysis [14, 15]. As additional cases 
became recorded and further understanding of the pathology grew, the currently used term of NSF has 
become accepted. This is due to the now recognised systemic nature of the pathology [16, 17]. Commonly, 
NSF commences with swelling at the distal aspects of the extremeties. This may then resolve, however, 
leaving behind thick, firm plaques over the affected skin. 
In the majority of patients, initial skin lesions appear on the legs, then the arms and lastly on the trunk of the 
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body. It has also been reported that the skin lesions are often symmetrical and bilateral. It may then progress 
to a point where the patient has significantly reduced range of motion of their extremities and joints [18]. In 
addition to the flexion and joint contractures accompanying extremity skin lesions [19, 20], fibrotic effects may 
also be widespread and penetrating; involving organs including the liver, lungs and heart, among others [20, 
21]. 
Today, the only successful approach in treating NSF is to restore the normal renal function. This can only be 
achieved by renal transplant surgery [18, 20]. NSF is almost always seen in patients with less than normal 
renal function or patients requiring ongoing renal dialysis. Therefore, NSF may be a resulting consequence in 
patients with renal impairment because the contrast media excretion half life is markedly increased [22]. This 
situation then permits disassociated or de-chelated gadolinium ions an increased circulation time. Some 
authors consider NSF to be an, “adverse reaction to gadolinium contrast agents in particular the less stable 
gadodiamide” [23].  
Even though all gadolinium-based preparations carry a level of risk, there is published evidence to suggest 
that some gadolimium-based contrast agents offer a greater risk than others in inducing NSF [23]. This 
variation in risk is linked to the overall molecular structure of the gadolinium-based contrast agent and in 
particular, its level of chemical stability within the human body [24]. Gadodiamide has been associated with 
the greatest incidence of induced NSF [23, 24]. On its own, gadolinium is highly toxic. Not only can it cause 
injury to the liver and spleen, but it can also inhibit secretions of certain enzymes and it can induce 
haematological ailments [24-26]. To minimise such toxic consequences, the gadolinium ion is chelated to 
other chemical elements and compounds [24]. This improves its biocompatibility. The molecule or atom that is 
bonded to the gadolinium can be referred to as a ligand. The gadolinium ion is chelated in either a linear or 
macrocyclic fashion and prepared as either ionic or non-ionic formulations [7, 24]. Published data reflect that 
the least stable preparations are non-ionic linear chelate formulations such as gadodiamide (Omniscan, GE 
healthcare, Chalfort, ST Giles, UK) and Gadoversetamide (OptiMark, Covidien, St Louis, USA). Gadodiamide 
has been reported to have a kinetic stability of 35 seconds. That is, at a pH of 1.0, half of the preparation will 
shed the linearly chelated material; thus leaving free gadolinium ions to search for other metals (body cations) 
to bind to within the body. These would include iron, copper, zinc and calcium. This process is referred to as 
transmetallation. Of the above body cations, zinc has the highest relative concentration (55-125 micromole 
per litre) within the blood stream [24]. 
The most stable gadolinium-based preparation is the ionic, macrocyclic chelate formulation; namely, 
gadoterate. As of April 2009, no cases of NSF linked to any macrocyclic formulation has been reported [24] or 
confirmed by the International Centre For Nephrogenic Fibrosing Dermopathy Research [27].  
This is because a macrocyclic structure provides relatively superior protection of the gadolinium ion. That is, 
the gadolinium ion is caged by the chelating agent [7, 24, 28, 29]. Conversely, a linear chelate is referred to 
as being a flexible open chain and thus not providing a strong bond to the gadolinium ion. Gadoterate is 
documented to have kinetic stability of greater than one month [24].  
High et al. [13] obtained paraffin embedded tissue samples from the NSF registry (the International Centre for 
Nephrogenic Fibrosing Dermopathy Research). These tissue samples had histopathologic diagnosis of NSF. 
This research group demonstrated with energy dispersive spectroscopy (EDS), a device used to characterise 
chemical elements, that in four of seven patients, gadolinium was able to be identified and all detectable 
gadolinium particles were less than 1 micrometre in size. Further analysis with field emission scanning 
electron microscope (FESEM) demonstrated that in all of the positive tissue samples, gadolinium particles 
were present within the intracellular space and most probably located within, or adjacent to, the lysosome 
structures. Also noteworthy was an excessive amount of iron deposition within the tissue samples. 
While the exact cause of NSF has not been conclusively established [20, 21, 29-33] and precise pathologic 
pathways are yet to be determined [15], there is however, convincing evidence that gadolinium may be 
responsible somehow [32, 34]. The most probable theory is that de-chelation occurs [35], resulting in the 
release of free gadolinium ions, which in turn may or may not lead to transmetallation [36, 37].  
IRON OXIDE NANOPARTICLES AS MRI CONTRAST AGENTS 
The most common form of iron oxides used in nanoparticle preparations are magnetite (Fe3O4) and 
maghemite (γFe2O3) [38, 39], and research with these has been intensive for about a decade now. They are 
both insoluble in water and because of their size, these superparamagnetic substances only exhibit their 
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magnetic properties when placed within a magnetic field [12, 40]. The hydrodynamic size of a nanoparticle 
preparation is the term used to describe its overall size, that is, the iron oxide core plus the coating plus any 
additional ligand attachments (see Figure 1). If the overall hydrodynamic size is greater than 50nm, then the 
preparation is referred to as a superparamagnetic iron oxide nanoparticle (SPION). If the hydrodynamic size 
is less than this, then the preparation is termed ultra small superparamagnetic iron oxide (USPION). For the 
purpose of this manuscript, the authors will use the term iron oxide nanoparticle (IONP) as a generic term to 
refer to nanosystems containing a core of iron oxide.  
Iron oxide nanoparticle preparations are highly complex. There are numerous production methods which can 
be used to generate them. Each method can result in iron oxide nanoparticles having specific dimensions, as 
well as unique imaging and therapeutic characteristics. Each manufacturing method is undertaken in a strict 
controlled environment to ensure consistency of dimensions, characteristics and biostability.  
The physiochemical properties of iron oxide nanoparticles are determined by the size of the iron oxide core, 
its overall charge and the zeta charges between coatings and the overall hydrodynamic size. With respect to 
magnetic resonance imaging, the above factors also play a fundamental role in determining their efficacy (or 
imaging efficacy), stability within the body’s environment, biodistribution, opsonisation, metabolism, clearance 
from vascular system and then excretion from the body [41]. 
Part one of this journal article series discussed the variety of production methods. The advantages and 
disadvantages of this method were also presented and therefore that information will not be presented here.  
The coating 
An understanding of the bonding and the geometry of the coating will help us appreciate the pharmokinetic 
pathways and biodistribution of contrast agents composed with iron oxide nanoparticles [40, 42-44]. From a 
chemical perspective, the iron oxide core is coated for four main reasons. Firstly, to prevent destabilisation; 
secondly, to prevent agglomeration (aggregation or sedimentation) as it will be a colloidal suspension; thirdly, 
it allows for the iron oxide nanoparticle formulation to be soluble in an aqueous solution or a biological 
medium; fourthly, it determines either the role it performs within the body (diagnostic magnetic resonance 
imaging, cell tracking or therapeutic purposes such as tailored drug delivery) or the ligand that can be bonded 
to it to support the imaging, tracking or therapeutic roles.  
The coating used can also facilitate the method of endocytosis [45]. For example, it has been shown that 
IONP coated with monomer citrate (overall hydrodynamic size of 8nm) demonstrated cell entry via 
phagocytosis. When the same iron oxide nanoparticles were coated with polymer carboxydextran (overall 
hydrodynabic size of 31nm), cell entry or penetration was demonstrated by pinocytosis. In both examples, the 
same cell line was used.  
Stabilisation 
In the literature, high density coatings have been reported to be effective in stabilising iron oxide 
nanoparticles [40, 46-48]. Such high density coatings are commonly polymeric and monomeric materials or 
species. Polymeric coatings include dextran, carboxymethylated dextran, carboxy dextran and starch. 
Whereas monomeric coatings include dimercaptosuccinic acid (DMSA), amino acids and α-hydroxamates 
(such as citric, tartaric or gluconic acids). 
The Hydrodynamic Size 
There is evidence to suggest that USPION is less prone to phagocytosis by the liver; whereas SPION greater 
than 50nm are rapidly phagocytosed [40]. Therefore, hydrodynamic size can affect biodistribution and blood 
half life in a time dependent manner [49]. Eventually, USPIO will actually be processed by the liver.  
Biodistribution 
Iron oxide nanoparticles greater than 50nm are readily macrophaged by the reticuloendothelial system (RES). 
This namely refers to the Kuppfer cells of the liver, the spleen and bone marrow [40]. Iron oxide nanoparticles 
less than 50nm have been used to demonstrate uptake by lymph nodes [40, 41, 50-53]. Of the available iron 
oxide-based contrast agents which are currently on the market and also undergoing clinical trials, the blood 
half life values can vary considerably from 40 mins to up to 36 hours. There is a link between the 
hydrodynamic size and the biodistribution and blood half life. 
    286
As has been established, particles greater than 50nm are readily taken up by the liver in a matter of minutes. 
USPION are not readily phagocytosed by the liver and can have a longer blood half life and thus reach other 
structures within the body [40]. It must also be emphasised that the coating itself can be responsible for 
aspects of biodistribution as well as ligands; for example the targeting of specific cells or organs [40, 41, 51]. 
Metabolism and excretion 
The manner in which the body metabolises iron oxide nanoparticles is determined by their overall chemical 
composition. In particular the immediate coating and any ligands are strong determinants as to the site (that 
is, which particular organ or body system) of metabolism and thus also the rate of metabolism and excretory 
pathways.  
The commonly used dextran coating should ideally be of low molecular weight. This is vital as higher 
molecular weight dextrans, such as those used as plasma substitutes, have a reported association with 
adverse reactions. Immunoglobulin G (IgG) antibodies have been reported to be reactive to such high 
molecular weight dextrans [54]. Low molecular weight dextrans will initially undergo dextranases which is an 
intracellular level breakdown process. The majority of the breakdown components are excreted with urine 
over a period of nearly 2 months [40]. Once the low molecular dextran has metabolised in this manner, the 
iron oxide core has been found to enter the normal iron store of the body. Such iron elements can also be 
found as haemoglobin with the body’s red blood cells [55]. This iron then follows the same excretory pathway 
as endogenous iron. That is, approximately one-fifth is eliminated mostly with the faeces and over a three-
month period. Therefore, as both dextran and iron from iron oxide nanoparticles are incorporated into the 
body’s normal metabolic pathways, without raising these levels noticeably, and with the evidence available 
today, it can thus be stated that these substances do not trigger any long-term toxicity. 
In the average healthy adult, normal total human iron stores is about 3500mg with the liver containing an 
average of 0.2mg of iron per gram [55]. From the currently approved iron oxide nanoparticles for diagnostic 
MR imaging, a regular adult dose can contain 50-200mg of iron. This value can be considered relatively small 
compared to the human body’s iron store. Chronic iron toxicity is known to occur when the concentration of 
iron within the liver reaches a level of 4mg of iron per gram of liver [38]. 
MRI IMAGING WITH IRON OXIDE NANOPARTICLES 
Phenomenon of superparamagnetism 
Iron oxide nanoparticles, as discussed here, are referred to as being superparamagnetic. The 
superparamagnetic phenomenon is observed when the thermal energy of the medium is sufficient to alter the 
crystallite or nanoparticles’s magnetisation direction by overcoming coupling forces. When crystallite or 
nanoparticles are placed within an external magnetic field, its magnetic moment will align with the externally 
applied magnetic field. 
At least two points distinguish superparamagnetism from paramagnetism. Firstly, with paramagnetism, it is 
each individual atom or ion that becomes aligned with an externally applied magnetic field. Secondly, 
superparamagnetism will occur when the crystal or hydrodynamic size is less than its ferromagnetic domain. 
Authors report this size to be less than 30nm [40], with the “critical size” being about 15nm [44, 56, 57]. 
When not in the presence of an externally applied magnetic field, superparamagnetic particles are not 
magnetised, nor do they demonstrate any remnents of magnetism once removed from the magnetic field. 
When the crystals or particles are under the influence of an applied magnetic field, their magnetic spins are 
considered to be in perfect alignment and very high local magnetic field gradients are generated. These 
gradients then cause spin dephasing of the surrounding water protons; thus reducing their T1 and T2 
relaxivity [12, 56, 58]. 
It must also be noted that there is a relationship between the iron oxide nanoparticle size and the level of 
superparamagnetic saturation. As the particle size decreases, so too does the superparamagnetic saturation. 
This then has an effect on reducing the observed relaxivity or further reducing T1 and T2 relaxation. 
IONP Influence on magnetic resonance image characteristics 
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Compared to a paramagnetic material such as gadolinium, the relatively high magnetic moment of 
superparamagnetic species, such as iron oxides, are sometimes referred to as super spins [40, 59]. The 
dipolar interactions between the super spins and adjacent water protons result in both high longitudinal (r1) 
and transverse (r2) relaxation values. IONPs therefore increase T2* relaxation rates through the susceptibility 
effect and thus have their greatest visual impact on T2*-weighted images produced with gradient echo-based 
pulsed sequences [48, 60-62]. The accelerated phase loss due to local field gradients generated by super 
spins, all stem from the (induced magnetisation) high susceptibility level of iron oxide.  
At the common clinically available field strengths of 1.5T and 3.0T, published data [40] indicate that any 
aggregation of SPION will only slightly decrease r1 (longitudinal relaxation) and dramatically increase 
r2 (horizontal relaxation). 
Magnetic resonance imaging with iron oxide nanoparticles 
Even though images composed with gradient echo pulse sequences posses lower signal-to-noise ratio and 
spatial resolution compared to spin echo pulse sequences, they are currently the most appropriate imaging 
sequence to use with SPIONs. This is often termed magnetic susceptibility imaging [4, 12, 48, 63]. The 
contrast enhancement captured on an MR image is dependant upon a number of factors. Most notable are 
the biodistribution and opsonisation of SPIONs. 
Iron oxide nanoparticles as contrast agents for MRI 
In addition to their superior biocompatibility, IONP MRI contrast agents have been documented to increase 
diagnostic sensitivity and specificity [41, 45, 64-66] in both animal model experimentation and in human trials.
This improved accuracy has been attributed to their superparamagnetic effects and relaxation times [41, 64, 
66]. Efficacy of IONPs as MRI dedicated contrast media also largely depends upon their physiochemical 
properties [41]. Such attributes include: size (both of the iron oxide core and the overall hydrodynamic 
dimensions); coating (dextran derivative or other); and the zeta surface charges. Their efficacy can be further 
increased with complex surface modifications. This is achieved by bonding or attaching active material such 
as monoclonal antibodies, receptor ligands and also proteins [41]. 
For intravascular administration, the hydrodynamic diameter of IONPs are very rarely greater than 150nm. 
The iron oxide core itself is usually no more than about 15nm [67]. The coating itself is preferably composed 
of dextran, or a derivative, of a low molecular weight. These are positive properties, as the dextran is 
biodegradable and its low molecular weight minimises possibilities of adverse reactions [54]. IONPs have also 
been incorporated into oral contrast media [41]. 
Imaging challenges to consider and overcome  
There are a few imaging challenges with the use of IONPs [68]. They are in relation to commonly 
encountered artefacts in MRI imaging. On their own, they can be frustrating to deal with in everyday imaging. 
However, when IONPs are included in the imaging regime, a further layer of complication is added.  
The first criticism is that it is difficult to determine or differentiate a signal void induced by IONPs compared to 
signal voids generated as artefacts by materials such as metal (susceptibility artefact). The second artefact is 
that of partial volume averaging. IONPs are capable of being involved in processes occurring at a cellular 
level. Hence, signal voids induced by IONPs that are smaller than the spatial resolution of the MRI image will 
not be represented as distinct and within a voxel; as individual signal intensities within a voxel are averaged 
together [4, 11, 12, 68].  
EMERGING TRENDS: APPLICATIONS OF IRON OXIDE NANOPARTICLES AND THE ROLE OF 
MRI 
Where possible and practicable, medical investigators and clinicians would prefer an investigation means that 
is non-invasive or minimally invasive. This approach is safer for patients, it expedites the medical 
management of patients, and can negate morbidity and mortality consequences. IONP preparations, 
combined with MRI, have the potential to revolutionise a number of investigative and treatment procedures. 
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This would be achieved by combining the advantages provided by IONP together with MRI, leading to safer 
and superior imaging alternatives. IONPs as MRI contrast agents have already been discussed in this 
manuscript. To re-iterate, they promise improved levels of toxicity and increased diagnostic sensitivity and 
specificity. These are achieved through careful chemical preparations, leading to IONPs having the required 
characteristics for biocompatibility and MRI image enhancement. It is recognised that further research is 
required to overcome the challenges mentioned.  
We now follow with a discussion on the innovative uses of IONPs combined with MR techniques. These 
promise to revolutionise clinical therapies and improve patient outcomes. 
Molecular imaging is a broad term concerning the imaging of biological events at the cellular or molecular 
level. It should also be non-invasive and the imaging characteristics representing the biological activity should 
be quantifiable [69]. MRI is seen as having an emerging and innovative role. Molecular imaging can be 
possible with MRI when IONPs are conjugated with biologically active materials such as antibodies. 
The near future looks promising for MRI, together with IONPs, to have a positive impact in leading non-
invasive imaging of biological and biochemical processes. Not only can such processes be diagnosed; but 
also progression and treatment can be imaged over time. 
Angiogenesis 
Angiogenesis, the growth of new blood vessels (for development, wound repair or tissue reproduction), is 
related to tumour growth and progression [70]. There are several known molecular markers associated with 
angiogenesis. That is, endothelial cells active in angiogenesis express known surface receptors compared to 
endothelial cells not partaking in angiogenesis [71]. The commonly occurring receptors include integrins and 
vascular endothelial growth factor receptors. Antibodies or drugs to seek out angiogenic markers, can be 
conjugated to IONPs and imaged with MRI. Thus, the angiogenic process can be identified and any success 
in treatment can be accurately monitored. This can be achieved by exploiting the increased permeability of 
newly formed tumour vessels compared to normal healthy vessels [72].  
Apoptosis 
Apoptosis is the self destruction of cells. When determined by cell age or cell health status, the nucleus 
triggers this process. It requires metabolic activity by the dying cell and is commonly characterised by a 
redistribution of phosphatidylsenine in the cell membrane [70]. It can even be associated with tissue 
development and homeostasis [71].  
The degree of apoptosis can determine how successful chemotherapy and radiation therapy can be. 
Identifying apoptotic events in vivo would hence further evaluate treatment regimes and progression of 
pathology [71]. It is known that apoptotic cells express lipid phospatidylserine (a phospholipid) on their cell 
membrane. Synaptotagmin I is a protein that is used to detect this phospholipid. When this protein was 
conjugated to IONPs, apoptosis was demonstrated in vivo with mice [73].  
The capability to image apoptosis can allow for almost real-time monitoring of efficacy of drug therapies [56]. 
Targeted drug delivery with IONP and MRI 
Many therapeutic drugs that are available, can be considered non-specific in nature. By non-specific, it is 
meant that such drugs are administered intravascularly and are thus distributed randomly. This can lead to 
unwanted effects on healthy tissue [74]. Specificity for target tissue or cells can be achieved by conjugating 
IONPs with ligands [71]. Such ligands include antibodies (in particular for targeting cancerous tissue or cells), 
proteins, peptides and other biological markers.  
Targeted drug delivery, as provided by superparamagnetic colloid suspensions, can be guided by an external 
magnetic field to the site of interest [41], thus, having the capability to minimise both side effects and required 
dose [57, 74, 75]. Therefore, pharmaceutical drugs can be binded to IONPs designed to reach a specific, or 
target, organ, and then be released there [41, 44]. The emerging breakthroughs that make magnetic drug 
targeting possible and promising are the new classes of IONPs less than 50nm. This allows for improved 
circulation time, thereby permitting delivery to the target site without the likelihood of being sequestrated by 
the RES before this can occur [41]. With the original classes of IONPs that became commercially available 
over ten years ago, RES uptake occurred within a few minutes following intravascular administration (hence, 
their original application as dedicated contrast agents for the liver) [41].  
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Drug targeting can be achieved by passive, active or physical means [41]. Magnetic drug targeting falls into 
the category of physical means; as the pharmaceutical is attached to a carrier system (the IONP) and its 
distribution is facilitated with an external influence (the magnetic field).  
Not all therapeutic drugs can be conjugated to one single variety of IONP. Characteristics of IONPs that can 
determine attachment of therapeutic drugs include their size, surface charges (zeta charges) and capacity for 
protein absorption [41]. The process of cell uptake is determined by the overall size of the nano-system 
(IONP, surface coating/s and pharmaceutical); phagocytosis or pinocytosis. Pinocytosis occurs for items less 
than 150nm [41, 74]. The condition under which a cell finds itself in, may alter its susceptibility to a nano-
system. For example, under normal conditions, walls of endothelial cells are permeable to objects 10nm or 
smaller. However, when involved in pathologic processes such as tumour infiltration and inflammation, the 
endothelial wall can be permeable to objects up to as large as 700nm [41]. Zeta charges need to be carefully 
managed. They determine whether or not nanoparticles aggregate or if they remain suspended in its medium. 
More importantly, they also play a part in endocytosis. It is noted that the likelihood of phagocytosis increases 
with a higher zeta charge [41, 76], while time spent within the circulatory system is reduced. There is an 
electrostatic process involved when particles and substances are absorbed by a cell’s outer membrane [77]. 
Understanding nanosystem interaction with proteins is vital, as when they are injected into the vascular 
system, their first interaction is with the plasma proteins. Therefore, the manner in which nanosystems are 
capable of interacting with opsonins (proteins that encourage phagocytosis such as IgG) and dysopsonins 
(proteins inhibiting phagocytosis) also determine if they are readily phagocytosed by the RES or if they can 
reach their intended target and release their pharmaceuticals. Hence, protein repulsive molecules such as 
polyethylene glycol (PEG) can be used to modify the surface of nano-systems to reduce their recognition by 
the RES [74] and reduce non-specific cellular uptake [78].  
A phase I/II clinical trial of IONPs combined with epirubicin designed to image and treat solid tumours (such 
as sarcomas), showed that these nanosystems were reasonably well tolerated by the fourteen patients 
involved. No organ toxicity attributable to iron oxide was noted. However, toxicity responses to epirubicin 
were recorded at doses greater than 50 mg/m3 [79].  
Thermal applications for cancer cells: magnetocytolysis and hyperthermia 
with IONP and MRI 
Compared to normal healthy cells, cancer cells are known to be sensitive to temperatures above 42 degrees 
Celsius. Normal cells can survive at higher temperatures [44]. In cancer cells, at temperatures above 42 
degrees Celsius, protein function is disrupted which can lead to apoptosis [80]. Thus, hyperthermia is a 
proposed treatment regime for certain cancers. Until recently, hyperthermic approaches have included 
irradiation with radiofrequency, ultrasound and microwaves. One known criticism of these approaches is the 
likelihood of hyperthermic injury extending to healthy tissue. The term, magnetic induction hyperthermia, now 
refers to cancer tissue being exposed to an alternating magnetic field [44].  
Hyperthermia using IONPs together with MRI has demonstrated positive results in pre-clinical evaluation 
studies. With this combined approach, magnetic nanoparticles can be either directly injected into a tumour 
volume or designed to be selectively uptaken by a tumour site. This target-selective capability improves local 
heating treatment to the tumour while dramatically minimising potential for injury to surrounding healthy tissue 
[81]. Furthermore, the alternating magnetic field (not absorbed by tissue), together with appropriately 
prepared IONP, can allow hyperthermia treatment [41] to be applied to areas deep within the body [44]. 
Radiofrequency pulses provided by MRI can be designed to provide frequencies and amplitudes to increase 
local cell temperature up to 55 degrees Celsius [80], thereby inducing cytolysis. This process, therefore, can 
be used to generate heat to target cells [82]. 
However, for magnetic hyperthermia to be successful, it requires accurate delivery of magnetic nanoparticles 
to the tumour site. 
A number of experiments report successful use of magnetic induction hyperthermia in cancerous cell models 
and also in animal models [44, 81, 83]. 
Salado et al. [84] successfully demonstrated in a rat model, with in vivo MRI imaging, that the IONPs which 
they developed were capable of providing positive contrast enhancement of induced liver tumour and also 
successfully treated these liver tumours with MRI-induced hyperthermia. Thereby, demonstrating that IONPs 
can have both a diagnostic and therapeutic use. Analysis of the rats following the experimental study 
demonstrated no vascular embolisms (the IONP preparation was injected through the ileo-colic vein) and 
specimens of the liver demonstrated insignificant inflammatory changes. 
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Xu et al. [85] have produced nanoparticles containing a core composed of iron and cobalt and a gold shell. 
These nanoparticles demonstrated a specific magnetisation value far greater (226 emu/g) than that 
achievable with commercially available iron oxides (78.8 emu/g). This higher magnetic moment is claimed to 
improve heating efficiency in hyperthermia applications. However, their publication did not mention any 
results or discussion of toxicity or biocompatibility studies.  
Initial success of magnetic hyperthermia with small groups of human patients provides a promising outlook for 
future clinical applications. Plotkin et al. [86] reports a study on eleven consecutive patients (mean age 44 
years), each with recurrent supratentorial glioblastoma. All patients had previously undergone surgery, nine 
patients also had radiation therapy and eight patients also had chemotherapy. Based on the prognosis 
following these treatments, these eleven patients were eligible as candidates for hyperthermia using 
nanoparticles and MRI. Nanoparticles were then administered directly into the tumour volume. MRI 
hyperthermia, or nano cancer therapy, followed and in ten patients, the mean reduction in gross tumour 
volume (GTV) was 74% as indicated with PET-CT fusion imaging.  
Cancer imaging with IONP and MRI 
Diagnosing cancer in its early stages significantly improves patient outcomes and survival rates. The initial 
use for IONPs was directed at imaging liver tumours [87]. This was due to the nanoparticles being greater 
than 60nm and therefore readily phagocytosed by the liver. This has been occurring for several years now 
and there are a few commercially available preparations for this specific purpose. The authors will therefore 
discuss IONPs in relation to other cancers. 
Current MRI techniques allow for the detection of tumour sizes in the order of one centimetre cubed. By 
conjugating known cancer antibodies with IONPs, then MRI can be used to identify cancerous tissue of 
smaller dimensions through molecular interactions. This is an improved sensitivity for cancer markers, 
compared with current cancer marker detection probes [88].  
IONP can be coated with (DMSA), a bi-functional chelating agent and ligand. Herceptin, a monoclonal 
antibody, uses elements from within the immune system to stop tumour progression by binding to HER2 
receptor and triggering a response by natural killer (NK) cells [89]. With a 1.5 Tesla clinical MRI scanner, Lee 
et al. [88] successfully demonstrated how to identify cancer sizes as small as 50mg in mice using IONPs 
conjugated with Herceptin. 
The above approach improves patient outcomes compared with just chemotherapy alone. 
This principle has also been used to target other tumour antigens. IONPs conjugated with peptide EPPT1 
(synthetic peptide EPPT1, also known as alpha-M2 peptide (YCAREPPTRTFAYWG), derived from the CDR3 
Vh region of a monoclonal antibody, ASM2) are able to target underglycosylated MUC-1 (mucin 1); which is a 
tumour antigen expressed by many epithelial cell adenocarcinomas such as pancreatic, colorectal, gastric 
and prostate [56]. 
The role that lymph nodes play in cancer staging has not gone unnoticed by researchers in this field. IONPs 
and MRI can be used to image the condition of lymph nodes and more accurately determine the extent of 
metastatic spread [69]. Oghabian et al. [90] demonstrated 98% detection sensitivity with in vivo imaging of a 
rat model at 1.5 Tesla. They also concluded that the type of surface coating and its thickness were factors in 
determining MRI signal intensity. 
Today, prostate cancer is still a leading cause of death in men. Current treatment, among others, involves 
brachytherapy, and as a procedure, it has its own level of invasiveness, morbidity and mortality. Wang et al. 
[91] have conjugated IONPs with prostate specific membrane antigen (PSMA) and also with doxorubicin, a 
chemotherapy drug. By performing whole cell assays on human cell lines, Wang et al. demonstrated that their 
conjugate can detect, with high sensitivity, prostate cancer cells expressing PSMA, thereby, promising the 
possibility of a multifunctional (diagnostic and therapeutic) nanoparticle system.  
IONPs can also be used to better identify tumour boundaries within the brain [69, 87, 92, 93]. This leads to 
improved quantification of tumour volumes. Compared with gadolinium-based contrast agents for MRI and 
also taking into consideration oedema surrounding a tumour volume, IONPs can define tumour margins for 
longer time periods [69, 92, 94]. This is as a result of the IONPs being endocytosed by tumour cells. Thus 
being internalised, their elimination rate from the tumour is longer compared to extracellular gadolinium-based 
contrast media. 
Cell labelling and tracking; including stem cell therapies 
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MRI imaging of cells labelled or endocytosed with IONPs is considered an indirect imaging technique. This is 
because changes in MRI signal intensity is in relation to the amount of IONPs and not due to the number of 
cells. One concern is the MRI signal characteristic and change over a time period. As stem cells rapidly 
divide, the fixed amount of IONPs is spread throughout the volume of newly divided daughter cells [68, 75]. 
This will be a relative decrease in MRI signal not accurately reflecting the activity of cells. The second 
noteworthy concern is the possibility of false positive signal findings. This is a result of iron presented from 
cells undergoing apoptosis or lysis [68]. Despite these challenges, possibilities are being created for many 
biomedical applications [77]. 
The possibility of imaging stem cells in therapeutic applications with MRI is becoming an ever increasing area 
of active research. Published research so far indicates that IONPs combined with peptides or transfection 
agents can be used for stem cell uptake [75].  
A study using stem cells with IONPs injected into the infarcted myocardium of pigs was able to be 
successfully imaged at 1.5 Tesla in vivo [95]. Following this, histological analysis revealed that the MRI signal 
appearance attributed to IONPs corresponded with stem cells that had taken up IONPs. 
Heymer et al. [96] combined human mesenchymal stem cells (hMSCs) with IONPs; placed these in collage 
type I hydrogel (clinically approved for the repair of articular cartilage) and imaged them in a 11.7 Tesla MRI 
scanner. Iron uptake was confirmed by histological analysis and correlated with hypo-intense regions 
demonstrated on the MRI images. Their technique offers the possibility to use MRI to track the migration of 
IONPs loaded with hMSCs following implantation for articular cartilage repair. 
Stem cell research is highly regarded as offering possible treatment solutions for patients with neuronal 
pathologies and injuries. Guzman et al. [97] proved that IONPs themselves do not alter survival rates, 
migration patterns or differentiation capabilities of stem cells from the human central nervous system (CNS), 
compared with unlabelled human CNS stem cells. They demonstrated this by administering the combined 
human CNS stem cells and IONPs into neonatal, adult and injured rodent brains. They used MRI to track the 
migration of stem cells and confirmed the image findings histologically.  
Stem cells labelled with IONPs have been widely used in animal models (mice, rats and pigs) to demonstrate 
regeneration of the myocardium following infarction [98]. The limitation of this technique is that the 
conjugation of IONPs and stem cells need to be injected directly into the myocardium. This introduces an 
element of invasiveness. However, the region of infarct can be clearly delineated [99]. So far, administration 
of stem cell and IONP conjugations for myocardial regeneration via a vascular route (intravenous or 
intracoronary), has not been as successful as direct injection into the infarcted myocardium. Furthermore, 
comparative high volumes are needed [98, 100].  
Cardiovascular imaging with IONP and MRI 
IONPs have also demonstrated capabilities in imaging cardiovascular pathologies including atherosclerosis, 
thrombosis and myocardial infarcts [56, 101]. 
Atherosclerosis is considered both a progressive disease and chronic inflammation. The endothelial cells of 
the vascular wall express receptors from their cell membrane to attract monocytes. Monocytes establish 
themselves in the subendothelial space and then differentiate into macrophages. The macrophages then take 
up oxidised low density lipoproteins. Therefore, this lipoprotein can be conjugated to IONPs and used to 
identify active regions of atherosclerosis with MRI. This approach has been often used in studies involving 
animal models [102]. Furthermore, apoptosis leads to plaque instability and is known to occur before plaque 
rupture [102]. Identifying apoptic plaques in vivo with MRI is seen as advantageous in improving patient 
outcomes, as inflammatory activity of atherosclerotic plaques may be associated with an increased risk of 
rupture [98].  
Aortic valve disease is also an inflammatory response with macrophage involvement [75]. Ruehm et al. [103] 
successfully used commercially available IONPs to demonstrate (with MR imaging) in hyperlipidemic rabbits 
that atherosclerotic plaques containing macrophages take up these nanoparticles. This was confirmed with 
histopathogical evaluation techniques on samples removed from the aorta. The MRI appearance 
demonstrated an aorta with irregular pattern where the signal dropout occurred at plaque sites containing 
macrophages endocytosing the IONPs.  
IONPs can also be used to target fibrin containing thrombi. This approach may be considered a sensitive 
method of identifying patients at risk of more serious cardiovascular consequences [104]. A study by Winter et 
al. [105] demonstrated that by using antifibrin antibodies together with nanoparticles, clots in canine plasma in 
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vitro could be identified with MRI (at 4.7 Tesla).  
Blood pool contrast agent 
There has been a high level of success in using IONPs as blood pool agents; in both animal models and in 
human subjects. 
One study [106] investigated size and dose of IONPs as a blood pool agent for MR angiography in New 
Zealand White rabbits. The rabbits were divided into a control group (administered with gadopentate 
dimeglumine), and three other groups (each receiving a different concentration of IONPs). MR angiography 
was performed at varying time points; ranging from first pass to 24 hours post-intravascular administration. 
Assessment included signal enhancement of the abdominal aorta, renal arteries and the iliac arteries. Results 
demonstrated that the highest level of signal enhancement was identified during the first pass imaging 
strategy. It was also noted that enhancement in the abdominal aorta was greatest with the smallest nano 
particle size of 21nm. In addition to this, a concentration of 40micromole of iron per kilogram was recognised 
as the dose providing signal enhancement comparable to gadopentate dimeglumine. The size and dose of 
IONPs provided sufficient signal changes to allow imaging from first pass time-point up to 25 minutes post-
intravascular administration. In this 25-minute window, multiple imaging acquisitions and measurements are 
possible. 
Another study [107] successfully demonstrated the use of IONPs as a blood pool agent in rats with induced 
myocardial injuries. Here, a commercially available blood pool agent, Clariscan, was used with an MRA 
technique. The image findings were also compared with post-mortem histochemical stains of the infracted rat 
myocardium. It was found that the Clariscan-enhanced MR angiogram images over-estimated the infracted 
myocardial regions when compared with histology inspection. The use of Clariscan identified the presence 
and dimensions of both transmural and non transmural microvasculature insults. The peri-infracted zone was 
seen to be over-estimated to a greater extent in rats with non-transmural ischaemic injuries. Overall, there 
was an over-estimation of the size of the true infarct but an under-estimation of the region at risk.  
Another commercially available IONP preparation (Resovist) has been used to assess the abdominal aorta 
and the inferior vena cava in a human pilot study [108]. With a 3D MRA (T1-weighted) acquisition technique 
at 1.5 Tesla, first pass imaging was achievable with results being comparable to those obtained by MRA with 
conventional Gadolinium based contrast agents.  
Ferumoxytol has also been used for first pass enhanced 3D MRA of blood vessels of varying dimensions in 
12 human subjects. The following vessels were investigated: the carotid arteries, thoracic aorta, abdominal 
aorta and peripheral arteries [109]. With delayed MRA imaging it was noted that both arterial and venous 
structures displayed enhancement characteristics. 
Nanosensor 
A critical and relatively new-found application of IONPs is to include them in preparations to produce what is 
now termed “nanosensors”. Nanosensors, in their broadest definition, are IONP preparations that have been 
designed to detect the presence of a specific biological interaction. 
Protease specific nanosensors have been developed for in vivo detection of enzyme activity with MRI [110]. 
In particular, T2* MRI together with nanosensors of 25 nm (hydrodynamic size) have demonstrated the 
involvement of the metalloproteinase 9 (MMP-9) enzyme in processes including inflammation, atherosclerosis 
and tumour spread. This opens the potential for early diagnosis of pathologies with altered protease activity 
and also the monitoring of treatment and therapies that act on protease enzymes. 
Protein functionalised nanosensors have also demonstrated capabilities in identifying and measuring the 
concentration of anti-human serum albumin antibodies [111]. One of the additional benefits of the combined 
approach of MRI with nanosensors is that the NMR capabilities can allow for detection in natural human 
substances such as blood and urine. 
Nanosensors have also been developed with the capability to detect single human alveolar cancer cells 
(A549) within 15 mins in blood in vitro [112]. High density folic acid, when conjugated to polyacrylic acid 
coated IONPs were designed to interact with A549 cancer cells expressing the folate receptor. 
Metal doped IONPs 
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Metal doping of IONPs is designed to provide a comparatively higher level of magnetism at the nano scale 
and also allow successful magnetic tuning [113]. Such metal doped IONPs can increase MRI signal contrast 
by as much as 14 times compared to conventional IONPs. The implication of this is that a lower dose or lower 
concentration can be administered to the patient. Their magneto-thermic effects can also increase by a factor 
of 4. 
Lanthanide metals have also been used to dope IONPs [114]. The advantages that lanthanide metals can 
offer include optical imaging properties, detection by neutron activation, utilised in neutron capture therapy 
procedures and also being detectable by time resolved fluorescence. 
IONPs doped with manganese have shown to improve the quality of contrast-enhanced MR imaging of the 
liver [115]. These nano systems have a mean diameter of 80nm. The highest level or change in signal 
intensity occurs at 5 mins post-intravascular administration. However, unlike early IONPs, the imaging 
window for IONPs doped with manganese can last for approximately 36 hours. 
CONCLUSION 
In the immediate future, the reviewers see that perhaps the most likely application of IONPs will be as an MRI 
contrast agent. This is because IONPs offer several important advantages over commonly available 
gadolinium based contrast agents; including, but not limited to, lower toxicity. They can be used to diagnose a 
variety of pathologies and biological activities such as inflammation, infarction and tissue repair. 
In addition to improved diagnostic outcomes, there can also be tailored therapeutic functions, in particular 
with tumour treatment. IONPs can be binded with antibodies, drugs, enzymes and proteins. They can be 
directed to specific organs or tissues and can also be guided with magnetic fields to target tumours and 
induce hyperthermic effects. 
Multifunctional IONPs, together with MRI, offer unique advantages with diagnostic and therapeutic 
capabilities. In particular, molecular imaging with IONPs and MRI has the potential to heavily impact upon 
early detection of a variety of diseases and pathologic processes. It can also be used to devise treatment 
approaches dedicated to individual patient circumstances. This should all lead to improved patient outcomes. 
These are areas of high research activity and there is no doubt that this will lead to a new frontier in magnetic 
resonance imaging. 
 
[View this Figure] 
 
Figure 1 Schematic representation of a basic iron oxide nanoparticle, or nanosystem.  
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